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Concurrent chronic disease and ensuing multi-morbidity are a debilitating reality for millions 
of Canadians. This adversity is compounded by increased pill burden and decreased patient 
adherence. Microemulsions (MEs) serve as a potential multi-drug therapy solution. MEs are 
thermodynamically stable, colloidal systems whose oil and water compositions and nano-sized 
droplets have the potential to facilitate simultaneous hydrophilic and lipophilic drug delivery, 
while improving bioavailability. However, the area of multi-drug delivery using ME technology 
is largely unexplored and unfulfilled. In order to develop a ME capable of simultaneous multi-
drug delivery, emulsifying agents as the heart of these systems must be investigated. 
 In this work, the potential for multi-drug delivery using ME systems was explored with 
a particular focus on emulsifying agent properties conducive to this purpose. A prenatal 
supplement comprised of eleven active pharmaceutical ingredients (APIs) of varying hydro- 
and lipophilicity was selected as a proof of concept. Five non-ionic surfactants were subjected 
to extensive ternary phase diagram (TPD) mapping with a medium chain triglyceride, Miglyol 
812 in order to identify regions of monophasic microemulsion formation. Optimization was 
performed via critical micelle concentration determination and the hydrophilic-lipophilic 
deviation (HLD) equation. A final microemulsion comprised of 3:1 Polysorbate 80:Cremophor 
RH 40 surfactant, Miglyol 812 and water in a surfactant:oil:water (S:O:W) ratio of 50:40:10, 
was identified as optimal for monophasic, microemulsion formation. Eleven active 
pharmaceutical ingredients- five lipophilic (Vitamins A, D, E, K and docosahexaenoic acid) 
and six hydrophilic (Vitamins B1, B2, B3, B6, B9, B12) were then successfully incorporated. The 
resulting microemulsion was determined to be of a bicontinuous nature and after 100x aqueous 
dilution, spherical droplets were identified via TEM with a diameter of 164 ± 37 nm, a charge 
of -14.1 ± 2.2 mV and a low viscosity of 1.04 ± 0.04 mPa/s. Twelve additional non-ionic 
surfactants were screened for possible use in the formulation. Polysorbate 81, with 15 less 
ethylene oxide head groups but equivalent carbon chain length to Polysorbate 80, was identified 
as most promising based on droplet diameter and zeta potential. Thus, this type of multi-drug 
formulation appeared to be tolerable to larger changes in non-ionic surfactant head group than 
hydrocarbon chain length; Hydrophilic-lipophilic balance (HLB), in contrast, appeared to have 
little to no effect. Two additional drug-loaded microemulsion formulations comprised of 3:1 
vi 
Polysorbate 81:Cremophor RH 40 surfactant, Miglyol 812 oil and water in S:O:W ratios of 
40:50:10 and 50:40:10, resulted in droplet diameters of 94 ± 15 nm and 81 ± 2.4 nm, and zeta 
potential values of -17 ± 4 mV and -23 ± 6 mV, respectively after 100x aqueous dilution. All 
final multi-drug loaded MEs demonstrated >70% dissolution improvement of folic acid and 
>90% dissolution improvement of riboflavin in 50 mM phosphate buffer (pH 7.4) as compared
to a commercial prenatal supplement in suspension form. Overall, it was demonstrated that the 
process of TPD mapping, HLD optimization and careful surfactant screening was instrumental 
in the successful development of a multi-drug microemulsion system with the potential to treat 
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Chapter 1: Introduction and Background 
Portions of this chapter are reflective of an original manuscript published by the Ph.D. 
candidate (Shannon P Callender) in the journal International Journal of Pharmaceutics. All 
pertinent dialogue included in this chapter was written by the Ph.D. candidate. Author 
contributions are detailed in the ‘Copyright Permission’ section. 
Callender, SP., Mathews, J.A., Kobernyk, K., Wettig, SD. Microemulsion utility in 
pharmaceuticals: Implications for multi-drug delivery. Int J Pharm 2017; 526: 1-2. doi: 
10.1016/j.ijpharm.2017.05.005.1 
1.1   Nanotechnology Drug Delivery in the 21st Century 
The ‘magic bullet’ approach represents one of the greatest conceptual shifts in drug delivery, 
beginning in the 20th century and progressing rapidly in the 21st century. Drug delivery tools 
affording a specific, targeted approach to abnormal cells or disease-causing entities while 
leaving healthy cells untouched remains the drug delivery gold standard. Nanotechnology 
tools, in particular, have received increased attention and interest from the scientific 
community for their potential as effective magic bullet and bioavailability-enhancing agents, 
due to their small sizes. The term ‘nanotechnology’ in the context of drug delivery often refers 
to systems on the scale of 1-100 nm in length2 though the upper limit may be 200 nm, 300 nm 
or even 1000 nm. Strictly speaking, ‘nano’ technology objects possess sizes in the nanometer 
size range from 1-1000 nanometers. Since the beginning of the nanotechnology revolution in 
the 1980s, a variety of tools have been developed for effective drug delivery purposes.3,4
1.1.1  Current Nanotechnology Drug Delivery Tools 
Liposomes, dendrimers, micelles and nanocrystals are just a few of the nanotechnology tools 
used in the treatment of widespread, chronic diseases such as cancer5 heart disease6 and 
diabetes.7,8 Other common nanotechnology tools include nanoemulsions, nanotubes, magnetic 
nanoparticles and pH-, temperature- or electro- sensitive nanoparticles.9 The potential of these 
nanotechnology tools for controlled drug release, increased stability, low toxicity and of 
course, improved absorption via their small sizes10 renders them invaluable in drug delivery. 
Nanotechnology drug delivery tools generally involve a carrier and active ingredient(s) 




carrier through solubilisation, functionalization or entrapment.11 The addition of proteins, 
polymers and other material to the surface of each nanoparticle may also enhance targeting 
efficiency.9 The amphiphilic nature of many nanotechnology tools such as nanoemulsions, 
liposomes, micelles etc. affords delivery of both hydrophilic and hydrophobic active 
pharmaceutical ingredients (APIs) or drugs.9 
 
1.1.2  Challenges in Drug Delivery 
Nanotechnology tools have the potential to overcome two of the major challenges in drug 
delivery: drug solubility and permeability.9 Poor biopharmaceutical properties, in particular, 
poor water solubility of active ingredients has resulted in the failure of many potentially 
marketable pharmaceutical products.12 The Biopharmaceutics Classification System (BCS) 
adopted by the US Food and Drug Administration (FDA)13 based on the work of Amidon et al. 
(1995)14 classifies orally administered drugs into four classes based on their solubility and 
permeability (Table 1.1). 
 
Table 1.1: Biopharmaceutics classification of drugs based on solubility and permeability. 
Upward arrows indicate high permeability or solubility while downward arrows indicate low 










 A drug is said to demonstrate high permeability when the extent of absorption is greater 
than 90% of the administered drug, and high solubility when the highest marketed dose is 
soluble in 250 mL aqueous media across pH 1.2-7.4, the entire gastrointestinal pH range.14 
Based on these criteria, it is evident that hydrophobic and/or lipophilic drugs exhibit low 
‘solubility’ given their incompatibility with aqueous media. Thus, these drugs are often 
classified as BCS Class II and IV compounds. Given that solubility is an important determinant 
BCS Class Solubility Permeability 
I é é 
II ê é 
III é ê 
IV ê ê 
3 
of drug concentration in systemic circulation, low solubility often results in low bioavailability. 
Therefore, lipophilic compounds face unique drug delivery challenges with respect to 
bioavailability.15 Nanotechnology carriers, in the form of a hydrophilic shell and hydrophobic 
core, afford a unique opportunity to solubilize lipophilic material and may improve 
bioavailability outcomes. The potential of nanotechnology tools in single drug delivery is 
generally well understood, but their potential in multi-drug delivery is more elusive.  
1.1.3  Multi-Drug Delivery 
The life expectancy at birth in Canada has increased substantially over the past century.16 
However, with the increase in life expectancy comes an increase in the burden of concurrent, 
chronic diseases. According to the Public Health Agency of Canada, nearly two thirds of 
Canadians over the age of 20 suffer from chronic illnesses- in particular, hypertension, mental 
illness and arthritis.17 These three chronic diseases tend to occur concurrently with others, 
resulting in multi-morbidity.18-24 Multi-drug therapies present an opportunity for better 
management of these concurrent, chronic diseases, improving patient adherence and reducing 
the burden on health care systems.25 However, despite these advantages, multi-drug therapies 
are often avoided due to formulation complexities.1  In particular, API-API interactions, 
instability and insufficient solubility of drugs of varying hydro- and lipophilicity are of primary 
concern.1  Nanotechnology emulsion systems with their small droplet sizes, oil and water 
composition and thermodynamic stability are well suited for the simultaneous solubilisation 
and delivery both lipophilic and hydrophilic active ingredients. 
1.2   Introduction to Emulsion Systems 
Emulsion technology is utilized in a variety of industries including the cosmetic, agricultural, 
food and of course, pharmaceutical industry.26, 27 Emulsions are metastable colloidal systems 
comprised of particles of one liquid dispersed in another immiscible liquid.28 These two 
immiscible liquids themselves cannot mix and require the presence of emulsifying agents 
(emulsifiers) or surface-active agents (surfactants).28,29 Both terms are used interchangeably in 
this thesis. Surfactants are amphiphilic molecules comprised of a polar, hydrophilic head and 




reduces the overall interfacial tension between the two immiscible phases, promoting 




Figure 1.1: Orientation of surfactant molecules at an oil-water interface. The polar head groups 
of the surfactant orient to face the polar, aqueous phase while the non-polar tail groups of the 
surfactant orient to face the non-polar, organic phase. This type of orientation reduces the 
interfacial tension between the two phases, promoting miscibility. Figure taken from Callender 
et. al. (2017)1 with permission.  
 
 
 There are three main types of emulsion systems: (i) macroemulsions, (ii) 
nanoemulsions and (iii) microemulsions. Each system is similar in composition, consisting of 
oil, water and emulsifying agent. However, they differ with respect to certain characteristics 
such as droplet size, methods of formation/energetics and stability. 
 
1.2.1  Macroemulsions 
Macroemulsions are often referred to as ‘coarse’ or opaque emulsions due to their relatively 
large droplet sizes of more than 400 nm in diameter, which result in a turbid solution. 28 This 
is in contrast to micro- and nanoemulsions, which consist of much smaller droplet sizes and 
slightly turbid to clear solutions.28 
 In general, there are two main types of macroemulsions: oil-in-water (O/W) and water-
in-oil (W/O) emulsions. O/W emulsions consist of oil droplets dispersed in a water continuous 
phase while W/O emulsions consist of water droplets in an oil continuous phase. In O/W 












as the inner, discontinuous phase (and vice versa). The two types of macroemulsions are 
depicted in Figure 1.2 and are often referred to as ‘single’ emulsions.30 Macroemulsions may 
also be prepared as multiple emulsions.   
 
 
Figure 1.2: Schematic representation of a typical W/O (left) and O/W (right) macroemulsion 
system. In a water-in-oil macroemulsion system, water is the inner, discontinuous phase 
dispersed in the outer, oil-continuous phase. The reverse is true for an oil-in-water 
macroemulsion system. Surfactant molecules concentrate at the interface of each emulsion 
droplet and orient themselves so that their polar heads face water while their non-polar tails 
face oil.  Upon increased addition of surfactant, the interface becomes saturated and micelle 
formation begins. O/W systems form ‘normal’ micelles with a hydrophobic core while W/O 
systems form ‘reversed’ micelles with a hydrophilic core. Figure taken from Callender et. al. 
(2017)1 with permission. 
 
 
In particular, there are oil-in-water-in-oil (O/W/O) and water-in-oil-in-water (W/O/W) 
emulsions where the continuous phases are oil and water, respectively. Multiple emulsions are 
often used in delayed or controlled release formulations, as the drug must cross an additional 
phase barrier before it can be released.31 
With respect to formation, macroemulsions require an input of energy usually in the 
form of shaking or stirring in order to deform the aqueous/organic interface and produce 
droplets.30 The energy input required to do this must be the same as or greater than that of the 
Laplace pressure of each droplet, i.e. the differential pressure between the outside and inside 
of a curved surface.30 Smaller droplets are desired for stability purposes and this can require 
significant agitation of the macroemulsion system beyond simply shaking or stirring.30 Because 










interfacial energy involved, macroemulsions are said to be kinetically, and not 
thermodynamically, stable. Thus, over time, a macroemulsion will inevitably revert to its phase 
separated components. Emulsifying agents and the use of strong agitation to introduce energy 
into the system for macroemulsion formation, simply delay this reversion process for a fixed 
amount of time.  
The most concerning stability factor with macroemulsions is their susceptibility to 
coalescence and flocculation. Coalescence is the merging of two droplets into one single larger 
droplet, which eventually leads to phase separation and emulsion ‘breaking’. Flocculation is 
the aggregation of dispersed-phase droplets and can be considered reversible.30 Both processes 
depend on the interfacial film surrounding individual droplets and the elasticity or rigidity of 
this film.28 Given that this interfacial film is comprised of surfactant molecules, it is the 
surfactant properties that dictate the system’s propensity for coalescence. In general, surfactant 
molecules at the interface of each droplet provide an elastic mechanical barrier to droplet-
droplet collision, reducing the overall probability of coalescence. If the head groups are 
charged, as in the case of ionic surfactants, an additional barrier is introduced as these charged 
droplets would repel each other. In the absence of an ionic surfactant, salt may also be added.28 
Temperature and the size range of droplets within the macroemulsion system also affect 
coalescence.28 In general, any factor that disturbs the emulsifier and its resulting interfacial 
film, disrupts stability.  
1.2.2  Nanoemulsions 
Nanoemulsions are commonly referred to as mini-emulsions or ultrafine emulsions. In 
comparison to macroemulsions and microemulsions, nanoemulsions are most similar to 
macroemulsions with the exception of their smaller droplet sizes.  Although size is the main 
differentiating factor between nanoemulsions and macroemulsions, there is much ambiguity in 
the scientific community regarding the exact droplet size range of nanoemulsions. Articles that 
do specify sizes often fail to mention whether they are referring to diameter or radii 
measurements. Contrary to their nomenclature and popular belief, however, nanoemulsions do 
not necessarily contain droplets that are smaller than those found in microemulsions. In fact, 
droplet sizes in nanoemulsions are usually in the mid-size range between that of 




small droplet sizes result in nanoemulsions appearing blue-white to semi-opaque in nature.28 
In terms of types, they are classified according to the same types as macroemulsions; either 
oil-in-water or water-in-oil.  
With respect to formation, nanoemulsions are much like macroemulsions, requiring an 
energy input and agitation of the system for formation. For this reason, many nanoemulsions 
are formed by high-pressure processes such as homogenization. Like macroemulsions, 
nanoemulsions are also kinetically and not thermodynamically stable, meaning that although 
the components can be sufficiently agitated to overcome an energy barrier for formation, the 
system will eventually revert to its original phases. This is due to the fact that the free energies 
of the separate oil and water phases of a nanoemulsion are at a lower energy state than free 
energy of the colloidal dispersion system, creating a thermodynamically unstable system. This 
instability may be overcome by ensuring there is a large enough energy barrier between the 
two phases. The greater the height of the energy barrier between the nanoemulsion and the 
separated phases, the greater the stability of the nanoemulsion.32 The smaller particle sizes of 
nanoemulsions lend improved resistance to coalescence compared to macroemulsions. 
Therefore, the reversion process is quite slow and some nanoemulsion formulations can 
therefore remain stable for months and even years. 
Content-wise, nanoemulsions are found to generally require less emulsifier than macro 
or microemulsions, typically on the order of 1-3% of the volume of the oil phase.28 The length 
of the co-surfactant (defined in Section 1.3) required is also found to be longer than that of 
microemulsions (at least 12 carbons as compared to the much shorter chain lengths required 
for microemulsions).28 
 
1.2.3  Microemulsions 
Microemulsions gained recognition in 1943 after Hoar and Schulman mixed a milky solution 
with hexanol to produce a uniform single-phase, non-conducting solution.33 The first 
commercial application of microemulsions was in the formulation of liquid waxes, discovered 
by Rodawald in 1928.27 By 1970, microemulsion research peaked, in part due to its application 
in enhanced oil recovery34 where the use of surfactants combined with the ultralow interfacial 




thermodynamically stable mixtures of oil and water stabilized by emulsifiers. They possess 
very different properties from nano- and macroemulsions.  
Contrary to their terminology, microemulsions consist of the smallest droplet sizes 
found in emulsion systems. Specifically, microemulsion droplet sizes generally range from 10 
to 100 nm in diameter.28,32 According to Eriksson, Ljunggren, Kegel and Lekkerkerker (2001), 
one of the most important factors influencing droplet size is the packing density of surfactant 
molecules in the interfacial film.35 This curvature and compressibility of the interfacial film 
then dictates the interfacial tension35 and contribution to overall free energy. In particular, the 
more rigid the film, the higher the packing density and the smaller the droplet size.36  
 
Figure 1.3. Schematic of the effect of temperature (T) or salinity (S) and surfactant 
concentration on microemulsion type. Spherical structures represent the microemulsion phase, 
yellow regions represent oil and blue regions represent water.  Figure taken from Callender et. 
al. (2017)1 with permission. 
 
 
 According to Winsor (1948)37 there are four types of microemulsions: (i) Type I- 
biphasic with an upper excess oil phase and lower O/W microemulsion, (ii) Type II- biphasic 
with an upper W/O microemulsion and lower excess water phase, (iii) Type III- triphasic with 
upper excess oil phase, middle bicontinuous microemulsion and lower excess water phase, (iv) 
Type IV- monophasic, single microemulsion phase. Each type can be obtained given different 
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in   Figure 1.3,   typically   referred   to   as   a   fish  diagram.  A  simple change  in temperature, 
T, in the case of a non-ionic surfactant or salinity, S, in the case of an ionic surfactant can result 
in transition from a Type Ià IIIà II microemulsion. An increase in surfactant concentration 
can also result in the effective solubilization of excess oil or water phases, inducing a transition 
from any of these microemulsion types to a Type IV microemulsion within temperature and 
salinity constraints. The rationale behind these trends is explained in Section 1.5.2. 
 
 
Figure 1.4: Schematic of the various micellar aggregates possible depending on the ratio of 
water, surfactant and oil utilized. As the water content decreases, structures shift from 
‘normal’, spherical micelles to inverted micelles. As the concentration of surfactant increases, 
micelles can be seen to aggregate into cubic, lamellar, hexagonal and finally, liquid crystalline 
structures. Adapted from Brinker (1999).38 Figure taken from Callender et. al. (2017)1 with 
permission. 
 
Each type of microemulsion differs in structural composition. Micellar, rod-like, lamellar and 
sponge-like structures are all possible depending on the composition of oil, water and 
surfactant.32 Figure 1.4 displays the various structural arrangements that can be obtained   
depending   on   the   concentration   of   oil,   water   and   surfactant   utilized.  In contrast  to 
10 
nanoemulsions, microemulsions usually require a higher percentage of surfactant or emulsifier 
(i.e., 15-30% w/w of the oil phase) for formation.28 Additionally, the co-surfactant required is 
usually of a shorter carbon chain length than that required in nanoemulsions.28 
With respect to formation and energetics, microemulsions possess an energy profile 
opposite to that of macro- and nanoemulsions. In a microemulsion system, little to no energy 
input is required for formation. This is due to the fact that the oil and water starting components 
are at a higher energetic state than that of the final microemulsion product. Thus, 
microemulsion formation is a forward-driven process and formation occurs spontaneously with 
little to no energy input required. These systems are considered thermodynamically stable; 
rather than energy being required for microemulsion formation, energy is required for 
microemulsion dissociation and phase separation. Figure 1.5 illustrates the energetic profile 
of microemulsions. 
Figure 1.5: Schematic of the energetics involved in a typical microemulsion system (*ΔG= 
activation energy). The microemulsion product is at a lower energy state than that of its 
separated phases or starting components, resulting in thermodynamic stability. Nanoemulsions 
and macroemulsions have the reverse profile with the emulsified systems at a higher energy 
state that the starting components, resulting in kinetic stability. Adapted from McClements 
(2012).32 Figure taken from Callender et. al. (2017)1 with permission. 
1.2.3.1 Advantages of Microemulsion Systems 
Microemulsions are uniquely equipped for drug delivery. Specifically, microemulsions are 
able to: i) present active pharmaceutical ingredients (APIs) in liquid form, ii) improve 








and lipophilic drugs, simultaneously and (iv) form spontaneously with relatively simple 
starting ingredients. 
i) Presentation of Active Ingredients in Liquid Form
It is generally well established that drugs in solid form must undergo an extra dissolution step 
before they can be absorbed. There are three main processes necessary for solid drug 
absorption for oral delivery: a) disintegration, b) dissolution and c) absorption.39 Disintegration 
is necessary in order for the solid particles to dissolve in liquid media before being absorbed.39 
Microemulsions are liquid in nature and thus, are able to bypass this additional disintegration 
step.39 The overall result is that microemulsions, and liquids in general, experience faster drug 
absorption rates independent of any effect of disintegration.39 In the context of drug 
formulations, this is beneficial for fast-acting relief purposes. Though liquid formulations are 
often encapsulated in solid dosage forms such as gelatin capsules, dissolution of a solid capsule 
containing drugs in liquid form is still faster than dissolution of a solid capsule containing 
drugs in solid form.39 
The presence of drug in liquid form is also advantageous in terms of transit time.40 While 
liquids may take 20-30 minutes to pass completely through the stomach, solids may take up to 
3 hours depending on the composition.40 These solids remain in the stomach for a longer period 
of time and are thus, exposed to gastrointestinal enzymatic degradation for longer periods of 
time.41 This may greatly affect drug stability and cause premature drug degradation.41 
ii) Small Droplet Sizes
As introduced above, microemulsions generally possess droplet sizes in the diameter range 10-
100 nm.28,32  These small droplet sizes increase the surface area to volume ratio for drug 
absorption leading to improved bioavailability.42-45 Additionally, these small droplet sizes are 
able to resist gravitational sedimentation and enhance the stability of the microemulsion 
system. The factors influencing droplet sizes in microemulsion systems generally include the 
type of surfactant used, surfactant chain length, the alkyl chain length of the oil, and the rigidity 
of the resulting interfacial film. These factors are discussed in Section 1.3. Many studies 
conducted in a five-year period between 2011-2016, have credited the small droplet sizes of 




particular, microemulsions have improved the stability and bioavailability of Aprepitant, a 
chemotherapy-induced nausea and vomiting preventor46, Troxerutin, a hydrophilic 
vasoprotector47, Fenofibrate, a cholesterol-lowering agent48, Pranlukast Hemihydrate, an 
asthma-treating agent49, Leuprorelin, a hormone-related disorder treatment drug50, Ritonavir, 
an HIV anti-retroviral51, Sirolimus, an  immune-suppressant52 and Gatifloxacin, an antibiotic53.  
Figure 1.6 depicts the various pathologies treated using microemulsion systems based on 
publications in the PubMed database from 2011-2016.1 
 
 
Figure 1.6: Graphic depicting the various pathologies treated by microemulsion systems over 
a period of five years. Cancer, inflammatory diseases, neurological disorders and 
cardiovascular diseases are amongst the leading pathologies treated by single drug, 
microemulsion systems. These diseases typically occur concurrently with a wide variety of 
other illnesses. Image taken from Callender et. al. (2017)1 with permission. 
Not only have microemulsions been used for the treatment of numerous pathologies, their 
small droplet sizes also afford delivery via a wide range of administration routes including 
oral, topical, parenteral and intranasal. Figure 1.7 depicts the various routes of administration 






























































































































































Figure 1.7: Microemulsion drug delivery publications by route of administration. Most 
microemulsion formulations contain non-ionic surfactants (discussed further in Section 1.3) 
which are generally regarded as the safest type of surfactant for ingestion purposes. Hence, 
most microemulsions are delivered via the oral route. The small droplet sizes of 
microemulsions also allow for favourable penetration in topical and parenteral delivery, as well 
as pulmonary and intranasal delivery to a lesser extent. Figure taken from Callender et. al. 
(2017)1 with permission. 
iii) Solubilization & Simultaneous Delivery of Hydrophilic and Hydrophobic Drugs
Another major advantage of microemulsion systems is their ability to solubilize poorly water-
soluble drugs (PWSDs). More than 40% of drugs in the development phase fail to reach the 
market due to poor biopharmaceutical properties, including poor water solubility.12,54,55 PWSDs 
often experience unfavourable dissolution profiles in vivo leading to dissolution being the rate-
limiting step with respect to absorption.56-59 Microemulsions are also able to solubilize 
hydrophilic APIs given the presence of both a hydrophilic and hydrophobic phase. Thus, the 
incorporation and delivery of both hydrophilic and hydrophobic APIs, separately and 

















































































well suited for lipophilic drug delivery while water-in-oil microemulsions are well suited for 
hydrophilic drug delivery. Bicontinuous microemulsions of the Type IV Winsor type are well 
suited to the delivery of both hydrophilic and hydrophobic drugs, simultaneously.  
 There is an increasing need for multi-drug therapies given the rapidly aging Canadian 
population and the growing burden of chronic diseases that tend to occur concurrently.17 In 
addition, the low patient adherence to concurrent disease treatments due to pill burden, 
exacerbates the already large burden on the health care system.25 Thus, the area of combination 
therapies represents an unfulfilled need that microemulsions may resolve. 
However, despite the substantial need for multi-drug therapies in Canada and the potential of 
microemulsion systems for multi-drug delivery, little research in this area has been performed 
to date. In a five-year period from 2011-2016 (Figure 1.8), microemulsions were 
predominantly formulated for use in single drug delivery as indicated by over 95% of 
publications in this period. In contrast, microemulsions formulated for multi-drug therapy 
purposes accounted for under 5% of publications published in this period. Many of the 
microemulsions formulated for use in multi-drug delivery consisted of active ingredients of 
the same degree of hydro- or lipophilicity.1 In addition, the most common type of 
microemulsion formulated was Type I, O/W microemulsions due to the predominant delivery 
of lipophilic active ingredients in comparison to that of hydrophilic active ingredients.1  Table 
1.2, below, displays a list of microemulsion, multi-drug formulations that have been researched 
and published between 2011-2016. 
 
iv) Spontaneous Formation and Simple Starting Ingredients 
The ability of microemulsions to form spontaneously32,60 due to the ingredients being driven to 
an energy state favourable for microemulsion formation32,45,61-64 results in an economical 
formation process. This means that in many cases, a high degree of energy is not required for 
microemulsion formation, unlike in the case of nano- and macroemulsions, resulting in a cost-
effective production method. Additionally, the simplicity of the components comprising 
microemulsion systems renders them suitable for drug delivery of almost every type. 




Figure 1.8: The distribution of research involving single and multi-drug microemulsion 
formulations published in peer-reviewed journals between 2011-2016. Due to their complex 
nature, multi-drug formulations are rare, comprising a mere 4.6% of total publications in this 
period. Figure taken from Callender et. al. (2017)1 with permission. 
1.2.3.2 Disadvantages of Microemulsion Systems 
Although microemulsions possess a number of advantages, their complex nature does not 
always make them a viable option for drug delivery. The presence of both an organic and 
aqueous phase allows for the delivery of both hydrophobic and hydrophilic APIs; however, 
this becomes problematic when dealing with APIs that do not fall into either category. In the 
case of prenatal supplements, minerals are a prime example of this. Minerals, metals and other 
compounds that do not fall into either of these categories, once added to a microemulsion 
system, would likely result in a suspension. In cases like this, a solid dosage form such as a 
tablet is likely a better option. Thus, microemulsion systems may not always be a favourable 
method of delivery for complex ingredients. It is also important to remember that in the case 











































Table 1.2: Publications regarding microemulsion, multi-drug delivery Jan 2011- April 2016.  The majority of these publications 
involved type I oil-in-water microemulsion drug delivery systems. Table taken from Callender et. al. (2017)1 with permission. 
APIs Function Formulation Ingredients Microemulsion 
Type 
Observations Ref. 
• Honokiol (p-gp inhibitor) 
• Sirolimus (p-gp substrate) 
Immunosuppressant Cremophor® EL (emulsifier), 
Propylene glycol (co-emulsifier) 
and Medium chain triglycerides 
(MCT) [9:2:9 w/w/w] 
I (SMEDDS) Improved oral absorption 
and transport of sirolimus 
65 
• Curcumin  
• Silibinin (UGT-mediated 
      clearance inhibitor) 
Antioxidant 
Antiinflammatory 
Cremophor® EL (emulsifier) and 
Carbitol™in 2:1 w/w with 
Captex®355 as oil (10:1 w/w 
surfactants to oil) 
I (SMEDDS) Improved curcumin 
bioavailability in vivo 
66 
• Curcumin  
• Piperine (clearance inhibitor) 
Antioxidant 
Antiinflammatory 
Cremophor® RH40 (emulsifier), 
Transcutol® HP (co-emulsifier), 
Capryol™ 90 (oil) 
I (SMEDDS) Improved local 
concentration of curcumin in 
colonic lesion site 
67 
• Simvastatin  
• Phytosterols (reduce cholesterol 
absorption) 
Statin Sucrose ester (surfactant) an 1,2-
propanediol (co-surfactant) [2:1 
w/w] and oleyl lactate as oil (9:1 







Favourable solubilization for 
both compounds in 1,2-
propanediol + nonionic + 
anionic surfactant  
68 
• Atorvastatin 
• Ezetimibe (inhibits cholesterol 
uptake) 
Statin Tween® 80 (surfactant), PEG 600 
(co-surfactant) [5:1 w/w], ethyl 
oleate as oil  (4:1 w/w surfactants 
to oil) 
I (SMEDDS) Higher bioavailability and 
faster dispersion 
69 
• Lycopene  





glycol (1:1 w/w surfactant blend) 
and monocaprylin as oil 
I or III Additive rather than 
synergistic effect observed; 







choice increased cutaneous 
delivery 
• Rifampicin  
• Isoniazid 
• Pyrazinamide 
Anti-tuberculosis Brij® 96 (surfactant), butanol (co-
surfacatant), ethyl oleate as oil 
[1.2:2 oil to surfactant w/w] 
I Rifampicin (lipophilic) 
localized near to oil 
interface; Isoniazid and 
pyrazinamide (hydrophilic) 






Tween® 80 (surfactant), ethanol 
(co-surfactant), eucalyptus oil 
and water [30:30:20:20 w/w, 
respectively] 





Cremophor® EL (emulsifier), 










Anesthetic Tween® 80 (surfactant), ethanol 
(co-surfactant), saturated lipids 
(Labrasol® and Lauroglycol™ 90); 
isopropyl myristate as oil; water 
and API mix [30%:5%:60%:5%, 
respectively] 




• Betamethasone dipropionate 




Tween® 20 (surfactant), 
isopropyl alcohol (co-surfactant); 
oleic acid and sefsol (1:1) as oil 
and water. 
[Surfactant mix (1:1): oil: water 
38:15:47] 
I Enhanced permeation, 
reduced dosage frequency, 




• Green tea catechins 
• Caffeine 
Antimicrobial Cremophor® EL (emulsifier), 
glycerol (co-emulsifier) [6:1 
w/w] and Labrasol as oil 








Cremophor® RH40 (surfactant): 
Labrasol® (surfactant):  
Transcutol® HP (cosurfactant):  
Capryol™90 (co-surfactant):   
Isopropyl myristate (oil) 
(2:2:6:1:1) 
I (SMEDDS) Increased inhibitory effect 
on human cervical HeLa 
cells 
77 
• Coix seed oil 
• Etoposide 






Cremophor® RH40 (surfactant); 
PEG 400 (co-surfactant); Coix 
seed oil (oil) 
I Enhanced cytotoxicity 
against A549 cells; 
promoted significant 
internalization of etoposide 
78 
• Huperzine A 
• Ligustrazine 
Acetylcholine 




Cremophor® RH40 (surfactant), 
ethanol (co-surfactant), oleic acid 
(OA), water [12:4:1:80 
w/w/w/w] 
I Demonstrated slowed 
progression of Alzheimer’s 
disease in rats 
79 





Tween® 80 (surfactant), ethanol 
(co-surfactant), DHA:Capmul 
1:1 (oil), water 
[surfactant:oil:water 60:30:10 
w/w/w) 
I Enhanced intranasal delivery 
when formulated with DHA 
(docosahexaenoic acid) 
80 
• Bovine serum albumin 




Pluronic F127 (surfactant); 
monoglyceride, polyglycerol 
ester, and tetradecane as oil mix 




As a result, the extent of solubilization is limited by the volume of phase available. This could 
prove to be a limiting factor depending on the amount of API required for delivery.  
 Microemulsions also require the presence of emulsifiers at a slightly higher 
concentration than their nanoemulsion counterparts.32 Some emulsifiers demonstrate toxicity 
(Section 1.3.5), and as a result are heavily regulated. This reduces the list of available 
surfactants for use in oral formulations. Those surfactants that are considered acceptable are 
only acceptable at certain concentrations. This rule also applies to oils. Finally, microemulsions 
are sensitive to temperature and salinity changes and may undergo phase changes when 
exposed to higher or lower than normal temperatures or salinity concentrations. This could 
lead to ‘breaking’ of the microemulsion and eventually, phase separation. It is thus, important 
to identify the temperature and salinity boundaries of the microemulsion system during the 
formulation stage. 
 
1.2.4  Self-emulsifying Drug Delivery Systems (SEDDS) 
SEDDS are a specialized category of emulsions. SEDDS are isotropic mixtures of oil, 
surfactant and sometimes co-solvent that are able to self-emulsify upon mild agitation and 
dilution with aqueous media to form O/W emulsions. These fine oil/water dispersions are able 
to spread throughout the gastrointestinal (GI) tract, as the digestive system provides the 
agitation needed for the microemulsion to form.82 SEDDS may be microemulsions (referred to 
as self-microemulsifying drug delivery systems- SMEDDS) or nanoemulsions (self-
nanoemulsifying drug delivery systems- SNEDDS).  
 According to the lipid formulation classification system (LFCS), SEDDS consisting of 
water-insoluble surfactants and oil are regarded as Type II LFCS formulations while those with 
oil, surfactant and a co-solvent are regarded as Type III LFCS formulations with optical clarity 
and smaller droplet sizes.82 SEDDS, particularly of the oil-in-water type, are a common 
emulsion formulation of choice for drug delivery, as demonstrated below in Figure 1.9.1 
 Macro-, nano- and microemulsions possess a variety of different properties, which are 
suitable for various applications. Figure 1.10 below summarizes the differences discussed in 






Figure 1.9: Types of microemulsion systems utilized in drug delivery from 2011-2016. Due 
to the fact that most new chemical entities are lipophilic, oil-in-water microemulsions 
comprised over 50% of publications in this period. Microemulsion systems have also been 




1.3   The Role of Surfactants in Microemulsion Systems 
As noted earlier, surfactants and/or emulsifying agents are essential components of any 
emulsion system. At a simple organic-aqueous interface, there is a difference in the potential 
energies between the molecules in the bulk liquid and those lying at the interface. Molecules 
lying at the interface possess higher potential energies as a result of their interactions not only 
with molecules of their respective phases, but also with molecules of the opposing liquid across 
the interface.28 This increase in potential energies represents the minimum work required to 
form the interface, or the interfacial tension. Upon addition of an amphiphilic emulsifying  
agent  or  surfactant,  the hydrophilic portions of the molecule orient themselves with the 
molecules of the aqueous phase (and vice versa for hydrophobic portions with the organic  
phase).  This  results  in  stronger  interaction  energies  between the  amphiphile and respective 











































































tension is reduced, promoting miscibility. Without a surfactant, it would be impossible to 
sufficiently stabilize such a system. 
 
Figure 1.10: Types and typical droplet diameter sizes of macro-, nano- and microemulsions. 




Where very low interfacial tensions are desired, co-surfactants may be added. Co-
surfactants act in consort with surfactants to further reduce interfacial tension and introduce an 
element of flexibility into the interfacial film. This allows the system to adapt a wider variety 
of curvature values across a wider range of conditions for droplet formation.83 Medium chain 
alcohols (8-12 carbons in length) or oils such as ethyl esters of fatty acids are often used as co-
surfactants as they reduce interfacial tension as well as introduce flexibility into the interfacial 
film.83 Co-surfactants can also have additional effects on an emulsion system. They can change 




Type of Stability 
Macroemulsion O/W and W/O >400 nm Yes Kinetic 
Nanoemulsion O/W and W/O 100-400 nm Yes Kinetic 
Microemulsion Type I: biphasic O/W;  
Type II: biphasic W/O;  
Type III: triphasic 
bicontinuous 
Type IV: monophasic  
10-100 nm No Thermodynamic 
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surfactant-partitioning characteristics, adjusting a parameter called the hydrophilic-lipophilic 
balance (HLB) (explained in Section 1.3.2), which can dictate the type of emulsion formed.83 
Co-surfactants can also curb the formation of gel-like and crystalline phases that inhibit 
emulsion formation and act to decrease sensitivity to fluctuations in structure.83 
Surfactants and co-surfactants are typically selected based on the type of emulsion desired, 
as the type of emulsion formed depends heavily on the type of emulsifier used.28 According to 
the well-established Bancroft rule (1913), O/W emulsions are produced by emulsifiers that are 
more soluble in water than oil while W/O emulsions are produced by emulsifiers that are more 
soluble in oil than water.84 In other words, the continuous phase of any emulsion is dictated by 
the phase in which the emulsifier is most soluble. This rule is counterintuitive, as emulsion 
formation can often be thought to depend on the relative volumes of oil to water. In addition 
to the Bancroft rule, several additional theories have been suggested for emulsion formation. 
Qualitative theories generally involve consideration of the interactions, i.e. interfacial tension 
and contact angles, between each immiscible phase and the emulsifier. Kinetic theories like 
those proposed by Davies (1957)85, as described by Rosen and Kunjappu (2012)28, rely on the 
rate of coalescence of each immiscible phase; the phase with a faster coalescence rate becomes 
the continuous phase of the macroemulsion. Regardless of the theory of emulsion formation 
proposed, the type of emulsifier plays a key role in the formation of any emulsion system.  
1.3.1  Types of Surfactants 
Surfactants may be categorized into four broad classes based on the nature of the hydrophilic 
head group. Table 1.3 below describes each class of surfactant, the nature of the head group 
as well as examples of each.86
Though there are benefits to each surfactant class, non-ionics are most commonly used 
in drug delivery applications regardless of the route of administration. Non-ionic surfactants 
do  not  possess  charged  head  groups like their ionic or zwitterionic/amphoteric counterparts.  
This affords them a lower critical micelle concentration  (the  concentration  at which  micelles 
form  and  thus,  can  solubilize  active ingredients- Section 1.3.4) than their ionic counterparts 
due to an absence of electrostatic repulsion between head groups.87, 88 Thus, these surfactants 









classes.86 In addition, they are known to have a better oral safety profile than ionic surfactants89-
93 and many are generally recognized as safe (GRAS) by the FDA for ingestion (Section 1.3.5). 
These advantages often result in non-ionics being preferred for use in pharmaceutical 
formulations. Anionic surfactants are slightly more toxic than non-ionics and thus, less 
common in pharmaceutical formulations while cationic surfactants are rarely used due to their 
high toxicity profiles.91, 94 Near the isoelectric point, zwitterionic surfactants may possess a 
neutral net charge, leading them to behave in a similar fashion to non-ionic surfactants.86 
Figure 1.11 depicts the distribution of surfactant class in microemulsion drug formulations 
from 2011-2016.  
 As seen below, non-ionic surfactants dominated almost 90% of the microemulsion 
formulation research between 2011-2016, likely due to their uncharged nature, insensitivity to 
salt/pH changes and favourable safety profile. Amphoteric surfactants (mainly natural oils such 
as lecithins and phospholipids) were the second most popular choice comprising almost 7%, 
likely due to their neutrality attributed to the cancellation of charges near the isoelectric point. 
Cationic surfactants are considered the most toxic of all the classes due to their positive 
charges, which interfere with the negative cell membranes of mammalian cells (Section 1.3.5). 
This explains their low occurrence in many microemulsion formulations. 
Type of 
Surfactant 
Nature of Head Group Examples 
Anionic Negatively-charged  Carboxyls,  Sulphates, 
Sulphonates, Phosphates 
Cationic Positively-charged Quaternary Ammonium 
Bromides 
Non-ionic Neutral Polyoxyethylenes (POEs), R-
polyol groups including 
sugars e.g. Tweens, Spans 
Zwitterionic/ 
Amphoteric 
Both negative and positive charges 
present/  
Either negative or positive based on 
environmental conditions such as pH 
Sulfo-betaines 
24 
Figure 1.11: Classes of surfactants utilized in microemulsion formulations between 2011-
2016. Figure taken from Callender et. al. (2017)1 with permission. 
1.3.2  The Role of Hydrophilic-Lipophilic Balance (HLB) 
Hydrophilic-lipophilic balance (HLB) is a surfactant parameter proposed by Griffin in 1949 
that relates the structure of a surfactant to its emulsification potential.95 The proportion of the 
amphiphilic hydrophilic group to that of the hydrophobic group is classified quantitatively 
resulting in an arbitrary scale of 0-20 where a HLB value <10 indicates surfactant 
hydrophobicity and >10 indicates surfactant hydrophilicity.95 Over the past few decades, HLB 
has become quite standard in the surfactant field and few commercial surfactants are shipped 
today without an HLB number on the label. The general equation for HLB96 is:  
!"# = 7 + ∑(ℎ*+,-.ℎ/0/1	3,-4.	54678,9)–	∑(ℎ*+,-.ℎ-7/1	3,-4.	54678,9)(Eq1.1)
From the equation above, it can be seen that a high HLB corresponds to a higher degree of 
hydrophilic groups while a low HLB corresponds to a lower degree of hydrophilic groups. 
Thus, a high HLB number corresponds to a hydrophilic surfactant, and tendency to form O/W 
emulsions or normal micelles while a low HLB number corresponds to a hydrophobic 
surfactant and tendency to form W/O emulsions or reverse micelles. Given that HLB is a 
7.0% Amphoteric
0.2%  Catanionic
2.5 %  Anionic
0.6 %  Cationic
89.7 %  Non ionic
              Class of Surfactant Utilized in Microemulsion




summative parameter, and that it depends on the relative proportion of hydrophilic groups to 
hydrophobic ones, it can be seen that the introduction of co-surfactants or linkers into the 
emulsion system can affect the HLB value. For formulators, the Bancroft rule combined with 
the HLB number can be used to obtain the desired emulsion system for drug delivery purposes. 
For example, if delivery of a lipophilic drug is desired, it is best to solubilize the lipophilic 
drug in an oily micellar core. Thus, an oil-in-water emulsion system would be most suitable 
and thus, a surfactant with a high HLB can be chosen.   
 Although HLB is arguably one of the most important surfactant parameters for 
formulators, two additional surfactant parameters to consider are the efficiency and 
effectiveness in the formulation in which the surfactant is meant to be active. Efficiency in the 
context of emulsifiers is the concentration required to reduce the interfacial tension by 20 
mN/m. Effectiveness is the maximum reduction in interfacial tension that a surfactant can 
achieve at a particular concentration. A more effective surfactant is one that lowers the 
interfacial tension to a greater extent than another. Surfactant efficiency can be improved by 
increasing the number of carbon atoms in a straight-chain hydrophobic group or through the 
addition of a fluorocarbon.28 Branching within the surfactant or the addition of a phenyl group 
decreases efficiency.28 Effectiveness can be controlled through the ionic strength of a solution 
for ionic surfactants, or via the hydrophobic tail for polyethoxylated non-ionic surfactants.28 
 
1.3.3  The Critical Packing Parameter (CPP) 
The critical packing parameter (CPP) is a quantitative parameter that predicts the degree of 
surfactant packing at an interface or in the bulk (aqueous) solution.97 The degree of packing is 
a function of surfactant structure and greatly influences the type of microemulsion obtained. 
The equation for CPP is shown below. Table 1.4 also depicts expected aggregate structures in 
relation to surfactant CPP, taken from Myers (2005).96,97 
 
                                                  <== = 	 !"#                                                                     (Eq. 1.2) 
 
where CPP = critical packing parameter (dimensionless parameter) 
   V = volume of the hydrophobic portion of the surfactant molecule  
    a = area of the surfactant head group 




 Surfactants with large head groups tend to form spherical micelles of the O/W type 
(CPP <0.33) while those with large tail groups tend to form inverse micelles of the W/O type 
(CPP >1). Surfactants with head and tail groups of relatively equal size demonstrate similar 
volumes and a × l values resulting in a CPP of close to 1, and the formation of bilayer 
structures.96,97 Thus, in addition to surfactant concentration (depicted earlier in Figure 1.4), 
surfactant molecular geometry also plays an important role in the type of aggregates expected. 
 





Recent work by Rodriguez-Abreu (2019) has linked the packing parameter to HLB.98 
Generally, with nonionic, polyethoxylated surfactants, spherical structures were favoured at 
high HLB values, cylindrical structures at intermediate HLB values and bilayers at low HLB 
values. 98 With respect to morphological transitions, the HLB required for a transition from 
bilayers to cylindrical structures (CPP 1 to 0.5) is approximately in the range of 10-15. In 
addition, the HLB required for further transition from cylindrical structures to spherical (CPP 
0.5 to 0.33) is approximately in the range of HLB 12-17.  With respect to the effect of surfactant 
concentration, the HLB required for the transition from bilayer to cylinder to spherical 




Expected Aggregates General Surfactant Description 




Single chain surfactants with small head groups; 
ionic surfactants in presence of high amounts of 
electrolyte 
0.5-1 Vesicles  Bilayer structures 
Double chain surfactants with large head groups 
and flexible chains 
1 Planar Bilayer structures 
Double chain surfactants with small head groups 
or rigid chains 




1.3.4  The Critical Micelle Concentration (CMC) 
Critical micelle concentration (CMC) is the concentration of amphiphile at which micellar 
aggregates form.97 At an organic-aqueous interface, upon addition of amphiphilic species, these 
species concentrate at the interface with their polar heads oriented towards water and their non-
polar tails oriented towards oil. However, upon continual addition of amphiphile, the interface 
becomes saturated such that additional amphiphiles organize themselves into spherical 
structures called micelles. Thus, at and above the CMC, micellar aggregates are assumed to be 
the predominant structure.97 If a hydrophilic surfactant is used, O/W micelles are formed with 
a polar ‘shell’ and non-polar ‘core’. If a hydrophobic surfactant is used, W/O micelles are 
formed with a non-polar shell and polar core.   
 Micelle formation follows two possible models: i) Mass action model where surfactant 
monomers and micelles are assumed to be in equilibrium and ii) phase separation model where 
micelles are considered to constitute a new, separate phase at and above CMC. Given the 
variation in thermodynamic models of micelle formation, there are many methods to determine 
CMC.97 Conductivity, dynamic light scattering, fluorescence and tensiometry are just a few of 
these methods, but each method makes certain assumptions. Thus, absolute experimental CMC 
values may vary greatly depending on the method, even by an order of magnitude.97 Therefore, 
in systems containing low surfactant concentrations, one would ideally conduct surface tension 
measurements using a variety of methods in order to ensure use above the CMC. This is, 
however, not a concern in microemulsion systems due to the relatively high surfactant 
concentrations utilized. Many factors such as the hydrophilic group, hydrophobic group, 
counterion effects in the case of ionic surfactants and other external factors affect CMC.97 In 
general, greater hydrophobicity either through extension of the alkyl chain or reduction of the 
size of the polyoxyethylene (PEO) head groups in non-ionic surfactants, causes a reduction in 
CMC.97 Consequently, an increase in hydrophilicity increases CMC.97 
 Tensiometry is one particular method of measuring CMC. Increasing amounts of 
surfactant are titrated into an aqueous solution and the tension at the surface is measured using 
a ring or plate.  As surfactant is continuously added to the aqueous solution, a steady decrease 
in surface tension is seen until the surface becomes saturated with surfactant. At this point, 
additional surfactant molecules begin to arrange themselves into micelles and the decrease in 




concentration. On a semi-logarithmic plot of surface tension versus surfactant concentration, a 
linear decrease in surface tension is seen followed by a plateau or negligible further decrease 
in surface tension. The intersection of these two lines is identifiable as the CMC. Aggregation 
number, i.e. the number of surfactant monomers comprising each micellar structure, affects 
this curve as the larger the aggregation number, the sharper the transition from monomers to 
micelles.97 The critical micelle concentration of mixed surfactant systems may also be 
determined in this manner.  
 In microemulsion systems, more than one surfactant is often used for HLB 
modification, stability or flexibility purposes in the case of co-surfactants.1 With respect to 
mixed surfactant systems, the expected or ‘ideal’ CMC of a surfactant mixture is obtained with 
consideration of the mole fraction of each individual surfactant:99 
 




)*),                                                         (Eq. 1.3) 
  
 
                    where a= the mole fraction of surfactant 1  
                    cmc1= critical micelle concentration of surfactant 1 
                    cmc2= critical micelle concentration of surfactant 2 
 
 
If the ideal CMC is lower than that of the individual CMCs of surfactant 1 and 2, the mixture 
is considered favourable and synergistic in nature. If the ideal CMC is higher than that of the 
individual CMCs of each surfactant, the surfactant mixture is considered unfavourable and 
antagonistic in nature. Synergistic surfactant mixtures afford a lower CMC and thus, a lower 
amount of surfactant becomes necessary in the pharmaceutical formulation. Considering the 
variation in absolute CMC values obtained through different experimental methods, the 
comparison of individual surfactant CMC values with that of the respective surfactant mixture 
are of greater importance than the absolute CMC values themselves. 
 
1.3.5  Safety Considerations for Surfactant Use 
Safety considerations for surfactant use in pharmaceutical products depend largely on the type 
of surfactant used. In general, charged surfactants such as anionics, cationics and to a lesser 
extent, zwitterionics, tend to exhibit greater toxicity than their uncharged, non-ionic surfactant 
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counterparts.100 Charged surfactants are more able to interact with structural components of the 
cell membrane including proteins and lipids, causing disruption in their structural integrity.100 
Though non-ionics are also able to interact with structural components of the cell membrane 
through associations such as hydrophobic interactions, these interactions are generally weaker 
than charge-charge interactions.100 Solubilization of cell membrane components is also 
possible depending on the detergent-protein or detergent-lipid w/v% ratio.100 It has been noted 
that the w/v% required for 90% solubilisation of membrane protein is lower for charged species 
than uncharged species, e.g. 0.9% for sodium dodecyl sulphate (SDS), an anionic surfactant 
versus 5% for Triton X-100, a non-ionic surfactant.100  
In terms of absorption, non-ionic alkyl polyoxyethylene esters reported rapid and 
extensive gastrointestinal absorption of approximately 75%.100 Cationics, particularly 
cetyltriammonium bromide (CTAB), reported up to 80% gastrointestinal absorption after 8 
hours while anionics of the linear alkyl benzene sulphonates type reported 60% recovery after 
intraperitoneal injection.100 With respect to metabolism, it has been reported that the ester link 
of non-ionic Polysorbate surfactants is easily degraded by intestinal lipase while the 
polyoxyethylene groups are not well absorbed and are mostly excreted.100 Cationics and 
anionics were found to have slower metabolism rates100, prolonging their effects in the body. 
The United States Food and Drug Administration (US FDA) provides useful guidelines 
for surfactant use in pharmaceuticals based on previously approved drug products. These 
guidelines are available through their Inactive Ingredient (IIG) Database101, which lists the 
names, amounts and GRAS (generally recognized as safe) statuses of surfactants used in FDA-
approved drug delivery formulations. Routes of administration as well as dosage forms are also 
listed. These are used as effective guidelines for acceptable surfactant amounts in drug delivery 
formulations. It is interesting to note that with respect to oral drug delivery, charged surfactants 
such as anionics and cationics are virtually non-existent in the IIG database. Instead, these 
types of surfactants are mostly listed in detergents and shampoos.  
1.4   Oral Drug Delivery 
Oral drug delivery is often preferred over parenteral routes of administration due to its non-
invasive nature, therapeutic efficiency and ease of administration, which result in high patient 
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compliance.102-104 The cost-effectiveness, low sterility demand, ease of production and variety 
of available dosage forms lend further support to this type of drug delivery.102,104  
The process of oral drug delivery varies based on pharmaceutical properties such as the 
type of drug or dosage form, and physiological conditions such as gastrointestinal transit time, 
pH, enzyme activity and microflora.102 However, in general, the process of oral drug delivery 
begins in the mouth where mucus, enzymes and saliva (pH 6.2-7.6) act to moisten and even 
disintegrate the dosage form, depending on its composition.102,105 The dosage form leaves the 
mouth and transits the esophagus before reaching the stomach where up to 3 L digestive fluid, 
comprised of hydrochloric acid, mucus, enzymes such as pepsinogen/pepsin and bicarbonate, 
are secreted every 24 hours.102,103,106 
Gastric pH varies based on whether a fed or fasted state is encountered; fasted gastric 
pH may range from ~ 0.3-1.9 while fed gastric pH may be as high as 5.102,103 Gastric pH is also 
a function of regional variations within the stomach itself.105 The proximal area of the stomach 
is generally of higher pH (~3) than the distal area due to the presence of fewer parietal cells 
that secrete hydrochloric acid.105 Nevertheless, immediate-release dosage forms disintegrate in 
the stomach, facilitating drug dissolution and possible drug transformation before absorption 
in the small intestine.102,103 Contents may remain in the stomach for up to 4 hours107, where low 
pH, small surface area and the presence of enzymes and microflora act as barriers to subsequent 
drug absorption.102 Release into the small intestine occurs via gastric emptying, which is largely 
controlled by the nature of the gastric contents; high fat, salt and acidity reduce emptying 
time.105 It is also dependent on the size of the dosage form, whether it is ingested in a fasted or 
fed state and, in the case of the latter, the volume of liquid/food ingested.105 Once in the small 
intestine, however, drug remnants are acted upon by enzymes (trypsins, lipases, nucleases), 
bile/bile salts and sodium bicarbonate, which facilitate lipid digestion and neutralization of 
stomach contents (chyme) to pH ~8.106 The exact pH of the small intestine varies by section; 
the duodenum is approximately neutral at pH 7 while the jejunum and ileum are slightly 
alkaline above pH 7.103  Nevertheless, the presence of villi as well as a transit time of up to 6-
7 hours facilitates the majority of drug absorption.102,107 Absorption may occur through simple, 
passive diffusion or active transport.108 Most small, hydrophobic drugs are absorbed across 
intestinal cells through passive, transcellular pathways while their hydrophilic counterparts 
must be absorbed through receptor-mediated transcellular pathways or paracellular pathways 
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(in the space between cells).109 The rate and extent of absorption depends on drug solubility 
and dissolution as discussed later in Section 1.7.3.102  
The high bacterial population and presence of mucus, fecal matter and dietary residues 
greatly inhibit further drug absorption in the large intestine.102,107 These challenges may be 
slightly offset by the prolonged transit time of at least 17 hours.102,107 The pH of the colon 
generally lies between 6-8 depending on regionality105, and is influenced by the presence of 
short chain fatty acids (weak acids, pKa 4.8)102. 
Transportation of absorbed drug material to the liver presents perhaps the greatest 
challenge to oral drug delivery in the form of the first-pass effect.110,111 Extensive drug 
metabolization may drastically reduce the amount of active ingredient reaching systemic 
circulation.110,111 Such effects may be bypassed through administration of the drug in highly 
lipophilic form to target the lymphatic rather than the portal route to circulation.110,111 In 
addition, pharmaceutical strategies to improve oral drug delivery outcomes include particle 
size reduction mechanisms, chemical modifications such as pH, drug dispersion in a carrier for 
protection or solubility purposes (as in the case of emulsions) and complexation/chelation with 
compounds that increase dissolution or absorption.102,108 
1.5   Techniques in Microemulsion Formulation 
Over the past century, a number of techniques have been used to identify and formulate 
microemulsion systems. Ternary phase mapping and oil/water titration methods have been 
employed for years as the most effective manner in which to identify microemulsion phase 
behaviour. Recently, however, more progressive techniques such as the hydrophilic-lipophilic 
deviation (HLD) equation have transformed our understanding of microemulsion formation. 
These two techniques are described in detail below. 
1.5.1  Ternary Phase Diagram (TPD) Mapping 
Surfactant phase behaviour, including the propensity to form microemulsions, is best 
represented by phase diagrams and in particular, ternary phase diagrams (TPDs). TPDs consist 
of three graduated axes ranging from 0% to 100% representing the concentrations of the three 
main components of microemulsion systems: surfactant, oil and water.1 Where co-surfactants 
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are used in combination with surfactants, this surfactant/co-surfactant mixture is treated as a 
single component and the diagram is referred to as a pseudo-ternary phase diagram (pTPD). 
The axes are read in a clockwise direction and each point in a TPD plot corresponds to a 
specific w/w% ratio of surfactant: oil: water (Figure 1.12).  
TPDs and pTPDs are of tremendous importance in deducing surfactant phase 
behaviours and types of microemulsions that may be obtained with certain surfactant/co-
surfactant, oil and water concentrations. This technique affords identification of specific 
surfactant:oil:water ratios or regions most useful for a particular application, and their 
boundaries. In general, as previously explained, hydrophilic surfactants tend to form O/W 
microemulsions,  represented  on  the  TPD  in  Figure 1.12  as  the  region to the bottom left. 
Hydrophobic surfactants tend to form W/O microemulsions, dominating in the bottom right of 
the TPD in Figure 1.12 while higher order structures of greater surfactant concentration tend 
to dominate at the top of the TPD in Figure 1.12 as previously alluded to in Figure 1.4. 
Traditionally, TPDs are generated through oil- and water-titration methods where 
various ratios of surfactant:water and surfactant:oil are titrated with oil and water, respectively, 
until a clear, homogenous system, or microemulsion, is obtained. This affords fast formation 
and deduction of Type IV microemulsion regions but ignores other resulting microemulsion 
types and phase behaviours. A more comprehensive approach to TPD mapping involves 
weighing various ratios of surfactant, oil and water into vials, mixing them together by simple 
manual shaking or stirring and leaving them to settle for a period of time before evaluating 
phase behaviour. These behaviours may then be plotted on a TPD. Such an approach affords 
changes along various tie lines to be determined so that care may be taken during formulation 
to stay within these boundaries and not venture beyond such regions. Therefore, the 
comprehensive approach to TPD mapping provides a ‘snapshot’ of surfactant phase behaviour 
with a particular oil type at a particular temperature. Comparisons of identical  systems  at  
increased or decreased temperatures or with varying oil types may then be made in order to 
deduce microemulsion sensitivity to each factor, along with possible phase transition 
behaviours.1 These phase behaviours are imperative in predicting the boundaries and limits of: 
i) microemulsion application (e.g. coarse emulsions for lotions/creams versus Type IV
microemulsions for multi-drug delivery), (ii) microemulsion route of administration (e.g. high 




microemulsion stability (e.g. resistance to change in microemulsion type upon water dilution). 
Thus, although considered an old and relatively simple technique, TPD mapping, especially 
when performed in the comprehensive manner described above, introduces invaluable insight 
and a degree of prediction into microemulsion behaviour and functionality. Although TPD 
mapping provides a ‘snapshot’ of microemulsion formation potential at specific conditions, 
the hydrophilic lipophilic deviation (HLD) equation, in contrast, affords prediction of 
microemulsion phase behaviour in consideration of multiple conditions, simultaneously. 
 
	
Figure 1.12: Example of ternary phase diagram of surfactant:oil:water. Each axis represents 
w/w% concentrations from 0-100% and is read in the direction indicated by the blue arrows. 
Therefore, the square point corresponds to a surfactant:oil:water ratio of 40:50:10. 
  
1.5.2  The Hydrophilic-Lipophilic Deviation (HLD) Equation 
In 1979, Salager et al. linked five major variables to microemulsion formation, laying the 
groundwork for the hydrophilic-lipophilic deviation (HLD) equation.112 Prior to this, the 
landscape of microemulsion formation was fairly different, although theories of microemulsion 
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formation evolved steadily over the previous century. Bancroft’s rule of formation in 191384 
was followed by Winsor’s proposal of the R-ratio in 194837, Griffin’s hydrophilic-lipophilic 
balance (HLB) classification system  in 194995 and Shinoda’s exploration of the phase 
inversion temperature (PIT) in 1964.113 Similar to Bancroft (1913) (discussed in Section 1.3), 
Winsor (1948) also proposed a study of the amphiphile and its interactions with surrounding 
organic and aqueous solvents as a means of emulsion formation.37 The Winsor interaction ratio, 
R, is given by the following equation: 
> = $-.$-/ (Eq. 1.4) 
where A is the solvent attraction between i) amphiphile (c) and oil (o) and ii) amphiphile (c) 
and water (w). This equation was developed to account for the interaction energies of an 
amphiphile adsorbed at an oil/water interface.37 A high R-value corresponds to increased 
interactions between the amphiphile and organic phase leading to the formation of W/O 
emulsions.37  The role of the R-ratio in the modern day HLD equation is described later. Around 
the same time, Griffin (1949) proposed the HLB as a system of surfactant classification and 
prediction of microemulsion formation based on the molecular structure of the surfactant95 
(Section 1.3). More recently, Shinoda and Arai (1964) identified a particular instance of 
microemulsion formation possible through a gradual heating of ethoxylated, non-ionic 
surfactants, resulting in a change from an oil-in-water (O/W) microemulsion to a W/O 
microemulsion, a parameter called the phase inversion temperature (PIT).113 The above four 
theories were sound in their own right and have uniquely contributed to, and advanced our 
understanding of, emulsion science over the past century. However, these theories possessed a 
number of limitations including a primary focus on the properties of the amphiphile and 
immediate organic/aqueous solvent environment, as well as an assumption of the use of pure 
surfactants. Such focus was considered somewhat short sighted as emulsion formation often 
occurs in an uncontrolled environment influenced by external factors, using commercially 
produced surfactants that behave very differently than their pure counterparts.112 Thus, Salager 
et al. (1979)112 using anionic, sulphonate surfactants and a semi-empirical methodology, linked 




type/concentration, surfactant structure and temperature, to optimum microemulsion 
formation, resulting in the following modern-day HLD equations:  
  
HLD	 = 	b	(S)	– 		K	(EACN) 	− 	ϕ	(A) 	+ 	CT	∆T	 + 	CC    for non-ionic surfactants  (Eq. 1.5)       
HLD	 = 	ln	(S)	– 	K	(EACN)	– 	f	(A) 	−  αT∆T	 + 	CC        for ionic surfactants          (Eq. 1.6) 
 
where S is the salinity concentration in g/100 ml, EACN is the effective alkane carbon number 
of the oil (a measure of oil lipophilicity),  f(A) and ϕ(A) depend on the type and concentration 
(w/w%) of co-surfactant or alcohol added, ΔT is the change in system temperature upon 
heating and CC is the characteristic curvature of the surfactant reflecting its 
hydrophilic/lipophilic nature. The parameters b, K, αT and CT are empirical constants 
associated with the type of salt and surfactant used.114 The parameter ‘b’ accounts for the 
addition of electrolytes and the potential salting-out effect on non-ionic, ethoxylated 
surfactants due to reduced hydration of the polyethoxylated head group.115 Monovalent and 
divalent ions partition differently in microemulsions formulated with non-ionic surfactants.116 
Surfactants have been found to be more sensitive to temperatures in solutions containing 
monovalent ions than divalent ones.116 Thus, the value for ‘b’ for non-ionic surfactants has 
been experimentally determined to be 0.13 for sodium chloride, 0.10 for calcium chloride and 
0.09 for potassium chloride as determined by the slope of the graph of optimal salinity versus 
mole fraction of alkyl polyethoxylated non-ionic test surfactants.115,117 Originally, the 
parameter ‘k’ was determined experimentally to be 0.16 ± 0.01 based on the slope of the natural 
log of salinity (ln S) versus EACN for alkyl aryl sulphonate surfactants (anionics).112 It was 
later determined to be between 0.1 and 0.2 to take into account the induced dipole interactions 
between the surfactant and oil phase.115 Today, it is generally accepted that k=0.17 for most 
surfactants115,118 with specific examples including sodium dihexyl sulfosuccinate (SDHS) being 
0.17, sodium dodecyl sulphate (SDS) being 0.1, and some iso-phenol ethoxylated non-ionic 
surfactants being 0.15.115,117,119 Finally, the parameters αT and CT are constants that consider 
the effect of increasing temperature on the weakening of hydrogen bonds between water 
molecules only (αT) and between water molecules and oxygen in the ethoxylated surfactant 
head group (CT). These values have been determined experimentally to be -0.01 K-1 for a 
number of alkyl anionic surfactants (αT) and 0.06 K-1 for a number of non-ionic, 
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polyethoxylated surfactants (CT) based on the slope of the natural log of salinity (ln S) versus 
temperature.112,115,117-120 Evidently, the HLD equation takes into account a number of important 
factors affecting microemulsion formation, affording a greater degree of predictability in the 
microemulsion formation process. 
It is important to note that some of the variables highlighted by Salager et al. (1979) 
were previously investigated. The relationship between salinity and “optimum” (Type III) 
microemulsion formation was previously investigated for oil recovery purposes121,122, as was 
the relationship between alcohol type / concentration and optimal salinity123-125, and the 
relationship between surfactant molecular weight and optimal salinity.126 Despite these 
previous works, however, Salager et al. (1979) was the first to correlate these variables into a 
semi-structured, empirical equation.112 In fact, Salager et al. (1979) categorized these variables 
into three types:  
i) formulation variables (salinity, oil ACN, alcohol type / concentration and surfactant
structure)
ii) external variables  (temperature and pressure) and
iii) position variables in ternary phase diagrams (surfactant concentration and oil/water
ratio).112
In microemulsion science, the practical use of the HLD equation involves the formation 
of Type III microemulsions, also known as ‘optimal’ formulations/microemulsions. These 
Type III microemulsions were considered ‘optimal’ due to their ultra-low interfacial tensions 
which originally afforded recovery of petroleum from water-flooded reservoirs.114  In Section 
1.2.3, we have described Type III microemulsions as three-phase systems comprised of an 
upper excess oil phase, a middle bicontinuous microemulsion region and a lower excess water 
phase. The amphiphilic molecules in these three-phase, bicontinuous systems exhibit no 
particular preference for either the organic or aqueous phase. Therefore, the interactions 
between surfactant and water, and surfactant and oil are considered equal, and the hydrophilic-
lipophilic deviation or difference (HLD) is said to be zero (0). This mirrors the Winsor R-ratio 
of 1, which also suggests equal interactions between the surfactant and oil, and the surfactant 
and water. Thus, an HLD value of 0 or an R-value of 1 corresponds to a Type III 
microemulsion. In contrast, a negative HLD value or R-value <1 corresponds to a Type I, O/W 




microemulsion. Once a Type III microemulsion is formed, either from a Type I or Type II 
microemulsion as depicted in Figure 1.13, one can then set the HLD value to 0 and solve for 
other equation variables such as EACN and CC. These variables may then be increased or 
decreased depending on the type of microemulsion system desired, i.e, a shift to a more 
negative HLD for O/W systems or to a positive HLD for W/O systems.  
It can be seen from Figure 1.13 that a transition from a Type I à Type III à Type II 
microemulsion is possible through salinity or temperature modifications while a transition 
from a Type II à Type III à Type I microemulsion is possible through lipophilicity 
modifications.114 These transitions can be explained through consideration of the Winsor ratio, 
R and the interactions between surfactant, oil and water. Recall that the interactive Winsor 
ratio, R (Eq. 1.4) involves ‘ACO’ which indicates solvent attraction interactions between 
surfactant and oil molecules, and ‘ACW’  which indicates  solvent  attraction interactions 
between surfactant and water molecules. An increase in parameters such as temperature or 
salinity results  in  a  decrease  in interactions between surfactant molecules and that of water.127  
This leads to an increase in R and thus, a progression from a Type I à III à II 
microemulsion.127 An increase in effective alkane carbon number (EACN) or lipophilicity 
results in an increase in both interactions between surfactant molecules and oil molecules, and 
interactions between oil molecules, the latter having a greater effect.127 This leads to a decrease 
in R and thus, a progression from a Type II à III à I microemulsion.127 Type IV 
microemulsions are typically obtained from Type III microemulsions upon an increase in 
surfactant concentration.  
Overall, the modern day HLD equation was conceived through consideration of i) five 
major variables and ii) the Winsor ratio, R involving interations and chemical potentials via 
the surfactant affinity deviation (SAD) parameter (a quantification of the free energy of transfer 
of a surfactant molecule from the aqueous phase to the oil phase).114 In microemulsion drug 
delivery, the HLD equation provides a useful way of determining the effects of lipophilicity, 
temperature and surfactant curvature on drug-loaded formulations. This eliminates the need to 
re-plot TPDs with drug-loaded oil or water phases and is especially ideal in situations where 







Figure 1.13: Formulation scan expected outcomes for microemulsion phase transitions given 
changes in salinity, temperature and oil lipophilicity based on the principles of the Winsor 
ratio, R. ‘Oil’ and ‘water’ labels represent excess phases. In the case of excess oil, the 
microemulsion is of the O/W type while in the case of excess water, the microemulsion is of 
the W/O type. In the case of both excess oil and water, the microemulsion is of the bicontinuous 
type.  
  
1.5.2.1 Advantages of the HLD Equation 
The development of the HLD equation has afforded a number of advantages in microemulsion 
science. Perhaps of highest importance, the equation although semi-empirical, considers the 
effect of a number of formulation, external and position variables, as defined previously, on 
microemulsion formation. Prior to the development of this equation, the Bancroft rule, Winsor 
R-ratio, HLB value and PIT were used to predict microemulsion formation behaviour. Though 
useful, these theories relied heavily on the structure of the amphiphile and its interactions with 
the surrounding solvents rather than on the effect of other contributing variables. Thus, 
microemulsion formation was still largely performed on a trial and error basis. The HLD 
equation eliminates much, though not all, of the trial and error previously associated with 
microemulsion formation. In addition to the simple consideration of external factors affecting 
microemulsion formation, the HLD equation affords adjustment of the HLD value itself, once 
all equation parameters are known. In turn, each equation parameter may also be adjusted once 
the HLD value is known. Therefore, it is evident that the HLD equation affords a novel 
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optimization process for microemulsion formation not afforded by previous microemulsion 
methods.  
The HLD equation is also unique in that it accounts for both ionic and non-ionic 
species. Based on the works of Shinoda and Arai (1964), certain surfactant classes such as non-
ionics were well known to be particularly sensitive to the temperature parameter.113 This is 
accounted for in the non-ionic HLD equation, as is the salinity parameter in the HLD equation 
for ionic surfactants. Previous theories of microemulsion formation were often unable to 
distinguish between ionic and non-ionic amphiphiles. Thus, although the work of Salager 
(1979)112 was originally based on the investigative work of sulphonates, a specific surfactant 
class of anionics, the HLD equation was later refined to account for modifications in surfactant 
type.114 
Finally, the use of commercial surfactants in microemulsion formation is not as large a 
setback as in previous microemulsion theories. The surfactant parameter or characteristic 
curvature (CC) of commercially utilized surfactants may be determined experimentally so as 
to reduce the effect of any unpredictability with respect to impure surfactant use, a problem 
which had plagued many earlier microemulsion formation theories.  
1.5.2.2 Limitations of the HLD Equation 
Despite the many advantages of the HLD equation, there are limitations that do not completely 
alleviate the complications of microemulsion formation. It must be noted that first and 
foremost, the HLD was originally a semi-empirically derived equation.112  A number of 
anionic, sulphonate surfactants along with various alcohols were evaluated with salinity, 
temperature and oil ACN in order to determine the effects of each variable on the system, as 
well as any correlations amongst them.112 These correlations were then organized into a 
structured equation. The semi-empirical nature of the HLD equation suggests that the value of 
the parameters obtained may not be an exact representation of what is occurring within the 
system. In addition, the output of the HLD equation has no numerical scale. Values are simply 
determined to be zero, positive or negative with no understanding of what constitutes a large 
or small difference in value. Therefore, with respect to optimization, there is no clear numerical 
boundary or criteria that can be set. Another drawback revolves around how the values 
themselves are obtained. Certain variables such as temperature and salinity are easily obtained. 
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However, values such as EACN and CC are complicated, especially when utilizing mixtures 
of commercial oils and surfactants. These values are largely obtained through formulation 
scans, which still involve a great deal of trial and error. Such formulation scans also rely 
heavily on the use of volumes versus that of mass or weight which are more common in 
microemulsion formation. Hence, the HLD is not only a semi-empirical equation that does not 
completely eliminate the process of trial and error, but it also requires the values of all 
parameters to be known which demands the need for a robust library of values for practically 
infinite surfactant and oil types and combinations.  
1.6   Prenatal Multivitamins: A Multi-Drug Model 
Prenatal supplements are vitamins and minerals taken by women before, during and even after 
pregnancy (during breastfeeding) in order to promote healthy fetal development. The United 
States Food and Drug Administration (US FDA) and Health Canada state that in order to 
supplement a healthy diet, prenatal supplements may be consumed by women planning on 
becoming pregnant, women in their first trimester of pregnancy and breastfeeding women.128,129 
Prenatal supplements should contain a variety of essential water-soluble and fat/oil-soluble 
vitamins and minerals including Vitamins A-E, Vitamin K and calcium and iron.128 Some of 
these vitamins and minerals are specifically recommended for inclusion in prenatal 
supplements due to their importance in fetal development. These include folic acid130, 
docosahexaenoic acid (DHA) from Omega-3 fatty acids131 and iron129, whose roles in fetal 
development are described below in Tables 1.5-1.7.  
Many factors contribute to prenatal supplements acting as an optimal multi-drug model 
in this thesis work. The primary advantage is that these supplements contain multiple active 
ingredients of varying hydro- and lipophilicity, often in higher quantities than that of typical 
multivitamins due to fetal requirements. This provides multiple layers of complexity due to the 
vastly different physicochemical, solubility and stability properties of each API, as well as the 
heightened potential for API-API interactions given the increased quantities of each. 
Considering that the goal of this work is to formulate a microemulsion system capable of 
complex, multi-API delivery, this pre-natal supplement model satisfies those requirements. In 




form (Section 1.6.3). As noted earlier, solid formulations may experience inferior absorption 
when compared to liquid formulations due to the extra dissolution step required. Thus, the 
formulation of a microemulsion containing these prenatal active ingredients would not only 
fill a market need, but would be advantageous in terms of comparing any enhanced dissolution 
effects of the microemulsion formulation with a solid or suspension formulation.   
 
1.6.1  The Role of Prenatal Vitamins and Minerals 
Each vitamin and mineral recommended by the US FDA and Health Canada for expectant, 
pregnant and breastfeeding women plays an important role not only in bodily function but in 
healthy fetal development. Tables 1.5-1.7 highlight the structural and functional properties of 
some of these compounds, including their BCS class and octanol-water partitioning coefficient 
profiles (log P). In general, it can be seen that the water-soluble vitamins consist of low log P 
values while the oil-soluble vitamins consist of higher log P values. In addition, due to the high 
aqueous solubility of the water-soluble vitamins, most are classified as BCS class III 
compounds while the low aqueous solubility of oil-soluble vitamins leads them to be classified 
as BCS Class II/IV compounds. All vitamins and minerals are important in the regulation of 
bodily function but folic acid, docosahexaenoic acid (DHA) via Omega-3 fatty acids and iron 
are of particular importance in fetal development. 
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Table 1.5: Physicochemical properties of some water-soluble vitamins typically included in prenatal multivitamin supplements. 130, 132-
139
Water-soluble Vitamins 130,138,139 






-3.1 III • Co-factor for enzymes involved in 
energy metabolism (Krebs Cycle) 




-0.92 III • Precursor for enzymes (flavin electron 
carriers) involved in energy 
metabolism (Krebs Cycle) 
Vitamin B3  
(Niacinamide) 
-0.39 III • Precursor for enzymes (NAD+) 

















• Co-enzyme involved in DNA and
RNA metabolism
• Aids enzymes in aminoacid 
catabolism and blood production 
• In pregnant women (1st trimester)




-14 III • Co-enzyme involved in DNA and RNA 
metabolism 
• Involved in red blood cell production 
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Table 1.6: Physicochemical properties of oil-soluble vitamins typically included in prenatal multivitamin supplements. 140-145 
Oil-soluble Vitamins 131,138,139 







11.12 II/IV • Maintains epithelial tissue 
• Produces visual pigments 
Vitamin D3 
(Cholecalciferol) 









9.7 II/IV • Aids in formation of proteins 
especially in blood clotting 




II/IV • During pregnancy, aids overall fetal 
growth and development including 
neurodevelopment 
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Table 1.7: Physicochemical properties of some important minerals needed in the body. Major minerals refer to minerals present in 
excess of 5 g in the body. 
Minerals 138,146 
Classification Mineral Function 
Major Minerals Calcium • Aids bone/tooth formation, blood clotting and nerve transmission 
• Produces visual pigments 
Magnesium • Cofactor in multiple enzyme systems regulating energy production; maintains nerve and muscle 
function 
Minor/Trace Minerals Iron • Major component in haemoglobin and myoglobin  
• Critical in pregnancy due to infant haemoglobin demands; deficiency implicated in low birth weight 
and infant mortality 
Iodine • Aids in thyroid regulation 
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1.6.2  Health Canada Requirements 
Health Canada has recommended daily allowances of specific vitamins and minerals for 
expectant and pregnant women.147-149 These daily recommended amounts, with the exception 
of minerals, were used as a general guideline for the multi-drug, microemulsion formulation 
developed in this thesis work (Table 1.8). 
Table 1.8: Daily recommended amounts of vitamins and minerals suggested for women who 
are pregnant or who may become pregnant.147-149
Class 
Vitamin/ 





Hydrophilic Vitamin Vitamin B1 (Thiamine mononitrate) 1.4 
Vitamin B2 (Riboflavin) 1.4 
Vitamin B3 (Niacinamide) 18 
Vitamin B6 (Pyridoxine hydrochloride) 2 
Vitamin B9 (Folic Acid) 0.6 
Vitamin B12 (Cyanocobalamin) 0.0026 
Hydrophobic Vitamin Vitamin A 0.55-0.77 
Vitamin D3  (Cholecalciferol) 0.015 
Vitamin E 15 
Vitamin K1 (Phytonadione) 0.09 
Omega-3 Fatty Acid (DHA) 3000 







1.6.3  Current Prenatal Supplement Dosage Forms 
A variety of dosage forms for prenatal supplementation are currently in existence. According 
to the National Institute of Health (NIH) Dietary Supplement Label Database, which houses 
label information of all multivitamins currently marketed in the US, the majority of prenatal 
supplements are formulated as powders in tablet form.150 Suspension formulations in caplets 
were the second most common form followed by liquid formulations in soft gelatin 
capsules.150 Edibles such as gummies were the least common.150 The NIH database produced 
no results with respect to emulsion prenatal supplements and instead returned only seven (7) 
emulsion products in total, one of which was a multivitamin in that it contained Vitamins D3 
and K2.150  All seven products were formulated as drinkable liquid dosage forms and were not 
encapsulated.150 Thus, there is a demand for a microemulsion system capable of delivering 
both hydro- and lipophilic active ingredients in the form of a multivitamin formulation. 
 
1.7   Microemulsion Evaluation Techniques 
Provided the successful development of a microemulsion capable of multi-drug delivery, it 
is important to evaluate and characterize the resulting formulation. In general, evaluation of 
a microemulsion formulation involves first determining the solubility of each API in various 
microemulsion components, followed by characterization and in-vitro analysis via 
dissolution or disintegration. The techniques associated with these evaluation and 
characterization procedures are described below. 
 
1.7.1  Saturation Solubility Testing 
Solubility is the ability of solute (or drug, in this case) to dissolve in a solvent.151 Saturation 
solubility is the maximum solubility of a particular solute in a particular solvent at 
equilibrium conditions.151 It also depends on external factors such as temperature.151 Poorly 
water-soluble compounds demonstrate low solubility in aqueous or aqueous-related media. 
Techniques such as concealed delivery in hydrophilic vehicles must, therefore, be employed 
to improve solubility.151 In general, saturation solubility tests involve careful addition of 
measured solute or drug into a specific volume of solvent with stirring until saturation is 




vessel. The saturated solution is then analyzed using chromatography or spectroscopy, 
typically high or ultra performance liquid chromatography (HPLC or UPLC)/ ultraviolet 
(UV) detection.152 The amount of solute (drug) recovered is compared against a calibration 
curve of peak area in order to determine the amount of drug dissolved per gram or litre of 
solvent at saturation. In microemulsion formulation studies, saturation solubility provides 
insight into drug solubility in the various surfactant, oil and water components in order to 
determine whether additional solubilization tehcniques may be required. 
 
1.7.2  Characterization 
The characterization of microemulsion systems on the basis of properties such as droplet 
size, charge, conductivity and morphology is crucial in confirming microemulsion type and 
predicting microemulsion behaviour and stability. Six important microemulsion 
characteristics are described below: 
 
1.7.2.1 Droplet Size  
Microemulsions typically possess small droplet sizes in the range 10-100 nm in diameter1 
but these boundaries are not thoroughly defined.32 The advantages of such small droplet sizes 
are numerous, as described in the previous sections of this chapter, but largely include 
thermodynamic stability and the potential to improve bioavailability through an increased 
surface area to volume ratio. In addition to the numerical size itself, microemulsions are 
homogenous in nature, demonstrating uniformity in droplet sizes throughout the system. This 
homogeneity is another characteristic that may be determined via identification of the size 
distribution in a microemulsion sample. The two properties of droplet size and size 
distribution may be determined through light scattering techniques such as dynamic light 
scattering (DLS).  
 Dynamic Light Scattering (DLS), also known as Photon Correlation Spectroscopy 
(PCS), is a light scattering technique involving the irradiation of a sample with a narrow 
beam of light or laser at a specific angle and temperature. The laser beam, automatically 
modified by an attenuator based on the size of the particles in the sample, is shone onto a 




makes use of the natural Brownian motion of particles in a sample, as well as the Stokes-
Einstein equation, in which larger particles diffuse or move more slowly than smaller 
particles.153 DLS measures the scattering intensity of these particles within a sample using a 
time correlation function. Larger particles exhibit greater light scattering than that of smaller 
particles and given Rayleigh’s theory that the scattering intensity is proportional to the sixth 
power of a particle’s diameter153,154, this higher intensity can be converted to a volume and 
number distribution.153,155 Given that DLS correlates the movement of a particle with the size 
of a hard sphere particle that diffuses at the same speed as that of the sample153, this poses 
complications for some surfactants, polymers and other surface-bound compounds on a 
particle, which do not conform to hard sphere morphology. Thus, the size output of the DLS 
method takes into account the presence of surface-bound compounds on a particular particle. 
This size output is referred to as hydrodynamic diameter rather than absolute diameter and is 
therefore, an overestimation of actual droplet size as it accounts for the immediate 
surrounding layer of solvent or other compounds on a droplet.  DLS studies, such as those 
undertaken in this work, must be interpreted with caution as the current system being studied 
involves non-ionic surfactants with multiple PEO head groups as well as hydrophilic APIs 
which may surround the microemulsion droplet being studied. In addition to the measured 
droplet size, uniformity of size may also be measured using DLS. DLS measures the size 
distribution of particles using a value called the polydispersity index (PDI). PDI values 
indicate the homo- or heterogeneity of a sample with values below 0.1 indicating a very 
narrow, homogeneous droplet size distribution and values above 0.5 indicating a 
heterogeneous droplet size distribution.153  
 Although DLS is a rapid method for the particle size determination of relatively 
simple and dilute systems, complex concentrated samples such as microemulsions pose a 
challenge.156 Concentrated samples often result in particle-particle interactions and multiple 
scattering.157 Thus, dilution of microemulsion samples prior to measurement is often 
required157,158, though this may result in changes to the microemulsion itself. Increased 
addition of aqueous solution to concentrated microemulsion systems causes transitions from 
higher order structures such as hexagonal, lamellar and cubic structures to spherical 




spherical micellar structures rather than the native microemulsion. 159 Microscopic methods 
may offer a more accurate representation of the droplet size of native microemulsion systems. 
 
1.7.2.2 Zeta Potential 
Zeta Potential (ζ Potential) is defined as the potential difference between the dispersed 
medium and the stationary layer of the dispersed medium attached to a dispersed particle or 
droplet.153, 160-162 Zeta potential is, thus, an indication of the surface charge of a droplet or 
particle; however, it is important to distinguish that it is not the actual surface potential (i.e. 
surface charge) which will be larger in absolute value compared to the zeta potential. High 
zeta potential values, whether negative or positive, are indicative of high stability as 
electrostatically repulsive forces exceed attractive forces, the latter of which lead to 
coagulation or flocculation and thus, physical instability. 153, 160-162 Values above +30 mV and 
below -30 mV are used as an arbitrary scale for particle stability;153,162 however, studies have 
shown that a more accurate indicator of stability is to examine the change in zeta potential 
with time or the zeta potential rate.1,162  Given that zeta potential is an indication of surface 
charge, the most important factor affecting zeta potential is pH153,160  as pH may confer certain 
charge effects on a particle. Additional factors include ionic strength and additives or 
impurities.160 Given that the formulation in this work is pH adjusted in order to accommodate 
the hydrophilic APIs, it is important to characterize the charge of the droplets in this 
microemulsion system not only for stability purposes, but in order to deduce any possible 
charge effects or contributions by certain APIs or other components in the system.  
 Zeta Potential can also be measured using an appropriate DLS instrument. Samples 
are placed in a capillary cell containing electrodes on either side. The instrument uses a 
combination of Electrophoresis and Laser Doppler Velocimetry (LDV) that measures the 
velocity of a particle in a liquid upon application of an electric field, which is then equated 
to charge.153  
 
1.7.2.3 Conductivity 
Electrical conductivity may be used in conjunction with other experimental techniques in 




medium’s ability to ‘conduct’ or pass electrical flow which is highly dependent on the ions 
present in solution. In microemulsion science, conductivity provides insight into the type of 
microemulsion present as water has the ability to conduct charge while oil does not. Thus, in 
an O/W microemulsion system where water is the continuous phase, conductivity readings 
are expected to be higher than those of a W/O microemulsion system where oil is the 
continuous phase.33,155 Specific values for conductivity are not given and depend on the 
components of the microemulsion system but Yotsawmimonwat et al. (2006) indicated that 
some generalizations may be made as W/O emulsions report very low to almost zero 
conductivity while O/W emulsions report higher conductivities which may be best 
determined through comparison measurements of the conductivity of water utilized in the 
system.163 This is due to the fact that tap, deionized, distilled and MilliQ water are vastly 
different in their conductivity potential. Conductivity is typically measured using a 
conductivity probe which measures the ability of the solution to conduct electricity between 
a pair of electrodes in a probe. The output is given in Siemens per meter or milliSiemens per 




Rheological studies are useful for determination of microemulsion type and even 
morphology to a limited extent. In terms of microemulsion type, rheology provides insight 
into Newtonian behaviour and thus, the type of microemulsion obtained.155 Bicontinuous 
microemulsions, in particular, exhibit Newtonian behaviour or constant viscosity at low to 
medium shear rates and shear thinning at high shear rates as the bicontinuous structures are 
dismantled.155 Type I and II microemulsions, however, exhibit Newtonian behaviour over a 
larger range of shear rates.155 Though rheology provides insight into microemulsion type as 
well as aggregate type, it must be used in conjunction with other techniques in order to 
characterize a microemulsion system definitively.155 Lower viscosity values indicate an O/W 
microemulsion while higher viscosity values indicate a W/O system.33 As noted previously 
in our group, higher viscosities afford greater stability according to the Stokes-Einstein 




 In addition to microemulsion type, the morphological behaviour of microemulsion 
systems may also be deduced to a certain extent using rheological studies. Microemulsion 
systems are comprised of a number of aggregates of various shape and type. Rheological 
studies afford insight into the shape and type of aggregates present with larger aggregates 
resulting in increased viscosity.155 In fact, rheological studies may enable the characterization 
of transitions in aggregate structure such as from spherical micelles to bicontinuous 
channels155, with changes in certain factors such as water content.  
 
1.7.2.5 Morphology 
Morphology is one of the most important properties to be characterized in microemulsion 
systems. Droplet size measurements often lead to inflated results when light scattering 
techniques such as DLS are employed. Morphology, usually via microscopic techniques, 
affords a visual representation of the microstructures present in microemulsion systems. This 
is particularly important in order to deduce the type of structural properties or aggregates 
present82,111,155, especially to confirm the presence of spherical aggregates. Transmission 
electron microscopy (TEM) is one of the most common microscopic techniques used to 
image microemulsion systems. A beam of electrons is focused onto a sample and magnified 
via a projector lens before hitting a fluorescent screen. Contrast studies using various stains 
are often performed.155 Microemulsions as dynamic, liquid systems are difficult to image, 
however, and freeze fracture or cryo-TEM is often used to identify surface 
characteristics.82,111,155 TEM and cryo-TEM afford visualization of microemulsions, 
bicontinuous structures and other mesophases including sponge phases155 However, electron 
microscopic techniques have disadvantages with respect to possible artefact imaging and 
dehydration.155   
 
1.7.2.6 Thermoanalytical Behaviour 
Differential Scanning Calorimetry (DSC) is a calorimetric technique that measures the 
thermal properties of a sample. The difference in the amount of heat required to increase the 
temperature of a sample, with respect to a reference, is measured as the sample is subjected 




melting and crystallization points unique to each formulation82, and are displayed as endo- 
or exothermic processes. Although there is certainly debate about the usefulness of this 
technique in microemulsion science, the identification of these exo- and endothermic peaks 
affords insight into the unique energetics of the microemulsion formulation and is most 
useful when compared to the individual components of the system such as the surfactant, oil 
and water components. In multi-API formulations, where interactions may be present, DSC 
profiles may be generated in order to determine the effects on melting and crystallization as 
well as possible instances of degradation. 
	
	
1.7.3  Dissolution 
In addition to the characterization techniques described above, dissolution is another 
important part of microemulsion evaluation. Dissolution in the context of pharmaceutics is 
the process by which a solid drug becomes dissolved in solvent and is a dynamic process. 
According to Shargel et al. (2012), the dissolution process for solid oral products includes (i) 
disintegration of the drug product, (ii) dissolution of the drug in aqueous solution and (iii) 
absorption across cell membranes.59 The first step in the dissolution of a drug involves the 
dissolution of drug at the surface of the solid particle, resulting in the formation of a saturated 
solution around said particle.59 This is followed by the diffusion of dissolved drug in saturated 
solution to the bulk solvent, from a region of high drug concentration to one of lower drug 
concentration.59 Dissolution testing is, thus, an important precursor and indicator for 
predicting systemic absorption.59  For hydrophilic drugs, dissolution is fast while permeation 
is slow, making the latter a rate-limiting step in absorption. For hydrophobic drugs, 
dissolution is slow and is considered the rate-limiting step.59  Thus, the rate at which organic 
drugs dissolve tends to dictate the rate and extent of systemic absorption.59 There are many 
methods for performing dissolution on pharmaceutical products. 
1.7.3.1 Dissolution Methods 
Dissolution tests are often performed in consideration of United States Pharmacopoeia (USP) 
guidelines, the standard for dissolution and disintegration regulation in North America, and 




of dissolution testing acceptable to regulatory agencies, depending on the type of product 
being tested (Table 1.9).164 
 
Table 1.9: USP Dissolution Methods I-IV along with their mechanisms and suitability for 




 Table 1.9 outlines each type of apparatus along with its main components, 
mechanism of action and suitability for a wide range of dosage forms. In general, Apparatus 
I and II are considered the most common but each apparatus follows the same general 
procedure. The dosage form held in a basket, cylinder or reservoir is introduced to a vessel 
containing dissolution medium and subjected to agitation for a specified period of time. 
Samples are drawn at specific time intervals and the content is analyzed via spectroscopy 
and/or chromatography in order to deduce the concentration of drug dissolved at each time 
interval. Specifications or pass criteria typically include the dissolution of a certain 
percentage of drug, e.g. 70%, within a certain period of time, e.g. 30 minutes.59  
 
1.7.3.2 Importance of IVIVC (In vivo- In Vitro Correlation) 
As stated earlier, dissolution testing is a precursor for the prediction of systemic absorption. 
One of the purposes of dissolution testing is to deduce a relationship between in vitro 
dissolution testing and in vivo performance, or in vivo- in vitro correlations (IVIVCs).59 
Apparatus 
Number 
Method Mechanism Utility 
I Basket Vessel, drive shaft and 
rotating cylindrical basket 
with mesh 
Immediate release & 
extended release tablets and 
capsules 
II Paddle Vessel, drive shaft and 
rotating paddle 
Immediate release & 




Vessel, reciprocating glass 
cylinders with mesh 
(vertical motion) 





through cell and water bath 





IVIVC is the relationship between the physicochemical property of a drug, such as 
dissolution rate, and a biological property of the drug, such as plasma drug concentration.59 
There are various levels of IVIVC; Level A correlations are the highest level and establish a 
point-to-point relationship between in vitro dissolution testing and absorption rate of the drug 
from the dosage form, Level B correlations are lower level and establish a relationship 
between mean in vitro dissolution time and mean in vivo dissolution time and finally, Level 
C correlations, the lowest level of all, typically demonstrate no statistical correlation and 
instead, establish a relationship between a single dissolution parameter and a 
pharmacokinetic parameter. 59 Though dissolution testing is important to establish IVIVC, 
such correlation studies were not undertaken in this thesis work, but are an important 
consideration for future analysis. 
  
1.7.3.3 How is it Measured Practically? Pharmaceutical Application 
Dissolution testing is typically conducted in accordance with USP standards as outlined in 
their respective modules. However, there are quite a few considerations. The dissolution test 
itself is valuable in formulation development but should be discriminating enough to detect 
changes in formulation variables such as particle size differences as well as manufacturing 
changes.59 Thus, this type of testing should be able to distinguish between a pharmaceutically 
acceptable and non-acceptable dosage form, within the context of USP criteria for acceptable 
dosage forms.59 There are numerous factors and conditions that affect dissolution testing 
including the type of drug itself (size, chemical stability, excipients), the media used (type, 
pH, concentration), environmental factors (temperature) and of course dissolution apparatus 
factors (agitation rate, placement of solid dosage in vessel). Nevertheless, the dissolution 
requirements for formulations containing vitamins and minerals, according to the USP, are 










Table 1.10: USP dissolution requirements for vitamin-mineral dosage forms 
 
 
1.7.4  Disintegration 
Disintegration as the name suggests, is the process by which any solid dosage form breaks 
apart in order to release drug material.  Disintegration  is  defined  as  the  state  in  which  no 
residue, except for fragments of insoluble coating, remains on the screen of the test 
apparatus.59 Specifically, this residue must not have a “palpably firm core”.59,165,166 According 
to the USP, the disintegration test is used to determine whether solid dosage forms such as 
tablets or capsules can disintegrate within a specified time in liquid medium given certain 
experimental conditions such as pH and temperature.165 It is important to note that contrary 
to dissolution testing, disintegration tests do not provide information regarding the 
dissolution rate of a drug and thus, no IVIVC can be explicitly implied.59 Instead, in addition 
to release time, disintegration tests afford insight into the presence of aggregates or fragments 
of the solid dosage form and are an important component in the quality control of tablet 
manufacture.59 
 
1.7.4.1 Disintegration Methods 
According to the USP, the disintegration apparatus is comprised of a basket rack assembly 
with 1000 mL low-form beakers of height 138-160 mm and diameter 97-115 nm, a heating 
USP Class Combination of Vitamins 
or Minerals Present 
Dissolution Requirement 
I Oil-soluble vitamins Not applicable 
II Water-soluble vitamins One index vitamin; folic acid (if present) 
III Water-soluble vitamins 
with Minerals 
One index vitamin and one index element; 
folic acid (if present) 
IV Oil- and Water-soluble 
vitamins 
One index water-soluble vitamin; folic acid 
(if present) 
V Oil- and Water-soluble 
vitamins with Minerals 
One index water-soluble vitamin and one 
index element; folic acid (if present) 




element capable of controlling temperature 35-39°C and a device for raising and lowering 
the basket in the immersion fluid at a constant rate of 29-32 cycles per minute.165 There are 
additional details surrounding the range of motion and distance moved during each stroke, 
the required distance of the wire mesh and its submersion in the fluid as well as specifications 
of the basket rack itself in terms of diameter, thickness etc.165 There is also a specific 
procedure for the evaluation of tablets and capsules depending on whether they are uncoated 
or plain-coated, intended for immediate or delayed release or their degree of effervescence.165  
 
1.7.4.2 How is it Measured Practically? Pharmaceutical Application 
Disintegration is measured in accordance with USP guidelines with consideration of the type 
of drug product being tested. In short, a certain number of drug product tablets or capsules 
must disintegrate within a specified period of time in order to obtain a ‘pass’ result. This 
period of time, as well as the media of choice, is dependent on the solid dosage form (capsule 
vs. tablet; coated vs. uncoated), route of administration (oral vs. buccal) and other 
considerations.166 For uncoated or plain-coated tablets or capsules (hard-shell), disintegration 
must occur in 16 of 18 tablets within 30 minutes.166 Soft gelatin capsules are held to a higher 
standard and require disintegration of 16 of 18 capsules within 15 minutes.166 Delayed release 
tablets require disintegration of at least 16 of 18 tablets within an hour while solid dosage 
forms administered for buccal delivery, require disintegration within 4 hours.166 According 
to Shargel et al. (2012), disintegration of a solid dosage product is usually more rapid than 
dissolution and absorption, except in the case of controlled release products.59   
 
1.8   The Art of Formulation in Microemulsion Science 
Despite the progression and advancement of microemulsion formation theories and 
evaluation techniques over the past century, microemulsion science is still primarily 
considered an art.167 According to one of the founding fathers of Colloid and Surface Science, 
Tharwat F. Tadros (2018), the science of microemulsion has not yet progressed to a place 
where accurate predictions may be made about resulting phase behaviours when various 
components are mixed.167 This is evident as even the most useful theory to date, the HLD 




current approach is still largely based on trial and error and involves: i) determining the type 
of microemulsion desired, ii) selecting a surfactant based on HLB theory and iii) performing 
phase mapping via oil- or water-titration methods in order to obtain a suitable surfactant for 
a given oil and water ratio.  
 The above limitations may be discouraging but the HLD equation is still the most 
useful microemulsion formulation tool to date.118 Abbott (2019) proposes, with good reason, 
that surfactant curvature may be more important than HLB given its consideration of 
parameters beyond simple surfactant structure.118 In addition, surface excess concentration 
and area per surfactant molecule may be more useful than the CMC118 given that surfactants 
are often used above this concentration anyway. Localization of the active ingredient in the 
micelle is also important as it provides insight into solubilization potential.118 Regardless of 
these recommendations, given the sheer number of surfactant and oil combinations, 
researchers must ensure that published work is as explicit as possible such that a library of 
HLD, EACN and CC values at specific temperatures and concentrations can be built. In this 
manner, should one want to use a similar surfactant or oil composition, this can be facilitated.  
 The aim of this thesis body work is to attempt to improve the current state of the field 
by reducing the level of trial and error involved in microemulsion science and highlighting 
properties of emulsifying agents, as the heart of microemulsion systems, that may better 
predict microemulsion behaviour suitable for multi-drug delivery. In the absence of clear-cut 
evidence of specific emulsifying agent properties responsible for this type of drug delivery, 
it is hoped that at the very least, a process for the formulation of a microemulsion, multi-drug 
system may be obtained. 
 
1.9   Objectives 
1.9.1  Short-term Objectives 
i) To design, formulate and optimize a basic microemulsion system capable of multi-
drug delivery  
ii) To incorporate multiple active pharmaceutical ingredients (APIs) of varying hydro- 




iii) To analyze the multi-drug loaded microemulsion formulation using a variety of 
microemulsion characterization techniques 
 
1.9.2  Long-term Objectives 
i) To develop a stable, multi-drug loaded microemulsion demonstrating superior 
dissolution over that of a conventional drug delivery form 
ii) To identify emulsifying agent properties important in microemulsion, multi-drug 
delivery  
 
1.9.3  Significance of Study 
Life with concurrent, chronic disease is debilitating. In Canada, the increasing life 
expectancy and rapidly aging population has resulted in a steady increase in the burden of 
concurrent, chronic disease, resulting in an urgent need for multi-drug therapies. Currently, 
multi-drug therapies encounter severe challenges with respect to the incorporation of 
multiple drugs of varying hydro- and lipophilicity. Microemulsions, due to their small droplet 
sizes, thermodynamic stability and simple oil and water composition are an under-utilized 
tool for the complex, simultaneous delivery of hydrophilic and lipophilic drugs. Despite their 
popularity, however, microemulsion formation is still an unpredictable process. In this thesis, 
emulsifying agents, the heart of microemulsion systems, will be investigated in order to 
determine the most important properties necessary for multi-drug, microemulsion formation. 
The significance of this investigation is that through this understanding, microemulsion 
formation may be better predicted, advancing the development of multi-drug therapies that 
may reduce the burden of concurrent, chronic disease in Canada and worldwide. 
 
1.10   Hypothesis Statement 
Careful selection of structural emulsifying agent properties such as hydrocarbon chain length 
and polyoxyethylene (POE) content will lead to the development of a microemulsion system, 
100 nm in diameter, capable of the simultaneous encapsulation of multiple hydrophilic and 










2.1   Introduction 
Emulsifying agents or surfactants are the heart of microemulsion systems. Without them, 
microemulsion formation is practically impossible. Therefore, the choice of surfactant is very 
important in the development of microemulsion formulations. As outlined in Chapter 1, 
there are generally four classes of surfactants to choose from based on the nature of the 
hydrophilic head group. However, non-ionic surfactants are most commonly used. 
 According to Callender et al. (2017), almost 90% of the research conducted on 
microemulsion drug delivery between 2011-2016 involved the use of non-ionic surfactants 
in the final microemulsion formulation.1 This is likely due to the uncharged nature of the 
head group, low toxicity profile and GRAS status of non-ionics (Chapter 1, Section 1.3). 
As a result, evaluation of specific surfactants utilized in microemulsion drug delivery within 
this period resulted in mostly non-ionic surfactants being identified (Figure 2.1).1 According 
to Figure 2.1, of the top 10 surfactants used in microemulsion drug delivery between 2011-
2016, all were non-ionic with the exception of lecithin, an amphoteric surfactant.1 Notable 
commonly used non-ionic surfactants were Polysorbate/Tween 80, Transcutol P and 
Cremophor RH 40/EL, although Transcutol was primarily used as a co-surfactant.1 
 Many of the surfactants presented in Figure 2.1 from Callender et al. (2017) were 
hydrophilic in nature, with HLB values >10.1 This was not surprising as the authors also 
found that lipophilic drug delivery accounted for almost 80% of the research publications 
between 2011-2016.1 Given the Bancroft rule outlined in Chapter 1, and the fact that 
hydrophilic surfactants facilitate O/W emulsion formation and thus, lipophilic delivery, the 
use of predominantly hydrophilic surfactants was not surprising. In this thesis work, 
lipophilic delivery was generally prioritized given that many pharmaceutical products 
developed today are lipophilic in nature and exhibit poor biopharmaceutical properties.2-4 
Thus, prioritizing this type of delivery would provide insight into overcoming such 
challenges. For these reasons, O/W microemulsion formation was considered of great 






Figure 2.1: Top 25 surfactants utilized in microemulsion drug delivery formulations 




 A variety of non-ionic surfactants of varying classes such as Polysorbates and 
Poloxamers were desired for further evaluation in this work. Although Polysorbate 80, 
Transcutol-P, Cremophor RH 40 (PEG-40 hydrogenated castor oil) and Cremophor EL 
(PEG-35 hydrogenated castor oil) were the most commonly used surfactants in 
microemulsion drug delivery (Figure 2.1), their HLB values were 15, 4.2, 14-16 and 12-14 
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respectively.5,6 Given the need for a high HLB surfactant for lipophilic solubilization 
purposes, Polysorbate 80 and Cremophor RH 40 were selected for further use. 
 The tri-block copolymer group of surfactants of the type, polypropylene (PPO)-
polyethyleneoxide (PEO)- polypropylene (PPO), also known as Poloxamers, are also of 
interest in drug delivery.7 These tri-block copolymers have reportedly lower critical micelle 
concentrations, higher stability and generally narrow micellar size distributions as compared 
to other surfactant micelles.8 There are a variety of tri-block copolymers, or Poloxamers, to 
choose from. However, given that Poloxamer 188 is one of the most commonly used 
surfactants (Figure 2.1) and that the HLB was 297, it was selected for further analysis.  
 Span surfactants, as sorbitan esters, typically have low HLB values and were not 
considered for further analysis. However, d-α-tocopherol polyethylene glycol succinate 
(TPGS) has been previously used as an emulsifier, stabilizer and absorption enhancer, with 
an HLB of 13.2.9 Based on the emulsifying potential of TPGS and the fact that it is a water-
soluble alternative to Vitamin E that may enhance Vitamin E solubility, TPGS was selected 
for further analysis.9 The above rationale, combined with literature support in other 
microemulsion formulations, resulted in the selection of a Polysorbate (Tween 80), a 
Cremophor (Cremophor RH 40), a tri-block copolymer (Poloxamer 188) and Vitamin E 
TPGS for further analysis of microemulsion formation potential. Their structures are shown 
in Table 2.1.  
 With respect to the oil phase of microemulsions, a variety of hydrocarbon oils are 
available for consideration. However, weakly polar oils such as triglycerides are common.10,11 
Triglycerides consist of three fatty acids attached to a glycerol backbone. The length of this 
fatty acid determines its classification as a short, medium, long or very long chain 
triglyceride. Short chain triglycerides (SCTs) consist of fatty acids with less than 8 carbons, 
medium chain triglycerides (MCTs) 8-12 carbons, long chain triglycerides (LCTs) 13-21 
carbons and very long chain triglycerides (VLCTs) more than 22 carbons.21 MCTs and LCTs 
have primarily been used in microemulsion drug delivery due to their ability to solubilize 
and improve lipophilic drug absorption.22 However, there is much evidence to  support the 
particular use of MCTs for oral microemulsion drug delivery.23  Medium chain triglycerides 
are preferred over long chain triglycerides due to their greater water solubility and smaller 






Table 2.1: Chemical structures of surfactants and medium chain triglyceride used in this work 
Surfactant  Chemical Name MW HLB Chemical Structure 
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Miglyol 812 C8-C10 
Caprylic/capric 
triglycerides 





water interface, faster lipid hydrolysis, reduced transit times in the gastrointestinal tract and 
thus, greater ability to improve absorption.10,11,21 The faster lipid hydrolysis of short and 
medium-chain triglycerides (less than 12 carbons) is due to the fact that these lipids are able to 
reach systemic circulation through the portal blood.21,24 In contrast, LCTs must first be 
incorporated into chylomicrons25 leading to slower absorption rates.24 MCTs have also been 
reported to enhance drug stability22 and require less emulsifier than LCTs.10,11 Within the MCT 
class itself, i.e. 8-12 carbons, little variation has been reported with respect to microemulsion 
formation potential. Prajapati et al. (2011) reported minimal differences in phase behaviour 
when using a C8 versus C12 triglyceride in Cremophor EL surfactant and water systems.26 An 
increase in gelling behaviour when using a C12 triglyceride in comparison to C8 was reported.26 
A variety of MCTs such as Neobee M5, Miglyol 810 and Miglyol 812 are commonly used for 
commercial use.27 However, Miglyol 812 is a medium chain triglyceride that has been reported 
to solubilize a large degree of poorly water-soluble drugs.28 For this reason, Miglyol 812, 
comprised of 50-65% C8 and 30-45% C10 was selected as the oil solubilizer in this work.29  
 
2.2   Study Objectives 
Given the major objective of this thesis work, to formulate a microemulsion system capable of 
multi-drug delivery, the first step involves determining a suitable surfactant(s) and ratio of 
surfactant:oil:water (S:O:W) necessary for microemulsion formation. Therefore, the objective 
of Chapter 2 is to assess the microemulsion formation potential of multiple non-ionic 
surfactants via TPD mapping. Promising surfactants will be further assessed using tensiometry 
in order to determine CMC and other important surfactant parameters that may confirm the 
suitability of each surfactant for microemulsion use. 
 
2.3   Hypothesis 
 If microemulsions are formulated with Cremophor RH 40, Poloxamer 188, Polysorbate 80 and 
Vitamin E TPGS, in Miglyol 812 oil, then Type I O/W microemulsion systems are 
predominantly expected while Type II W/O microemulsions are not, given the surfactant HLB 




2.4   Materials and Methods 
2.4.1  Materials 
All surfactants: PEG-40 hydrogenated castor oil, Poloxamer 188, Polysorbate 80 and D-α-
tocopherol polyethylene glycol succinate were generously gifted from Accucaps Industries 
Limited/Catalent Pharma Solutions Inc. PEG-40 hydrogenated castor oil (Cremophor RH 40), 
Poloxamer 188 (Kolliphor P188) and Polysorbate 80 (Kolliphor PS80) were supplied by BASF 
Care Creations (Ontario, Canada) while D-α-tocopherol polyethylene glycol succinate 
(Vitamin E TPGS) was supplied by Sigma Aldrich Canada (Ontario, Canada). Medium chain 
triglyceride (MCT) Miglyol 812 was also gifted from Accucaps Industries Limited/Catalent 
Pharma Solutions Inc. but supplied by IOI Oleochemical (Ontario, Canada). Sudan III 90.0% 
lipophilic dye was purchased from Fischer Scientific (Ontario, Canada). 
 
2.4.2  Methods 
2.4.2.1 Ternary Phase Diagram (TPD) Analysis 
Varying ratios of surfactant, MCT and deionized (DI) water were weighed into a 20 mL 
scintillation vial using a Sartorius Secura 225D-1S analytical balance. Each vial was inverted 
manually for approximately 20 seconds until the mixture appeared uniform. The vials were 
stored in the dark at room temperature for a period of 24 hours before phase behaviour was 
analyzed. For phase analysis at 37ºC, vials were placed in a Fisher Scientific Isotemp GPD 10 
water bath set at 37 ºC for a period of 24 hours. Microemulsion phases were primarily identified 
visually through observation of transparency, turbidity and viscosity. The Tyndall effect was 
also employed using a red laser beam in order to identify microemulsion phases given that the 
colloidal particles scatter light. Thus, in all microemulsion phases, the path of the red laser beam 
was clearly visible. In select samples, conductivity was performed using a SevenEasy 
Conductivity Meter and In-Lab® 752-6 mm micro-conductivity probe to confirm higher 
conductivity in the lower O/W microemulsion phase than the upper excess oil phase (Type I 
microemulsions) and lower conductivity in the upper W/O microemulsion phase than the lower 
excess water phase (Type II microemulsion). Sudan III red lipophilic dye was also used in 
selected samples to confirm the presence of an upper excess oil phase in Type I microemulsions. 
Each phase was recorded and plotted as a single point specific to a certain surfactant:oil:water 
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(S:O:W) concentration on a ternary phase diagram using OriginLab® 8.5 software. 




Figure 2.2: Illustration of ternary phase diagram methodology utilized in this work. 
Microemulsion type was confirmed in two of three ways: visually by identification of phase 
behaviour, visually via laser detection making use of the Tyndall effect and experimentally 
through conductivity measurements. Coloured points in the ternary phase diagram indicate that 
a variety of emulsion structures may be obtained. 
 
 
2.4.2.2. Tensiometry: Critical Micelle Concentration (CMC) Determination 
Critical Micelle Concentrations (CMCs) were determined via tensiometry on a T3 Lauda 
Tensiometer using the DuNoüy ring method. 40 mL MilliQ water was filtered using a 0.22 µm 
Sartorius sterile minisart filter and added to a tensiometry glass vessel along with a clean mini 
stir bar. The DuNoüy ring was immersed 10 times in MilliQ water followed by methanol, then 
flamed until bright orange to clean off any previous solution. Temperature was controlled at 
25°C using a Lauda circulating water bath. Surfactant solutions were carefully titrated into a 
tensiometry glass vessel followed by stirring for 7 minutes before each surface tension 
measurement was collected. The instrument recorded a minimum of three surface tension 
measurements for each titration, until the standard deviation between readings was below 0.1 
mN/m. A graph of surface tension versus the logarithm of surfactant concentration was plotted 
and the breakpoint identified in order to obtain the CMC. Specifically, the CMC was determined 
by the intersection of the linear trendlines before and after this breakpoint. CMC experiments 
were performed in triplicate and the results averaged. Additional surfactant parameters, namely 
surface excess, head group area, micellization energy, critical packing parameter, efficiency, 
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effectiveness and the beta interaction parameter, as explained later, were obtained using CMC 
values via the equations listed in Section 2.5.7. 
 
2.5   Results and Discussion 
The ternary phase plots showed distinct one-, two- and three-phase regions depending on 
the type of surfactant mixed with water and MCT. In general, biphasic regions (Winsor I and 
II) were more easily obtained than monophasic and triphasic regions (Winsor IV and III, 
respectively). In terms of localization, one-phase regions were seen to dominate at higher 
surfactant concentrations, two-phase O/W regions at higher water concentrations and two-phase 
W/O regions at higher oil concentrations. These observations are in agreement with surfactant 
aggregation behaviour.30,31 All surfactants tested in this work possessed HLB values >13, which 
according to the Bancroft rule, should result in the production of large O/W microemulsion 
regions.32 The following surfactant-specific observations were noted. 
 
2.5.1  PEG-40 Hydrogenated Castor Oil  
Cremophors are polyethoxylated castor oils that are synthesized by reacting hydrogenated 
castor oil with varying amounts of ethylene oxide.33 In particular, for PEG-40 hydrogenated 
castor oil, 40 moles of ethylene oxide are reacted with 1 mole of hydrogenated castor oil.33 The 
hydrophobic portion of such surfactants consists of glycerol polyethylene ricinoleate while the 
hydrophilic portion consists of polyethylene glycols and glycerol ethoxylates.33 In general, 
PEG-40 hydrogenated castor oil is comprised primarily of hydrophobic constituents of which 
the main component is glycerol polyethylene glycol 12-hydroxystearate.33 As a result of the 
many hydrophilic polyethylene oxide (PEO) groups, however, the HLB value remains high (14-
16)14 and its solubility in water is enhanced. Thus, PEG-40 hydrogenated castor oil is able to 
act as an oil solubilizer and O/W microemulsion emulsifier34 as can be seen in Figure 2.3.  
 In general, PEG-40 hydrogenated castor oil primarily demonstrated Winsor Type I 
microemulsion formation at room temperature. However, its semi-solid, paste-like state at room 
temperature made phase behaviour interpretations difficult at surfactant concentrations above 
20% w/w, resulting in an incomplete phase diagram. Monophasic opaque systems, likely coarse 
emulsions, dominated at low water concentrations between 15-40% w/w while triphasic 
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behaviour was particularly seen along the 10% w/w water tie line between 35-50% w/w 
surfactant concentration. Monophasic Winsor IV microemulsions dominated at surfactant 
concentrations between 45-80% w/w. As the temperature increased from room temperature to 
37ºC, no significant changes in phase behaviour were seen but for small phase changes along 
the 10% w/w water tie line. The melting temperature of PEG-40 hydrogenated castor oil, which 




Figure 2.3: Ternary phase diagram for PEG-40 hydrogenated castor oil, Miglyol 812 and water 
at room temperature (left) and at 37°C (right).  
  
 
 Winsor I microemulsions comprised the primary region in the ternary phase diagrams 
in this work. In particular, O/W regions dominated at or below 20% w/w surfactant 
concentration, which has previously been reported by Hasan (2016) in PEG-40 hydrogenated 
castor oil- Imwitor 308-water systems.35 These O/W regions also dominated in water-rich 
regions of the TPD at ≥60% w/w water, which has been previously reported by Zeng et al. 
(2017) in PEG-40 hydrogenated castor oil-ethyl oleate-water systems.5 Such observations can 
be explained structurally. In PEG-40 hydrogenated castor oil micelles, the PEO chains expand 
to maximise penetration of water into the chains.5 The branched alkyl chain also enhances 
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emulsification, increasing oil penetration into the curved surfactant film leading to high 
flexibility of the oil-water interface and low droplet sizes.36-38 
 The monophasic opaque area was the second most dominating region, particularly 
between 15-40% w/w water. The physical state of the surfactant is likely responsible for this 
observation as its waxy consistency attributable to its three C18 tails, likely results in highly 
turbid solutions. Bicontinuous, Winsor III and Winsor IV microemulsions were the least 
dominating microemulsion types noted in these PEG-40 hydrogenated castor oil- MCT- water 
systems. Type III microemulsions were observed along the 10% w/w water line. The propensity 
of PEG-40 hydrogenated castor oil to form bilayer aggregates has been reported by Hasan 
(2016).35 The triple-tailed nature of this surfactant versus that of a single-tailed surfactant, leads 
to the favouring of spherical or cylindrical aggregates due to consideration of the packing 
parameter.31,35 This critical packing parameter (CPP) considers the head group and flexible triple 
chain area of PEG-40 hydrogenated castor oil which together result in a similar volume to area 
× length ratio and CPP of between 0.33 and 1.30 This CPP value affords easy formation of 
cylindrical structures, as well as vesicles and flexible bilayer structures.30 The PEO groups are 
also unable to pack as efficiently as in a single-tailed surfactant due to the three hydrophobic 
chains in the micelle core (i.e. the cis double bond and the alcohol groups in the ricinoleic acid 
moiety).39 Monophasic clear regions were observed at surfactant concentrations above 45% 
w/w. This is in line with work reported by Suys (2019) who observed monophasic, liquid 
crystalline regions above 50% w/w PEG-40 hydrogenated castor oil.39 Winsor Type II 
microemulsions were only minimally observed at very high oil concentrations of approximately 
90% w/w. This is likely due to the high HLB value and packing constraints of the PEG-40 
hydrogenated castor oil surfactant molecules.  
 Gelled regions were observed at particularly high oil concentrations (> 70% w/w) and 
low water concentrations (< 30% w/w). This is in line with previously reported works. Suys 
(2019) reported that at >25-30% w/w Cremophor with water, larger structures with higher 
viscosity were formed rather than typical micelles.39 Zeng et al. (2017) reported that when used 
alone with water and oil, PEG-40 hydrogenated castor oil demonstrated large gel-like regions5 
likely due to the triple chain nature of the Cremophor surfactant, which imparts greater viscosity 
than conventional single chain surfactants. This type of behaviour was also apparent in this 
work at 0% water content. Thus, although Cremophors are effective at solubilizing hydrophobic 
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drugs, they are not typically used alone.33 The semi-solid state of these surfactants also renders 
them less desirable for drug delivery on their own due to the fact that even if melting is 
performed, phase separation will still likely occur upon cooling to room temperature.40 These 
observations were notable as even upon an increase to 37ºC and slight melting, the phase 
behaviours only clarified slightly; no significant changes were seen. Triple chain surfactants, 
though bulkier in nature than their single-chain surfactant counterparts, are also known to 
produce more stable emulsions than single or double-chained surfactants due to their enhanced 
viscosity and lower diffusion constant.41 They have been reported to be more efficient at 
lowering surface tension as their triple chain helps form stable, branched, threadlike 
microstructures.41 These features coupled with Cremophor’s ability to inhibit p-glycoprotein 
and cytochrome enzymes, promoting enhanced permeability36, make Cremophor a widely used 
surfactant in oral and parenteral (injectables and intravenous) applications.33,42 In concentrations 
of 50 mg/mL and above, Cremophor EL and Cremophor RH 40 have been reported to cause 
cell damage after 2-3 hours and cell death after 12 hours in endothelial and intestinal epithelial 
cells.42 Epithelial cells appeared to be more resilient to surfactant treatment than endothelial 
cells and Cremophor EL proved to be more toxic than Cremophor RH 40 in both cell types.42  
  
2.5.2  Poloxamer 188 
Poloxamers, or Pluronics® as trademarked by BASF Corporation, are tri-block copolymers 
comprised of polyethylene oxide- polypropylene oxide- polyethylene oxide (PEO-PPO-PEO).16 
In particular, Kolliphor P188 (also known as Poloxamer 188 or Pluronic® F-68) is comprised 
of approximately 27 PO groups flanked by 80 EO groups.16 The molecular weight of 
Kolliphor® P188 is approximately 8400 g/mol40 which is higher than that of typical emulsifying 
surfactants.43 In addition, there are two hydrophilic chains unlike typical non-ionic surfactants43, 
leading to a PEO/PPO ratio of almost 344 and a high HLB value of 29.16 The oxygen groups 
present in both hydrophilic and hydrophobic portions of the molecule afford hydrogen bonding 
with water43 leading to high water solubility44 and the propensity to form O/W microemulsions. 
Structures formed with Poloxamer 188 depend on temperature and concentration.43 Poloxamer 
188 is present as single molecules (unimers) below 50 ºC and above this temperature, polymeric 
micelles are formed.43 The variation of microemulsion types obtained through the use of 




Poloxamer 188 (Figure 2.4) at room temperature demonstrated large Winsor I 
microemulsion formation behaviour at 30% w/w surfactant and below. This surfactant faced 
similar challenges to PEG-40 hydrogenated castor oil; the solid, powder consistency prevented 
phase behaviour analysis above 40% w/w Poloxamer 188 as the solubility limit was reached. 
Triphasic behaviour was concentrated along the 20-30% w/w water line. There was no 
observable monophasic behaviour and once heated to 37ºC, virtually no change was seen but 
for slight phase clarification along the 30% water line. This clarification is possible despite the 
reduced solubility of non-ionic, PEO surfactants at higher temperatures, as both the cloud and 
melting points of Poloxamer P188 are high (>100°C and 52°C, respectively).16,40 
 Winsor I microemulsions represented the primary phase obtained, as Pluronics can self 
assemble to form micelles with the PEO groups forming the shell or corona and the PPO groups 
forming the core of O/W micelles.45,46 In particular, they assemble at the interface between the 
oil core and water with the PEO hydrophilic groups pointing outward into the water phase.47 A 
single Winsor II microemulsion at 10% surfactant, 80% oil and 10% water was observed due 
to the high water solubility and HLB of Poloxamer 188, which may be too high to afford oil 
solubility.  
 Gel regions were obtained throughout the ternary phase diagram at surfactant 
concentrations above 30% w/w which has previously been reported by Bodratti (2018).46 The 
high PEO to PPO ratio leads to well-hydrated outer shell PEO segments that can stick and stack 
together to form structures of high viscosity.46 In general, O/W PEO systems are found to be of 
high viscosity above 10% w/w concentrations because below this, the droplets are too widely 
spaced to be bridged by the polymer molecule.48 Reverse thermal gelation behaviour is typically 
observed with Poloxamer 188 (Pluronic F68) at surfactant concentrations of 50% w/w and 
above.44 However, in this work, surfactant concentrations above 40% w/w were difficult to 






Figure 2.4: Ternary phase diagram for Poloxamer 188, Miglyol 812 and water at room 
temperature and at 37°C.  
 
 
2.5.3  Polysorbate 80 
Polysorbate 80 is a polyethoxylated (PEO) sorbitan monooleate non-ionic surfactant.49 It is 
comprised of an oleate ester of sorbitol and its anhydrides, copolymerized with approximately 
20 moles of ethylene oxide for each mole of sorbitol and sorbitol anhydrides.49 There are four 
hydrophilic EO head groups, summing to 20, that are attached to a sorbitan ring. The 
hydrophobic region is comprised of an oleyl, unsaturated tail connected to one PEO group via 
an ester.50 The kink present in the hydrophobic tail of Polysorbate 80 affords flexibility, leading 
to an optimal curvature and packing parameter that promotes microemulsion formation.51 
 Polysorbate 80 (Figure 2.5) demonstrated a wide range of mono-, bi- and tri-phasic 
behaviour across various ratios of surfactant, MCT oil and water. At room temperature, a large 
monophasic Type IV microemulsion region dominated mainly at surfactant concentrations 
above 50% w/w. Below 50% w/w surfactant, monophasic opaque, biphasic and triphasic 
behaviours dominated. Winsor I microemulsions were evident below 40% w/w surfactant and 
at or above 30% w/w water. Winsor II microemulsions dominated above 70% w/w oil and 
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Winsor III microemulsions, though rare, were evident along the 10-15% w/w water line. As 
temperature was increased to 37ºC, virtually no change in phase behaviour was observed.  
 
Figure 2.5: Ternary phase diagram for Polysorbate 80, Miglyol 812 and water at room 
temperature and at 37°C. 
 
 
 The extensive monophasic, microemulsion region observed in this work was previously 
reported in Polysorbate 80-Captex 355-water systems52 and Polysorbate 80-isopropyl 
myristate-water systems.53 Winsor I microemulsions have also been previously reported in 
Polysorbate 80-isopropyl myristate-water systems.53 According to the critical packing 
parameter, one can expect the relatively large head group and single tail of Polysorbate 80 to 
form spherical, Type I O/W micelles based on the small volume to area x length ratio (CPP < 
0.33).30 Opaque emulsions obtained between 30-50% w/w surfactant correlate with the 
previously reported work of Shah et al. (2017) in Polysorbate 80-Captex 355-water systems.52 
Winsor II microemulsion regions, the largest of all surfactants tested in this work, were 
previously reported by Syed et al. (2014) in Polysorbate 80-isopropyl myristate-water 
systems.53 Surfactants with small head groups and large tails have a propensity to form reverse, 
Type II W/O micelles.54 Since Polysorbate 80 contains a cis-double bond in the oleyl chain of 
Polysorbate 80, this leads to a widely spaced tail.54 This unsaturation also causes kinking55 and 
affords flexibility of the surfactant tail to assume an optimum curvature and packing parameter 
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for many conformations56 including that of W/O micelles and thus, Type II microemulsions. 
Winsor III microemulsions observed at 30-40% w/w surfactant were also in good agreement 
with previous studies using Polysorbate 80-isopropyl myristate- water systems.53 
 Gelling was observed primarily between 10-50% w/w water. This is in good agreement 
with work by Shah et al. (2017) who studied Polysorbate 80-Captex 355-water systems and 
observed gelling between 15-60% w/w water.52 No significant phase changes were seen upon 
heating to 37°C and gelling regions remained the same. This is in contrast to work by Prieto 
and Calvo (2013) who reported that in Polysorbate 80-decane-oil systems, when temperatures 
rose from 25 to 30°C, gel regions decreased due to a reduction in viscosity.57 However, it should 
be noted that decane oil is a straight chain oil versus a MCT. 
 In general, Winsor I O/W microemulsions dominated due to Polysorbate 80 being a 
hydrophilic surfactant (HLB 15) with a preferred solubility in water than oil, a result of the 
previously explained Bancroft effect. Phase separated microemulsion regions were seen 
primarily below 50% w/w surfactant, which correlated with work by Shah et al. 2017.52 A large 
spread of microemulsion types was obtained with this surfactant given the common head and 
tail structure. In Polysorbate 80-palm oil-water systems, Mahdi (2011) previously reported a 
wide spread of microemulsion types obtained due to the unsaturated nature of the hydrocarbon 
chain, which affords mobility and flexibility.58 
 
2.5.4  D-α-tocopherol Polyethylene Glycol Succinate (TPGS) 
TPGS is a water-soluble alternative to fat-soluble vitamin E.59 Its lipophilic alkyl tail consists 
of tocopherol succinate (natural vitamin E) while its hydrophilic head consists of polyethylene 
glycol 1000 (~22 ethylene glycol groups).59,60 It is a bulky molecule with a molecular weight of 
~1513 g/mol that forms low viscosity solutions with water at concentrations of up to 20% w/w 
surfactant.59,60 
 TPGS (Figure 2.6) is a solid wax at room temperature that requires heating prior to 
phase behaviour analysis. As a result, evaluation at room temperature above 10% w/w 
surfactant concentrations was difficult. In general, though coarse monophasic emulsions were 
evident throughout the phase diagram, clear monophasic Type IV microemulsion regions were 
seen at and above 60% w/w surfactant concentration and Winsor I microemulsions were evident 
below 50% w/w oil. Winsor II microemulsions were evident at and above 50% w/w oil and at 
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37ºC, slight decreases of the monophasic opaque emulsion areas were seen, along with an 
expansion of the monophasic clear, Type IV microemulsion region. 
 This Winsor IV microemulsion region was previously observed by Ke at al. (2005) who 
reported monophasic regions in TPGS-MCT-water systems above 30% w/w surfactant.59 Type 
I microemulsions were expected at high water concentrations given that the CMC of TPGS is 
approximately 0.02% w/w at 37°C in water, and that O/W micelles form above this 
concentration.60 At 37ºC, many of the opaque emulsion phases clarified and were able to be 
differentiated into different microemulsion types. This is a result of the melting temperature of 
TPGS, which is also 37ºC.60 
 Large gelling regions were observed throughout this ternary phase diagram mainly 
above 60% w/w surfactant concentrations and between 0-50% water. This has previously been 
reported by Ke et al. (2005).59 Gelling can be explained due to TPGS’ large hydrophobic 
tocopherol group and long hydrophilic PEG 1000 chain which allows water to be adsorbed to 
the PEG chains, resulting in a rigid hydrogen bonding structure or gel.59 Ke et al. (2005) noted 
that TPGS on its own is unable to form isotropic solutions with water and oil across a broad 
range of compositions59 and these observations were evident in this work. 
 
 
Figure 2.6: Ternary phase diagram for D-α-tocopherol polyethylene glycol succinate, Miglyol 
812 and water at room temperature and at 37°C 
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2.5.5  PEG-40 Hydrogenated Castor Oil, Poloxamer 188, Polysorbate 80 & D-α-
tocopherol Polyethylene Glycol Succinate 
Based on Figures 2.3-2.6, a few observations were noted. In general, Winsor I, O/W 
microemulsions dominated these ternary phase diagrams irrespective of the solubility 
challenges faced with solid and wax-based surfactants. This result was expected given that the 
surfactants used in this work possessed an HLB ≥13. According to the Bancroft rule, the 
continuous phase is reflective of the phase in which the surfactant is most soluble. Thus, in this 
case, water dominates as the continuous phase. Winsor II microemulsions of the water-in-oil 
type were less frequently obtained for this reason as well. Winsor III microemulsions were the 
most difficult to obtain due to their need for a delicate balance of oil, water and surfactant, no 
particular preference for a continuous phase and a zero net curvature.61 Winsor IV 
microemulsions were primarily present in high surfactant concentrations near 50% w/w or 
higher.61 This was particularly evident in Polysorbate 80 but less evident in PEG-40 
hydrogenated castor oil due to its waxy nature and Poloxamer 188 due to the water solubility 
limit being reached.   
  Opaque emulsions were obtained in the order PEG-40 hydrogenated castor oil = 
Polysorbate 80 > TPGS > Poloxamer 188. Coarse emulsions are well suited to a number of drug 
delivery applications, particularly in lotions or creams. They may also be homogenized to 
produce nanoemulsions, which affords a variety of additional drug delivery applications.   
 Winsor I, O/W microemulsions were obtained in the order Polysorbate 80 > PEG-40 
hydrogenated castor oil > Poloxamer 188 > TPGS. Although Polysorbate 80, PEG-40 
hydrogenated castor oil and Poloxamer 188 demonstrated large Winsor I microemulsion 
regions, TPGS demonstrated a much smaller region. This may be attributed to the solid state of 
TPGS, which required significant heating before phase regions could be observed. It should 
also be noted that while a relatively complete ternary phase diagram was obtained for 
Polysorbate 80, this was not necessarily the case with the other surfactants studied in this work. 
Nevertheless, O/W microemulsions in general are well suited for lipophilic drug delivery.62  
 Winsor II microemulsions were obtained in the order Polysorbate 80 > PEG-40 
hydrogenated castor oil = TPGS > Poloxamer 188. The high HLB value of the surfactants tested 
in this work may be responsible for decreasing the tendency to form W/O microemulsions given 
the Bancroft rule. Winsor III microemulsions were obtained in the order Poloxamer 188 > PEG-
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40 hydrogenated castor oil = Polysorbate 80 > TPGS. Type III microemulsions are uncommon 
in drug delivery applications but are useful for oil-recovery methods. 
 Type IV microemulsions were obtained in the order Polysorbate 80 > TPGS > PEG-40 
hydrogenated castor oil > Poloxamer 188.  Polysorbate 80 demonstrated a Type IV 
microemulsion region up to 5X larger than that of the other surfactants. This type of 
microemulsion is homogenous and uniform and thus, well suited for many types of drug 
delivery especially multi-drug delivery. In addition, the typically higher viscosity of these 
microemulsions renders them especially suitable for other types of drug delivery applications 
such as ocular, topical and rectal delivery. 
 
2.5.6  PEG-40 Hydrogenated Castor Oil: Polysorbate 80 
Multi-drug delivery represents an unmet need given the burden of chronic disease in Canada.1 
The demand for this type of drug delivery requires further exploration of the Type IV 
microemulsion region, as these microemulsions are able to facilitate simultaneous delivery of 
both hydrophilic and lipophilic drug compounds. Based on Figures 2.3-2.6, Polysorbate 80 
demonstrated the largest Winsor Type IV microemulsion region. However, there is literature 
support for the use of PEG-40 hydrogenated castor oil as a solubilizer, particularly for 
hydrophobic active pharmaceutical ingredients (APIs).33 The high HLB value of PEG-40 
hydrogenated castor oil affords lipophilic drug delivery due to the propensity to form O/W 
micelles and solubilize lipophilic drug material.34 PEG-40 hydrogenated castor oil has also been 
reported to be efficient at lowering surface tension41 and promoting enhanced permeability of 
drugs.36 Despite these advantages, PEG-40 hydrogenated castor oil is unable to form large Type 
IV microemulsion regions. Given the high propensity for Polysorbate 80 to form Type IV 
microemulsions, PEG-40 hydrogenated castor oil was combined with Polysorbate 80 in order 
to determine whether expansion of the Type IV microemulsion region in PEG-40 hydrogenated 
castor oil was possible. 
 Polysorbate 80 and PEG-40 hydrogenated castor oil were mixed in increasing ratios of 
Polysorbate 80 from 1:2, 1:1 and 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil (Figures 
2.7-2.9). As the concentration of Polysorbate 80 increased and that of PEG-40 hydrogenated 
castor oil decreased, there was a clear reduction in monophasic opaque emulsion areas and 




note is that monophasic formation was scarce below 60% w/w surfactant in 1:1 and 1:2 
Polysorbate 80: PEG-40 hydrogenated castor oil. However, in 3:1 and Polysorbate 80: PEG-40 
hydrogenated castor oil systems, monophasic behaviour can be seen at as low as 50% w/w 
surfactant. Heating these samples to 37°C appears to somewhat afford expansion of this Type 
IV, monophasic microemulsion region. These results prove that expansion of the Type IV 
microemulsion region in PEG-40 hydrogenated castor oil is possible with the combination of 




Figure 2.7: Ternary phase diagram for 1:1 Polysorbate 80:PEG-40 hydrogenated castor oil, 








Figure 2.8: Ternary phase diagram for 1:2 Polysorbate 80:PEG-40 hydrogenated castor oil, 
Miglyol 812 and water at room temperature and at 37°C. 
 
Figure 2.9: Ternary phase diagram for 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil, 





 The ability of Polysorbate 80 to afford expansion of the Winsor IV microemulsion 
region in PEG-40 hydrogenated castor oil can be explained through examination of various 
surfactant characteristics and packing properties, both individually and upon mixing. Figures 
2.7-2.9 demonstrate a gradual expansion in the variety of microemulsion types produced upon 
mixing PEG-40 hydrogenated castor oil with increased concentrations of Polysorbate 80. Thus, 
it can be inferred that the mixing of these two surfactants is favourable with respect to 
microemulsion formation potential. In terms of packing, Polysorbate 80 micelles in water 
contain three hydrophilic heads with terminal OH groups and a fourth PEO segment attached 
to an 18-carbon alkyl tail.63 This results in a ‘cactus-type’ orientation with two heads assuming 
a V-shape, perpendicular to the third head and fourth tail in an almost linear backbone.63 
Polysorbate 80 micelles assemble very quickly in water, with the OH groups covering the 
surface of the micelle, while the hydrophobic tails remain within the micelle core.63 The tails of 
Polysorbate 80 do not assume a straight or 180° angle; rather, they assume a conformation 
between 50 and 180°, peaking at approximately 140°.63 Thus, these tails do not point to the 
centre of the micelle but are somewhat slanted at approximately 25° rather than at 0°.63 
 The packing of Cremophor surfactant micelles in water is slightly different and highly 
dependent on concentration. Below 25% w/w, micelles are the dominant form but above 25% 
w/w larger, gel-like structures are seen.39 In water, Cremophor surfactant molecules aggregate 
with glycerol and its three connected PEO chains on the outer micellar core in a relatively 
expanded conformation to maximize water penetration.39 The hydrophobic ricinoleic acid 
moieties concentrate in the core of micellar structures, but the presence of a cis double bond in 
these moieties leads to inefficient packing of the PEO chains.39 Thus, micelles of Cremophor 
are found to be larger than that of Polysorbate 80.39 
 In a study of mixed micelles containing POE (10) stearyl ether and either Polysorbate 
20 or Polysorbate 60, it was found that when the length of the alkyl tail of the ether and that of 
the Polysorbate surfactant were the same, the two hydrophobic chains tended to remain 
elongated within the micelle, rather than tangling and becoming globular in the case of unequal 
alkyl chain lengths.64 This is supported by the investigative work of Weerapol et al. (2014) on 
Cremophor RH 40 and Span 80 micelles, who found that surfactants with similar alkyl chain 
lengths pack favourably, leading to small droplet sizes.37 Given that PEG-40 hydrogenated 
castor oil and Polysorbate 80 have the same number of carbons in their hydrophobic alkyl tails, 
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it is possible that the hydrophobic tails pack well together, remaining somewhat linear and 
elongated in the core of the micelle in contrast to a tangled or globular orientation. In addition, 
there is the possibility of a type of symmetry in the packing of Polysorbate 80:PEG-40 
hydrogenated castor oil mixed micelles at an interface, due to the fact that Polysorbate 80 
consists of three hydrophilic heads and one lipophilic tail while PEG-40 hydrogenated castor 
oil consists of one hydrophilic head (with three interconnected PEO chains) and three 
hydrophobic tails. The interactions between Polysorbate 80 and PEG-40 hydrogenated castor 
oil leading to this favourable packing may be further explained through consideration of CMC, 
surface excess, efficiency, effectiveness and the β interaction parameter (Table 2.2). 
 
2.5.7  Tensiometry  
 Mixed surfactant systems may be characterized through examination of their ideal and 
experimental CMCs. The ideal CMC is the calculated CMC of a surfactant mixture using molar 
fractions and CMC values of each individual surfactant. If the experimental CMC is lower than 
that of the ideal as predicted by Eq. 2.1, the surfactant mixture is said to behave synergistically. 
If the ideal CMC is greater than the experimental CMC, the surfactant mixture behaves 
antagonistically. Using the following equation proposed by Clint (1975)65 for mixed micelle 








                                 (Eq. 2.1) 
 
where CMC1,2 is the ideal CMC, a and (1-a) are the mole fractions of surfactant 1 and surfactant 
2, respectively, and cmc1 and cmc2 are the CMCs of surfactant 1 and 2, respectively. Using Eq. 
2.1, the ideal CMC for 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil is 4.77 µM 
(Appendix A). The results in Table 2.2 indicate that the experimental CMC for 3:1 Polysorbate 
80: PEG-40 hydrogenated castor oil (Figures A6-A8, Appendix A) was lower than that of the 
ideal CMC, which was 3.59 µM. This is despite the fact that the experimental CMCs for the 
individual surfactants were higher than that of the literature values, an occurrence that has 
previously been reported.66 The low experimental CMC confirms the presence of attractive 
forces between these two surfactants and thus, a degree of synergism. CMC plots may be found 
in Figures A-1 – A-8, Appendix A. 
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Table 2.2: Surfactant parameters for Polysorbate 80, PEG-40 hydrogenated castor oil and a 



















































































































































* standard deviations not computed for Polysorbate 80 due to absence of replicates 
 
 Surface excess (Γ) is a measure of the amount of “excess” surfactant molecules per unit 
area at the interface relative to that present in the bulk.67 It is given by the following equation67: 
 
                                                   Γ = 	− !".$%$&'( 	(
)*
) +,-.)                                                           (Eq. 2.2) 
 
where R is the gas constant in J/K.mol, T is the temperature in K and ( *	,
* -./ 0
) is the slope of the 
initial decreasing surface tension line (line 1). A positive surface excess value indicates that a 
surfactant decreases surface tension and vice versa.68 Based on Eq. 2.2 and the results from 
Table 2.2, all surface excess values are positive, indicating surface activity and surface tension 
lowering capacity in all surfactants investigated. PEG-40 hydrogenated castor oil has a lower 
surface excess value than that of Polysorbate 80. This can be explained structurally, as PEG-
40 hydrogenated castor oil is quite bulky with a large hydrophilic head and three unsaturated 
hydrophobic chains, leading to steric limitations and thus, a lower amount of surfactant 
molecules that are able to pack per unit area of the interface.69 Polysorbate 80 has the largest 
surface excess of all surfactants tested, indicating close packing at the interface and little 
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repulsive forces between the Polysorbate head groups.66 3:1 Polysorbate 80: PEG-40 
hydrogenated castor oil has lower surface excess values than that of Polysorbate 80 alone, 
likely due to the presence of larger PEG-40 hydrogenated castor oil molecules which are able 
to pack less efficiently between the Polysorbate 80 surfactant molecules.  
 A0 is the molecular area (in nm2/molecule) occupied by each surfactant molecule at the 
interface and is therefore, an indication of the amount of space each surfactant head group 
occupies at said interface.67 It is given by the following equation:70 
 
                                              %1 =
!1/0
21.4
                                                             (Eq. 2.3) 
 
where NA is Avogadro’s number and Γ is the surface excess in mol/m2. As expected, PEG-40 
hydrogenated castor oil molecules occupy a larger area than that of Polysorbate 80 molecules 
(Eq. 2.3, Table 2.2). 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil surfactant 
molecules occupy an area that is between that of the individual surfactant molecules. 
 ΔG°mic, the Gibbs free energy of micellization, is a measure of the tendency of surfactant 
molecules to form micelles and is measured in KJmol-1.70 It is calculated via the equation: 
 
ΔG°mic = RTln(cmc) 
Therefore, ΔG°mic = RTln	( '
55.56'
)                              (Eq. 2.4) 
 
where R is the gas constant in J/K, T is the temperature in K, C is the concentration of surfactant 
in M and the CMC is expressed as a mole fraction in bulk water. Large and negative ΔG values 
indicate spontaneous micelle formation and a thermodynamically stable micellar solution at the 
tested temperature70, in this case, 25°C. The results in Table 2.2 from the use of Eq. 2.4 indicate 
similar spontaneity of micellization in Polysorbate 80 and PEG-40 hydrogenated castor oil 
individually, and more favourable spontaneity upon the mixing of these surfactants in 3:1 
Polysorbate 80: PEG-40 hydrogenated castor oil systems. This lends further support to the use 
of Polysorbate 80: PEG-40 hydrogenated castor oil mixed micelle systems in drug delivery. 
 CPP, the critical packing parameter, is an indication of the packing geometry of 
surfactant molecules in water.67 It relates the volume of the hydrophobic portion of the 
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surfactant molecule to that of the area occupied by the head group multiplied by the length of 
the hydrocarbon tail. It is given by the following equation67 : 
 
                                                          122 = 	 7
&283
                                                     (Eq. 2.5) 
 
where v is the volume of the hydrophobic portion of the surfactant molecule in nm3, a0 is the 
area occupied by the head group in nm2 and lc is the length of the hydrocarbon tail in m. The 
values of v and l were obtained using Tanford’s equations67: 
 
                                  3 = 0.0274 + (0.0269 ∗ <')  and                                        (Eq. 2.6) 
                                               = = 0.15 + (0.1265 ∗ <')                                        (Eq. 2.7) 
 
where nc is the number of carbons in the surfactant hydrocarbon chain. The CPP values listed 
in Table 2.2, as obtained from Eqs. 2.5-7, are below 0.33 and consistent with spherical micelle 
formation, as is expected for each surfactant given its head and tail structures. Surfactant 
efficiency and effectiveness are indicators of surfactant performance. Efficiency is the 
concentration of surfactant required to reduce the surface tension by a specified amount of 20 
mN/m, while effectiveness is the maximum reduction of surface tension that can be obtained 
with a particular surfactant.67 Surfactant efficiency is given by the equation67: 
 
                                               @AABCBD<CE = 	− log 1%1                                         (Eq. 2.8) 
 
where C20 is the concentration of surfactant, typically in mM, required to reduce the surface 
tension by 20 mN/m. In contrast, surfactant effectiveness is given by the equation67: 
 
                                             ∆'('° =	J'('	 + 2.3<LΓ. log	(
'('
'/
)                             (Eq. 2.9) 
 
where πcmc is the surface pressure as calculated by the difference between the surface tension 
of water and that of the system at the critical micelle concentration (typically in N/m), R is the 
gas constant in J/K.mol, T is the temperature in K, Γ is the surface excess in mol/m2, cmc is 
the critical micelle concentration (typically in M) and C1 is the lowest surfactant concentration 
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(M) obtained from line 1 in the semi-log plot of surface tension versus surfactant concentration. 
According to Table 2.2 and Eqs. 2.8-9, 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil 
proved to be an efficient surfactant mixture while effectiveness appeared to decrease upon 
mixing the two surfactants. The highest surfactant effectiveness was seen in Polysorbate 80, 
likely due to its small hydrophilic head group, which is able to pack neatly at the interface as 
has been previously reported.69 This small hydrophilic head also leads to relatively large 
CMC/C20 and Γ values69 as seen in this work. PEG-40 hydrogenated castor oil with its multi- 
hydrophobic tail structure had a smaller effect on efficiency than effectiveness as has been 
previously reported for multi-chain surfactants.71 CMC/C20 sheds insight into the micellization 
and adsorption processes, where CMC is the critical micelle concentration and C20 is the 
concentration of surfactant required to reduce the surface tension by 20 mN/m.69 An increase 
in CMC/C20 indicates that micellization is inhibited more than adsorption while a decrease in 
this parameter indicates that micellization is facilitated more than adsorption. 3:1 Polysorbate 
80: PEG-40 hydrogenated castor oil demonstrated lower CMC/C20 values in comparison to that 
of the individual surfactants, indicating that this surfactant mixture exhibits a strong tendency 
for micellization. This lends further support to the use of Polysorbate 80 and PEG-40 
hydrogenated castor oil mixed micelle systems for multi-drug delivery. 
 The β interaction parameter is an indicator of the nature and strength of an interaction 
between two different surfactants in a mixed micelle system.72,73 The value of this parameter is 
dimensionless and relates to the free energy change between mixed and unmixed systems.72,73 
A negative β value indicates more attractive or less repulsive forces between the two 
surfactants and thus, synergism.72 Consequently, a positive β value indicates less attractive or 
more repulsive forces between the two surfactants and thus, antagonism. A β value of 0 
indicates little to no change in interaction.72,74 The equation for calculating the β interaction 
parameter and its variables was given by Rubingh in 197975; the value itself depends heavily 
on surfactant structure including the  bulkiness  of  head  and  tail  groups  as well as the mole 
fraction of each surfactant used.72 The β parameter is valid assuming: 1) a lack of solution 
impurities, 2) an absence of counterion effects and 3) an absence of free water in all mixed 
micelle systems.72  It is given by the following equation:73 
                                                                                       N = ln( '('.&/
'('/.:/




where a1 is the mole fraction of surfactant 1, cmc is the critical micelle concentration of the 
surfactant mixture, cmc1 is the critical micelle concentration of surfactant 1 and X1 is the 
micellar composition (solved iteratively) using the following equation:73 
 









= 1                                       (Eq. 2.11) 
 
where all variables are as defined above with cmc2 being the critical micelle concentration of 
surfactant 2. 
 According to Table 2.3 and based on Eqs. 2.10 and 2.11, 3:1 Polysorbate 80: PEG-40 
hydrogenated castor oil mixtures resulted in negative β values that deviate from zero, indicating 
attractive interactions between these two surfactants and thus, synergism. This could possibly 
be due to the facilitated packing of Polysorbate 80 between the bulky PEG-40 hydrogenated 
castor oil molecules. Nevertheless, it is evident that Polysorbate 80 and PEG-40 hydrogenated 
castor oil exhibit attractive tendencies, leading to synergism and thus, favourable 
microemulsion formation, which may find application in a variety of drug delivery spheres. 
 
Table 2.3: Mole fraction (α1), ideal CMC, experimental CMC, mixed micellar composition 
(X1) and interaction parameter (β) for 3:1 Polysorbate 80: PEG-40 hydrogenated castor oil 














3:1 Polysorbate 80: 
PEG-40 hydrogenated 
castor oil 
0.75 4.77 3.59 ± 0.00 0.67 -2.2 
 
 
2.6   Conclusion 
The phase mapping performed in this work demonstrated that despite the similarities in HLB 
value amongst the non-ionic surfactants utilized, a broad range of microemulsion types, unique 
to each surfactant, was obtained. In general, all surfactants used in this work demonstrated high 
Winsor I, O/W microemulsion formation potential at increased water concentrations, and low 
Winsor II W/O microemulsion formation potential at increased oil concentrations, as 
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hypothesized. This is a direct result of the high HLB value and propensity to form O/W 
emulsions in accordance with the Bancroft rule. Winsor III microemulsions were generally 
concentrated in the middle of each ternary phase diagram while Winsor IV monophasic 
microemulsions were concentrated primarily at high surfactant concentrations above 40% w/w. 
 Given that all surfactants tested in this work had the tendency to form O/W 
microemulsions, it can be concluded that PEG-40 hydrogenated castor oil, Poloxamer 188, 
Polysorbate 80 and TPGS are suitable for lipophilic drug delivery. Type II W/O microemulsions 
were difficult to obtain. However, of the surfactants tested in this work, Polysorbate 80 
demonstrated the largest W/O microemulsion potential rendering it suitable for hydrophilic 
drug delivery. Type IV microemulsion drug delivery was notable in all surfactant systems but 
most prominent in Polysorbate 80. Type IV microemulsions were formed at higher surfactant 
concentrations and thus, are well suited for a multitude of drug delivery applications including 
multi-drug delivery. Overall, Polysorbate 80 demonstrated the highest versatility in terms of 
microemulsion formation type, most likely due to its large hydrophilic head and hydrocarbon 
tail structure, which was able to assume a variety of conformations. 
 This work also demonstrated the promotion of Type IV microemulsion formation in 
PEG-40 hydrogenated castor oil upon mixing with Polysorbate 80. The propensity of 
Polysorbate 80 to induce Type IV microemulsion formation in PEG-40 hydrogenated castor oil 
is a direct result of the molecular structures and packing arrangements afforded by each 
surfactant. It appears that Polysorbate 80 with its triple PEO head group and monooleate alkyl 
tail was able to pack efficiently between the large head group and triple monooleate tail 
structure of PEG-40 hydrogenated castor oil. An investigation of important mixed surfactant 
parameters such as CMC, ΔG°mic and the β interaction parameter proved that these two 
surfactants have a particular affinity for each other, leading to synergistic tendencies and an 
ability to form a myriad of microemulsion types. Thus, this work has determined that 
Polysorbate 80 and PEG-40 hydrogenated castor oil are a novel, non-ionic surfactant pair that 







Chapter 3: Optimization of Microemulsion Formulation 




3.1   Introduction 
In Chapter 2, a microemulsion system comprised of 3:1 Polysorbate 80:Cremophor RH 40, 
Miglyol 812 and water was identified for further analysis and incorporation of active 
pharmaceutical ingredients (APIs). Given that the proof-of-concept in this work is a multi-
vitamin comprised of multiple APIs of varying hydro- and lipophilicity, the challenge involves 
developing a strategy for incorporating them into the existing microemulsion formulation. 
 
3.1.1  Lipophilic versus Hydrophilic API Incorporation 
As noted in Chapter 1 of this work, literature regarding multi-drug delivery and specifically, 
microemulsion, multi-drug delivery is limited. Research involving this type of multi-drug 
delivery has typically focused on the incorporation of drugs of similar hydro- or lipophilicity, 
such that similar solubilisation conditions were used.1 The type of multi-drug delivery 
necessary in this work, where drugs of varying hydro- and lipophilicity are used, presents 
greater challenges. 
 The involvement of more than one API results in complications not only in solubility, 
but upon exposure to temperature, salinity and lipophilicity as these parameters may affect 
various APIs in solution as well as the resulting microemulsion. One approach to this problem 
is to group APIs based on their hydro- or lipophilicity and treat this multi-API group as a single 
entity. In this manner, complex, multi-drug delivery is simplified and similar incorporation 
conditions may be used for each group of APIs; this is the approach that has been used in this 
work. The lipophilic API component was comprised of beta-carotene (precursor to Vitamin 
A), cholecalciferol (Vitamin D3), d-α-tocopherol acetate (Vitamin E acetate), phytonadione 
(Vitamin K1) and docosahexaenoic/eicosapentaenoic acid (DHA/EPA) while the hydrophilic 
API component was comprised of thiamine mononitrate (Vitamin B1), riboflavin (Vitamin B2), 
niacinamide (Vitamin B3), pyridoxine hydrochloride (Vitamin B6), folic acid (Vitamin B9) and 
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cyanocobalamin (Vitamin B12). Amounts were added in accordance with Health Canada 
requirements, adjusting for potency as outlined in Table B-1, Appendix B. Minerals were not 
considered for future formulation due to their inability to be solubilized and the fact that they 
would simply remain suspended in solution. This suspension may present further 
complications with respect to stability due to gravitational separation and potential metal 
incompatibility with the aqueous component of the formulation. 
 As noted in Chapter 1, Section 1.5.2, lipophilicity impacts the type of microemulsion 
obtained and shifts the HLD value to the left.2 Incorporation of highly lipophilic APIs into the 
oil phase of a microemulsion can result in a change in lipophilicity of the system, affecting the 
ability of the surfactant to sufficiently solubilize the oil component and produce a 
microemulsion. Incorporation of hydrophilic, charged APIs into the water phase of the 
microemulsion, while unlikely to produce as large an effect as lipophilic API incorporation, 
may also affect ionic strength and the type of microemulsion produced. In addition, the 
presence of slightly surface-active APIs may affect partitioning into either aqueous or organic 
phase and may act along with the emulsifying agent to either decrease or increase the interfacial 
tension, affecting microemulsion type. Therefore, optimizing such a system for drug delivery 
involves solubilizing the lipophilic APIs in oil, the hydrophilic APIs in water, and examining 
the overall effect on the microemulsion. The HLD equation may be used to examine this effect. 
  
3.1.2  Optimization of Microemulsion Formulation via the HLD Equation 
In Chapter 1, Section 1.5.2 the HLD equation was identified as a powerful tool for 
microemulsion formulation that not only considers structural properties of the surfactant, but 
also environmental factors that greatly impact microemulsion formation such as temperature 
and lipophilicity, as depicted by the equations below2 :  
 
HLD	 = 	b	(S)– 		K	(EACN) − 	ϕ	(A) + 	CT	∆T	 + 	CC			for non-ionic surfactant       (Eq. 3.1)                  
HLD	 = 	ln	(S)	– 	K	(EACN)	– 	f	(A) 	− 	αT∆T	 + 	CC    for ionic surfactants              (Eq. 3.2)                  
  
 One way to evaluate the effect of lipophilic API incorporation on microemulsion 
formation is to determine the value of the effective alkane carbon number (EACN) term in the 
HLD equation. EACN has practical relevance given that formulation studies are not often 
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performed with straight chain oils. Rather, oils that are commercially available contain a 
mixture of structurally related oils.3 In addition, complications may arise from commercial, 
non-ionic surfactants that tend to preferentially partition into oil4 or polar oils that tend to 
partition into water.5,6 Thus, the EACN is a practical approach to quantifying many of the non-
linear oils most commonly used today, though impure oils must be used with caution.5,7 EACN 
assigns a straight-chain carbon number to non-linear oils but the assignment of an EACN to a 
particular oil does not necessarily mean that the oil behaves analogously to its straight chain 
counterpart. It merely means that there is a way to quantitatively determine the degree of 
lipophilicity of complex oils typically used in microemulsion formulations, and to adjust the 
HLD value accordingly as a formulation optimization tool. The EACN of the oil phase before 
and after API incorporation may be compared in order to determine any differences in 
microemulsion formation potential. The higher the EACN, the more lipophilic the oil phase 
and the more negative the HLD or propensity to form O/W microemulsion systems.  
 Characteristic curvature (CC) is another term unique to each surfactant, essential in 
determining the HLD value. CC is a surfactant parameter like HLB that takes into account the 
structure of the head and tail groups of a surfactant.4 It describes the tendency of a surfactant 
to curve towards a particular interface.4 A negative CC refers to a hydrophilic surfactant with 
a tendency to form O/W micelles while a positive CC refers to a hydrophobic surfactant with 
a tendency to form W/O micelles.4 Oleic acid with 18 carbons including a carboxylic acid 
group and unsaturated double bond, has been determined to possess a CC value of 0.8 Thus, a 
CC value above or below 0 indicates a surfactant more hydrophobic or hydrophilic than oleic 
acid, respectively.8 As can be seen from the HLD equation, the lower the CC, the lower the 
HLD. This increases the tendency to form O/W microemulsion systems. 
 Oil EACN and surfactant CC are two of the most difficult values to obtain in the HLD 
equation. Both EACN and CC are determined via formulation scans which involve keeping all 
parameters but one, constant. Typically, oil, water and surfactant ratios are kept constant while 
one variable such as salt concentration or temperature or oil alkane carbon number is varied. 
For EACN determination, temperature is varied in the case of non-ionic surfactants, while 
salinity is varied in the case of ionic surfactants. For CC determination, oil EACN is varied. 
Formulation scans often involve a large degree of trial-and-error in order to obtain the right 
conditions to observe a shift from a Type Ià IIIà II microemulsion. However, despite these 
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difficulties, formulation scans afford the determination of how microemulsion behaviour 
changes upon API incorporation. Once these changes are determined, the plotting of ternary 
phase diagrams (TPDs) with each individual API to determine microemulsion behaviour may 
not be necessary. 
 In this work, lipophilic APIs are likely to demonstrate an ease of solubility in oil versus 
that of hydrophilic APIs in water, given the low water solubilities of some B vitamins. As a 
result, saturation solubility testing (Chapter 1, Section 1.7.1) will be performed on the 
hydrophilic B vitamins with the microemulsion components identified in Chapter 2 i.e., 
Miglyol 812, Polysorbate 80 and Cremophor RH 40. Components in which the B vitamins 
demonstrate favourable solubility will be confirmed for use as the microemulsion into which 
both hydrophilic and lipophilic APIs may be incorporated. 
 
3.2   Study Objectives 
Ternary Phase Diagram (TPD) analysis in Chapter 2 culminated in the selection and 
finalization of a basic microemulsion system comprised of 3:1 Polysorbate 80:Cremophor RH 
40 surfactant, Miglyol 812 oil and water. The broad aim of this chapter, Chapter 3, is to 
incorporate all lipophilic and hydrophilic APIs, treating each as a separate group in order to 
assess potential impacts of each type of incorporation on the microemulsion system. Specific 
aims include: 
i) To assess the solubility of hydrophilic APIs in individual microemulsion components via 
saturation solubility testing 
ii) To assess the effect of lipophilic API incorporation on microemulsion formation via 
EACN determination 
iii) To determine the HLD value of the lipophilic drug-loaded microemulsion system in 
order to facilitate O/W delivery 





3.3   Hypotheses 
3.3.1  Hydrophilic API Solubility 
All water-soluble B vitamins (thiamine mononitrate, riboflavin, niacinamide, pyridoxine 
hydrochloride, folic acid and cyanocobalamin) will demonstrate greater solubility in water than 
in Miglyol 812 oil or Polysorbate 80/Cremophor RH 40 surfactant. Riboflavin and folic acid 
will exhibit the lowest saturation solubility results due to their low water solubilities. 
 
3.3.2   Lipophilic API Incorporation 
The addition of five lipophilic APIs (beta-carotene, cholecalciferol, d-α-tocopherol acetate, 
phytonadione and docosahexaenoic/eicosapentaenoic acid) to Miglyol 812 will result in an 
increase of EACN by at least 1 carbon unit, relative to the EACN value of Miglyol 812 alone.  
 
3.4   Materials and Methods 
3.4.1  Materials 
Unless explicitly stated, all materials were generously gifted by Catalent Pharma Solutions 
Inc., formerly Accucaps Industries Limited (Ontario, Canada), and were used without 
purification. Thiamine mononitrate, riboflavin, niacinamide, pyridoxine hydrochloride, folic 
acid, cyanocobalamin, beta-carotene, cholecalciferol, d-α-tocopherol acetate and 
phytonadione were produced by DSM Nutritional Products (Ontario, Canada). Omega-3 fatty 
acid ester (20% eicosanopentaenoic acid/ 60% docosahexaenoic acid) was produced by Huatai 
Biopharm Inc. (Sichuan, China). Miglyol 812 was produced by IOI Oleochemical (Ruhr, 
Germany), PEG-40 hydrogenated castor oil (Cremophor/Kolliphor RH 40) was produced by 
BASF Care Creations (New Jersey, USA) and Polysorbate 80 was produced by BASF 
(Ontario, Canada). Chemical structures and log P values of all APIs are outlined in Chapter 
1: Table 1.5 and Table 1.6. All water-soluble vitamins were present in solid powder form while 
all oil-soluble vitamins, surfactants and Miglyol 812 were present in liquid form. Cremophor 




 Dihexyl sodium sulphosuccinate (SDHS) (80% in water), hexane (HPLC grade ≥ 
98.5%), hexadecane (reagent plus 99%), sodium chloride (ACS reagent, ≥99%) and sodium 
hydroxide pellets (≥97%) were purchased from Sigma-Aldrich (Ontario, Canada). Dodecane 
(99% pure, ACROS organics) and ethyl caprate (99%) were purchased from Thermo Fisher 
Scientific (Ontario, Canada). Toluene (certified ACS ≥99.5%) was purchased from 
Chemstores at the University of Waterloo and manufactured by Fisher Scientific (Ontario. 
Canada). 100% pure sunflower and canola oil were obtained from PC Organics (Ontario, 
Canada).  
 
3.4.2  Methods 
A series of Health Canada-recommended vitamins and minerals for prenatal supplementation 
were selected as APIs. Each API was literature-screened for stability, toxicity and performance 
in previous microemulsion formulations. Alternative forms of each API were also considered. 
A final list ranking the suitability of each API and its alternate form was completed and the 
formulation was built around these ingredients. Tables 1.5-1.6 in Chapter 1 contain the list of 
final ingredients and structures. 
 
3.4.2.1 Saturation Solubility 
An empty weighing boat was placed onto a Mettler AT261 Delta Range Analytical Balance 
and its weight recorded. The scale was tared and between 0 and 1 g ± 0.1 mg of water-soluble 
API was added to the weighing boat. The weighing boat and its contents were then reweighed 
and some of the API was carefully transferred to a 20 mL scintillation vial containing 15 g ± 
0.1 mg solvent and a magnetic stir bar. The scintillation vial was placed onto a stir plate and 
set to stir at 300 RPM until all API was dissolved. The time taken for dissolution was recorded 
in minutes. The weighing boat containing the remaining API was reweighed and subtracted 
from the original weight of the weighing boat and its contents, giving an accurate weight of 
API added to each vial. When all APIs appeared dissolved, the above steps were repeated until 
saturation was observed or until excess API was seen at the bottom of the scintillation vial. 
This saturation test was repeated for all water-soluble APIs in 15 g ± 0.1 mg deionized (DI) 
water, 15 g ± 0.1 mg Miglyol 812, 15 g ± 0.1 mg Polysorbate 80 and 15 g ± 0.1 mg Cremophor 
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RH 40. Each solution of API and solvent was centrifuged, filtered and diluted for Ultra 
Performance Liquid Chromatography (UPLC). Calibration curves of concentration versus 
peak area were obtained for pure API and used to quantify the amount of API recovered from 
each saturated sample. A Waters Acquity H-Class UPLC instrument was used along with a 
C18 silica column. The mobile phases consisted of 0.1% phosphoric acid and acetonitrile at 
55°C with 2 µL injection volume at wavelengths 275, 260 and 192 nm. Saturation solubility 
tests were only performed on the hydrophilic APIs given the low water solubilities of many of 
these compounds. The lipophilic APIs exhibited high log P values and thus, an ease of 
solubility was expected in Miglyol 812. As a result, these lipophilic APIs were instead 
evaluated using temperature, salinity and lipophilicity scans. 
 
3.4.2.2 Formulation Scan: Temperature 
Polysorbate 80 aqueous solution (10% w/w) was prepared in a scintillation vial by weighing 1 
g ± 0.1 mg surfactant into 10 g DI water using a Mettler AT261 Delta Range Analytical 
Balance and/or Sartorius Secura225D1S Analytical Balance. The solution was inverted 
manually until dissolved. 5 g ± 0.1 mg of this surfactant stock solution was added to a 
scintillation vial containing 5 g of oil phase*. The solution was inverted manually 20-25 times 
and left to settle for a period of 24 hours in a dark cupboard before evaluating phase behaviour. 
Each sample was heated for a period of 24 hours at each respective temperature point in 2-5ºC 
increments from 25 ± 0.1ºC to 80 ± 0.1ºC mg using a Fisher Scientific Isotemp GPD 10 water 
bath and a hot plate with a temperature controlled beaker of water. At each temperature 
increment, the mixes were removed from the water-bath, visually observed for any changes in 
phase behaviour using a red laser pointer (Tyndall effect), photographed and then replaced into 
the water bath at a higher temperature. Temperature scans were performed in triplicate.  
*two oil phases were prepared for comparison purposes: 5 g Miglyol 812 and 5 g 50% w/w 
Miglyol 812: oil-soluble actives (drug-loaded Miglyol 812) 
 
3.4.2.3 Formulation Scan: Salinity and Conductivity 
Dihexyl sodium sulphosuccinate (SDHS) aqueous surfactant solution (32.5% w/w) was 
prepared and added to equal volumes of deionized water and oil. SDHS is a commonly-used 
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surfactant for salinity scans due to its ionic nature and well-characterized characteristic 
curvature (CC) value.8 The oil phases were the same as mentioned previously and consisted 
either of Miglyol 812 or 50% w/w Miglyol 812:oil-soluble APIs. All surfactant, water and oil 
mixtures were exposed to increasing amounts of 20% sodium chloride solution from 1 g/100 
mL to 19 g/100 mL. The aqueous surfactant concentration in each vial was maintained at 10%. 
Following manufacture, each sample was left to settle in a dark cupboard for a period of 24 
hours before conductivity was measured using a Mettler Toledo InLab 752-6 mm 
microconductivity probe and SevenEasy conductivity meter. Conductivity readings were also 
recorded after 48 and 72 hours in milli Siemens per cm (mS/cm) ± 0.1. Graphs of conductivity 
versus sodium chloride concentration were generated in Graphpad Prism 6 software. Salinity 
scans were performed in duplicate.  
 
3.4.2.4 Formulation Scan: Lipophilicity  
1 mL 3:1 Polysorbate 80:Cremophor RH 40 surfactant mixture, 2.5 mL DI water, 10 mL 25-
30% NaCl solution and 10 mL oil ranging from EACN 1-18 were weighed to ± 0.1 mg using 
a Sartorius Secura225D1S Analytical Balance into a 30 mL scintillation vial and mixed 
manually by inverting. Therefore, all conditions were kept constant except for that of 
lipophilicity or EACN, affording a shift to a Type III microemulsion. The samples were left to 
settle for a period of 24 hours in a dark cupboard before phase behaviour was visually analyzed 
and examined using a red laser pointer. Given that the EACN value is additive, oils of known 
EACN value were mixed together in varying proportions in order to obtain the desired EACN. 
Lipophilicity scans were performed in duplicate. 
 
3.4.2.5 Tensiometry 
Tensiometry to determine the critical micelle concentration (CMC) was conducted using a T3 
Lauda Tensiometer and DuNoüy ring, in the same manner as described in Chapter 2. Briefly, 
the surfactant solution was carefully titrated into a glass vessel containing 40 mL MilliQ water 
with stirring for 7 minutes. A semi-log graph of surface tension versus surfactant concentration 
was generated and the breakpoint identified. The CMC was determined by the intersection of 
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the linear trendlines before and after this breakpoint in the plot. Tensiometry experiments were 
performed in triplicate. 
 
3.4.2.6 Hydrophilic API Incorporation  
A number of approaches were employed in an effort to solubilize all water-soluble active 
ingredients, riboflavin and folic acid being the most challenging due to their low water 
solubility. These approaches included:  i) an increase in temperature, ii) an increase in pH, iii) 
a change in solvent, iv) dissolution of riboflavin and folic acid in the oil-soluble API phase and 
v) dissolution of riboflavin and folic acid in the fully formulated microemulsion. Approach ii) 
was most successful.  
 The final protocol for successful incorporation of all six hydrophilic APIs involved first 
tarring a section of weigh paper on a Sartorius Secura225D1S Analytical Balance. Desired 
amounts of each vitamin (Table B-1, Appendix B) were then added individually to the 
weighing paper, the weight recorded, and the contents transferred to a beaker of (pre-measured) 
MilliQ water on a hot/stir plate set to stir at 300 RPM using a magnetic stir bar. The weighing 
paper with the empty contents was reweighed in order to determine the exact amount of each 
API added to the water phase. This process was first carried out for the easily soluble water-
soluble vitamins, i.e. thiamine mononitrate (B1), niacinamide (B3), pyridoxine hydrochloride 
(B6) and cyanocobalamin (B12).  Riboflavin (B2) and folic acid (B9) were then added where 
insolubility was immediately evident. 1 M sodium hydroxide solution was added in small 
increments of 100 µL until riboflavin and folic acid were dissolved. The final pH of the 




3.5   Results and Discussion 
3.5.1   Saturation Solubility  
The amount of hydrophilic API added to 15 g of solvent, until the point of saturation, is 
displayed in Table 3.1. As expected, the solvents most and least able to accommodate the 
majority of hydrophilic APIs were water and Miglyol 812 oil, respectively. Many of the APIs 
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also demonstrated high solubility in Cremophor RH 40 which, in some cases, surpassed their 
solubility in water. Polysorbate 80 was less accommodating, with vitamins recording low 
solubilities similar to that of Miglyol 812. 
 With respect to water, the order of solubility was Vitamin B3> Vitamin B6> Vitamin 
B12> Vitamin B1> Vitamin B2> Vitamin B9. This is generally comparable to solubilities 
reported in the literature for each form of vitamin used in this work- 500 mg/g9, 220 mg/g10, 
12.5 mg/g11, 27 mg/g12, 0.657 mg/g13 and 0.0761 mg/g14, respectively.  Cremophor RH 40 also 
acted as a favourable solvent for many hydrophilic APIs with the ranking following a similar 
pattern to that of water: Vitamin B3> Vitamin B12> Vitamin B1> Vitamin B6> Vitamin B2> 
Vitamin B9. In Polysorbate 80, API solubility was generally low and in the order Vitamin B3> 
Vitamin B12> Vitamin B6> Vitamin B2> Vitamin B9> Vitamin B1 while in Miglyol 812, the 
same trend applied with the Vitamins B1, B2 and B6 exhibiting practically equal solubility 
followed by B9. These results are depicted in Figure 3.1.  
 The reasons for the varying solubilities may be explained through consideration of the 
physicochemical structures of the B vitamins outlined in Chapter 1 in Table 1.5. The water 
solubility of all vitamins followed literature trends except in the case of Vitamin B1 and B12 
where solubility trends were reversed. This is attributable to the low potency of 
cyanocobalamin (1%) used in this work. The other 99% is likely comprised of stability-
enhancing sugar components15, resulting in higher water-solubility values in comparison to 
Vitamin B1.  
 With respect to API solubility in the surfactants, Cremophor RH 40 and Polysorbate 
80, Vitamins B3 and B12 demonstrated the greatest degree of solubility. Vitamin B3, 
niacinamide, consists of a single pyridine ring and amide bond as well as one hydrogen donor 
and two hydrogen acceptors.9 These donors and acceptors may afford hydrogen bonding with 
the ethoxylated head groups of Cremophor RH 40 and Polysorbate 80. The high water 
solubility, low log P value (-0.39)9 and low permeability results in niacinamide being classified 







Table 3.1: Saturation solubility results (to 3 significant figures) of water-soluble APIs in 15 g 
water, oil or surfactant. 
API Solvent API added 





Miglyol 812 8.90 
Polysorbate 80 3.70 




Miglyol 812 9.00 
Polysorbate 80 9.70 




Miglyol 812 38.3 
Polysorbate 80 54.6 




Miglyol 812 8.90 
Polysorbate 80 16.6 




Miglyol 812 3.80 
Polysorbate 80 6.30 




Miglyol 812 17.2 
Polysorbate 80 29.8 
Cremophor RH 40 122 
 
  
Despite its generally low log P value, however, niacinamide possesses the highest log P value 
of all the B vitamins tested in this work. In other words, it is the most lipophilic of all the B 
vitamins. This may be attributed to its small molecule structure and low molecular weight of 
approximately 122 g/mol9, which allows the contribution of the lipophilic pyridine ring to be 
greater than expected for a pyridine ring present in a larger molecule. This degree of 
lipophilicity versus that of the other B vitamins tested in this work, may enable interactions 




Figure 3.1: Solubility (mg/g) of vitamins, B1, B2, B3, B6, B9 and B12 in water, Miglyol 812, 
Polysorbate 80 and Cremophor RH 40 as determined by saturation solubility test, categorized 
by solvent. 
 
    
Polysorbate 80, resulting in high solubility in these surfactants, as well as in Miglyol 812 (a 
medium chain triglyceride). Vitamin B12 is an organometallic compound with a cobalt (Co3+) 
corrin ring at its center, along with multiple, amide side chains, a ribose-3-phosphate sugar and 
a benzimidazole ring. It has the most complex structure of all the B vitamins with 
approximately 9 hydrogen donors and 19 hydrogen acceptors, which are likely able to interact 
with the polyethoxylated head groups of Cremophor RH 40 and Polysorbate 80. This is further 
compounded by the solubility-enhancing sugars likely present in its structure as a result of its 
low potency. These hydrogen donors and acceptors result in cyanocobalamin having the lowest 
log P of all the B vitamins, -14.11 This high water solubility and low permeability makes 
cyanocobalamin a BCS class III compound.17 Its low permeability is likely a result of both its 
high water solubility and high molecular weight of 1355.37 g/mol.11 However, the complex 
corrin ring structure may have offered an advantage over B1, B2, B6  and B9 with respect to 


























































Solubility of Water-Soluble Vitamins 









 In contrast to Vitamins B3 and B12, Vitamins B1, B2, B6 and B9 demonstrated lower 
solubilities in Cremophor RH 40 and Polysorbate 80. The main difference in the order of 
solubility in both surfactants involved Vitamin B1, which was most soluble in Cremophor RH 
40 and least soluble in Polysorbate 80. Given that Polysorbate 80 contains half as many 
hydrophilic, ethylene oxide groups as Cremophor RH 40, resulting in a slightly higher 
lipophilic profile18-20, it is not surprising that the solubility of hydrophilic Vitamin B1 was lower 
in Polysorbate 80. Pyridoxine hydrochloride, the salt form of Vitamin B6 consists of an 
associated hydrochloride and pyrimidine ring with multiple side groups including two 
methanol groups, one hydroxyl and one methyl group. Its slightly lower log P value of -0.9521, 
along with a total of approximately 4 hydrogen acceptors and donors on a small molecule with 
molecular weight of only 205.64 g/mol, leads to higher hydrogen bonding potential with the 
head groups of Cremophor RH 40 and Polysorbate 80, as compared to Vitamins B2 and B9. As 
a result of its high water solubility and low permeability, Vitamin B6 is a BCS Class III 
compound.22    
 With respect to solubility in oil, trends would generally be expected to be the reverse 
of those seen in water. However, in the case of Miglyol 812, the most and least soluble APIs 
were the same as those in water- B3 and B9, respectively. This is likely due to the fact that 
Miglyol 812, as a medium chain triglyceride, is a polar oil.23,24 Therefore, though the lipophilic 
rings of Vitamin B9 appeared to confer an advantage with respect to solubility in Polysorbate 
80, this advantage was not seen in Miglyol 812. Due to its poor solubility and permeability, 
folic acid is classified as BCS Class IV compound.25  
 In general, based on the results in Table 3.1 and Figure 3.1, Vitamins B3, B12, B6 and 
B1, respectively, were the easiest to dissolve across all solvents while Vitamins B2 and Vitamin 
B9 were the most difficult; Vitamin B2 exhibited slightly less difficulty than Vitamin B9. 
Vitamin B2, riboflavin, is comprised of an isoalloxazine ring and ribityl group with multiple 
electronegative (hydrogen acceptor) groups such as nitrogen and oxygen and multiple hydroxyl 
(hydrogen donor) groups. Although these groups theoretically promote hydrogen bonding with 
water, the additional lipophilic ring restricts solubility in water, resulting in the low values seen 
in Table 3.1 and Figure 3.1. Consequently, the log P of riboflavin is higher than that of 
Vitamin B1 at -0.9213, indicating greater lipophilicity. With respect to Vitamin B9 (folic acid), 
though multiple hydrogen donors and acceptors are able to participate in hydrogen bonding 
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with water, the pyrimidine and benzene rings which outnumber those in B1, result in lower 
water solubility. This is confirmed in the log P of -0.6814 similar to that of Vitamin B2. 
 In addition to the solubility results contained in Table 3.1 and Figure 3.1, UPLC 
analysis was performed on the APIs in this work in an effort to determine whether each API 
could be recovered from its respective solvent, once solubilized. As noted in Chapter 1 
(Section 1.7.1), saturation solubility via liquid chromatography (LC) confirms whether the 
amount of API introduced into a system can be recovered and quantified. This is especially 
important in the case of vitamins, which as discussed later on in this Chapter, are susceptible 
to degradation upon exposure to a variety of conditions and as a result, present many analytical 
challenges.26 Given the unique LC conditions also required for each vitamin with respect to 
column choices, mobile phases and detection wavelengths, it was important to establish an 
appropriate recovery method.27,28   
 The results in Figure 3.2 illustrated that despite the low solubilities in Miglyol 812 oil 
and Polysorbate 80, recovery of the APIs in these solvents was still possible and, in cases such 
as that of Vitamin B3, very high. The highest recovery for all APIs was noted in Cremophor 
RH 40 where five of the six water-soluble APIs demonstrated over 60% recovery with Vitamin 
B6 and B12, in particular, exhibiting over 90% recovery. Water also demonstrated high 
recoveries with four of the six vitamins exhibiting 90% or higher recovery. Not surprisingly, 
the most difficult vitamins to recover in water were riboflavin (B2) and folic acid (B9). Similar 
to Figure 3.1, not only were water and Cremophor RH 40 able to demonstrate the highest 
solubility for the water-soluble APIs tested in this work, but according to  Figure 3.2  they  
were  also  the  easiest  solvents  to recover dissolved APIs from.  As in Figure 3.1, Vitamin 
B3 had the highest recovery in consideration of all solvents. Recovery was highest in 
Polysorbate 80 (100%) followed by water (91%) then Miglyol 812 and Cremophor RH 40. 
Vitamin B6 also exhibited a high degree of recovery in almost all solvents. 100% recovery was 
seen in water, and approximately 90% was seen in both Polysorbate 80 and Cremophor RH 40 
but less than 2% was recovered in Miglyol 812. Vitamin B12 was similar to Vitamin B1 in that 
high recovery percentages were obtained in water and Cremophor RH 40 but virtually none in 
Miglyol 812 oil as well as Polysorbate 80. Vitamins B2 and B9 demonstrated very low 
recoveries in all solvents tested. However, it is worth noting that at least some degree of 




Figure 3.2: Recovery percentages of Vitamins, B1, B2, B3, B6, B7, B9 and B12 in water, Miglyol 
812, Polysorbate 80 and Cremophor RH 40 as determined by UPLC. 
 
 
Figure 3.1, show that API solubility in a particular solvent does not necessary reflect its ability 
to be analytically recovered. Analytical methods are complex when dealing with multi-
component drug formulations and care must be taken when developing them.26,29 Thus, despite 
the suitability of liquid chromatography techniques for multivitamin recovery due to their high 
sensitivity and selectivity30, each vitamin has specific physiochemical properties and stability 
requirements (re: pH, temperature, light and oxidation) that must be accounted for.27,30 
 With respect to the water-soluble vitamins, riboflavin is relatively hydrophobic, folic 
acid is acidic and pyridoxine and thiamine are generally basic.31 Thiamine must often be 
oxidized to thiochrome prior to LC detection and even then, its UV absorption range is pH-
dependent.27 Riboflavin and its vitamers may possess similar UV absorbance but riboflavin is 
extremely photosensitive and care must be taken during extraction and analysis, as with 
pyridoxine and cyanocobalamin.27,28 Nicotinamide is less stable than nicotinic acid and 
extraction techniques involving dilute acid are typically required, while folic acid is susceptible 
to oxidation often requiring the use of antioxidants.27,28 For the fat-soluble vitamins, 


















































isomers must often be resolved during LC analysis.26,28,32 Vitamin D recovery is complicated 
due to the presence of pre-D forms, and the OH group which requires elution with a more polar 
solvent than many other fat-soluble vitamins.28,32 Vitamin E has up to eight homologs 
(tocopherols and tocotrienols) that may be detected, while Vitamin K is sensitive to 
saponification.28,32 These unique requirements and challenges highlight the fact that API 
solubility is not necessarily reflected analytically as is evident in Figure 3.2. 
 In Chapter 2, Polysorbate 80 and Cremophor RH 40 were selected as surfactants given 
their propensity to form Type IV microemulsions. These saturation solubility results 
demonstrate the additional advantage of adding Cremophor RH 40 to the formulation, as many 
APIs exhibited preferred solubility in this surfactant. 
 
3.5.2  Effective Alkane Carbon Number (EACN) Determination 
3.5.2.1 Lipophilic API Incorporation 
All lipophilic APIs (beta-carotene, cholecalciferol, d-α-tocopherol acetate, phytonadione and 
docosahexaenoic/eicosapentaenoic acid) were easily incorporated into Miglyol 812 with 
simple stirring, given their lipophilicity. Amounts were added based on the daily recommended 
dosages provided by Health Canada (Chapter 1: Table 1.8) and potencies as provided by the 
manufacturer (Table B-1, Appendix B).  
 
3.5.2.2 Formulation Scan: Temperature  
The results of the temperature scan conducted on Miglyol 812 and 50% w/w Miglyol 812:Oil-
soluble actives are seen in Figure 3.3. Vials containing white or clear solutions represent 
Miglyol 812, while amber vials or yellow formulations represent 50% w/w Miglyol 812:Oil-
soluble API mixtures. It can be seen from Figure 3.3 that Type I microemulsions were obtained 
from 25ºC to 57ºC. At 59ºC, however, a shift was seen in the samples containing Miglyol 812, 
from a Type I microemulsion with two phases to a Type III microemulsion with three phases. 
This shift occurred later in samples containing 50% w/w Miglyol 812: Oil  soluble  actives,  at  
61ºC.  Beyond this  point  and  until  67ºC,  Type  III microemulsions were evident. However, 





Figure 3.3: Temperature scan performed on Miglyol 812 and a 50/50 mixture of Miglyol 812 
and five oil-soluble APIs in order to determine the EACN value of both oils. 
  
 
 The temperature scan was repeated and the results are depicted in Figure 3.4. White 
samples contained Polysorbate 80 and Miglyol 812 while orange samples contained 
Polysorbate 80 and 50% w/w Miglyol 812:oil-soluble APIs. Results indicated the presence of 
Type I microemulsions from room temperature to 63ºC (not pictured). At 65ºC, a transition 
from Type I to Type III microemulsions was seen in both Miglyol 812 and drug-loaded Miglyol 





Setting the HLD to 0 at the temperature at which a Type III microemulsion occurs, the HLD 
equation was rearranged in order to calculate the EACN of Miglyol 812 and 50% w/w Miglyol 
812:Oil-soluble APIs. Therefore, using the HLD equation for non-ionic surfactants:         
                                             




Figure 3.4: Replicates of temperature scan performed with Polysorbate 80 only on Miglyol 
812 and a 50/50 mixture of Miglyol 812 and five oil-soluble APIs in order to determine the 
EACN value of both oils. White samples (AE) contain Polysorbate 80 and Miglyol 812 while 
orange samples (AF) contain Polysorbate 80 and drug-loaded Miglyol 812. 
 
 
When HLD=0, as in the case of a Type III microemulsion, then, 
 
	EACN = 	 b(S)	-	ϕ	(A)	+	CT	∆T	+	CC				
K
	                                                                               (Eq. 3.3) 
 
where EACN is unknown 
b(S)= the salt/electrolyte concentration; 0 g/100 mL as no salt was used 
f (A)= the alcohol concentration; 0 g/mL as no alcohol was used 
CT= constant associated with the effect of temperature on surfactant; 0.06 for non-ionic 
ethoxylated surfactants4, 33, 34 
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DT= the change in temperature from 25ºC  
CC= the characteristic curvature of surfactant; -3.7 for Polysorbate 80  
k= slope of ln (S) vs EACN; 0.17 for most surfactants34,35 
 
Based on Figures 3.3 and 3.4, the results from the temperature scan are summarized in Table 
3.2.  
 
Table 3.2: Replicated temperature scan results of Miglyol 812 and a 50/50 mixture of Miglyol 
812 and five oil-soluble APIs in Polysorbate 80 surfactant. 
 
Replicate Temperature (ºC) at transition from Type Ià III microemulsion 
Miglyol 812 Miglyol 812:Oil-soluble APIs 
1 59 61 
2 65 65 
3 65 65 
Average ± SD  63 ± 3.4 64 ± 2.3 
 
 
Thus, using Eq. 3.3, the calculated EACNs for Miglyol 812 and Miglyol 812:oil-soluble APIs 
are:       
 
                Miglyol 812:                 
@%1^ =	
0	 − 	0	 + (0.06	(63	ºC − 25	ºC) + (−3.7)				
0.17
 
EACNMG 812 =  8.4  
  
 
Miglyol 812: Oil-soluble APIs: 
@%1^ =	
0	 − 	0	 + (0.06	(64	ºC − 25	ºC) + (−3.7)				
0.17
 
                                      




 Therefore, it can be concluded that Miglyol 812 and 50% w/w Miglyol 812:Oil-soluble 
APIs have EACN values of 8.4 and 8, respectively, equating to approximately an 8 carbon oil. 
Thus, the lipophilicity of Miglyol 812 upon incorporation of five oil-soluble APIs does not 
appear to vary remarkably. Further confirmation of these results was determined via salinity 
scanning as described below.  
 
3.5.2.3 Formulation Scan: Salinity and Conductivity 
In order to supplement temperature scan results, salinity scans were also performed on Miglyol 
812 and 50% w/w Miglyol 812:Oil-soluble actives using an ionic surfactant, sodium dihexyl 
sulphosuccinate (SDHS). A visual shift in Type IàIIIà II microemulsions, followed by 
conductivity measurements in order to ascertain this shift, afforded the obtaining of a Type III 
microemulsion (HLD=0), which was then used to calculate the EACN using the HLD equation. 
Salinity scan results are seen in Figure 3.5.  
 
 
Figure 3.5: Salinity scan from 0.5-8 g/100 mL (labelled in white) performed with dihexyl 
sodium sulphosuccinate (SDHS) on Miglyol 812 and a 50/50 mixture of Miglyol 812 and five 
oil-soluble APIs in order to determine the EACN value of both oils. White samples contain 
Miglyol 812 only (image A) while orange samples contain a mixture of 50:50 Miglyol 812/oil-
soluble APIs (image B).  
 
 
 In Figure 3.5, a shift in microemulsion type from a Type I microemulsion to a Type III 
microemulsion occurred at approximately 8 g/100 mL sodium chloride salinity for both 
0.5      1       1.5      2       2.5      3      3.5      4        5       6        7       8 















Miglyol 812 and the 50:50 Miglyol 812:Oil-soluble APIs phase. These results are in agreement 
with theoretical results shown in Figure 3.6 using the Steven Abbott HLD calculator.36 
 
 
Figure 3.6: Theoretical EACN results for an oil of EACN 8 as estimated by the Steven Abbott 
HLD calculator34 for salinities from 0.5- 8 g/100 mL.  
 
 
   
 
Figure 3.7: Salinity scan from 3-19 g/100 mL (labelled in white) performed with dihexyl 
sodium sulphosuccinate (SDHS) on Miglyol 812 and a 50/50 mixture of Miglyol 812 and five 
oil-soluble APIs in order to confirm the EACN value of both oils. White samples contain 
Miglyol 812 only (image A) while orange samples contain a mixture of 50:50 Miglyol 812/oil-
soluble APIs (image B). 
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The salinity scan was replicated as shown in Figure 3.7, with an increase in salinity to confirm 
the results obtained in Figure 3.5.  A visible shift in microemulsion type from a Type I to a 
Type III microemulsion was observed at 9 g/100 mL and 11 g/100 mL salinity for Miglyol 812 
and Miglyol 812:Oil-soluble API-containing samples, respectively. These results were also in 
line with predicted EACN results as depicted in Figure 3.8.36 
 
 
Figure 3.8: Theoretical EACN results for an oil of EACN 8 as estimated by the Steven Abbott 
HLD calculator for salinities ranging from 3-19 g/100 mL. These theoretical samples align 
with the results obtained in Figure 3.7. 
 
 
 The conductivity results from the salinity scans in Figure 3.5 and Figure 3.7 are 
depicted in Figure 3.9. For the first replicate, a drop in conductivity from approximately 15-
16 mS/cm to 0 mS/cm at a salinity of 8 g/100 mL for both Miglyol 812 and 50% w/w Miglyol 
812:Oil-soluble APIs was seen. For the second replicate, a drop in conductivity from 
approximately 19 mS/cm to 0 mS/cm at a salinity of 9 g/100 mL and 11 g/100 mL for Miglyol 
812 and 50% w/w Miglyol 812:Oil-soluble APIs, respectively, was seen. This decrease in 
conductivity occurred upon an increase in lipophilicity as the system transitioned from a Type 
IàIIIàII microemulsion. Though the decrease in conductivity between replicates appears 






Figure 3.9: Conductivity results from salinity scans performed on Miglyol 812 and Miglyol 
812: Oil soluble API phases. A drop in conductivity indicates a shift in microemulsion type as 
indicated by the red circles. 
 
Using the HLD equation for ionic surfactants: 
 
HLD	 = 	ln	(S)	– 	K	(EACN)	– 	f	(A) 	− 	αT∆T	 + 	CC                                              (Eq. 3.2)                  
 
 






    (Eq. 3.4) 
































































































































































where EACN is unknown 
ln(S)= the natural logarithm of the salt/electrolyte concentration; various depending on whether 
samples are Miglyol 812 or 50:50 Miglyol 812: oil-soluble APIs 
f (A)= the alcohol concentration; 0 g/mL as no alcohol was used 
αTDT= constant associated with the effect of temperature on surfactant/change in temperature 
from 25ºC; 0 as no change in temperature occurred 
CC= the characteristic curvature of surfactant; -0.92 for dihexyl sodium sulphosuccinate 
(SDHS)  
k= slope of ln (S) vs EACN; 0.17 for most surfactants34,35 
 
Based on results from Figures 3.5-3.9, the calculated EACNs for Miglyol 812 and Miglyol 
812:oil-soluble APIs are summarized in Table 3.3: 
 
Table 3.3: Duplicated salinity scan results of Miglyol 812 and a 50/50 mixture of Miglyol 812 
and five oil-soluble APIs in SDHS surfactant. 
 
Replicate Salinity (g/100 mL) at transition from Type Ià III 
microemulsion 
Miglyol 812 Miglyol 812:Oil-soluble APIs 
1 8 8 
2 9 11 
Average ± SD 8.5 ± 0.7 9.5 ± 2 
 
 
Thus, using Eq. 3.4, the calculated EACNs for Miglyol 812 and Miglyol 812:oil-soluble APIs 
are:                       
 















Av.EACNMG 812:OSA = 7.8 
 
Therefore, combining both temperature and salinity scan results, the EACN values are best 
represented by Table 3.4: 
 
Table 3.4: Overall EACN results of Miglyol 812 and 50:50 Miglyol 812: oil-soluble APIs 
confirmed via both temperature and salinity scanning with non-ionic and ionic surfactants, 
respectively. 
 




50:50 Miglyol 812:Oil-soluble APIs 
Temperature 8.4 8.0 
Salinity 7.2 7.8 
Average ± SD 7.8 ± 0.8 7.9 ± 0.1 
 
 
 Consideration of both temperature and salinity scans confirmed that overall, both 
Miglyol 812 and 50:50 Miglyol 812:oil-soluble APIs possessed an EACN value of 
approximately 8 carbons. It can be concluded then, that both oils tend to behave in a similar 
fashion to that of a straight-chain alkyl oil with 8 carbons, or octane. In terms of temperature, 
it has been previously discussed that the hydrophilic polyethoxylated head groups of non-ionic 
surfactants are temperature sensitive and become dehydrated upon exposure to increased 
temperatures, forcing a shift from a Type Ià IIIà II microemulsion.37 With respect to the 
Winsor interactive ratio, R = ACO /ACW, this increase in temperature leads to a decrease in 
interactions between the amphiphilic species and water (ACW) and high R value, resulting in a 
transition to a Type II microemulsion.38 According to Shinoda (1964)37, the more soluble a 
hydrocarbon in a non-ionic surfactant species, the lower the phase inversion temperature (PIT). 
Given the PIT of 63ºC and 64ºC for Miglyol 812 and 50% w/w Miglyol 812:oil-soluble APIs, 
respectively, and the overall EACN values of 7.8 and 7.9 for Miglyol 812 and 50:50 Miglyol 
114 
 
812:oil-soluble APIs, respectively, it can be concluded that both oils behave in a similar fashion 
with respect to solubility in the non-ionic surfactant species. 
 Some of the lipophilic APIs tested in this work are temperature-sensitive. However, it 
is generally accepted that fat/oil-soluble vitamins are less heat-labile than that of their water-
soluble vitamin counterparts.39 Table 3.5 contains information regarding the effect of 
temperature on each lipophilic API based on previous literature works. Based on the various 
degradation studies reported in the literature for the lipophilic APIs, no significant degradation 
was expected for any lipophilic APIs at the PIT of 63 and 64ºC. 
 In terms of salinity, it has been previously discussed and reported that an increase in 
salinity decreases the interactions between surfactant and water, forcing a shift from a Type 
Ià IIIà II microemulsion.7 In consideration of the Winsor interactive ratio, R = ACO /ACW, 
ACW is reduced leading to a high R value, resulting in a transition to a Type II microemulsion.7,38 
This effect may also be explained in terms of surfactant packing as the monovalent cation in 
the salt shields the anionic surfactant head group of SDHS, reducing the head group area and 
increasing the packing parameter value (recall CPP= v/al).2 An increase in this packing 
parameter consequently results in a negative curvature or formation of W/O micelles.2 Salager 
et al. (1979) reported an increase in oil lipophilicity or alkane carbon number (ACN) with an 
increase in salinity.40 This relationship is linear when plotting the natural logarithm of the 
salinity in g/100 mL (ln (S)) against oil ACN.40 Given the salinity scan results indicating a 
transition from a Type I microemulsion to a Type III microemulsion at 8.5 g/100 mL sodium 
chloride and 9.5 g/100 mL sodium chloride for Miglyol 812 and 50:50 Miglyol 812:oil-soluble 
APIs, respectively, it can be concluded that the 50% w/w Miglyol 812:oil-soluble APIs phase 
demonstrates a higher lipophilicity than that of Miglyol 812.  This is expected as the five fat- 
soluble vitamins, although considered small molecules, exhibit very high log P values: 11 for 
beta-carotene41 7.1 for Vitamin D342 10 for Vitamin E acetate43 9.7 for Vitamin K144 6.8 for 
DHA45 and 6.2 for EPA46. These high log P values are not surprising given the structural 
compositions of these compounds, which primarily consist of multiple cyclic rings and lengthy 
alkyl chains. Beta-carotene has a molecular weight of 536.9 g/mol and consists of two 
cyclohexene rings connected via an unsaturated, methyl-branched  C20 chain with no hydrogen 
donors or acceptors leading to the highest log P of the fat-soluble vitamins.41 Vitamin D3  
consists  of  a  molecular weight of 384.6 g/mol and has a structure similar to cholesterol. The  
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 Beta Carotene:  





• 180ºC (2h): cis-isomers  & oxidation 
products47,48 
• 97ºC (3h): epoxide, cyclohexanone and 
carboxaldehyde products47,49 
• 100ºC: degradation in soybean oil50 




MP: 85ºC42 • 150ºC: degradation in canola oil52 
• 200-210ºC (10 mins): 24% degradation in 
sunflower oil53 
Vitamin E Acetate 
(D-α-tocopherol 
acetate) 
MP: 10ºC43 Stable to very high temperatures in absence 
of oxygen 54 
• 180ºC (1h): 6% degradation in triolein 
oil54 




MP: -20ºC44 • 185-190ºC (40 mins): 15% degradation in 
peanut, corn and olive oil; 6% degradation 
in safflower, sunflower, rapseed and 
soybean55 
DHA/EPA Fish Oil 
 
N/A Depends on fish source  
• 180ºC: minor degradation 56 
• 40-60ºC (1.5h) followed by 85ºC (30 
mins): 30% degradation DHA/EPA in 
trout; 50% degradation DHA/EPA in 
carp57 
• 50-150ºC: degradation seen in salmon oil58 
• 60ºC (2h), 100ºC (2h), 160ºC (2h): no 
degradation EPA/DHA in rainbow trout 
and European; 25% EPA/DHA 




fused cyclohexane and cyclopentane along with the C6branched, saturated chain are conserved. 
However, an unsaturated C2 chain connects to a third cyclohexane.42 It consists of 1 hydrogen 
donor and 1 hydrogen acceptor leading to the lowest log P of the fat-soluble vitamins.42 
Vitamin E acetate has a molecular weight of 472.2 g/mol and is comprised of a tetrahydropyran 
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and benzene ring along with a C13 saturated, branched chain. Its structure yields 2 hydrogen 
acceptors and 3 hydrogen donors.43 This results in a log P of 10.43 Vitamin K1 has a molecular 
weight of 450.7 g/mol and is comprised of a 1,4-naphthoquinone. In addition, it consists of a 
C17 chain that is branched and saturated for the most part leading to its high log P of 9.7.44 DHA 
and EPA both consist of carboxylic acids attached to a C22 and C20 unsaturated chain, 
respectively and molecular weights of 328.5 g/mol and 302.5g/mol, respectively.46 The 
carboxylic acid group provides a degree of hydrophilicity leading them both to have log p 
values around 6- the lowest of the lipophilic APIs used in this work.45,46 Salt concentration, in 
general, has little effect on oils and can be assumed to generally not affect the lipophilic APIs 
in this work. The physiological charges of beta-carotene, Vitamin D3, Vitamin E acetate and 
Vitamin K1 are 0.41-44 Miglyol 812 is also noted to be a neutral oil.60 The physiological charge 
of DHA and EPA are -1 given their carboxylic acid group so these are the lipophilic APIs 
likely most affected by the salt concentration.45,46   
 Based on the overall temperature and salinity scan results, the EACNs of Miglyol 812 
and 50% w/w Miglyol 812: Oil-soluble APIs were determined to be practically equal: 7.8 
versus 7.9. Given the hydrophobicity of the lipophilic APIs as described above, these results 
may seem counterintuitive. However, Miglyol 812, comprised of C8 and C10 caprylic and capric 
triglycerides60 has been utilized as a medium chain triglyceride (MCT) solubilizer for the oil-
soluble APIs, in a very high concentration of 50% w/w. In addition, it has been previously 
reported that oils comprised of cyclical structures, in particular, aromatic structures, contribute 
to low EACN values.7 In fact, benzene is known to possess an EACN of 0, and toluene is said 
to possess an EACN of 1.7,35 Given this information, it is logical to assume that the lipophilic 
APIs in this work possessing aromatic rings, Vitamin E acetate and Vitamin K1, contribute to 
a lowering of the EACN that brings the overall value of the 50% w/w Miglyol 812:Oil-soluble 
API phase close to that of Miglyol 812. Given that Miglyol 812 is comprised of 50-65% C8, a 
result of EACN 8 is expected. 
3.5.3  Characteristic Curvature (CC) Determination 
3.5.3.1 Formulation Scan: Lipophilicity  
With the determination of the EACN of Miglyol 812 and the 50% w/w Miglyol 812:oil-soluble 
API oil phase, all of the variables in the HLD equation are now complete except for that of 
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characteristic curvature (CC). 3:1 Polysorbate 80:Cremophor RH 40 was selected as the 
surfactant phase for our microemulsion system based on the results in Chapter 2. However, 
although the CC value of Polysorbate 80 is known (-3.7), that of Cremophor RH 40 is unknown 
and must be determined. Determining the CC allows for all variables in the HLD equation to 
be known such that the HLD may be calculated and adjusted or optimized for multi-drug 
delivery, based on Eq. 3.1. 
 A lipophilicity scan, keeping all variables constant but varying the EACN of numerous 
oils, is the most efficient way to determine the characteristic curvature of a surfactant.4,35 
Lipophilicity scans were performed with oils of known EACN value; two such results are 
shown here. Figure 3.10 depicts a lipophilicity scan of 3:1 Polysorbate 80:Cremophor RH 40 
where all other variables, including temperature and salinity were kept constant. A shift from 
a Type Ià Type III à Type II microemulsion was seen at EACN 18àEACN 16à EACN 1, 
respectively. 
 The scan depicted in Figure 3.10 was expanded by including all EACN values between 
EACN 18 (Canola oil) and EACN 1 (Toluene), in increments of 1. Two oils of known EACN 
may be combined in order to produce an oil of a particular EACN. This was performed in 
Figure 3.11. In general, Figure 3.11 depicted a transition from a Type I à III à II 
microemulsion given a decrease in oil EACN. There were a number of outliers in this scan, 
which may be due to the use of impure oils.  Specifically, samples of EACN 7, 8 and 13 should 
have indicated triphasic behaviour or Type III microemulsion behaviour. Nevertheless, a shift 
from a Type I microemulsion to a Type III microemulsion was seen to occur at EACN 16, 
consistent with the results in Figure 3.10. Using the theoretical lipophilicity scan calculator 







Figure 3.10: Lipophilicity scan conducted on 3:1 Polysorbate 80:Cremophor RH 40 using a 
variety of oils of known EACN37: Canola (18), Hexadecane (16), Sunflower oil (14*), 
Dodecane (12), Hexane (6), Ethyl Decanoate/Caprate (2.3) and Toluene (1) at fixed surfactant 
concentration, temperature and salinity (25 g/100 mL). 
*The literature EACN value of Sunflower oil is 14 but given its similarity in appearance to EACN 18, an 
independent EACN scan of sunflower oil was conducted and found to be 17. (see Figure B-1, Appendix B) This 




Figure 3.11: Lipophilicity scan conducted on 3:1 Polysorbate 80:Cremophor RH 40 using a 
variety of oils from EACN 1 to EACN 18 at fixed surfactant concentration, temperature and 
salinity (25 g/100 mL). The red dots indicate possible outliers. EACN 1= toluene, EACNs 2-5 
were manufactured through mixtures of toluene (1) and dodecane (12), EACN 6= hexane, 
EACNs 7-11 were also manufactured through mixtures of toluene (1) and dodecane (12), EACN 
12= dodecane, EACN 13 was manufactured through mixtures of toluene (1) and hexadecane 
(16), EACNs 14-15 were manufactured through mixtures of dodecane (12) and hexadecane (16), 




Type I                                      Type III                                         Type II 
 





Figure 3.12: Theoretical CC results for a non-ionic surfactant using oils ranging from EACN 
18 to EACN 1 keeping all other variables constant including surfactant concentration, 
temperature and salinity (25 g/100 mL). Results show that this unknown surfactant has a CC 
value of between -0.5 and -0.6. 
 
 
Given that this CC value is representative of a surfactant mixture of 3:1 Polysorbate 
80:Cremophor RH 40, and that the CC value of Polysorbate 80 is -3.763, the CC value of 
Cremophor RH 40 may be determined using weight % properties. Using Eq. 3.1 and 
rearranging for HLD=0, as in a Type III microemulsion, then: 
 
CC	 = 	−	(b(S)	– 	K	(EACN) 	− 	ϕ	(A) 	+ 	CT	∆T)					                                             (Eq. 3.5) 
 
where CC of Cremophor RH 40 is unknown; CC Polysorbate 80= -3.7** 
EACN = 16 (hexadecane) 
b(S)= 0.13 (25 g/100 mL)33,34 
f (A)= 0 g/mL as no alcohol was used 
CTDT= 0º C as there was no change in temperature 
120 
 
k= 0.17, a constant for most surfactants (slope ln (S) versus EACN)34,35 
**CC of Polysorbate 80 was verified separately using EACN scan (see Figure B-2, Appendix 
B) 
 
Based on the results of the lipophilicity scan, the calculated CCs for Polysorbate 80 and 
Cremophor RH 40 are listed in Table 3.6: 
 
Table 3.6: Lipophilicity scan results aimed at determining the characteristic curvature of 
Polysorbate 80 and Cremophor RH 40. 
 
Replicate EACN value at transition from Type Ià III microemulsion 
Polysorbate 80 Cremophor RH 40 
1 16 16 
2 16 16 
Average 16 ± 0.0 16 ± 0.0 
 
 
Based on Eq. 3.5, the calculated CCs for Polysorbate 80 and Cremophor RH 40 are:  
                   
	CC	 = 	−	(0.13(25	g	/	100	mL)	– 	0.17	(16) 	− 0	 + 	0)					                                               
CC3:1 P80:C40 = -0.53 ± 0.0                            
                                    
 
Therefore, CC of Cr40: 
3: 1	280: 140 = 0.75%	280 + 0.25%	140 
11J:!	LM1:0N1 = 0.75 ∗ 11LM1 + 0.25 ∗ 110N1			                                                      (Eq. 3.6) 
−0.53 = (0.75 ∗ (−3.7)) + (0.25 ∗ (8.98))			 
Av. CCCR40: 8.98 ± 0.0                  
 
 The calculation above based on Eq. 3.6 demonstrated a characteristic curvature value 
of 8.98 for Cremophor RH 40. As described earlier, characteristic curvature considers the 
structural composition of a surfactant and its tendency to curve towards an oil or water 
interface. A negative characteristic curvature indicates a hydrophilic surfactant with a tendency 
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to curve towards oil, while a positive characteristic curvature indicates a hydrophobic 
surfactant with a tendency to curve towards water. Acosta et al. noted that a general 
characteristic curvature scale from -4 to +4 supports a linear correlation between HLB and CC 
for most non-ionic surfactants, especially as it pertains to surfactants with very high HLB 
values (above HLB 25).8 The characteristic curvature of +8.98 obtained for Cremophor RH 40 
is highly positive which suggests a very hydrophobic surfactant, despite its high HLB value of 
14-16. However, these linear correlations and other associations between CC and HLB are 
difficult to predict in complex surfactants. The structure of Cremophor RH 40 is atypical of 
many non-ionic surfactants and relatively complex. It consists of three ricinoleic fatty acid 
chains which together with glycerol, form castor oil. This castor oil is hydrogenated and 
substituted with polyethoxylated chains. Each ricinoleic fatty acid chain is comprised of 18 
carbons with an unsaturation at the C9 and C10 position. Therefore, this triple chain surfactant 
closely resembles a triglyceride versus that of a typical single chain, linear surfactant. As a 
result, there are complications with fitting this surfactant to typical non-ionic surfactant 
models. For comparison, Polysorbate 80, of HLB 15, possesses a single 18 carbon unsaturated 
tail and polyethoxylated head group but consists of a CC value of -3.7. 
 To examine this disparity, it is worth considering the CC values for similar surfactants 
of high HLB value which have been tabulated by Abbott.62 One such surfactant is lecithin 
which, despite its lipid structure, has been stated to have as high a HLB as 12.63 Lecithin is a 
phospholipid comprised of two fatty acids, one of which is also an 18 carbon, unsaturated 
chain. Although lecithin has the potential to act as a hydrophilic surfactant (given a HLB of 
12), the CC value of +4 would indicate that this surfactant is hydrophobic. Sucrose distearate 
is another surfactant that possesses a CC value of +4 yet has a HLB value of 8, which is not 
strongly hydrophobic.64 Sucrose distearate surfactant is also comprised of two C18 unsaturated 
fatty acid tails but with a sucrose head group. An additional example of the discrepancy 
between CC and HLB can be found in sophorolipid lactone, purported to have a CC value of 
+4.5 despite the HLB of sophorolipids which has been found to be 8-10.65 Sophorolipid is 
comprised of a C17, unsaturated fatty acid chain as well as a lactonic group yet the CC is found 
to be highly hydrophobic. These three surfactants may be considered complex due to the 
presence of more than one hydrophobic tail and extensive head groups, resulting in a disparity 
between quoted CC values and HLB. Therefore, the concept of CC as it relates to multi-chain 
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surfactants is an area that requires further investigation by researchers. Nevertheless, given the 
CC value of 8.98 for Cremophor RH 40, the HLD value for a system containing 3:1 Polysorbate 
80:Cremophor RH 40, five oil-soluble APIs in Miglyol 812 and water may be calculated using 
Eq. 3.1 and the following variables: 
 
HLD= unknown 
b(S)= 0 g/100 mL as no salt was used in this final microemulsion, multi-drug formulation 
k*EACN = 0.17*7.9 for Miglyol 812 containing 50% oil-soluble APIs 
f (A)= 0 g/mL as no alcohol was used in this final microemulsion, multi-drug formulation 
CTDT= 0ºC as there was no change in temperature since all mixes were performed at room 
temperature 
CC= -0.53 for a 3:1 Polysorbate 80:Cremophor RH 40 mixture where CC Polysorbate 80 = -
3.7 and CC Cremophor 40= +8.98 
             
 The calculated HLD value for a microemulsion, multi-drug delivery system comprised 
of 3:1 Polysorbate 80:Cremophor RH 40 surfactant, Miglyol 812 oil, 5 lipophilic APIs (fat-
soluble vitamins) and water was -1.9 ± 0.02. According to Salager et al. (2005), a negative 
HLD results in the production of a Type I, O/W microemulsion.2 It can also be seen that the 
HLD is proportional to the CC such that an increase in CC results in an increase in HLD and 
vice versa.  
 Given that the CC value of 3:1 Polysorbate 80:Cremophor RH 40 was only slightly 
negative at -0.5, a more negative CC value and consequently, a more negative HLD value for 
O/W microemulsion formation, was explored. The goal was to determine whether an increase 
in negative HLD would result in an increase in O/W microemulsion formation, despite there 
being no objective scale of HLD values readily available in the literature. An arbitrary value 
of four times the CC value of 3:1 Polysorbate 80:Cremophor RH 40, from -0.5 to -2, was 
selected in order to determine whether the resulting shift in HLD would be enough to produce 
a larger O/W microemulsion than originally seen in 3:1 Polysorbate 80:Cremophor RH 40. A 
CC value of -2 equates to a Polysorbate 80:Cremophor RH 40 ratio of approximately 8:1. 
 Ternary Phase Diagram (TPD) mapping was performed on this 8:1 Polysorbate 
80:Cremophor RH 40 surfactant mixture, Miglyol 812 and water at room temperature and 
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37ºC, as in the case of 3:1 Polysorbate 80:Cremophor RH 40 in Chapter 2. Results are shown 
in Figure 3.13 and indicated that despite the increased negative CC value of -2 in  8:1 
Polysorbate 80:Cremophor RH 40, no increased benefit in terms of an expansion of the O/W 
microemulsion region was seen. Given that the EACN value of  Miglyol 812  was  similar  to   
that of drug-loaded Miglyol 812, it can be inferred that these TPDs are also reflective of 
lipophilic API incorporation. Therefore, an increase in CC from -0.5 to -2 and thus, an increase  
Figure 3.13: Ternary Phase Diagram (TPD) results of 3:1 Polysorbate 80:Cremophor RH 40 
(CC= -0.53) as compared to 8:1 Polysorbate 80:Cremophor RH 40 (CC= -2.3) at room 




in HLD from -2 to -4 did not appear to confer any additional benefit of Type I microemulsion 
formation potential in this multi-drug delivery system. 
Tensiometry performed on 3:1 Polysorbate 80:Cremophor RH 40 (Figure 3.14A, 
reproduced from Chapter 2) and 8:1 Polysorbate 80:Cremophor RH 40 (Figure 3.14B), 
surfactant solutions resulted in average CMC values of 0.0036 ± 0.001 mM (Chapter 2) and 
0.0028 ± 0.001 mM, respectively. As in the case of 3:1 Polysorbate 80:Cremophor RH 40 
(Chapter 2), the experimental CMC for 8:1 Polysorbate 80:Cremophor RH 40 was below that 
of the ideal CMC (0.0048 mM, Appendix B) indicating synergism. However, the degree of 
synergism for both 3:1 and 8:1 Polysorbate 80:Cremophor RH 40, as determined by the 
Rubingh β interaction parameter (Appendix B), was -2.2 and -2.8, respectively. Given that the 
CMCs for both ratios were within the standard deviations of each other, and that their degrees 
of synergism was similar, no notable advantage to using a higher percentage of Polysorbate 80 
in this formulation was observed. As a result, the final microemulsion system was determined 
to consist of 3:1 Polysorbate 80: Cremophor RH 40 as the surfactant component, Miglyol 812 
as the oil component into which five lipophilic APIs may be incorporated, and water as the 
aqueous component into which six hydrophilic APIs may be incorporated. 
 
Figure 3.14: Tensiometry results for 3:1 (A) and 8:1 (B) Polysorbate 80:Cremophor RH 40 in 
water at 25ºC. 
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3.5.4  Hydrophilic API Incorporation 
The process of hydrophilic API incorporation was found to be more complicated than that of 
lipophilic API incorporation. Where high log P values and generally neutral charges prevailed 
in the case of the lipophilic APIs, the hydrophilic APIs exhibited a number of challenges 
including poor water solubility in the cases of Vitamins B2 and Vitamin B9 (0.7 mg/ml13 and 
0.08 mg/mL14 respectively), light sensitivity (Vitamin B166, Vitamin B267-69, Vitamin B666,67, 
Vitamin B966 and Vitamin B1266,69), oxygen sensitivity (Vitamin B166,70, Vitamin B1266,70), acid 
sensitivity (Vitamin B966,67 and Vitamin B1266,67) and alkaline sensitivity (Vitamin B1, Vitamin 
B2 and Vitamin B12).66,67,69 The B vitamins are generally stable to dry heat but rapidly degrade 
when subjected to an additional factor such as pH or light exposure.66,67  
 The high water solubilities of thiamine mononitrate (Vitamin B1), niacinamide 
(Vitamin B3), pyridoxine hydrochloride (Vitamin B6) and cyanocobalamin (Vitamin B12) 
resulted in easy water incorporation in the amounts listed in Table 3.7.  However, riboflavin 
(Vitamin B2) and folic acid (Vitamin B9) remained insoluble and required pH adjustment as 
described earlier in Materials and Methods. This adjustment resulted in a final pH of the 
microemulsion formulation of approximately 8.5. The effect of this pH adjustment on all APIs 
is outlined here.  
 
Table 3.7: The water-soluble APIs were incorporated in the following Health Canada amounts 






Vitamin B1 (Thiamine mononitrate) 1.4 
Vitamin B2 (Riboflavin) 1.4 
Vitamin B3 (Niacinamide) 18 
Vitamin B6 (Pyridoxine hydrochloride) 2 
Vitamin B9 (Folic Acid) 0.6 




 At physiological pH, all APIs except for thiamine mononitrate, riboflavin and folic acid 
remain neutral or uncharged. Thiamine mononitrate exhibits a charge of +1 at physiological 
pH73 given the positive nitrogen in the thiazole ring.74 Riboflavin exhibits a charge of -1 at 
physiological pH13 due to protonation of the nitrogen on the pyrazine ring (pKa 10)13 
subsequently leading to a resonance shift which causes a negative charge on the adjacent 
oxygen atom.75 Finally, folic acid exhibits a charge of -2 at physiological pH14 due to its four 
pKa values of 2.4, 3.4, 4.8 and 8 at the N1, α-COOH, γ-COOH and N3 positions, respectively.76 
At physiological pH, both COOH moieties are deprotonated leading to a charge of -2. Upon 
an increase from physiological pH to a more alkaline pH, changes in some of the APIs can be 
seen. 
  For thiamine mononitrate, its pKa1 and pKa2 values are 4.8 and 9.2, respectively.74 
Thus at a pH above 9.2, the nitrogen on the thiol ring becomes deprotonated leading to an 
uncharged intermediate that later results in a negatively charged thiol upon further addition of 
base.74 For riboflavin at alkaline pH above 10.2, deprotonation of the nitrogen on the pyrazine 
ring would occur, leading to a restoration of the carbonyl bond and overall neutrality in the 
molecule. Studies involving the sole effect of pH on riboflavin have rarely been conducted; 
many studies tend to focus on the effect of pH upon light or heat exposure. Upon exposure to 
light and/or oxygen at pH 7-12, the ribityl side chain of riboflavin is oxidized to form 
lumiflavin.68 In acidic conditions upon exposure to light and/or oxygen, riboflavin degrades to 
lumichrome.68 For folic acid, its four pKa values dictate the charge of the molecule at alkaline 
pHs. Given its fourth pKa value, at pH values above 8, the molecule would be negatively-
charged as the hydrogen on the nitrogen would simply be deprotonated. As is the case with 
riboflavin, pH studies with folic acid were often conducted in combination with factors such 
as light and temperature. Gazzalli et al (2016) found that below pH values of 5, folic acid was 
very unstable while pH values of 5-12 rendered stability.77 Between pH 4 and 12, folic acid 
was found to shift between its acidic and basic form, i.e. from an amide at approximately pH 
5 to a phenolate at approximately pH 10.77 At alkaline pHs above 8, the degradation of folic 
acid was only seen to be approximately 7% in contrast to >45% at pHs below 6.77 The authors 
also found that folic acid was heat stable even when heated at 100˚C for an hour, and stable to 
degradation below 180˚C.77 The degradation of folic acid in alkaline pHs with exposure to UV 
127 
 
light or temperature has been recorded77 but little evidence of the degradation of folic acid upon 
exposure to pH alone has been recorded.77 
 The pKa of niacinamide 3.3.78 Thus, below pH 3, the nitrogen in the pyridine ring is 
protonated and positively charged.78 However, above pH 3, as in this formulation, the nitrogen 
is deprotonated and the molecule remains neutral.78 Pyridoxine hydrochloride is stable to heat, 
acid and alkali but in the presence of light, rapidly degrades in alkaline conditions.67 It has a 
pKa1 value of 5.6 and a pKa2 value of 8.621,79 pKa1 is located at the nitrogen position while 
pKa2 is located at the phenolic position. Thus, at high alkaline pHs above that of 8.6, it can be 
expected that the phenolic group is deprotonated while that of nitrogen remains neutral. The 
large, complex structure of cyanocobalamin provides many opportunities for degradation. The 
acetamide and propionamide side chains in the corrin ring are susceptible to hydrolysis by both 
acids and bases, to carboxylic acids.66 In highly acidic conditions, the phosphate bond in ribose-
3 phosphate is cleaved to produce an amide and nucleotide moiety that can be further broken 
down.66 In highly alkaline conditions, lactam formation of the acetamide side chain in the 
corrin ring occurs.66 Given the above analysis, the APIs most susceptible to interference at a 
final microemulsion pH of 8.5 are thiamine mononitrate, riboflavin and folic acid. 
 
3.5.5  API-API Interactions 
Following the successful development of a methodology for lipophilic and hydrophilic API 
incorporation into Miglyol 812 and water, respectively, it is imperative to be wary of any 
potential API-API interactions within these systems. Both water-soluble and fat-soluble APIs 
consist of a number of functional groups that may interact with each other. For example, 
lipophilic APIs such as Vitamin E acetate and Vitamin K1 are comprised of a number of 
aromatic pi-bonds which may participate in pi-pi stacking or even –CH2–pi stacking with 
nearby methyl groups. These chemical interactions, though not previously reported in the 
literature to our knowledge, are expanded further in Chapter 4. Here, their biological 
interactions are discussed. 
 With respect to lipophilic API interactions, Vitamin E has been reported to prevent the 
oxidation of Vitamin A, enhancing absorption.80,81 Inversely, Vitamin A/beta-carotene has been 
reported to decrease serum levels of Vitamin E80 and excess levels of Vitamin A may increase 
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the requirement for Vitamin E.81 High levels of Vitamin A have also been reported to decrease 
Vitamin D uptake80 and Vitamin K absorption.81 Medium to high levels of Vitamin E have 
been reported to reduce Vitamin D absorption81 and uptake by up to 14%.80  Similarly, Vitamin 
D has been reported to reduce the intestinal uptake of Vitamin E.80 High doses of Vitamin E 
have also been reported to affect the absorption and metabolism of Vitamin K181-83 and 
similarly, large doses of Vitamin K1 have been reported to inhibit the intestinal absorption of 
Vitamin E.80 The uptake of Vitamins E and K1 has been reported to follow a common pathway 
used in Vitamin D uptake, thus explaining their interference with Vitamin D absorption.84  
 Hydrophilic API interactions are more complex. Vitamin B1 was reported to interfere 
with the absorption of Vitamin B2.81 The decomposition products of Vitamin B1 have also been 
reported to affect the breakdown of Vitamin B9 (accelerated through the presence of hydrogen 
sulphide especially from pH 5.9-7) and Vitamin B1266 (accelerated though the cleavage of 
thiamine resulting in the breakdown from cyanocobalamin to 4-methyl-5-ß-hydroxyethyl 
thiazole.69,70). Vitamin B1 has also been found to inhibit biosynthesis of Vitamin B6.81 
Conversely, Vitamin B1 has been reported to be necessary for Vitamin B3 formation.81 
 Riboflavin may lead to the partial reduction of Vitamin B170 through possible oxidative 
effects leading to the formation of thiochrome.69 Riboflavin may also degrade Vitamin B9/folic 
acid70 through cleavage of the methylene link resulting in the release of aromatic amide, i.e. p-
aminobenzoyl glutamic acid77 despite the report that riboflavin is required to convert folic acid 
to its co-enzyme.81 This is especially evident in the presence of light and at pH 6.5.69 Riboflavin 
has also been reported to degrade Vitamin B12/cyanocobalamin.66 Despite the negative effects 
of riboflavin on Vitamins B1, B9 and B12, riboflavin has been reported to be needed for the 
metabolism of Vitamin B6 and Vitamin B3.69,81 Riboflavin is an essential component of two co-
enzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) that play an 
important role in energy production85 ; FMN is required for the conversion of Vitamin B6 to 
the co-enzyme pyridoxal 5’-phosphate while FAD is required for the conversion of tryptophan 
to niacin.85     
 Niacinamide/Vitamin B3 has been reported to degrade cyanocobalamin (B12) and 
thiamine (B1)66 but acts as a solubilizer for Vitamins B2 and B969. It is also necessary in the 
conversion of Vitamin B6.81 Although Vitamin B6 may inhibit the biosynthesis of B1 in the case 
of excess levels of the latter, it is also necessary for Vitamin B1 absorption.81 Similarly, 
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although Vitamin B6, affects the absorption of Vitamin B3, it is necessary for its metabolism81, 
as enzymes in the metabolic pathway of B6 are involved in the conversion of tryptophan to 
B3.86 Vitamin B6 has also been reported to be necessary for the optimum absorption of Vitamin 
B1281 and leads to an increased requirement of Vitamin B9.81 
 Vitamin B9 has been reported to increase the need for Vitamin B12 due the former’s 
ability to obscure deficiency in the latter.81 Vitamin B9 has also been reported to be needed for 
optimal absorption of Vitamin B181 as a depletion in folic acid reduces thiamine absorption 
through a down-regulation of transporters on polarized absorptive epithelial cells.87 Vitamin 
B12 has been reported to be necessary for the optimum absorption of Vitamin B181 yet is a 
contributor to the destruction of Vitamin B6.81 
 In terms of cross API-API interactions between both hydrophilic and lipophilic APIs, 
Vitamin E appears to be necessary for metabolism of Vitamin B12.81 This is due to possible 
assistance of Vitamin E in the conversion of cyanocobalamin to its coenzyme form (B12 to 5’-
deoxyadenosylcobalamin and thus, the metabolism of methyl malonyl co-enzyme A to 
succinyl co-enzyme A).88 These API-API interactions are important considerations for future 
reference, especially in the characterization stages of the microemulsion. 
 
3.6   Conclusion 
This chapter has presented a methodology for the API incorporation and possible optimization 
of a microemulsion system capable of multi-drug delivery. Miglyol 812 and lipophilic drug-
loaded Miglyol 812 exhibited a similar degree of lipophilicity as demonstrated by EACN 
values of 7.8 and 7.9, respectively. This was in opposition to what was hypothesized. The 
characteristic curvature of Cremophor RH 40 was much larger than that of Polysorbate 80 
(+8.98 versus -3.7), despite their similar HLB values. This is likely due to greater lipophilicity 
in the case of Cremophor RH 40 attributed to its triple tailed structure.  
 Upon determination of the EACN and CC values of the microemulsion components, 
the HLD was shifted to the left (to a more negative value) in order to deduce any possible 
advantages of O/W microemulsion formation. Results indicated that an 8:1 Polysorbate 
80:Cremophor RH 40 surfactant mixture demonstrated no appreciable advantage over a 3:1 
Polysorbate 80:Cremophor RH 40 surfactant mixture in terms of microemulsion formation 
130 
 
potential, critical micelle concentration or degree of synergism. Thus, a simple shift in HLD 
from -2 to -4 conferred no apparent advantage in terms of microemulsion formation. This is 
important because unlike HLB, there is no quantifiable HLD scale currently in existence that 
indicates boundaries for microemulsion formation. The results of this Chapter led to the 
development of a final microemulsion formulation comprised of 3:1 Polysorbate 80: 
Cremophor RH 40 surfactant, Miglyol 812 oil and water. This served as the basis into which 























Chapter 4: Characterization and Stability of Multi-Drug 
Loaded 3:1 Polysorbate 80:Cremophor RH 40, Miglyol 812 
and Water Microemulsion Systems 
 
4.1   Introduction 
4.1.1  Characterization 
The process of microemulsion formation is often performed on a trial-and-error basis with the 
main objective being to obtain a clear, homogenous solution- the hallmark of microemulsion 
formation. However, the presence of a clear, homogenous microemulsion formulation provides 
little in the way of information about the properties of such a system. Thus, characterization 
techniques are an essential part of elucidating these unique properties. Scattering, microscopic 
and thermo-analytic techniques provide important insight into critical properties of a 
microemulsion system including size, charge, morphology and droplet energetics (Chapter 1, 
Section 1.7.2).   
 
4.1.1.1 Droplet Size 
As noted earlier, droplet size is an important property of microemulsion systems. However, 
the technique employed in this work, Dynamic Light Scattering (DLS) involves some 
considerations before results may be interpreted. Given that DLS correlates the movement of 
a particle with the size of a hard sphere particle that diffuses at the same speed as that of the 
sample1, this poses complications for surface-bound compounds on a particle, which do not 
conform to hard sphere morphology. In this particular formulation, the PEO groups of 
Polysorbate 80 and Cremophor RH 40 surfactant, and the localization of some hydrophilic 
active pharmaceutical ingredients (APIs) around these PEO head groups, may inflate the size 
output of the microemulsion using this technique. Therefore, the hydrodynamic diameter 




4.1.1.2 Zeta Potential 
Zeta potential, as noted earlier, is an important indicator of droplet charge and thus, propensity 
for coagulation, flocculation or general, physical instability.1-4 The droplet charge for core-
shell structures is generally straightforward given that API is contained within the core. 
However, in the case of this microemulsion formulation, PEO head groups as well as 
hydrophilic APIs that prefer to localize around these surfactant head groups may contribute to 
the charge values obtained in zeta potential measurements. Therefore, zeta potentials results 
must also be interpreted with caution. 
 
4.1.2  Stability 
One of the major advantages of microemulsion systems is their thermodynamic stability. The 
free energy of a microemulsion’s colloidal droplets is lower than that of the microemulsion 
starting components, oil and water.5 This difference in energy drives microemulsion formation 
forward and confers thermodynamic stability.5 Thermodynamic stability is advantageous in 
drug delivery and pharmaceutical formulations as delayed phase separation leads to drug 
uniformity and increased shelf life, respectively. However, the incorporation of active 
ingredients may impart instability by shifting the free energies between the microemulsion and 
its separated phases. In particular, the free energy involved in microemulsion formation may 
be affected by the presence of lipophilic and surface-active APIs in solution, and possible 
interactions of these ingredients with the microemulsion starting components.6,7 This may 
result in a less thermodynamically stable microemulsion as compared to the native system in 
the absence of API. Thus, in microemulsion systems, stability studies after API incorporation 
are essential in deducing formulation fitness for drug delivery applications.  
 The stability mechanisms most important in pharmaceutical formulations include: a) 
physical stability, b) chemical stability and c) microbiological stability.8 Physical stability 
involves the physical attributes of the formulation, particularly appearance. Odour, the 
presence of precipitate, a change in rheology and phase separation in  the case of emulsion 
systems, are important indicators of physical instability.8 Chemical stability is often the most 
important indicator of formulation instability that limits the shelf life of pharmaceutical 
products9, and refers to chemical reactions that occur among components within a formulation. 
Hydrolysis, oxidation, photochemical and thermal degradation reactions occurring between 
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pharmaceutical components are important indicators of chemical instability within a 
formulation.8 Finally, microbiological stability refers to the presence of microbial entities such 
as bacteria, yeast and mold in pharmaceutical formulations.8 Physical, chemical and 
microbiological factors pose great risk not only to the stability of the formulation, but more 
importantly, to patient safety.8 
 In Chapter 3, a number of factors were shown to affect microemulsion systems- 
namely temperature, salinity and the presence of additives. However, additional factors that 
affect API stability must also be taken into consideration such as light and pH. Therefore, the 
physical stability of the selected formulation, F1A (comprised of 50% 3:1 Polysorbate 
80:Cremophor RH 40 surfactant, 40% Miglyol 812 loaded with beta carotene, cholecalciferol, 
vitamin E acetate, phytonadione, docosahexaenoic acid and eicosapentaenoic acid and 10% 
water loaded with thiamine mononitrate, riboflavin, niacinamide, pyridoxine hydrochloride, 
folic acid and cyanocobalamin) was evaluated on the basis of temperature, light, pH, 
conductivity and accelerated gravitational separation via centrifugation. Many of these factors 
do not affect the microemulsion components themselves, but are rather a stability concern for 
the APIs present in the system. Each factor and its relevance in drug-loaded microemulsion 
systems are outlined below. In all cases, droplet sizes and zeta potentials were measured before 
and after exposure to each condition.  
 
4.1.2.1 Temperature 
Microemulsion systems are greatly affected by changes in temperature. As previously 
discussed in Chapter 3, temperature has unique effects on non-ionic surfactants in 
microemulsion systems due to dehydration of the PEO head groups. In addition, an increase in 
temperature results in a transition from a Type IàIIIà II microemulsion. However, with the 
incorporation of API, the chemical effect of temperature is more pronounced given the number 
of temperature sensitive APIs present in F1A. As noted earlier in Chapter 3, the lipophilic 
APIs are generally heat stable. The hydrophilic APIs are also stable to dry heat, but rapidly 
degrade when simultaneously exposed to additional factors such as pH and light. Nevertheless, 
exposure to changes in temperature provides useful insight into the physical and chemical 
stability of this pharmaceutical formulation. There are two well-established methods of 
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determining the effect of temperature on the stability of emulsion systems: freeze-thaw cycling 
and heat cycling.  
 
 
 4.1.2.1.1 Freeze-thaw Cycle 
Freeze-thawing, as the name suggests, is the process of freezing and thawing at set 
temperatures for specific periods of time, typically 24 hours per condition, in order to deduce 
possible changes in emulsion behaviour. Emulsion systems tend to phase separate and often 
become “grainy and watery” upon thawing.10 This phase separation occurs not only as a result 
of the freeze-thawing conditions, but primarily as a result of the individual components of the 
emulsion system.10  Lipid crystallization is one of the main determinants of a freeze-stable 
emulsion system.10 Upon freezing, lipid crystals may form leading to partial coalescence of the 
semi-frozen emulsion which, upon subsequent heating, fully coalesces leading to phase 
separation.10  Emulsions with higher oil compositions, because of the increased probability of 
crystallization, tend to be more susceptible to phase separation or freeze-thaw instability than 
those with lower oil compositions.10 Emulsifying agent selection is also important as these 
provide a layer of protection around emulsion droplets that may delay crystallization 
processes.10 Cryo-protectants and other materials that alter the crystallization of water may be 
added to the emulsion system in order to increase freeze-thaw stability and improve shelf life.1 
 
 4.1.2.1.2 Heat Cycle 
High temperatures affect microemulsion stability as we have seen in Chapter 3 where phase 
transitions may occur. This effect is especially important in systems that contain non-ionic 
surfactants. In order to deduce the effect of heat on microemulsion systems, samples are 
typically subjected to increasing temperatures for specific periods of time in order to evaluate 
possible physical and chemical changes including changes in phase behaviour, colour, 
viscosity and degradation. This enables the boundaries of temperature stability to be identified. 
The results of both the freeze-thaw cycle and heating cycles are often compared to calorimetry 






Light exposure is an important chemical stability factor in formulations containing light-
sensitive APIs. The water-soluble vitamins B1, B2, B6, B9, B12 and the fat-soluble vitamins A 
and K1 are light sensitive (Chapter 3), requiring reduced visible light or amber light 
conditions. Thus, exposure of a microemulsion system containing light-sensitive APIs to 
visible light for specified periods of time provides insight into possible chemical degradation 
behaviours that may destabilize the formulation.  
 
4.1.2.3 pH 
A change in pH, similar to light exposure, is also an important indicator of chemical stability 
in pharmaceutical formulations. In the current formulation, two water soluble APIs in F1A, 
riboflavin and folic acid, were unable to be incorporated without pH adjustment of the water 
phase to alkaline conditions. Thus, there is a possibility of a change in pH with time as the 
microemulsion system slowly equilibrates.  In Chapter 3, vitamins B1, B2, B9 and B12 in 
particular, were noted to possess alkaline sensitivity, undergoing chemical degradation in some 
cases. In addition, at pH 8.5, Vitamins B2, B9 and DHA/EPA possess negative charges. Thus, 
measuring any effect of pH on the microemulsion formulation may afford insight into possible 
API mobilization behaviours, degradation or destabilization. 
 
4.1.2.4 Conductivity 
Conductivity provides insight into microemulsion type, and enables changes in phase 
behaviour to be determined if evaluated over a period of time. The nature of F1A as a 
bicontinuous microemulsion should result in low conductivity values given the presence of 
interconnected oil and water channels. However, the presence of charged APIs, some of which 
may be attached to droplet surfaces, could impart charges into solution and must be measured 






Centrifugation stress testing, similar to the freeze-thaw cycle, is one of the only other 
established microemulsion thermodynamic stability indicators noted in the literature.11 
Microemulsions are thermodynamically stable and not greatly susceptible to phase separation. 
However, centrifugation stress testing where microemulsion samples are subjected to 
centrifugal force for a prolonged period of time is an indicator of accelerated gravitational 
sedimentation.10 Phase separations can then be measured and quantified in order to determine 
the degree of physical stability of a microemulsion formulation.  
 
4.2   Study Objectives 
Chapter 2 culminated in the selection of the surfactant phase of 3:1 Polysorbate 80:Cremophor 
RH 40 while Chapter 3 outlined the process of API incorporation as well as system 
optimization. Given the finalization of the microemulsion components, the aims of this chapter, 
Chapter 4 are: 
i) To characterize the finalized microemulsion formulation(s) on the basis of several 
properties including droplet size at various stages of drug-loading, charge, rheology and 
morphology 
ii) To assess the stability of the finalized microemulsion formulation on the basis of 
temperature and centrifugation, the two tests most indicative of thermodynamic 
stability.11 An additional aim is to assess specific, API-affecting stability factors such as 
light exposure in order to identify the most critical formulation stability factors 
 
4.3   Hypotheses 
4.3.1  Characterization 
If a combination of 3:1 Polysorbate 80:Cremophor RH 40, Miglyol 812 and water results in 
the formation of a multi-drug loaded, Type IV microemulsion, then the following 
characteristics are expected: droplet sizes of approximately 100 nm and zeta potential values 
below -30 mV (after 100x dilution with water), conductivity values above 0 mS/cm, Newtonian 




4.3.2  Stability 
If F1A is exposed to three freeze thaw cycles, heat exposure beyond 60°C‡ and light exposure 
for 24 hours, droplet size changes of greater than 50%* are expected due to droplet rupture, 
phase separation and degradation of Vitamins A, K1 and the B1, B2, B6, B9, B12, respectively. In 
addition, if the pH and conductivity of F1A are tested, changes of at least 1 pH unit over the 
period of one month and 10 uS/cm over the period of one week are expected, given increased 
API mobility with time. 
	
4.4   Materials and Methods 
4.4.1  Materials 
Surfactant and active ingredient materials were the same as those used in Chapter 3. 
 
4.4.2  Methods 
4.4.2.1 Characterization 
 4.4.2.1.1 Droplet Size 
Microemulsion formulations were prepared by weighing respective amounts of 3:1 
Polysorbate 80:Cremophor RH 40 surfactant, drug-incorporated Miglyol 812 oil (containing 
beta carotene, cholecalciferol, d-a-tocopherol acetate, phytonadione, docosahexaenoic acid 
and eicosapentaenoic acid) and drug-incorporated water (containing thiamine mononitrate, 
niacinamide, pyridoxine hydrochloride, cyanocobalamin- and riboflavin and folic acid in later 
measurements) into a 20 mL scintillation vial using a Sartorius Secura225D1S Analytical 
Balance. Each vial was inverted manually 20-25 times and left to settle for a period of 72 hours 
in a dark cupboard before size measurements were conducted. Droplet size measurements were 
performed using a Malvern Zetasizer Nano ZS. Samples were diluted 100x with water based 
on instrument recommendations that particle sizes in the range of 10-1000 nm be prepared as 
1% w/w solutions  that  are  slightly  turbid.1  In  addition,  this  
_________________________________________________________ 
‡Changes expected at 60°C given cloud point of Polysorbate 80 (60°C)12  and Cremophor RH 40 (80°C)13 
*The emulsion stability index (ESI) is an indicator of stability measured by the change in droplet size with time, expressed as a percentage.14 
There is no acceptable ESI range but the closer the value to 1 (100%), the more stable the emulsion. 50% was selected as this is representative 
of a poor stability index.15 
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dilution factor affords easier facilitation of size measurements in the optimal count rate range 
(200-500 kcps or kilo counts (of photons) per second).16 Size measurements of F1A placebo at 
100x, 500x and 1000x showed no notable differences (Figure C-1, Appendix C). The use of 
a 100x dilution factor for droplet size and zeta potential measurements has also been previously 
reported for microemulsion systems.17,18	500 µL sample was pipetted into a Fisherbrand 1.5 
mL polystyrene cuvette and inserted into the cuvette holder. Samples were left to equilibrate 
for 300 seconds at 25ºC (and 37ºC in some cases) before readings were taken at a scattering 
angle of 173º. Three measurements were taken per sample. No replicates were prepared in the 
initial droplet size studies but after incorporation of all eleven active ingredients, samples were 
prepared and measured in triplicate at the very least. Graphs were plotted in Graphpad Prism 
6 software.  
  
4.4.2.1.2 Zeta Potential 
Zeta potential measurements were performed using a Malvern Zetasizer Nano ZS. 700 µL 
sample was introduced via syringe into a primed Malvern folded capillary zeta cell and inserted 
into the cuvette holder. Samples were left to equilibrate for 300 seconds at 25ºC before readings 
were taken. pH was measured with a Fisher Scientific Accumet AB15 pH meter and probe. 
Samples were prepared in triplicate at the very least, with three measurements taken per 
sample. Graphs were plotted in Graphpad Prism 6 software. 
 
 4.4.2.1.3 Conductivity  
Conductivity measurements on formulation samples were performed using an InLab 752-6 mm 
micro-conductivity probe connected to a SevenEasy Conductivity meter. The probe was 
calibrated with 0.01 M potassium chloride calibration solution before each measurement was 
taken. Temperature was set to automated control at 25ºC. Conductivity measurements for water 
diluted samples were performed with a Malvern Zetasizer Nano ZS using the same protocol as 
that for zeta potential measurements. Measurements were performed in duplicate for the 
microemulsion formulation and using ten replicates for diluted samples. Graphs were plotted 





 4.4.2.1.4 Rheology 
Rheological measurements were carried out using an m-VROC RheoSense rheometer. 800 µL 
sample was introduced into a 1 mL Hamilton glass syringe and carefully placed into the syringe 
jacket. The lid of the syringe jacket was tightened and the drive nut knob adjusted to 
approximately 2 cm from the syringe end. The instrument was set to run at increasing shear 
rate values and the viscosity and shear stress recorded using Rheosense Inc. m-VROC 
software. Measurements were performed in duplicate with ten measurements per sample.  
Graphs were plotted in Graphpad Prism 6 software. 
 
 4.4.2.1.5 Morphology 
5 µL sample was carefully pipetted onto a copper grid held with tweezers. The underside of 
the copper grid was blotted with filter paper. 1 drop of 1% phosphotungstic acid was added to 
the grid and left for 15 seconds before the underside of the grid was blotted again with filter 
paper. The copper grid containing stained sample was placed into a protective case and left in 
a fume hood to dry for 24 hours. Samples were imaged on a Philips CM10 Transmission 
Electron Microscope (TEM) at 60 kV. 
 
 4.4.2.1.6 Thermoanalytic Behaviour 
A Perkin Elmer Differential Scanning Calorimeter (DSC) 4000 was set to a heating and cooling 
cycle from -50 to 25ºC. Approximately 2-6 mg of sample was placed into a standard aluminum 
sample pan, sealed and placed in the instrument sample holder. An empty aluminum pan was 
used as a reference. Each sample was held for 1 minute at 25 ºC, then cooled from 25ºC to -
50ºC at a rate of 5ºC per minute. The sample was then held for 3 minutes at -50ºC then heated 
from -50ºC to 25ºC at a rate of 10ºC per minute. Experiments were carried out under nitrogen 
gas. Surfactant and microemulsion formulation measurements were performed twice on one 
sample of each. DSC graphs of heat flow vs. temperature were generated using Pyris software.  
 
   4.4.2.1.7 Statistical Analysis: Characterization  
An independent, two-tailed, two-sample Student’s t-test was performed on the size and zeta 
potential measurements of placebo and drug-loaded samples in order to determine whether any 
statistically significant differences existed. Test assumptions included a normal distribution 
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with equal variance at 95% confidence intervals (p-value ≤ .05). All data were analyzed using 
Graphpad Prism 6 software. 
 
4.4.2.2 Stability 
10 g final formulation (F1A) was prepared and added to an amber scintillation vial. The 
formulation was subjected to various stability tests as described below, before measurement of 
droplet size and zeta potential using the methodology described earlier (Sections 4.1.1.1 and 
4.1.1.2). Samples were measured in duplicate with three measurements per sample. All graphs 
were plotted in Graphpad Prism 6 software. 
 
 4.4.2.2.1 Temperature: Freeze-thaw Cycle  
F1A was placed in a -25°C Thermo Fischer Forma freezer, removed after 24 hours and left to 
thaw to room temperature with limited light exposure for an additional 24 hours. This 
represented one cycle. The test was repeated until three cycles were completed. Experiments 
were performed in duplicate with three measurements per sample. 
 
 4.4.2.2.2 Temperature: Heat Cycle  
F1A was left for 24 hours at room temperature in a dark cupboard before being placed into a 
Fisher Scientific Isotemp GPD 10 water bath set at 37, 50, 60 and 70°C and held for 24-48 
hours at each temperature. Samples were taken at each temperature point before dilution and 
size/zeta potential measurement. Experiments were performed in duplicate with three 
measurements per sample. 
 
 4.4.2.2.3 Light Exposure Test  
F1A was left for 24 hours and 1 week at room temperature in a flow-controlled fume hood 
with exposure to fluorescent light. Samples were taken at each time point before dilution and 







 4.4.2.2.4 pH Test 
After 24 hours at room temperature in restricted lighting, the pH of F1A was measured with a 
Fisher Scientific Accumet AB15 pH meter and probe three times and the measurements 
recorded. The pH was continually measured at 48, 72, 96, 120 and 164 hours as well as at 2, 3 
and 4 weeks. One sample was measured, with three readings of said sample per time point. 
 
 4.4.2.2.5 Conductivity Test 
After 24 hours at room temperature in restricted lighting, the conductivity of F1A was 
measured with an InLab 752-6 mm micro-conductivity probe connected to a SevenEasy 
Conductivity meter three times and the measurements recorded. Conductivity and temperature 
were measured immediately after manufacture and at 24 hours, 48 hours and 1 week after 
manufacture.  One sample was measured, with three readings of said sample per time point. 
 
 4.4.2.2.6 Centrifugation Stress Testing  
Approximately 5 g F1A was placed into two graduated centrifuge tubes and subjected to 
centrifugation using a Beckman Coulter floor centrifuge with JA-12 rotor at 5000 RPM for 30 
minutes and 10000 RPM for 30 minutes. The volume of intact phase was compared to that of 
the entire sample and quantified as a percentage in order to determine stability. One sample 
was measured. 
 
 4.4.2.2.7 Statistical Analysis: Stability  
A dependent, two-tailed, two-sample Student’s t-test was performed on the size and zeta 
potential measurements of F1A samples before and after subjection to three freeze-thaw cycles 
in order to determine whether any statistically significant differences existed. Test assumptions 
included a normal distribution with equal variance at 95% confidence intervals (p-value ≤.05). 
For all other stability samples, a matched, one-way Analysis of Variance (ANOVA) was 
conducted along with a Dunnett’s multiple comparisons test, where samples after treatment 
were compared to those before treatment. Test assumptions included a normal distribution with 
no equal variability of differences (sphericity). As a result of the latter, the Geisser-Greenhouse 
correction was used. 95% confidence intervals (p-value ≤ .05) were used. All data were 
analyzed using Graphpad Prism 6 software. 
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4.5   Results and Discussion 
4.5.1  Characterization 
4.5.1.1 Droplet Size 
 4.5.1.1.1 Lipophilic Active Pharmaceutical Ingredient (API) Incorporation 
Droplet sizes of three potential microemulsion formulations were evaluated at 25ºC and 37ºC. 
Given that a Type IV microemulsion was preferred, the ternary phase diagram for 3:1 
Polysorbate 80:Cremophor RH 40, Miglyol 812 and water (Chapter 2) was assessed and three 
surfactant:oil:water (S:O:W) ratios selected based on their ability to form Type IV 
microemulsions: i) 50:40:10 (Formulation F1A), ii) 50:45:5 (Formulation F2A) and iii) 
60:30:10 (Formulation F3A). According to the TPD plot in Chapter 2, 50:40:10 and 50:45:5 
possessed the lowest surfactant concentration for Type IV microemulsion formation, while 
60:30:10 required a slightly higher (10% w/w) surfactant concentration than its counterparts. 
Thus, the latter provides insight into the effect of increased surfactant concentration on droplet 
size. Hydrodynamic diameter results are shown in Figure 4.1 at 100x dilution with water. 
Given that the critical micelle concentration of the 3:1 Polysorbate 80 and Cremophor RH 40 
surfactant phase was 0.0036 mM, this aqueous dilution still afforded use of the surfactant phase 
above the CMC (see Appendix C for calculation). Therefore, micelles were still present at 
100x aqueous dilution for DLS measurements.  
 Based on the results in Figure 4.1, some general trends were noted. Overall, drug-free 
microemulsion formulations F1A, F2A and F3A possessed sizes of 110 ± 0.3 nm, 142 ± 0.3 
nm and 54 ± 0.7 nm, respectively while drug-loaded samples possessed sizes of 56 ± 0.0 nm, 
63 ± 0.2 nm and 28 ± 0.2 nm, respectively. Thus, it can be seen that droplet size in both drug-
free and drug-loaded formulations followed the order F2A>F1A>F3A, where F2A recorded 
the largest sizes and F3A, the smallest. Based on these results, four general observations were 
noted. First, all formulations demonstrated a two-fold reduction in droplet size upon 
incorporation of the lipophilic active ingredients. Though microemulsions typically experience 
an increase in droplet size upon most types of API incorporation, a decrease in size upon API 





Figure 4.1: Droplet size and polydispersity indices (PDIs) of three microemulsion 
formulations before and after lipophilic API incorporation of A, D3, E acetate, K1 and Omega-
3 fatty acids DHA/EPA upon 100x dilution with water. 
 
 
 These previous studies by Nikolakakis et al. (2015), Patel et al. (2013) and Shahba et 
al. (2016) utilized medium chain mono-, di- and triglycerides and a Cremophor surfactant for 
incorporation of lipophilic APIs. The proposed mechanism for the reduction in droplet size 
upon incorporation of lipophilic drug material in medium chain oil and Cremophor surfactant 
systems largely involved effects and interactions of the drugs themselves with other system 
components. Nikolakakis et al. (2015) proposed that the API of choice tested in their work, 
furosemide, acted as a co-surfactant reducing the interfacial tension and causing a reduction in 
droplet size. Patel et al. (2013) proposed that droplet sizes decreased in their study because of 
the interactions between the amine group in their drug, lumefantrine, and the carboxylic acid 
group in oleic acid, which was also present in their formulation. Finally, Shahba et al. (2016) 
proposed a reduction in droplet sizes in their work due to an interaction between the amine 
group in cinnarizine, their lipophilic drug, and the carboxylic acid group of oleic acid also 


















































































 With respect to API-surfactant/polymer interactions responsible for size decreases, 
Ahmad at al. (2014) observed a decrease in droplet size upon incorporation of lipophilic drug, 
meta-tetraphenyl porphyrin (mTPP), due to an interaction between the phenyl group of mTPP 
and the alkyl group of its surfactant, polyethyleneglycol 500- distearoyl phosphatidyl 
ethanolamine  (PEG 5000- DSPE). Such –CH - pi bond interactions may be explained by 
previously reported works such as that of Brunner et al. (2014).22 Desale et al.  (2013) also 
reported a decrease in droplet size upon incorporation of cisplatin into polymer PEG-glutamic 
acid-phenylalanine micelles due to complexation via neutralization and condensation of 
cisplatin with the glutamic acid moiety.23 Similarly, Chen at al. (2012) reported a decrease in 
droplet size upon incorporation of lipophilic norcantharidin in polymeric PEG-
polycaprolactone micelles due to Van der Waals interactions of the drug with the 
polycaprolactone moiety.24 Additional explanations for a reduction in droplet size upon API 
incorporation, include the ability of the API to decrease micelle aggregation number25,26 and 
the ability of the API to induce erosion or hydrolysis in core-shell systems.27,28   
 In this work, the decrease in droplet size upon incorporation of Vitamins A (beta-
carotene), D3 (cholecaliferol), E acetate, K1 (phytonadione) and omega-3 fatty acids DHA and 
EPA, implies evidence of interactions between the APIs and other system component(s). These 
interactions though not explicitly examined in this work, may be deduced by structural 
considerations of each component. Of great consequence may be the presence of slightly 
surface-active APIs in this formulation. DHA and EPA consist of 22 and 20-carbons, 
respectively, which present as cis-unsaturated alkyl chains with a terminal carboxylic acid 
group. These molecules may concentrate at the droplet interface, acting in a similar manner to 
co-surfactants, thereby reducing the interfacial tension and resulting in smaller droplets. 
Triglyceride molecules themselves are also surface-active, although this fact is rarely 
addressed.29 Surface tensions of 30 mN/m at 20ºC have been previously reported for 
tricaprylin30 leading to the assumption that Miglyol 812 is also slightly surface-active, given 
its glycerol head and fatty acid tails. Thus, Miglyol 812 while largely concentrated in the core 
of O/W micelles, may also be present in some concentration, albeit a low one, at the interface. 
These surface-active APIs in Miglyol 812, which itself is slightly surface-active, may be one 
mechanism responsible for the reduction in droplet size upon API incorporation as seen here. 
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 Additional interactions may arise as a result of cyclic π-systems contained in some API 
structures. Vitamin E acetate is comprised of a phenyl ring with a methyl group at the para-
position and Vitamin K1 is comprised of a naphthoquinone. It is possible that π -π stacking 
interactions, or even –CH- π interactions, though weak in nature, may occur given the 
proximity of the methyl groups in Vitamin E acetate to the benzene ring. Weak -CH- π 
interactions may also occur between the methyl groups in the tails of Cremophor RH 40 and 
Polysorbate 80 and the π systems of Vitamin E acetate and K1. The carboxylic acid groups of 
DHA/EPA and the hydroxyl groups of Cremophor RH 40 may also act as proton donors to the 
carbonyl groups in Vitamin E acetate and Vitamin K1 phytonadione resulting in a degree of 
hydrogen bonding that furthers such interactions. DHA and EPA, in addition to being surface-
active, are also comprised of cis-unsaturated alkyl chains, which are more readily available for 
interactions versus that of trans-unsaturated alkyl chains as in the case of beta-carotene. In 
general, all lipophilic APIs examined in this work are of high octanol/water partition 
coefficient values (< 5) and consist of alkyl tails and aromatic structures that likely localize in 
the lipophilic core of the microemulsion droplets. The presence of such a large amount of 
hydrophobic material within a confined space would undoubtedly lead to a number of 
hydrophobic and additional weak interactions which may be responsible for the reduction in 
droplet size. 
  The second general observation was that there was no notable difference in droplet size 
at 25ºC and 37ºC. As noted in Chapter 3, the lipophilic APIs in this work are heat tolerant and 
unlikely to experience degradation effects at this temperature. The third general observation 
was that a higher surfactant concentration as in the case of F3A, led to a reduction in droplet 
size and increased homogeneity as indicated by the PDI values. This is understandable in 
consideration of emulsification principles. An increase in surfactant concentration with a 
simultaneous decrease in concentration of the oil phase to be solubilized leads to greater 
emulsification power and smaller droplet sizes. Even though measurements were conducted 
above CMC, the presence of 30% w/w oil in formulation F3A versus 40% and 45% oil w/w in 
F2A and F1A, respectively, likely leads to smaller, more monodisperse droplet sizes. In 
general, all PDI values fell below 0.4, the threshold value for a polydisperse sample1 and it can 
be seen that PDI values decreased and samples became more monodisperse and homogenous 
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upon lipophilic API incorporation. This is demonstrated by the size histograms of F1A, F2A 
and F3A in Figures C-2, C-3 and C-4, respectively in Appendix C. 
 
 4.5.1.1.2 Hydrophilic Active Pharmaceutical Ingredient (API) Incorporation 
Figure 4.2 shows droplet size results of F1A, F2A and F3A after 100x dilution with water 
upon incorporation of the most soluble B-vitamins: B1 (thiamine mononitrate), B3 
(niacinamide), B6 (pyridoxine hydrochloride), and B12 (cyanocobalamin). Overall, drug-free 
microemulsion formulations of F1A, F2A and F3A exhibited sizes of 110 ± 0.3 nm, 142 ± 0.3 
nm and 54 ± 0.7 nm, respectively while drug-loaded samples exhibited sizes of 224 ± 4 nm, 
199 ± 4 nm and 107 ± 6 nm, respectively. Thus, it can be seen that droplet sizes in drug-loaded 
formulations followed the order F1A>F2A>F3A, where F1A recorded the largest sizes and 
F3A, the smallest. These results led to two general observations. The first is that, in contrast to 
lipophilic API incorporation, droplet sizes were not reduced upon hydrophilic API 
incorporation. In fact, droplet sizes were doubled in most cases. These results were expected, 
as hydrophilic APIs are not typically incorporated into O/W droplets, but rather align 
themselves with the surfactant head groups around the circumference of O/W droplets as 
previously observed.31  
 The original microemulsions formulated in this work were bicontinuous in nature, 
where both aqueous and organic phases acted as the continuous phase. Upon 100x dilution 
with water, however, as in this case of droplet size determination, these bicontinuous 
microemulsions dilute to O/W microemulsions and the O/W droplets are unable to facilitate 
the incorporation of hydrophilic material. Thus, these hydrophilic APIs concentrate around the 
droplet. Though interactions between the hydrophilic APIs and the surfactant head groups have 
not been experimentally determined in this work, inferences may be made from the chemical 
structures of these hydrophilic APIs. It is notable that of the six hydrophilic APIs incorporated 
in this work, four of them namely Vitamins B2, B3, B6 and B9 consisted of log P values between 
-0.3 and -0.95. Given that log P values of 1 indicate equal partitioning between the organic and  
aqueous phases,  it can be deduced that although these negative partition coefficients indicate 
preferential aqueous solubility, these compounds may arguably be considered weakly 




Figure 4.2: Droplet size and polydispersity indices (PDIs) of three microemulsion 
formulations before and after hydrophilic API incorporation of Vitamins B1, B3, B6 and B12 
upon 100x dilution with water. 
 
 
of -3.1 and -14, respectively.  Thus, it can be hypothesized that Vitamins B1 and B12 are most 
likely to concentrate near the outer layer of the O/W droplet near the surfactant heads given 
their highly negative log P values while Vitamins B3 and B6 are also likely to concentrate near 
the surfactant head groups, but closer to the palisade layer due to their weakly hydrophilic 
nature. All APIs, however, possess a number of hydrogen donor groups as detailed in Chapter 
3, with Vitamin B12 possessing the most (at least 11 hydrogen donor groups). These hydrogen 
donor groups may also participate in hydrogen bonding with surfactant PEO head groups. The 
concentration of hydrophilic APIs around the circumference of the O/W droplet, regardless of 
the specific interactions, may explain the increase in hydrodynamic diameter upon hydrophilic 
API incorporation.  
 The second observation in Figure 4.2 is that, again in contrast to lipophilic API 
incorporation, PDI values increased upon hydrophilic API incorporation leading to a more 
polydisperse sample as demonstrated in the size histograms of F1A, F2A and F3A in Figure 
C-5, Appendix C. The explanation hypothesized for the increase in droplet size upon 
hydrophilic API incorporation is also relevant in explaining this observation. The four Vitamin 
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hydrogen bonding to varying degrees with the PEO groups of Polysorbate 80 and Cremophor 
RH40. These interactions are likely irregular due to the sheer number of APIs and surfactant 
head groups in a confined space. Thus, these interactions may be responsible for the increase 
in size variations of the droplets. It must be noted that all hydrodynamic diameter results plotted 
in Figure 4.2 are z-average values, which are considered a reliable indicator of size in instances 
of PDI values 0.4 and below.1 In the case of F3A where the PDI value was 0.58, the main peak 
demonstrated a hydrodynamic diameter closer to 250 nm rather than 107 nm indicated by the 
multi-modal size histogram of F3A in Figure C-5, Appendix C. 
 All three formulations demonstrated similarities in size after lipophilic (30-60 nm 
diameter) and hydrophilic API incorporation (~200 nm diameter). Given these similarities, the 
size results alone were not sufficient to select a final microemulsion formulation for further 
studies. Rather, the surfactant content in the formulation was considered the determining 
factor. Despite promising results, F3A was eliminated as a potential candidate due to the fact 
that 60% w/w surfactant is above the acceptable safety limit for Polysorbate 80 and Cremophor 
RH 40, according to the US Food and Drug Administration (FDA) inactive ingredient limit 
(IIG) database (418.37 mg per unit dose for an oral capsule containing P80 (CAS#9005656 | 
Unique Ingredient Identifier or UNII 6OZP39ZG8H)32 and 414.83 mg per unit dose for an oral 
capsule containing Cremophor RH 40 (CAS# 61788850 | UNII 7YC686GQ8F)).33 F2A and 
F1A contain the same % w/w surfactant but F1A contains a higher percentage of water than 
F2A (10% w/w vs 5% w/w). Thus, preference was given to F1A due to the consideration that 
both hydrophilic and lipophilic API incorporation were of importance. This was the final 
formulation selected for further investigation. 
 
 4.5.1.1.3 Lipophilic and Hydrophilic Active Pharmaceutical Ingredient (API) 
 Incorporation 
Figure 4.3 shows the results of F1A (S:O:W 50:40:10) upon incorporation of all lipophilic 
APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and four hydrophilic 
APIs (B1, B3, B6 and B12). Despite inclusion of up to nine (9) APIs, droplet sizes of 65 ± 0.5 nm 
were recorded as compared to sizes of 56 ± 0.0 nm and 224 ± 4 nm after incorporation of 
lipophilic APIs or hydrophilic APIs, respectively. Thus, the results in Figure 4.3 indicate the 
possible presence of interactions between hydrophilic and lipophilic APIs, barring interactions 
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occurring amongst lipophilic APIs alone (including pi-pi interactions) and hydrophilic APIs 
alone (including API-surfactant head group interactions and hydrogen bonding). Though not 




Figure 4.3: Droplet size and polydispersity indices (PDIs) of F1A before and after 
incorporation of all lipophilic APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids 
DHA/EPA) along with the four hydrophilic APIs B1, B3, B6 and B12 upon 100x dilution with 
water. 
 
 The low surface activity of DHA and EPA affords exposure of their carboxylic acid 
groups (near the surfactant head groups) to hydrogen bonding with any of the hydrogen donor 
groups present in the hydrophilic APIs. This may result in a ‘tightening’ or constricting of the 
droplet in comparison to the absence of lipophilic API material. Vitamin E acetate has an ester 
functional group in its acetate moiety and a C14 carbon alkyl chain. This may result in an 
orientation of the Vitamin E acetate molecule such that the alkyl tail projects into the core of 
the O/W droplet while the ester moiety orients closer to the surfactant head group. This 
proximity, again, could lead to possible hydrogen bonding with hydrogen donor groups present 
in many of the hydrophilic APIs. The type of interaction between Vitamin E acetate and the 
hydrogen bond donors of the hydrophilic APIs may also be possible with Vitamin K1 given its 
dione structure and long C17 alkyl tail. However, the presence of the neighbouring benzene ring 



























0.26 F1A (API-free, 100x dilution) 
Legend: 
F1A (100x dilution, API-loaded: 
          5 lipophilic/ 4 hydrophilic)
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possibility of low surface activity in triglycerides such as Miglyol 812, adds another layer of 
possible interactions between the ester groups in Miglyol 812 and the hydrogen bond donor 
groups in Vitamins B1, B3, B6 and B12. It is also possible that the presence of pyridine rings in 
Vitamins B3 and B6, a pyrimidine ring in Vitamin B1 and an aromatic benzene ring in Vitamin 
B12 leads to additional interactions of weak pi-CH type with the surfactant tails or tails of 
slightly surface-active lipophilic APIs (DHA/EPA) in the formulation. PDI values before and 
after incorporation were the same and passed criteria as a homogenous, monodisperse sample 
(< 0.4).1 
 Subsequent to incorporation of the easily water-soluble vitamins, Vitamins B2 and B9 
were successfully incorporated into the formulation via pH adjustment of the water-soluble 
API phase from pH 6.5 to pH 11. Figure 4.4 shows the results of F1A before and after 
incorporation of all lipophilic APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids 
DHA/EPA) and all hydrophilic APIs B1, B2, B3, B6, B9 and B12. It can be seen that after the 
addition of all eleven (11) active ingredients, droplet sizes were approximately 164 ± 37 nm in 
diameter. Using the two-sample, T-test where API-free microemulsions (N=4) possessed 
average sizes of 150 nm (SD±37) and drug-loaded microemulsions (N=14) possessed average 
sizes of 164 nm (SD±37), no statistically significant difference in size, t(16)=.62, p=.547, was 
seen between samples. The assumption of equal variances was satisfied using the F-test, F(16)= 
1.04 , p>0.999. (Table C-1, Appendix C). This non-significant increase in hydrodynamic 
diameter was observed despite the concentration of hydrophilic APIs at the surface of the 
droplet around the surfactant head groups.  
 In comparison to the hydrodynamic diameter results for F1A containing lipophilic 
material only, the presence of all six hydrophilic APIs resulted in an increase of approximately 
100 nm. Despite this increase, the droplet sizes upon dilution with water of F1A containing all 
eleven (11) active ingredients, were still below 200 nm in diameter or 100 nm   in   radius,  the   
generally  accepted  boundary  for  true  nanotechnology  vehicles  and microemulsion 
systems.5 Literature evidence of multi-drug incorporation in microemulsion systems is poor, 
and never to the extent of 11 APIs to the best of our knowledge. Ding et al. (2015) loaded two 
hydrophobic drugs, honokiol and sirolimus, into a self-emulsifying system and recorded 
droplet sizes of 20-30 nm upon 200x dilution with water.34 Ujhelyi et al (2015) loaded three 
hydrophilic drugs, bleomycin, cisplatin and ifosfamide into a self-emulsifying microemulsion 
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with sizes between 68 to 149 nm in diameter, although the dilution factor was not specified.35 
Kaur (2014) loaded one lipophilic drug, rifampicin, and two hydrophilic drugs, isoniazid and 
pyrazinamide into a microemulsion system with sizes of 20 nm, though the formulation was 
mostly comprised of water (56%).36 Given these studies, the hydrodynamic diameter results 
for this type of drug-saturated system is promising. 
 
	
Figure 4.4: Droplet size and polydispersity indices (PDIs) of F1A before and after 
incorporation of all lipophilic APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids 
DHA/EPA) and all hydrophilic APIs (B1, B2, B3, B6, B9 and B12) upon 100x dilution with water. 
Size histograms are depicted in Figure C-6, Appendix C. A two-sample T-test showed no 
significant difference in size (p=.547) between drug-free and drug-loaded samples.  
 
 
4.5.1.2 Zeta Potential 
The zeta potential of F1A (pH 8.5) at 100x aqueous dilution is depicted in Figure 4.5. The zeta 
potential value before incorporation of all APIs was -10.5 ± 4 mV while the zeta potential after 
incorporation of all APIs was -14 ± 2 mV. This small increase in absolute magnitude of zeta 
potential (to a more negative value) indicates that the incorporation of APIs has a stabilizing 
effect for the microemulsion droplets. Given that zeta potential values typically +/- 30 mV 
have been reported to confer stability and delay phase separation as discussed earlier, it can be 
deduced that this formulation is not, in strict terms, electrostatically stable. However, it has 
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0.26 F1A (API-free, 100x dilution)
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physical stability in emulsion systems, it may be more practical to consider a change in zeta 
potential value upon subjection to a specific parameter.2  
 Using the two-sample T-test where API-free microemulsions (N=4) recorded average 
zeta potential values of -10.5 mV (SD±4) and drug-loaded microemulsions (N=12) recorded 
average zeta potential values of -14 mV (SD±2), a statistically significant difference in charge, 
t(14)=2.36, p=.033, was observed between samples. The assumption of equal variances was 
satisfied using the F-test, F(14)= 2.88, p=.168 (Table C-1, Appendix C). Non-ionic 
surfactants do not carry a charge and theoretically, should not confer a charge in emulsion 
droplets. However, droplets formed with Tweens (Polysorbates) and Spans have been reported 
to exhibit a negative charge due to the presence of free fatty acids and possible contaminants 
present in impure, commercial surfactants.4 The change in zeta potential from -10.5 ± 4 mV to 
-14 ± 2 mV implied a direct effect of APIs on the surface charge of the droplet. At pH 8.5, a 
number of APIs carry a negative charge based on their pKa values discussed in Chapter 3. 
Vitamin B2, riboflavin, carries a negative charge of -1 due to its pKa value of 10.2. Below this 
value, the nitrogen on the pyrazine ring becomes protonated, leading to a resonance shift and 
negative charge imparted on the neighbouring oxygen. Vitamin B9, folic acid, carries a 
negative charge of -2 due to its pKa values of 3.4 and 4.8 on the glutamic acid moiety leading 
to negative charges on both carboxylic acids. DHA and EPA also carry one negative charge 
each due to the deprotonation of their carboxylic acid groups given pKa values of 4.9 and 4.8, 
respectively.37,38  These negative  charges  corroborate  the  previous hypothesis regarding 
droplet size- that vitamins riboflavin, and folic acid tend to concentrate at the surfactant head 
groups around the circumference of the O/W droplet, increasing the negative zeta potential of 
the system. DHA and EPA have been previously reported to be slightly surface-active and in 
this case, the carboxylic acid moieties may concentrate around the O/W droplet near the 
surfactant head groups while the alkyl tails localize in the oily core of O/W droplets. Given 
that the carboxylic acid groups are negatively charged at pH 8.5, this theory is plausible given 




               
Figure 4.5: Zeta potential values of F1A before and after incorporation of all lipophilic APIs 
(Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and all hydrophilic APIs 
(B1, B2, B3, B6, B9 and B12) upon 100x dilution with water. Zeta potential curves are depicted in 
Figure C-7, Appendix C. A two-sample T-test showed a statistically significant difference 




Trends in conductivity were similar to those obtained via zeta potential after 100x dilution with 
water as depicted below in Figure 4.6.  Prior to API addition, conductivity values were 
approximately 10 ± 0.1 μS/cm; after incorporation, this increased to 58 ± 21 μS/cm. The 
increase in conductivity is likely due to the presence of charged APIs as explained in the 
previous section (Section 4.5.1.2). Although there are no strict agreed-upon threshold values 
for conductivity that define microemulsion type, high conductivities are indicative of O/W 
droplets while conductivities of zero or close to zero are typically indicative of W/O droplets 
(although bicontinuous microemulsions may also be represented at near zero conductivity 
values).39 A trend or shift in conductivity values, especially in comparison to water, has been 
purported to be valuable. In this case, a shift and increase in conductivity in the presence of 
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Figure 4.6: Conductivity values of F1A before and after incorporation of all lipophilic APIs 
(Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and all hydrophilic APIs 
(B1, B2, B3, B6, B9 and B12) upon 100x dilution with water 
 
 
 According to Acharya et al. (2012), conductivity is best evaluated in conjunction with 
other techniques rather than in isolation.40 It is important to note that in microemulsion 
formulations containing low water concentrations such as the one in this work, conductivity 
measurements upon dilution with water are inflated, even in the absence of API, due to the 
hydration effect of the PEO head groups of Polysorbate 80.41 Conductivity measurements of 
MilliQ water used to dilute these samples have been previously measured in our lab to be 4.35 
μS/cm while measurements of F1A before dilution with MilliQ water have been measured to 
be 4.78 μS/cm. Bicontinuous microemulsions due to the presence of interconnected oil and 
water channels are expected to have lower conductivities than their O/W microemulsion 
counterparts where water is the continuous phase. This was observed here, as the conductivity 
of F1A before and after 100x dilution with water exhibited a ten-fold increase. 
 
4.5.1.4 Rheology 
Similar to conductivity, rheological measurements for emulsion systems are best interpreted 
in conjunction with other techniques.41 However, they are useful in elucidating important 
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microemulsions may exhibit either Newtonian (lamellar) or non-Newtonian (non-lamellar) 
flow behaviours42, where Newtonian behaviour results in constant viscosity with increasing 
shear rate as well as a linear relationship between shear stress and shear rate. Winsor Type I 
and II microemulsions tend to demonstrate Newtonian behaviour while bicontinuous 
microemulsions tend to exhibit non-Newtonian (weak shear thinning) behaviours at high shear 
rates42, especially if their low-shear viscosities exceed approximately 10 cP or mPa/s.43 At low 
shear rates, however, bicontinuous microemulsions are reported to be Newtonian.40 The 
rheological results for F1A at 100 and 1000x dilution with MilliQ water are depicted in Figure 
4.7. MilliQ water can be seen to be Newtonian given the linear relationship (R2= 0.999)  
between shear rate and shear stress and the constant viscosity despite increasing shear rates. 
Water is known to possess a dynamic viscosity value of 0.89 mPa/s at 25°C and 1.002 mPa/s 
at 20°C.44 The results in Figure 4.7 show a water viscosity of approximately 0.95 ± 0.02 mPa/s 
across all shear rates at room temperature. With respect to F1A, similar trends were seen. 
Newtonian behaviour as demonstrated by a linear relationship (R2= 0.996 at 100x dilution;  
R2= 0.999 at 1000x dilution)  between  shear  stress  and  shear  rate,  and a constant viscosity 
despite increases in shear rate, was observed at room temperature. The viscosity of F1A at 
100x and 1000x aqueous dilution and room temperature was 1.04 ± 0.04 mPa/s and 1.02 ± 0.05 
mPa/s, respectively. Thus, both MilliQ water and F1A upon dilution with water exhibited 
Newtonian behaviours, lending credence to the existence of an O/W microemulsion, in the 
case of the latter. The viscosity of F1A at room temperature   prior   to   aqueous dilution was 
recorded using a ViscoQC 300/100 Rotational Viscometer. The instrument indicated a 
viscosity of 447 mPa/s at 40-100 RPM and Newtonian behaviour. This corroborated work by 
Acharya et al (2012) in that bicontinuous microemulsions tend to remain Newtonian at low 
shear rates.40 Thus, it was concluded that F1A was bicontinuous in its native form but upon 













Figure 4.7: Viscosity values of water and F1A after incorporation of all lipophilic APIs 
(Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and all hydrophilic APIs 
(B1, B2, B3, B6, B9 and B12) upon dilution with water. 
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Figure 4.8 depicts the TEM images obtained for Formulation F1A. Panels A and B illustrate 
F1A in its native, bicontinuous, Type IV microemulsion form. Interconnected channels of oil 
and water were seen throughout both panels with individual structures averaging 30 nm (Panel 
A) and 38 nm (Panel B) in diameter. These interconnected channels are similar to previous 
vitamin microemulsion studies conducted by Salimi at el. (2013).47 At 10x dilution with water 
(Panel C), the tight interconnected structures disappeared as droplets became diluted with 
aqueous solution. Here, droplet sizes ranged from 50-200 nm in diameter and finally in Panel 
D, upon 100x dilution with water, the droplets assumed a defined, spherical shape 
characteristic of O/W droplets. It was noted that the droplets were not completely 
monodisperse and ranged in sizes from 25 nm to 150 nm in diameter. Compared to the 
hydrodynamic diameter results of 164 ± 37 nm for F1A (Figure 4.4), even accounting for the 
standard deviation, this is still an appreciable size difference. It is likely, then, that the PEO 
chains and presence of hydrophilic APIs around the surfactant head groups contributes to an 
inflation of the size value as obtained by DLS, given that hydrodynamic diameter also accounts 







Figure 4.8: TEM images of S:O:W 50:40:10 microemulsion formulation after incorporation 
of all lipophilic APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and 
all hydrophilic APIs (B1, B2, B3, B6, B9 and B12) in its native state (a) and (b) and after dilution 





4.5.1.6 Thermoanalytic Behaviour 
DSC results are depicted in Figure 4.9. Heat flow is dependent on whether a process is 
endothermic or exothermic. Freezing is an exothermic process as less heat is required to raise 
the sample temperature at the same rate as that of the reference.48 Melting, however, is an 
endothermic process and heating of the sample is required in order to raise the temperature at 
the same rate as that of the reference.48 Endothermic peaks in this work, indicating heat 
absorption, are facing down and are shown in an ‘upside down’ orientation.  Pure water (Panel 
A) showed a gradual cooling with a sharp exothermic, crystallization peak occurring at 
approximately -18ºC as previously reported49, and a gradual heating until the appearance of an 
endothermic, melting peak at 0-8ºC, also previously reported.50 Although the melting peak is 
intuitive, the crystallization peak is more obscure. This is explained by Dalmazzone et al. 
(2009) who noted that for pure compounds, the melting temperature does not appear to depend 
on sample size while the crystallization or freezing temperature does.50 Thus, for bulk water 
with a volume of 1cm3, freezing appears to occur at approximately -14ºC while for 1 mm3 , 
freezing appears to occur around -24ºC.   
 For systems containing oil such as emulsions, investigations of the endothermic and 
exothermic profiles of bulk oil have been suggested.50 Figure 4.9, Panel B depicts the DSC 
results of Miglyol 812 oil. Upon cooling, a crystallization peak was observed at approximately 
-45ºC. This crystallization peak is bell shaped and symmetrical indicating a monodisperse 
sample in which all droplets freeze at approximately the same time. Upon heating, a second 
crystallization peak albeit smaller and broader, is seen at -31ºC. A pronounced melting peak is 
then seen at approximately -2ºC. In Miglyol 812-containing PEG oil systems, it has been 
previously reported that the increased incorporation of Miglyol 812 led to slight decreases in 
enthalpy.51 The presence of a small crystallization peak in Miglyol 812 upon heating is unique 
and will be discussed below. 
 The DSC graph of the surfactant phase, 3:1 Polysorbate 80:Cremophor RH 40, is 
depicted in Panel C. The results of this DSC graph were clearly more complex than that of 
pure water and Miglyol 812. A crystallization or freezing peak was seen at approximately -
28ºC. Heating resulted in a second large, symmetrical crystallization peak at approximately -








































Figure 4.9: DSC graphs of A) pure water, B) Miglyol 812, C) 3:1 Polysorbate 80:Cremophor 
RH40 and D) S:O:W 50:40:10 microemulsion formulation after incorporation of all lipophilic 
APIs (Vitamins A, D3, E acetate, K1 and Omega-3 fatty acids DHA/EPA) and all hydrophilic 





































Additional heating resulted in two small, broad melting peaks at approximately -14ºC and -
8ºC. A small increase in heat flow is seen around 7ºC, though it cannot be definitively 
characterized as a peak. Rather it is likely a slight change in heat capacity due to a parameter 
change like viscosity, rather than a true phase change.52 Both Miglyol 812 and the surfactant 
phase (Cremophor RH 40, specifically) consist of triglycerides. Thus, it is possible that this 
commonality may be responsible for coinciding peaks, particularly the crystallization peak at 
-45ºC. 
 The DSC graph of F1A is depicted in (Figure 4.9, Panel D). It was immediately evident 
that the peaks were remarkably similar to that of the surfactant phase, 3:1 Polysorbate 
80:Cremophor RH 40. Upon cooling, there was a small, broad crystallization peak at 
approximately -28ºC. Upon heating, a second crystallization peak that is large and 
symmetrical, similar to that of the surfactant phase, was seen at approximately -38ºC. 
Additional heating resulted in one small, broad peak at approximately -12ºC. Slight changes 
in heat flow were also seen at approximately -7ºC and 5ºC. The small melting peak at -12ºC 
and the heat flow change at -7ºC coincide with that of the surfactant phase at -14ºC and -8ºC, 
respectively. The heat change of F1A at 5ºC is also similar to that of the surfactant phase at 
7ºC. 
 The DSC graphs of Miglyol 812 (albeit to a low extent), 3:1 Polysorbate 80:Cremophor 
RH 40 and F1A demonstrated a unique characteristic with respect to the crystallization peaks; 
they all occurred upon heating rather than cooling. The presence of a crystallization peak at 
approximately –45ºC, -42ºC or -38ºC in the case of oil, surfactant or microemulsion phase, 
respectively, has been previously described as the possibility of ‘bound’ water in contrast to 
free water.50,53 This is plausible in the case of the F1A microemulsion as there is ‘bound’ water 
via interconnected bicontinuous channels but in the case of oil and surfactant, this may indicate 
the presence of water as an impurity (or possibly other chemical impurities). Although 
crystallization typically occurs during the cooling phase, crystallization that occurs during the 
heating phase such as in the case of Miglyol 812, 3:1 Polysorbate 80:Cremophor RH 40 and 
F1A before the melting peak, indicates that the sample being measured is in a non-equilibrium 
state.54 This non-equilibrium state is reasonable given that these peaks were obtained in impure, 
mixed components: Miglyol 812 (containing varying percentages of C6, C8, C10 and C12 fatty 
acids), the surfactant phase containing both Polysorbate and Cremophor and the final 
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microemulsion formulation containing Miglyol 812, two surfactants and eleven active 
ingredients. This type of crystallization has also been referred to as ‘cold crystallization’, often 
seen in polymers where the system is cooled too rapidly to afford crystallization such that only 
subsequent heating affords such formation.55  
 Overall, it can be noted that F1A exhibited a thermal profile most similar to the 
surfactant phase, which is not surprising given the fact that surfactant is the main component 
in this formulation (at 50% w/w composition in the microemulsion). In addition, despite the 
presence of 11 APIs in F1A, no new or unidentified peaks not seen in either the surfactant, oil 
or water components were observed, indicating no obvious evidence of degradation. Evidence 
of chemical reactions including decomposition, are typically notable in the exothermic 
curves.54 The exothermic curves in this case do not show a high degree of variance between 
that of the surfactant phase and that of the microemulsion. However, it should also be cautioned 
that microemulsion analysis at sub-zero temperatures is not reliable given the presence of 
multiple components which may phase separate.53 Finally, the DSC curves of Miglyol 812, the 
surfactant phase and F1A did not exhibit the high exothermic heat flows values seen in the 
DSC graph of pure water. This may be explained by the lack of water in these systems resulting 
in a lack of freezing ability. 
 
4.5.2  Stability 
4.5.2.1 Temperature 
 4.5.2.1.1 Temperature: Freeze-thaw Cycle  
After three consecutive cycles of freezing at -25°C for 24 hours followed by thawing to room 
temperature for 24 hours, no evidence of phase separation was seen in F1A. However, tiny 
precipitates yellow/orange in colour were seen when examined closely. The results in Figure 
4.10 below, demonstrate changes in hydrodynamic diameter and zeta potential after three 
freeze-thaw cycles. Droplet sizes greatly reduced by almost 50% from 200 ± 59 nm to 125 ± 
61 nm while zeta potential values increased (i.e. became less negative, which is consistent with 
decreased stability) from -15 ± 2 mV to -10 ± 0.3  mV.  Using the paired, two-sample T-test, 
F1A (N=2 pairs) demonstrated a statistically significant difference t(1)=77, p=.008 in average 
size before, 203 nm (SD±59) and after, 126 nm (SD±61) exposure to three freeze-thaw cycles.  
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In contrast, there was no statistically significant difference t(1)=3.5, p= .177 in average zeta 




Figure 4.10: Hydrodynamic diameters and zeta potentials of drug-loaded microemulsion 
formulation F1A before and after three consecutive freeze-thaw cycles from -25°C to room 
temperature at 24 hours each. PDI values before and after treatment were 0.28 and 0.24, 
respectively. Size histograms and zeta potential curves can be found in Figure C-8 (Appendix 
C). A paired two-sample T-test indicated a statistically significant difference (p=.008) in size 
but not zeta potential (p=.177) after exposure to three freeze-thaw cycles. A paired two-sample 
T-test indicated a statistically significant difference in size (p=.008) but not zeta potential 
(p=.177) before and after exposure to three freeze-thaw cycles. 
 
 
  Though no phase separation was visibly apparent, the presence of yellow/orange 
precipitates suggests the precipitation of riboflavin and folic acid. Thus, it is possible that these 
APIs, which are likely localized near the hydrophilic surfactant head groups at the oil/water 
boundary, became displaced upon water crystallization and thawing. DSC studies, as discussed 
earlier, revealed that water crystallized before, and melted after, Miglyol 812 leading to the 



















































it is further possible that these APIs did not completely revert to their original state in the 
aqueous phase, resulting in precipitation. Although the temperature ranges studied in DSC 
were wider than that of the freeze-thaw cycle, we suggest that the crystallization and melting 
of both water and Miglyol 812 were still possible here; the crystallization and melting peaks 
of water, according to DSC, were both within range of this freeze-thaw cycle (-25°C to +25°C) 
and although the crystallization peak of Miglyol 812 was slightly outside this range (-32°C), 
the peak was not fully depressed until -18°C. Thus, some crystallization activity of Miglyol 
812 may still have occurred upon freeze-thawing at -25°C to +25°C, leading to the presence 
of both Miglyol 812 and water crystals, and the forcing out of respective APIs. 
  The large reduction in droplet size before and after exposure to three freeze-thaw cycles 
was unexpected as freeze-thaw cycling in microemulsion systems tends to lead to droplet 
rupture56 and phase separation.10 Theoretically, this should result in an increase in droplet size 
as has been previously reported throughout the literature. Instead, this reduction in droplet size 
suggests a possible release of API material. Tcholakova et al. (2017) previously reported that 
the crystallization of both water and oil at separate temperatures, as in this case, could lead to 
possible rupture of the interface and release of API, resulting in a decrease in droplet size.56 A 
previous study of an amphotericin B-loaded microemulsion comprised of glyceryl monooleate 
oil and PEG-40 stearate/PEG-15 hydroxy stearate surfactants also demonstrated an almost 50% 
reduction in droplet size after three freeze thaw cycles from -20 to +32°C.57 In F1A, droplet 
sizes were approximately 164 ± 37 nm when loaded with all eleven APIs and approximately 
65 ± 0.5 nm when loaded with nine APIs, excluding riboflavin and folic acid. Thus, given the 
final droplet size of 126 ± 61 nm after these three freeze-thaw cycles, it is possible that some 
of these APIs, likely riboflavin and folic acid, were released. This is corroborated by the 
yellow/orange precipitates seen in F1A after freeze-thawing.  
  The increase in zeta potential was indicative of destabilization and the possible release 
of interface-associated, negatively-charged APIs. Given that freezing and melting has 
previously been reported to result in rupture and bursting of droplets56, it is possible that this 
disruption of the surfactant layer resulted in a disruption of APIs bound near the surface of the 
droplet. Given the increase in zeta potential to a less negative charge, this may coincide with a 




  4.5.2.1.2 Temperature: Heat Cycle 
 Upon exposure to heat at 37°C for 48 hours, there were indications of potential phase 
separations beginning in F1A. This phase separation and API precipitation was particularly 
pronounced at 70°C and a gradual darkening of sample from red-brown to dark brown/black 
was also seen, beginning at 50°C. Figure 4.11 below illustrates changes in hydrodynamic 
diameter and zeta potential after 48-hour consecutive heating cycles at 37°C, 50°C, 60°C and 
70°C.  Size decreases of approximately 35% from approximately 180 ± 37 nm to 115 ± 25 nm 
were seen at the first temperature point, i.e. after two consecutive days of heating at 37°C. The 
droplet sizes never seem to recover after this point, varying only slightly between 120-140 nm 
as the temperature was increased from 37 to 60°C. Similar trends in zeta potential were seen 
where values increased (became less negative) from -16 ± 1 mV to between -14 ± 3 mV and -
18 ± 6 mV as samples were heated from 37°C to 70°C. A matched one-way ANOVA, however, 
indicated no statistically significant difference in size F(1,1)=16.9, p=.152 or zeta potential 
F(1,1)=1.91, p=.399 of individually treated samples as compared to samples before treatment 
(Table C-3, Appendix C). Nevertheless, it is important to make the distinction between 
statistical and practical significance here as such changes in droplet size and charge pose 
stability concerns for the drug formulation. 
  It was evident based on Figure 4.11 that prolonged heating of F1A at 37°C for 48 hours 
led to a decrease in droplet size of approximately 65 nm. Given that the lipophilic APIs in F1A 
are generally heat-stable (Chapter 3), the cause for this size decrease may be attributed to i) 
surfactant behaviour and ii) hydrophilic APIs and their potential precipitation.  In terms of 
surfactant behaviour, we previously explained the effect of increasing temperatures on the 
dehydration of non-ionic, polyethylene oxide head groups in Chapter 3. Small increases in 
temperature have been reported to reduce hydration of the PEO head group of Polysorbate 80 
resulting in a more lipophilic head group and lower interfacial tension between oil and water.58 
This small temperature increase favours micellization58 and the production of small  droplet  
sizes.59  With  larger  increases  in  temperature,  however,  a breakdown of the structure of 
surrounding water disfavours micellization58 which may result in larger droplet sizes. This 
temperature ‘sweet spot’ of Polysorbate 80 where a minimum in critical micelle concentration 
and low in droplet size is experienced, has been reported to be 40°C.58 This would align with 
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the minimum droplet sizes recorded at 37°C. Above 37°C, droplet size behaviour may be 
attributable to hydrophilic APIs and their precipitates. 
 
 
Figure 4.11: Hydrodynamic diameters and zeta potentials of drug-loaded microemulsion 
formulation F1A before and after consecutive heating for 48 hours at each temperature point. 
PDI values before treatment were 0.27 and remained between 0.22-0.27 after treatment. Size 
histograms and zeta potential curves can be found in Figure C-9 (Appendix C). A matched 
one-way ANOVA with Dunnett’s post-hoc test indicated no statistically significant differences 
in size (p=.152) or zeta potential (p=.399) before and after treatment. 
 
  
  Prolonged heating combined with the alkaline pH of F1A may have degraded folic acid 
as explained in Chapter 3. In addition, it has been previously reported that in high alkaline 
conditions, riboflavin experiences degradation between 50°C and 70°C.60 These degradation 
behaviours in addition to increased dehydration of the surfactant head groups with increasing 
temperatures may have resulted in a dissociation of APIs (such as riboflavin and folic acid) 
affiliated with these head groups. Such observations would corroborate the yellow-orange 
precipitate increasingly seen at the bottom of these vials as the temperature increased, as well 
as the increased clarity of F1A upon heating as these APIs precipitated out. In addition, the 

















































peaks beginning at 60°C.  The greatest degree of clarity and precipitation (phase separation) 
was seen at 70°C, where the lowest droplet sizes were recorded as this sample likely contained 
the highest amount of precipitated API.  
  The transition in colour of F1A from red-brown to brown-black was first observed at 
50°C and may be a result of a number of thermal oxidation processes of various APIs in 
solution. In terms of fat-soluble APIs, it has previously been reported that oxidation (including 
thermal oxidation) results in the degradation of essential fatty acids and Vitamins A, D, E and 
K as well as colour changes such as the darkening of some of these fats and oils.61 Heat favours 
oxidation of beta-carotene62 and possible cis-trans isomerization behaviours63 which may result 
in red-brown colour changes.64 Vitamin E and tocopherols have been reported to darken upon 
oxidation, an effect that may also be seen upon exposure to air and light.64,65 DHA and EPA in 
Omega-3 Fatty Acids are also said to degrade in temperatures as low as 50°C.66 In terms of 
hydrophilic APIs, the cobalt in cyanocobalamin, originally pink-red, may have undergone 
oxidation to cobalt (III) oxide which is black in colour.  
  Finally, with respect to zeta potential, the change from -16 ± 1 mV to between -14 ± 3 
mV and -18 ± 6 mV after treatment was not significant and was likely a result of dehydration 
of the surfactant head group as well as loss of negatively charged API (riboflavin and folic 
acid) at the droplet interface. 
 
4.5.2.2 Light Exposure Test 
 The beginnings of API precipitation were immediately seen upon exposure to fluorescent light 
after just 24 hours and this became more pronounced after 1 week. Figure 4.12 below depicts 
droplet sizes and zeta potentials of F1A before and after exposure to fluorescent light for 24 
hours and one week. After 24 hours, droplet sizes decreased by almost 30% from 180 ± 40 nm 
to 130 ± 8 nm while zeta potentials experienced just over 40% reduction from -14 ± 5 mV to -
8 ± 4  mV. Exposure to light for 1 week had virtually the same effect as exposure for 24 hours, 
except in the case of zeta potential where charge was restored after one week. A matched, one-
way ANOVA  indicated  no  statistically  significant  difference  in  either  size F(1,1)= 6.44, 
p= .239 or zeta potential F(1,1)= 1.16, p= .476 between treated and untreated samples. 
However, practically, it is evident that F1A and its contents are quite sensitive to light 






Figure 4.12: Hydrodynamic diameters and zeta potentials of drug-loaded microemulsion 
formulation F1A before and after exposure to fluorescent light after 24 hours and one week. 
PDI values were 0.29 (before treatment), 0.33 (24 h treatment) and 0.28 (1 week treatment), 
respectively. Size histograms and zeta potential curves can be found in Figure C-10 
(Appendix C). A matched one-way ANOVA with Dunnett’s post-hoc test indicated no 




  The phase separation observations along with the droplet size reduction and zeta 
potential increase after only 24 hours of light exposure were a clear indication of the light 
sensitivity of the APIs present in F1A. The fact that these results remained virtually unchanged 
one week later suggested that the greatest degree of degradation occurred at the 24-hour mark 
and continued degradation was negligible one week later. The size histograms  in  Figure C-
10,  Appendix C   illustrate   gradual   polydispersity   and   the development of a bimodal 
distribution after light exposure for 24 hours and 1 week. Over 50% of the APIs in F1A have 
been reported to possess light sensitivity as highlighted previously in Chapter 3. In terms of 
lipophilic active ingredients, exposure of beta-carotene to fluorescent light was reported to 
result in 50% loss at 24 hours, although this  rate was found to decrease in the presence of α-















































Although degradation in visible light was not observed, exposure to UV light was previously 
reported to degrade the quinone moiety in Vitamin K1.68 In terms of hydrophilic APIs, Vitamin 
B2, riboflavin, may be degraded into various photoproducts upon light exposure including 
lumichrome, lumiflavin, formylmethylflavin and carboxymethylflavin.60 In a recent study, 
upon one hour exposure to combined visible and UV light, B3, B6, B9 and B12 were also 
degraded by over 50% but the degradation products could not be identified.69 Folic acid 
(Vitamin B9) was recently reported to degrade in the presence of light to 6-formylpterin and 
para-aminobenzoic acid (PABA)- glutamic acid.70 In cyanocobalamin, Vitamin B12, the 
formation of hydroxocobalamin was recently reported as a light degradation product.70 In 
addition, complete degradation of cyanocobalamin was seen in formulations also containing 
vitamins B1 and B6 after exposure to normal laboratory light for 5 days.71 This was reportedly 
due to possible degradation products of B1 and B6 acting on B12.71 Unlike in the case of the 
heating cycle, no apparent change in colour of  F1A was observed  after 1 week of light 
exposure. 
 
4.5.2.3 pH Test 
 Figure 4.13 depicts the change in pH of F1A over the course of 1 month. The pH 
remained stable with a slight downward trend beginning at the 7-day mark. These small 
decreases continued until the 28-day mark. A decrease in pH of approximately 1 unit (0.9 ± 
0.0) over the period of one month, from 8.8 ± 0.0 to 7.8 ± 0.0 was recorded at room temperature. 
The consistency in pH over the course of this 1-month time frame was highly unexpected given 
the multi-component nature of F1A, and the absence of any compounds with buffering capacity 
in F1A. A change of -1 unit was not concerning given that the system appeared to approach 
physiological pH. The low water composition in F1A, however, suggests that any further pH 







Figure 4.13: pH changes in drug-loaded F1A at room temperature over the course of 4 weeks 
on a pH scale of 0-14 (left).  
 
4.5.2.4 Conductivity Test 
 Figure 4.14 presents the change in conductivity of F1A from immediately after formulation to 
1 week after formulation. Conductivity remained low at just under 5 μS/cm from the time of 
manufacture to one week later with values ranging between 4.78 uS/cm and 3.32 uS/cm. 
Conductivity values were within expected ranges for bicontinuous microemulsions where both 
oil and water serve as the continuous phases as noted earlier. The consistency in conductivity 
was surprising given the presence of many charged species in F1. However, the  
 
 
Figure 4.14: Conductivity changes in drug-loaded F1A over the course of 1 week. Values 
remained relatively constant and under 5 us/cm. 
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low conductivity was surprising given the presence of many charged species in F1. However, 
the low variation in conductivity values suggest that despite any observations in phase 
behaviour, there is no shift in microemulsion type from bicontinuous Type IV to Type I O/W 
or Type II W/O over the period of one week. It follows that if the conductivity of F1A was 
consistent across the period of one week, zeta potentials should also remain consistent over 
this time period. This was corroborated by a F1A control kept in the dark at room temperature 
for one week which exhibited a slight decrease in size (30 nm) from the original 
microemulsion, but no change in zeta potential. (Figure C-11, Appendix C) 
	
4.5.2.5 Centrifugation Stress Test 
 Figure 4.15 depicts results before (left) and after centrifugation at 5000 RPM for 30 minutes 
(middle) and 10000 RPM for 30 minutes (right). An equal volume of water was used as a 
balance. There was notable phase separation after centrifugation at 5000 and 10000 RPM. This 
phase separation can be quantified in terms of volume 72 and this phase volume may also be 
equated to the height of liquid in the vial or centrifuge tube. The emulsion stability may be 








Figure 4.15: Effects of centrifugation on drug-loaded F1A before (A), after centrifugation at 
5000 RPM for 30 minutes (B) and after centrifugation at 10000 RPM for 20 minutes (C).  
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Based on the results obtained for these centrifugation studies, and on Eq. 4.1, the emulsion 
stability percentages were as follows: 
 





     = 69% 
 





     = 85% 
 Despite the presence of eleven APIs, subjection to high centrifugal force demonstrated 69% 
stability at 5000 RPM for 30 minutes and 85% stability at 10000 RPM for 30 minutes. These 
results were in contrast to expected results where low stabilities <10% were anticipated given 
this multi-component system and the extensive pH adjustment required for API incorporation.  
 
4.6   Conclusion 
A 50:40:10 microemulsion comprised of 50% w/w surfactant, 40% w/w oil and 10% w/w water 
was selected as the optimal formulation given IIG limits for surfactant content as well as water 
content considerations. The surfactant phase was comprised of 3:1 Polysorbate 80:Cremophor 
RH 40, the oil phase was comprised of Miglyol 812 and 5 lipophilic APIs (Vitamins A, D, E, 
K and Omega-3-fatty acids) and the water phase contained 6 hydrophilic APIs (Vitamins B1, 
B2, B3, B6, B9 and B12). The droplet size of this formulation, F1A, was approximately 164 nm 
after 100x aqueous dilution (larger than hypothesized) and the zeta potential was -14 mV, 
which fell short of the widely accepted -30 mV value purported to impart stability, as 
hypothesized. Conductivity values of just under -5 μS/cm for F1A and 57 μS/cm after 100x 
dilution of F1A with water, were in line with the low conductivity values characteristic of 
bicontinuous microemulsions and the higher conductivity values as a result of the presence of 
water, respectively. Rheology measurements indicated a viscosity of F1A of approximately 
447 cP but closer to 1 cP upon dilution with 100 and 1000x with water. Newtonian behaviour 
characteristic of bicontinuous microemulsions (at low shear rates) and O/W microemulsions 
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was also observed, as hypothesized. TEM images illustrated bicontinuous, interconnected oil 
and water channels and small droplets with sizes closer to 25-150 nm in diameter, given 
removal of the effect of surface-bound APIs and PEO groups as determined by DLS. DSC 
results exhibited a lack of exothermic peaks typically characteristic of system degradation. 
Rather, the DSC graph of F1A was akin to that of the surfactant phase, 3:1 Polysorbate 
80:Cremophor RH 40, which is unsurprising given the high surfactant content in this 
formulation but surprising given the number of active ingredients in the formulation which we 
hypothesized, would have resulted in numerous outlier peaks. 
With respect to the stability of F1A, temperature appeared to be the factor with the 
greatest impact on microemulsion instability. Results indicated that the largest decreases in 
droplet size (35-50%, lower than hypothesized) and increases in zeta potential (to a less 
negative value) occurred during subjection to three freeze-thaw cycles and subsequent heating 
at increasing temperatures. The second most important factor impacting microemulsion 
stability was light exposure, with droplet size reductions of 30% experienced, lower than 
hypothesized. In terms of pH, a decrease of 1 unit was seen over the period of 1 month as was 
hypothesized. Conductivity also remained constant over the period of 1 week as did zeta 
potential which was contrary to our hypothesis that there would be a fluctuation in charge due 
to the presence of charged APIs. Centrifugation studies indicated 69% stability after 5000 RPM 
for 30 minutes and 85% stability after 10000 RPM at 30 minutes. Given these results, it can be 
concluded that F1A, as a Type IV, bicontinuous microemulsion containing eleven (11) 
successfully incorporated APIs of varying hydro- and lipophilicity, is best maintained in cool 
temperatures away from light sources. It may also be beneficial to consider inclusion of a buffer 
and stabilizer to assist with pH changes and centrifugation phase separation, respectively.  
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Chapter 5: Identification of Emulsifying Agent Properties 
Necessary for Microemulsion Formation and Dissolution/ 
Stability Testing 
5.1   Introduction 
Emulsifying agents and surfactants play an important role in microemulsion formation. 
Throughout this work, it has been shown that the formation of a microemulsion system suitable 
for multi-drug delivery relies on successful surfactant selection, along with a multitude of 
factors. These factors include phase behaviour as determined by ternary phase diagram 
mapping, critical micelle concentration, hydrophilic-lipophilic balance (HLB), characteristic 
curvature (CC), hydrophilic-lipophilic deviation (HLD) of the microemulsion system and 
effective alkane carbon number (EACN) of the oil (Chapters 2 and 3). Following the 
formulation of F1A, a Type IV microemulsion suitable for the incorporation of both hydro- 
and lipophilic active ingredients (Chapter 4), one major goal of this thesis work was to identify 
additional surfactants, or alternatives to Polysorbate 80 and Cremophor RH 40, also suitable 
for multi-drug microemulsion formation. To achieve this, formulations containing surfactants 
of varying head and tail groups will be prepared and their emulsification potential, as well as 
their ability to act synergistically in mixed surfactant systems, will be evaluated via droplet 
size and tensiometry measurements, respectively. This will allow for the identification of 
emulsifying agent properties suitable for multi-drug, microemulsion formation. 
Upon formulation of these additional microemulsion systems, the final goal of this 
thesis work- to determine the pharmaceutical relevance of each formulation- will be pursued. 
One of the greatest drivers for the use of microemulsion systems in drug delivery is their 
potential to improve bioavailability due to their small droplet sizes and large surface area to 
volumes, as reported previously.1-4 Dissolution testing determines whether a formulation is 
readily dissolvable in physiologically relevant media, such that inferences about bioavailability 
may be made. Disintegration of the pharmaceutical dosage form is also important, as drug 
material cannot be physiologically absorbed otherwise. Finally, stability studies provide 
insight into formulation integrity as well as pharmaceutically relevant storage conditions. 
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Dissolution, disintegration and stability have been described previously in Chapter 1: Section 
1.7.3, Chapter 1: Section 1.7.4 and Chapter 4, respectively.  
5.1.1  Emulsifying Agents 
5.1.1.1 Surfactant Head Groups 
In contrast to surfactant tail groups, which typically consist of alkyl chains and possible 
variations such as branching, an almost infinite variety of surfactant head groups may be 
utilized in emulsion systems. Anionic surfactants may be comprised of sulphate, sulphonate, 
carboxylic or phosphate head groups that impart a negative charge, cationic surfactants may 
be comprised of quaternary ammonium or amine salts that impart a positive charge and 
amphoteric surfactants may be comprised of betaines or phosphatides that impart both negative 
and positive charges.5 Non-ionic surfactants on the other hand, are arguably less variable and 
mainly consist of ethoxylated groups, polyglycerols/polyols or block co-polymers.5 Given the 
low variability of the non-ionic surfactant class, polyethyleneoxide (PEO) groups are less 
challenging to work with as a simple increase or decrease in the number of ethylene oxide (EO) 
units results in an increase or decrease in water solubility, respectively. Thus, one can attempt 
to control the emulsification potential of a non-ionic surfactant for a particular application 
through manipulation of the number of ethylene oxide units.  
In this work, non-ionic surfactants analogous to Polysorbate/Tween 80 (a sorbitan fatty 
acid ester) with the same hydrocarbon chain length, but different number of ethylene oxide 
units, were selected for further analysis of emulsification potential. Sorbitan fatty acid ester 
surfactants with 0, 5, 10, 15, 20 and 40 ethylene oxide units were initially selected to evaluate 
the effect of PEO number on microemulsion droplet size and formation. However, only three 
such surfactants were commercially available from reputable manufacturing sources- Span 80, 
Tween 81 and Tween 80 (Polysorbate 80) with a degree of polyethoxylation of 0, 5 and 20, 
respectively.  Given that Polysorbate 80 was already present in the current formulation (F1A), 
Span 80 and Tween 81 were selected for further analysis. (Table 5.1) 
177 
Sorbitan Ester-based Surfactants (Tween Class)
Table 5.1: Structural properties of sorbitan esters, Span 80, Polysorbate 81 and Polysorbate 
80, tested in this work as a substitute for Polysorbate 80 in 3:1 Polysorbate 80:Cremophor 
surfactant mix. Hydrocarbon chain length remained constant at 18 carbons while EO content 
was varied. 
Ethers represent another important class of non-ionic surfactants, similar in nature to 
esters as they are both considered weak hydrophiles.5 The Brij class of surfactants consists of 
polyethoxylated alkyl ethers with low toxicity.6 Given the similarities between the Tween and 
Brij surfactant classes, Brij surfactants with differing PEO content but the same C18 
hydrocarbon tail as that of Polysorbate 80, were selected for further evaluation. (Table 5.2) 
The higher the PEO number, the more hydrophilic the surfactant and the more likely the 
formation of an O/W emulsion.7 Thus, the amount of aliphatic hydrocarbon that can be 
solubilized generally decreases with an increase in PEO content.8 An increase in PEO chain 
also results in a decrease in both efficiency and effectiveness of adsorption.9 These effects may 
be reflected in the emulsification potential of both Tween and Brij surfactant classes. 







(Sorbitan monooleate) 10 
0 428.62 4.311 
Polysorbate 81 
(EO (5) sorbitan monooleate) 10 
5 648.85 1012 
Polysorbate 80 
(EO (20) sorbitan monooleate) 10 
20 1309.6 1511 
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Ether-based Surfactants (Brij Class) 
Table 5.2: Structural properties of Brij ether-based surfactants, Brij 93, Brij 97, Brij 98 and 
Brij S 100 tested in this work as a substitute for Polysorbate 80 in 3:1 Polysorbate 
80:Cremophor surfactant mix. Hydrocarbon chain length remained constant at 18 carbons 
while EO content was varied. 
5.1.1.2 Surfactant Tail Groups 
Surfactant tails are typically comprised of alkyl chains 8-22 carbons in length, as well as their 
variants.5 These variants may be unsaturated carbons, fluorocarbons, benzenes, silicones, 
polyoxypropylenes and in less common instances, hydroxyl groups as in the case of surfactants 
derived from castor oil.5 The complexities of alkyl branching and saturation, render surfactant 
classification via head group a more practical approach. In the context of emulsions, 
hydrophobic tail groups play an important role. Longer alkyl tails reduce critical micelle 
concentration (CMC) while branching increases CMC.18 This impact on CMC affects the 
interfacial tension between oil and water and thus, the resulting droplet size and emulsification 
potential. Correct selection of the hydrophobic group may also even dictate the type of 
surfactant structure possible in emulsion systems as branched alkyl systems lead to higher 
order structures such as bicontinuous and lamellar structures being formed.19 Thus, for the 
emulsification purposes necessary in this work, consideration of surfactant hydrophobe is just 
as important as consideration of PEO content. In order to minimize complexity, variations in 
alkyl chain length were explored rather than branching or the introduction of reactive 
functional groups such as fluorine and silicones. Given that the diameter of spherical structures 






(EO (2) Oleyl ether)13 
2 356.6 514 
Brij O10/Brij 97 
(EO (10) Oleyl ether)13 
10 709.0 1215 
Brij O20/Brij 98 
(EO (20) Oleyl ether)13 
20 1149.5 1516 
Brij S100 
(EO (100) Stearyl ether)13 
100 4675.0 1917 
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is roughly twice the length of the hydrocarbon chain19, it can be inferred that the longer the 
hydrocarbon chain, the larger the diameter and thus, the larger the droplet size. Polysorbates 
20, 40 and 60 with 12, 16 and 18 carbons were selected for further analysis. (Table 5.3) 
Table 5.3: Structural properties of Polysorbate 20, Polysorbate 40, Polysorbate 60 and 
Polysorbate 80 tested in this work as a substitute for Polysorbate 80 in 3:1 Polysorbate 
80:Cremophor surfactant mix. EO content remained constant at 20 groups while hydrocarbon 



































(EO (20) Sorbitan 
monolaurate)10
12 1227.5 16.711 
Polysorbate 40 
(EO (20) Sorbitan 
monopalmitate)10 
16 1283.6 15.611 
Polysorbate 60 
(EO (20) Sorbitan 
monostearate)10 
18 1311.6 14.911 
Polysorbate 80 
(EO (20) Sorbitan 
monooleate)10 
18 1309.6 1511 
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5.1.1.3 Other Substitutions 
In addition to evaluating surfactants similar in nature to Polysorbate 80, a surfactant 
similar in nature to Cremophor RH 40 was also selected for further analysis. As outlined in 
Chapter 2, Cremophor RH 40 is a polyethoxylated, hydrogenated castor oil amphiphile 
comprised of 40 PEO groups and three C18 hydrocarbon chains. Cremophor RH 60 is 
analogous to Cremophor RH 40 but contains 60 PEO groups instead of 40. Thus, this surfactant 
was evaluated as a substitute for Cremophor RH 40 in 3:1 Polysorbate 80:Cremophor RH 40 
surfactant mixtures. The increase in PEO content of 20 is expected to have the same impact on 
oil solubilization as outlined earlier. (Table 5.4) 
Table 5.4: Structural properties of Cremophor RH 60 surfactant as a substitute for Cremophor 
RH 40. The hydrocarbon chain length is the same as that of Cremophor RH 40 and Polysorbate 














































An additional single surfactant was screened in order to determine whether it could 
replace 3:1 Polysorbate 80:Cremophor RH 40 altogether. Tween 85 is a polyethoxylated 
sorbitan trioleate amphiphile comprised of 20 EO units and a triple oleate (C18) surfactant 
chain with a double bond at the C9-C10 position, similar to that of Polysorbate 80 and 
Cremophor RH 40. (Table 5.5) Tween 85 possesses a molecular weight of approximately 1839 
g/mol which is higher than that of the other surfactants tested in this work, except for Brij S100 
and the Cremophors. According to Myers (2006), higher molecular weight surfactants increase 







Table 5.5: Structural properties of Polysorbate 85 surfactant information tested in this work as 
a substitute for 3:1 Polysorbate 80: Cremophor RH 40. The hydrocarbon chain length is the 
same as that of Cremophor RH 40 and Polysorbate 80 and the PEO number is the same as that 














































20 18 1838.5 1124 
5.1.2  Pharmaceutically Relevant Tests 
5.1.2.1 Dissolution 
Dissolution testing of multi-drug formulations is complex. In multivitamin formulations, to 
simplify this process, the United States Pharmacopeia (USP) requires quantification of an 
‘index’ vitamin instead.25 An ‘index’ vitamin is typically used as a single indicator of 
dissolution for all other compounds of its kind in a formulation. As required by the USP, this 
vitamin must be riboflavin.25 Riboflavin has poor water solubility and as such, its dissolution 
is likely to be much lower than that of other hydrophilic vitamins. Thus, if riboflavin is 
dissolved to an appreciable degree, it is an indicator that this is also likely for the other 
hydrophilic vitamins present in the formulation. 
Given that folic acid is essential for prenatal development25, the USP also requires 
quantification of this vitamin. With respect to fat-soluble vitamins, beta-carotene presents the 
greatest challenge due to its high lipophilicity and sensitivity to light and oxygen. Therefore, 
although fat-soluble dissolution is not required by the USP, the dissolution of beta-carotene 
will be tested in this Chapter as an ‘index’ fat-soluble vitamin. Dissolution testing is typically 
performed with filled formulation dosage forms such as tablets or capsules. However, in the 
absence of a filled dosage form as in this case, dissolution testing solely with the fill 
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formulation may provide insight into the dissolution potential of the microemulsion 
formulation. 
5.1.2.2. Disintegration 
According to the USP, a drug product undergoes successful disintegration when after 30 
minutes, 89% of the dosage form shows no residue (with a palpably firm core) on the 
dissolution apparatus mesh.25 Disintegration is not an indicator of drug dissolution rate.26 
However, it is still an important parameter given that rupture of the dosage form is the first 
step in drug dissolution and absorption. In addition, disintegration provides insight into the 
quality of the manufacturing process for a pharmaceutical dosage form.26 Disintegration testing 
may be performed on a number of dosage forms including tablets and capsules. In this work, 
the disintegration of filled hard-gelatin capsules will be tested. This is in contrast to dissolution 
testing where filled dosage forms were not used. 
5.1.2.3 Stability 
The importance of stability testing on microemulsion pharmaceutical formulations was 
previously described in Chapter 4. Upon microemulsion formation with the newly identified 
emulsifying agents, stability will be tested on the basis of temperature, light, pH, conductivity 
and accelerated gravitational separation as in Chapter 4. The results of this study, along with 
dissolution testing, will provide insight into whether careful surfactant selection leads to the 
identification of favourable microemulsion formulations analogous to F1A or F1. 
5.2   Study Objectives 
At this stage, Polysorbate 80 and Cremophor RH 40 have been identified as a successful 
surfactant pair for microemulsion formation (Chapter 2), multiple hydro- and lipophilic active 
ingredients have been incorporated (Chapter 3) and F1A, a successful microemulsion 
formulation, was identified, characterized and tested for stability (Chapter 4). The objectives 
of this chapter, Chapter 5, are: 
(i) To identify additional emulsifying agents suitable for microemulsion formulation, based
on droplet size and zeta potential measurements
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(ii) To determine emulsifying agent properties implicated in microemulsion formulation
based on results from (i)
(iii) To perform dissolution, disintegration and stability testing of all microemulsion
formulations to deduce pharmaceutical relevance and practical application
5.3   Hypothesis 
If surfactant head groups are increased from 0-20 ethylene oxide (EO) groups, and hydrocarbon 
chain lengths are decreased from 18 to 12 carbons, then a general decrease in droplet size of 
the resulting microemulsions is expected, as the amount of aliphatic hydrocarbon that can be 
solubilized decreases.18
It was hypothesized that all selected microemulsion formulations would achieve >75% 
dissolution of riboflavin in water within 60 minutes. Dissolution of <75% folic acid in water 
within 60 minutes was expected for all microemulsions given the low water solubility of folic 
acid in comparison to riboflavin. 
5.4   Materials and Methods 
5.4.1  Materials
Polysorbate 80, Cremophor RH 40, Miglyol 812 and all APIs were generously gifted from 
Accucaps Industries Limited/Catalent Pharma Solutions (Ontario, Canada) as stated earlier. 
The BRIJ class of surfactants, BRIJ 93 (BRIJ O2-MBAL-LQ- (AP)-098), BRIJ 97 (BRIJ O10-
LQ- (AP)), BRIJ 98 (BRIJ O20-SO- (AP)) and BRIJ S100 (BRIJ S100-MBAL-SO- (AP)), 
along with Polysorbate 81, were generously gifted from Croda Canada Limited (Ontario, 
Canada). Polysorbate 20, 40, 60 and 85 were obtained from VWR International (Ontario, 
Canada) and supplied by TCI America. Span 80 and Triton X-100 were obtained from Sigma-
Aldrich (Ontario, Canada) and Cremophor RH 60 was generously gifted from BASF. (Ontario, 
Canada). Potassium dihydrogen monophosphate and dipotassium phosphate were purchased 
from EMD Millipore (Ontario, Canada) and 99% Citric acid and Tris base were purchased 
from Fisher Scientific (Ontario, Canada). 18 mm oblong, opaque hard gelatin capsules were 
184 
generously gifted from the Flex lab at the University of Waterloo School of Pharmacy for 
disintegration testing.
5.4.2  Methods 
5.4.2.1 Surfactant Screening 
Surfactants were screened on the basis of surfactant head group (PEO content), surfactant tail 
group (length of the hydrocarbon chain) and hydrophilic-lipophilic balance (HLB). 
Specifically, the head group composition via EO content and the tail group composition via 
hydrocarbon chain length, were either increased or decreased as systematically as possible. In 
the majority of cases, Polysorbate 80 in the 3:1 Polysorbate 80:Cremophor RH 40 surfactant 
mixture was replaced with each Span, Tween or Brij surfactant followed by subsequent 
formulation with Cremophor RH 40, Miglyol 812, water and all hydro- and lipophilic active 
ingredients in a surfactant:oil:water (S:O:W) ratio analogous to F1A- 50:40:10. In the case of 
placebo samples, no active ingredients were incorporated and the formulation simply consisted 
of surfactant mixture, Miglyol 812 and water in a S:O:W ratio of 50:40:10. Droplet sizes and 
zeta potentials were determined using Dynamic Light Scattering (DLS) in the same manner as 
outlined in Chapter 4. Surfactants demonstrating favourable droplet sizes were then 
formulated with Cremophor RH 60, Miglyol 812, water and all active ingredients and again, 
evaluated on the basis of droplet size and zeta potential. Four approaches to variations in 
surfactant head and tail groups were taken. 
5.4.2.1.1 Consideration of Surfactant Head Group: Variation in EO Content
The effect of surfactant head group was evaluated through a gradual increase in EO content 
from 0-20, 20 being the EO content in Polysorbate 80. The idea was to increase EO content at 
a rate of 0, 5, 10 and 20 while keeping the number of carbons in the hydrocarbon chain constant. 
For the sorbitan ester surfactants, however, only those of EO content 0, 5 and 20 were 
commercially available from reputable manufacturing sources. For the alcohol ether 
surfactants, only those of EO 2, 10, 20 and 100 were available. Thus, 5 g 3:1 x: Cremophor RH 
40 surfactant (where x is Span 80, Tween 81, Tween 80, Brij 93, Brij 97, Brij 98 or Brij S100), 
4 g Miglyol 812 containing all oil-soluble actives and 1 g water containing all water-soluble 
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actives were weighed into a glass scintillation vial using a Sartorius Secura 225D Analytical 
Balance.  The vial was inverted manually for approximately 20 seconds until the mixture 
appeared homogenous. Each microemulsion mixture was placed in a dark cupboard and left to 
settle for at least 72 hours before dilution with water for droplet size and zeta potential 
measurements. Droplet size and zeta potential measurements were performed using a Malvern 
Zetasizer Nano ZS in the same manner as that described in Chapter 4. Briefly, for droplet size, 
500 µL sample was pipetted into a Fisherbrand 1.5 mL polystyrene cuvette and inserted into 
the cuvette holder. Samples were left to equilibrate for 300 seconds at 25ºC before readings 
were taken at a scattering angle of 173º. Measurements were performed in triplicate. Graphs 
were plotted in Prism 6 software. For zeta potential, 700 µL sample was introduced via syringe 
into a primed Malvern folded capillary zeta cell and inserted into the cuvette holder. Samples 
were left to equilibrate for 300 seconds at 25ºC before readings were taken. Measurements 
were performed in triplicate. Graphs were plotted in Prism 6 software. 
5.4.2.1.2 Consideration of Surfactant Tail Group: Variation in Hydrocarbon 
Chain Length  
The effect of hydrocarbon chain length was evaluated through a gradual increase in alkyl chain 
carbon number from 12-18, 18 being the number of carbons in the alkyl chain of Polysorbate 
80. Only Tween surfactants of carbon number 12, 16 and 18, corresponding to Tween 20,
Tween 40, Tween 60/80, respectively, were commercially available from reputable 
manufacturing sources. 5 g 3:1 y: Cremophor RH 40 surfactant (where y is Tween 20, Tween 
40, Tween 60 or Tween 80) was combined with the oil and water phases as described above in 
the previous section, before dilution for size and zeta potential measurements.  
5.4.2.1.3 Consideration of Substitution of Cremophor RH 40
Substitution of Cremophor RH 40 was evaluated through consideration of Cremophor RH 60, 
which is similar in nature to Cremophor RH 40 but with 20 additional EO units. Promising 
surfactants (derived from 5.4.2.1.1 and 5.4.2.1.2 above) were combined with Cremophor RH 
60 in a 3:1 ratio before incorporation of the oil and water phases as described earlier. Size and 
zeta potential measurements were also carried out as described previously.   
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5.4.2.1.4 Consideration of Substitution of 3:1 Polysorbate 80:Cremophor RH 
40 for a Single Surfactant 
Substitution of 3:1 Polysorbate 80:Cremophor RH 40 for a single surfactant was evaluated 
through consideration of Tween 85 which consists of the same structure as that of Tween 80 
but with a triple oleate chain, similar to that of Cremophor RH 40. 5 g of Tween 85, 4 g Miglyol 
812 containing all oil-soluble actives and 1 g water containing all water-soluble actives were 
combined as described previously before dilution for size and zeta potential measurements. 
5.4.2.1.5 Tensiometry
Surface tension studies were conducted as outlined in Chapter 2.        
5.4.2.2 Pharmaceutically Relevant Tests 
5.4.2.2.1 Dissolution 
Each formulation (1 g) was weighed into black, polytetrafluoroethylene (PTFE) caps using a 
Sartorius Secura 225D Analytical Balance. Dissolution was conducted using a Hanson Vision 
6 Classic Dissolution Apparatus containing six 1 L precision vessels and USP Apparatus II 
(paddle method).  Each vessel was set to heat to 37 ± 0.5ºC before 500 mL dissolution media 
was introduced. Dissolution media were chosen in accordance with USP guidelines for 
multivitamin dietary supplements25 and consisted of water, 0.01 M citric acid (pH 6) and 50 
mM phosphate buffer (pH 7.4) for the water-soluble APIs, and 4% Triton X-100 in 50 mM 
phosphate buffer and 2% Polysorbate 80 in 100 mM tris buffer (pH 8) for the oil-soluble APIs. 
Once temperature was confirmed with a thermometer, each formulation was introduced to the 
dissolution vessel, the paddle lowered and the apparatus set to stir at 100 RPM. The timer was 
set and samples were extracted at 15, 30, 60, 90 and 120 minutes. Samples (3 mL) were 
extracted using a 5 mL syringe attached to a 0.45 μM GE Whatman or Sartorius filter. In the 
case of citric acid and phosphate buffer media, studies were conducted in triplicate using newly 
prepared formulations each time 
Samples were analyzed by Accucaps Industries Ltd./Catalent Pharma Solutions 
(Windsor, Ontario) using a Waters Brand High Performance Liquid Chromatography (HPLC) 
instrument with Waters Brand C18, 250 x 4.6 mm column, 5 uM particle size. Additional 
details with respect to run time, flow rate, mobile phases and gradients are outlined in Table 
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D-5, Appendix D. The amount of dissolved folic acid and riboflavin was determined in mg/mL 
and reported as a percentage.  The amount of beta-carotene was also determined in this manner, 
though not required for multivitamin formulations.25 All graphs were generated with Graphpad 
Prism 6 software. 
 
 
 5.4.2.2.2 Disintegration 
Each formulation (0.7 g) was weighed into six (6) 18 mm oblong red, opaque hard gelatin 
capsules using a Mettler Toledo MS205DU Analytical Balance. Disintegration testing was 
conducted with a PharmaTest DIST-3 Standard 3 Position Disintegration Tester comprised of 
three test baskets connected to a central stroke arm fixed at a height of 55 mm and set at 30 
strokes per minute. 750 mL of media (water, 0.1 N hydrochloric acid and 0.05 M acetate buffer, 
pH 4.5), the latter being the recommended USP medium for hard shell capsules25 was 
introduced into each vessel and the temperature set to 37°C. After confirming the temperature 
with a thermometer, two filled hard gelatin capsules of each formulation were introduced into 
separate baskets and the apparatus switched on and timer set. The time taken for disintegration 
of all capsules in each medium was recorded. According to the USP, this type of multivitamin 
drug product passes disintegration when no residue with a palpably firm core is observed on 




 5.4.2.2.3 Stability 
Stability was determined in the same manner as outlined in Chapter 4 on the basis of 
temperature, light, pH, conductivity and accelerated gravitational separation via centrifugation. 
All graphs were generated with Graphpad Prism 6 software. 
 
 
5.4.2.3 Statistical Analysis  
An independent, two-tailed, two-sample Student’s T-test was performed on the size and zeta 
potential measurements of placebo and drug-loaded microemulsions in order to determine 
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whether any statistically significant differences existed between the two. All test assumptions 
included a normal distribution with equal variance at 95% confidence intervals (p-value ≤ .05). 
Data were analyzed using Graphpad Prism 6 software.  
An ordinary, one-way ANOVA was also performed on size, zeta potential and 
polydispersity index measurements of various microemulsions as well as on all dissolution 
data. Test assumptions included a normal distribution with equal variance at 95% confidence 
intervals (p-value ≤ .05). In the case of equal variance, a Tukey multiple comparisons test was 
conducted while in the case of unequal variance, the Welch’s statistic was used followed by 
the Games-Howell multiple comparisons test. All data were analyzed using IBM Statistical 
Product and Service Solutions (SPSS) software.  
5.5   Results and Discussion 
5.5.1  Surfactant Screening  
5.5.1.1. Consideration of Surfactant Head Group: Variation in PEO Content 
Sorbitan Ester-based Surfactants (Tween Class) 
Figure 5.1 depicts emulsions formulated in a S:O:W ratio of 50:40:10 with the surfactant phase 
consisting of 3:1 Span 80: Cremophor RH 40, 3:1 Polysorbate 81: Cremophor RH 40 or 3:1 
Polysorbate 80:Cremophor RH 40, the oil phase consisting of Miglyol 812 + five oil-soluble 
APIs and the water phase consisting of six water-soluble APIs. The microemulsion containing 
3:1 Polysorbate 80:Cremophor RH 40 is currently the lead formulation, F1A. Formulations 
comprised of 3:1 Span 80:Cremophor RH 40 exhibited coarse emulsion behaviour, evidenced 
by highly turbid placebo (white) and active ingredient (orange) samples. In contrast, 
formulations comprised of Polysorbates 81 and 80 exhibited ideal microemulsion behaviour 
as indicated by their clarity and apparent homogeneity. Each sample was diluted 100x with 
water prior to droplet size and zeta potential measurement (Figure 5.2). Size histograms and 
zeta potential curves may be found in Figure D-1, Appendix D.   
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Figure 5.1: Formulations (S:O:W=50:40:10) comprised of 3:1 Span 80/Polysorbate 
81/Polysorbate 80: Cremophor RH 40 surfactant, Miglyol 812 oil and water. Drug-loaded 
samples contain five lipophilic and six hydrophilic APIs, and are red/orange in colour versus 
placebo samples (clear/white). C40= Cremophor RH 40, P80/81= Polysorbate 80/81 
Formulations containing Span 80 were 792 ± 21 nm in size, with an extreme 
polydispersity index (PDI) of 1. Three separate size populations of over 2000 nm, 500 nm and 
200 nm were observed in active ingredient samples. In contrast, formulations containing 
Polysorbate 81 and 80 were monodisperse with sizes of 80 ± 0.2 nm and 140 ± 1.2 nm, 
respectively after inclusion of all APIs. Despite the high polydispersity index and large droplet 
sizes obtained in Span 80 emulsion samples, zeta potential values were -47 ± 0.9 mV after 
active ingredient addition. Thus, API incorporation appeared to result in a potentially 
stabilizing effect of the droplets from a strictly electrostatic consideration. Unlike Span 80, the 
zeta potentials of formulations containing both Polysorbate 81 and Polysorbate 80 did not 
change by an appreciable degree after API inclusion and were -16 ± 0.6 mV and -14.5 ± 1.1 
mV, respectively. 
The non-ethoxylated sorbitan head group of Span 80 results in a low degree of 
hydrophilicity in comparison to that of Polysorbate 81 and 80, as reflected in a HLB value of 
4.3 versus 10 and 15 for Polysorbates 81 and 80, respectively.11,12 The low HLB of Span 80, 
even when combined with Cremophor RH 40 in a 3:1 ratio, results in a mismatch with the HLB 








Figure 5.2: Hydrodynamic diameter and zeta potential values for formulations containing 3:1 
Span 80/Polysorbate 81/Polysorbate 80:Cremophor RH 40 surfactant. The current formulation, 
F1A, is depicted by the striped bars (black= placebo; grey= active ingredients).	 
 
 
This mismatch in HLB may be responsible for the formation of large droplets, as it is possible 
that the interfacial tension between oil and water was not sufficiently reduced. The advantage, 
however, is that the non-ethoxylated hydrophilic head group is smaller, resulting in less steric 
hindrance to hydrophilic APIs that prefer to localize around the surfactant head group, such as 
folic acid and riboflavin. The increased localization of these APIs around the relatively small 
head group of Span 80 may be responsible for the highly negative zeta potential values 
recorded after drug loading. This phenomenon of reduced steric hindrance may also be 
responsible for the more negative zeta potential values seen in Polysorbate 81   (-19 ± 4.2 mV) 
versus Polysorbate 80 (-14 ± 2.2 mV), given the lower PEO content of the former. Of greater 
importance, however, are the small droplet sizes of Polysorbate 81-containing microemulsions 
as compared to Polysorbate 80. This may be attributed to the combined effect of more efficient 
packing of Polysorbate 81 between Cremophor RH 40 molecules at the interface, as well as 
more pronounced hydrophobic interactions between Polysorbate 81 and lipophilic API 
material, given that Polysorbate 81 is more hydrophobic than Polysorbate 80. As one proceeds 
from Span 80 to Polysorbate 81 to Polysorbate 80, the number of EO units increases from 0 to 
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5 to 20, respectively. Given that Polysorbate 81 demonstrated the most favourable overall 
results with respect to droplet size and zeta potential for this group of surfactants, it must be 
considered that, barring PEO contributions from Cremophor RH 40, an EO content of 5 rather 
than 20 (as in the case of Polysorbate 80 in F1A), may be sufficient for the production of a 
homogeneous, microemulsion formulation containing 11 active ingredients. According to 
Myers (2006), at least 5 to 6 EO units are required for appreciable water solubility.5 Polysorbate 
81 is at this threshold value, suggesting that in a system where both hydrophilic and lipophilic 
active ingredients must be accommodated, a lower EO content may be an appropriate 
compromise. 
Ether-based Surfactants (Brij Class) 
Figure 5.3 depicts emulsions formulated in a surfactant:oil:water ratio of 50:40:10 with the 
surfactant phase consisting of 3:1 Brij 93: Cremophor RH 40, 3:1 Brij 97: Cremophor RH 40, 
3:1 Brij 98:Cremophor RH 40 or 3:1 Brij S100:Cremophor RH 40, the oil phase consisting of 
Miglyol 812 + five oil-soluble APIs and the water phase consisting of six water-soluble APIs. 
Size histograms and zeta potential curves may be found in Figure D-2, Appendix D. 
Formulations comprised of 3:1 Brij 93:Cremophor RH 40 and 3:1 Brij S100:Cremophor RH 
40  exhibited  phase  separation,  with  the  latter  presenting  as  a  coarse,  immovable gel. In 
Figure 5.3: Formulations (S:O:W=50:40:10) comprised of 3:1 Brij 93/ Brij 97/ Brij 98/ Brij 
S100: Cremophor RH 40 surfactant, Miglyol 812 and water. Drug-loaded samples contain five 
lipophilic and six hydrophilic APIs, and are red/orange in colour versus placebo samples 
(clear/white). C40= Cremophor RH 40, P80= Polysorbate 80, B93/97/98/S100= Brij 
93/97/98/S100 






contrast, formulations comprised of 3:1 Brij 97:Cremophor RH 40 and 3:1 Brij 98:Cremophor 
RH 40 were clear and homogenous, though the latter was viscous in nature. Each sample was 
diluted 100x with water followed by droplet size and zeta potential determination (Figure 5.4). 
 Active ingredient formulations containing Brij 93 were similar to those of Span 80, 
possessing large droplet sizes of 421 ± 6 nm with a very polydisperse nature (PDI=1). This 
was not surprising given that these two surfactants differ by only 2 EO groups. Three size 
populations of over 3000 nm, 200 nm and 250 nm were also observed in Brij 93 formulations, 
similar to Span 80. However, these large droplet sizes were smaller than that of Span 80, which 
was expected given the less turbid nature of the Brij 93 emulsion. Separation of the water-
soluble APIs was also apparent, as evidenced by the presence of precipitate on the bottom of 
the vial in Brij 93 samples.	Brij 97 and 98 emulsion formulations were 160 ± 2.6 nm and 219 
± 2.2 nm in size, respectively, after API incorporation. These sizes were comparable to that of 
Polysorbate 80 but larger than those of Polysorbate 81-containing microemulsions. Size and 
zeta measurements were not determined for Brij S100 emulsions due to their phase separated 
and viscous nature, the latter of which is likely due to the saturated stearyl chain that results in 
a rigid, inflexible interface. 
 
 
Figure 5.4: Hydrodynamic diameter and zeta potentials for formulations containing 3:1 Brij 
93/Brij 97/Brij 98:Cremophor RH 40 surfactant. The current formulation, F1A, is depicted by 
the striped bars (black= placebo; grey= active ingredients). 
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With respect to zeta potential, Brij 93 exhibited the largest change in zeta potential, 
becoming more negative by approximately 10 mV, from –10 ± 0.5 mV to –20 ± 0.2 mV after 
API incorporation. Smaller changes of approximately 4-5 mV were seen for Brij 97 and 98 
after API inclusion. Thus, the Brij class of surfactants appeared to demonstrate a slightly 
greater shift to more negative zeta potential values upon API incorporation, in comparison to 
the current formulation, F1A. This suggests that a degree of electrostatic stability was imparted 
onto the droplets once APIs were introduced into the formulation.  
The low degree of polyethoxylation in Brij 93 results in a HLB value of 5. As in the 
case of Span 80, this represents a mismatch with the HLB of the oil phase resulting in the 
formation of larger droplets. However, the less sterically hindered head group may have led to 
possible localization of charged water-soluble APIs, resulting in a decrease in zeta potential 
after drug loading. This decrease was not as prevalent in Brij 97 and 98 formulations where 
the PEO content was much higher at 10 and 20, respectively, and the HLB values were closer 
to that of Miglyol 812 at 1215 and 1516, respectively. 
Overall, an increase in EO content from 2 to 10 or 20 EO units resulted in a decrease 
in droplet size, as hypothesized. Similar to the case of the sorbitan esters tested earlier, the 
smallest droplet sizes of this surfactant group were observed in Brij 97, which has a lower EO 
content (10 EO units) than that of the current formulation (20 EO units). This, again, suggests 
that a lower EO content than used in the current formulation may be sufficient for the formation 
of a homogeneous, Type IV microemulsion. Interestingly, Brij 98 which is remarkably similar 
to Polysorbate 80 in terms of hydrocarbon chain length and PEO content, but for the absence 
of a sorbitan head group, possessed larger droplet sizes (219 ± 2 nm) and smaller (less negative) 
zeta potential values (-8 ± 0.2 mV) than that of F1A. Thus, the presence of a sorbitan head 
group may be of importance in this type of formulation. In the case of PEO ether surfactants, 
the phenomenon of better surfactant properties with lower EO content, has been previously 
explained.5 PEO ether surfactants with 10 EO units exhibited moderate water solubility and 
good surfactant properties.5 However, PEO ether surfactants with 5 EO units exhibited poor 
water solubility and surfactant usefulness, while those with 20 or more EO units exhibited high 
water solubility such that most of the good surfactant properties were lost.5 
The findings of slightly higher droplet sizes in the Brij surfactant class as compared to 
the Tween surfactant class have been previously reported.28 In the production of 
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polyhydroxybutyrate particles with various emulsifiers, Tweens 80, 81 and 85 exhibited lower 
sizes and size distributions than Brij 35 and Brij 58.28	Ethers have also been reported to possess 
higher toxicity than esters due to the fact that the latter are readily hydrolyzed and metabolized, 
while the former must be degraded by microbial enzyme systems of the liver and intestine.29 
Despite these disadvantages, Brij surfactants appear to trump Tween surfactants with respect 
to stability. A previous study of ethylene glycol distearate emulsions using Brij L23 and 35P 
surfactants versus Tween 20 and 80, resulted in emulsion stability for over one month versus 
only a few hours, respectively.30 The simple oxyethylene head group of Brij in comparison to 
the sorbitan ring head group of Tween may have been able to cover the droplet more efficiently 
leading to a more stable emulsion.30  
 
5.5.1.2. Consideration of Surfactant Tail Group: Variation in Hydrocarbon Chain 
Length 
Figure 5.5 depicts emulsions formulated in a surfactant:oil:water ratio of 50:40:10 with the 
surfactant phase consisting of 3:1 Polysorbate 20: Cremophor RH 40, 3:1 Polysorbate 40: 
Cremophor RH 40, 3:1 Polysorbate 60:Cremophor RH 40 or 3:1 Polysorbate 80:Cremophor 
RH 40,  the  oil  phase consisting of Miglyol 812 + five oil-soluble APIs and the water  phase 
consisting of six water-soluble APIs. Size histograms and zeta potential curves are shown in 
Figure D-3, Appendix D. Phase separation was observed in two samples: drug-loaded 
Polysorbate 20 and the Polysorbate 60 placebo. All other formulations appeared homogenous 
in nature. The sample containing 3:1 Polysorbate 60:Cremophor RH 40 was highly viscous 
and gel-like in nature for both placebo and active ingredient-containing samples. Each sample 
was diluted 100x with water followed by droplet size and zeta potential determination (Figure 
5.6).  
 The results in Figure 5.6 demonstrated no obvious pattern in droplet size differences 
given an increase in chain length. Overall, droplet sizes in both placebo and active samples for 
all surfactants tested remained within a narrow range, between 100 and 200 nm. Sizes for drug-
loaded formulations containing Polysorbate 20, 40, 60 and 80 were 134 ± 5 nm, 201 ± 3 nm, 
147 ± 1 nm and 140 ± 1.2 nm, respectively, and except  in  the  case  of  Polysorbate  20,  
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Figure 5.5: Formulations (S:O:W=50:40:10) comprised of 3:1 Polysorbate 20/Polysorbate 
40/Polysorbate 60/Polysorbate 80: Cremophor RH 40 surfactant, Miglyol 812 and water. Drug-
loaded samples contain five lipophilic and six hydrophilic APIs, and are red/orange in colour 
versus placebo samples (clear/white). C40= Cremophor RH 40, P20/40/60/80= Polysorbates 
20/40/60/80 
Figure 5.6: Hydrodynamic diameter and zeta potential values for formulations containing 3:1 
Polysorbate 20/Polysorbate 40/Polysorbate 60/Polysorbate 80: Cremophor RH 40 surfactant. 
The current formulation, F1A, is depicted by the striped bars (black= placebo; grey= active 
ingredients). 
droplet sizes increased after API incorporation. The size distribution or polydispersity index 
also decreased after API incorporation. In terms of zeta potential, a progressively stable droplet 
of increasing negative charge was generally seen from Polysorbate 20 to Polysorbate 40 to 
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Polysorbate 60. This continued increase was not seen in the sample containing Polysorbate 80 
(F1A). A slight increase in zeta potential to a more negative value (an indicator of stability) 
was seen upon API incorporation in Polysorbate 40 and 60 samples. 
 The phase separation in Polysorbate 20-containing formulations may be explained by 
the relatively short nature of the C12 hydrocarbon tail, which is likely insufficient for lipophilic 
solubilization. Thus, a layer of phase-separated oil can be seen at the top of the vial in Figure 
5.5. The gel-like nature of Polysorbate 60-containing formulations, in comparison to that of 
Polysorbate 80, is likely attributable to its saturated C18 tail which reduces film flexibility and 
imparts rigidity (unlike the unsaturated tail of Polysorbate 80). 
 In theory, a longer hydrocarbon chain results in a lower critical micelle concentration 
and higher aggregation number, such that more non-polar material may be incorporated into 
the micelle, causing an increase in size.8 However, a decrease in droplet size with increasing 
hydrocarbon length has also been previously reported. In the case of nanoparticles containing 
metal-carbon manufactured with Tweens 20, 40 and 80, nanoparticle size was found to 
decrease from Tween 20 to Tween 40 to Tween 80.31 Thus, the longer surfactant (Tween 80) 
produced smaller nanoparticle sizes than those manufactured with the shorter chain surfactants, 
Tween 40 and Tween 20.31 Despite this evidence, neither an increase nor a decrease upon 
increasing hydrocarbon chain length was clearly seen in this work. Instead, droplet sizes for 
all samples remained within a narrow size range of approximately 100-200 nm. This may be 
explained in consideration of the HLB values of these surfactants. The HLB values of 
Polysorbate 20, Polysorbate 40, Polysorbate 60 and Polysorbate 80 are 16.7, 15.6, 14.9 and 
1511, respectively. As a result, the HLB range is very narrow and only spans a difference of 1.8 
units across all four surfactants. Thus, it may be hypothesized that solubilization of all active 
ingredients occurs to a similar extent across these four surfactants.  
 In terms of zeta potential, it has previously been reported by Stachurski et al (1996), 
that alkanes of shorter hydrocarbon chains have less negative values than that of longer 
hydrocarbon chains.32 Such a decrease to a more negative zeta potential was very generally 
seen in this work from Polysorbate 20 to Polysorbate 60, but not in Polysorbate 80. However, 
the authors of the aforementioned work noted that in subsequent studies with aliphatic 
hydrocarbons from n-nonane to n-hexadecane, zeta potential values were more dependent on 
pH rather than solely on hydrocarbon chain length.32  
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 In all above surfactant-containing microemulsions, an independent, two-sample T-test 
was performed in order to determine whether any statistically significant differences existed 
between the sizes and zeta potentials of drug-free and drug-loaded formulations. Where drug-
free formulations (N=10) exhibited average sizes of 244 nm (SD±62) and drug-loaded 
formulations (N=10) exhibited average sizes of 268 nm  (SD±67), no significant difference 
was noted, t(18)= 0.27, p= .789. An F-test to compare variances showed no significant 
difference between drug-free and drug-loaded samples, F(18)= 1.19, p= .800, satisfying the 
assumption of equal variance. In addition, where drug-free formulations (N=10) exhibited 
average zeta potential values of -17.5 mV (SD±6.3) and drug-loaded formulations (N=10), 
exhibited average zeta potential values of -21.9 mV (SD±5.6), no significant differences were 
noted, t(18)= 0.52, p= .609. The assumption of equal variances in this case was also satisfied 
using the F-test, F(18)= 1.24, p=.754 (Table D-1, Appendix D). 
 
5.5.1.3. Substitution of Cremophor RH 40 with Cremophor RH 60 
Based on homogeneity and droplet size, Brij 97 and Polysorbate 81 were selected for further 
analysis. Brij 98 exhibited gelling behaviour and was discounted for further use while 
Polysorbate 40 resulted in large and polydisperse droplets, especially with respect to the 
placebo sample, where the highest PDI of all the Tween surfactants was observed. Figure 5.7 
depicts  emulsion  formulations containing S:O:W  ratios of  50:40:10  with the surfactant 
phase consisting of 3:1 Polysorbate 80: Cremophor RH 40/60, 3:1 Polysorbate 81:Cremophor 
RH 40/60, 3:1 or 3:1 Brij 97:Cremophor RH 60, the oil phase consisting of Miglyol 812 + five 
oil-soluble APIs and the water phase consisting of six water-soluble APIs. A S:O:W ratio of 
60:30:10 was also studied for 3:1 Polysorbate 80:Cremophor RH 40 and 3:1 Polysorbate 
80:Cremophor RH 60, based on previous formulation studies in Chapter 4. No visual 
differences were observed between samples made with Cremophor RH 40 and Cremophor RH 
60. Each sample was diluted 100x with water prior to evaluation of droplet size (Figure 5.8), 
polydispersity index (Figure 5.9) and zeta potential (Figure 5.10). All size histograms and 





Figure 5.7: Emulsion formulations comprised of S:O:W ratios of 50:40:10 and 60:30:10. The 
surfactant phase was comprised of (l-r) 3:1 Polysorbate 80: Cremophor RH 40, 3:1 Polysorbate 
80: Cremophor RH 60, 3:1 Polysorbate 81: Cremophor RH 40, 3:1 Polysorbate 81: Cremophor 
RH 60 or 3:1 Brij 97:Cremophor RH 60. Drug-loaded samples contain five lipophilic and six 
hydrophilic APIs, and are red/orange in colour versus placebo samples (clear). C40/60= 




Figure 5.8: Hydrodynamic diameter values for formulations comprised of 3:1 Polysorbate 80: 
Cremophor RH 40, 3:1 Polysorbate 80: Cremophor RH 60, 3:1 Polysorbate 81:Cremophor RH 
40, 3:1 Polysorbate 81:Cremophor RH 60 or 3:1 Brij 97:Cremophor RH 60 surfactant. The 
current formulation, F1A, is depicted by the striped bars (black= placebo; grey= active 
ingredients). Statistical significance from the Welch’s statistic and Games-Howell post-hoc 

































































































































Polysorbate 80 and Polysorbate 81 produced the smallest droplet sizes, especially at S:O:W 
ratios of 60:30:10 for the former and 50:40:10 for the latter (Figure 5.8). Brij 97 formulations 
exhibited the largest droplet sizes and overall, no difference in size was observed between 
formulations manufactured with Cremophor RH 40 and Cremophor RH 60. The exception to 
this was Polysorbate 81, where an increase of approximately 100 nm was seen in active 
ingredient samples manufactured with Cremophor RH 60 rather than Cremophor RH 40. An 
ordinary, one-way ANOVA comparing the effect of surfactant type on droplet  size revealed a 
statistically significant effect for both placebo [F(6,2.95) = 270.59,  p <.001] and active 
ingredient [F(6,2.7)=826.56, p<.001] samples. Given that  homogeneity of variance, as 
calculated by Levene’s F-statistic, was violated in both drug-free (F(6,7)= 2.2*1030, p<.001) 
and drug-loaded (F(6,7)= 1.5*1029, p<.001) data, reported p-values were obtained using the 
Welch’s test. A Games-Howell post-hoc analysis revealed statistically significant differences 
in droplet size between F1A (134 ± 13.6 nm) and 3:1 Polysorbate 80:Cremophor RH 40 
60:30:10 placebo formulations (38.8 ± 6.3 nm), and F1A and 3:1 Polysorbate 81:Cremophor 
RH 40 placebo formulations (83.0 ± 0.01 nm) (depicted in Figure 5.8). No statistically 
significant differences were noted between F1A and any other formulation with respect to 
active ingredient samples. All other statistically significant differences are reported in Table 
D-2, Appendix D.  
 With respect to polydispersity (Figure 5.9), 3:1 Polysorbate 80:Cremophor RH 40 
(F1A) and 3:1 Polysorbate 81:Cremophor RH 40 exhibited the lowest polydispersity indices- 
between 0.17 and 0.29. The highest polydispersity indices were observed in formulations 
containing 3:1 Polysorbate 80:Cremophor RH 40 (S:O:W 60:30:10), 3:1 Polysorbate 
80:Cremophor RH 60 (S:O:W 50:40:10) and Brij 97. A one-way ANOVA comparing the effect 
of surfactant type on polydispersity index revealed a statistically significant effect for both 
placebo [F(6,2.72)=44.14, p=.008] and active ingredient [F(6,2.7)=102, p=.003] samples. 
Homogeneity of variance, as computed by Levene’s F-statistic, was violated in both drug-free 
(F(6,7)= 1.1*1030, p<.001) and drug-loaded samples (F(6,7)= 1.1*1031, p<.001). Therefore, all 
reported p-values were obtained using the Welch’s test. A Games-Howell post-hoc analysis 
revealed no statistical differences between F1A and any of the tested microemulsions. Other 




Figure 5.9: Polydispersity indices for formulations comprised of 3:1 Polysorbate 80: 
Cremophor RH 40, 3:1 Polysorbate 80: Cremophor RH 60, 3:1 Polysorbate 81:Cremophor 
RH 40, 3:1 Polysorbate 81:Cremophor RH 60 or 3:1 Brij 97:Cremophor RH 60 surfactant. 
No statistically significant differences were noted between the PDI values of F1A and the 
other formulations. Statistical significance involving F1A microemulsions only, are depicted 
here (none, this case).  
 
 
 In terms of zeta potential (Figure 5.10), samples containing Polysorbate 81 and Brij 97 
exhibited the most and least negative values, respectively. Thus, of all surfactants tested, 
Polysorbate 81 possessed the highest stability and Brij 97, the lowest. Zeta potential values 
mainly decreased or became more negative upon API-incorporation and no large differences 
were seen between Cremophor RH 40 and Cremophor RH 60-containing samples, even for 
Polysorbate 81, which had previously recorded a 100 nm size increase in samples formulated 
with Cremophor RH 60 rather than Cremophor RH 40. A one-way ANOVA comparing the 
effect of surfactant type on zeta potential revealed a statistically significant difference in both 
placebo [F(6,3.03)=339, p<.000] and active ingredient [F(6,2.96)=17.18, p=.021] samples. 
Homogeneity of variance, as determined by Levene’s F-statistic, was violated in both placebo 

























































































































Therefore, the reported p-values were obtained using the Welch’s test. A Games-Howell post-
hoc analysis revealed statistically significant differences between F1A (-10.6 ± 0.9 mV) and 
3:1 Polysorbate 81:Cremophor RH 60 (-26.3 ± 0.3 mV), and F1A and 3:1 Brij 97:Cremophor 
RH 60 (-0.53± 0.5 mV) placebo samples. No further statistically significant differences were 
noted between the zeta potential values of F1A and the other formulations. All other 





Figure 5.10: Zeta potential values for formulations comprised of 3:1 Polysorbate 80: 
Cremophor RH 40, 3:1 Polysorbate 80: Cremophor RH 60, 3:1 Polysorbate 81:Cremophor RH 
40, 3:1 Polysorbate 81:Cremophor RH 60 or 3:1 Brij 97:Cremophor RH 60 surfactant. The 
current formulation, F1A, is depicted by the striped bars (black= placebo; grey= active 
ingredients). Statistical significance from the Welch’s statistic and Games-Howell post-hoc 


























































































































 The fact that no large difference in droplet size or zeta potential was seen between 
samples manufactured with either Cremophor RH 40 or Cremophor RH 60, except for in the 
case of Polysorbate 81, lends credence to the loss of importance of PEO content above a certain 
value. Cremophor RH 60 has a total of 60 EO units in comparison to 40 in Cremophor RH 40. 
This PEO increase of 20 is likely not beneficial to any further solubilization of APIs. In 
addition, the use of a surfactant ratio of 3:1 results in a low concentration of Cremophor RH 
60 in each formulation, such that any contribution to size or zeta potential may be masked. 
These results suggest no benefit to including Cremophor RH 60 in future formulations. 
 
5.5.1.4. Substitution of 3:1 Polysorbate 80:Cremophor RH 40 for a Single Surfactant 
Figure 5.11 depicts S:O:W 50:40:10 formulations comprised of Tween/Polysorbate 85 
surfactant, Miglyol 812 oil and water. Tween 85 was used as a single surfactant substitute for 
the 3:1 Polysorbate 80:Cremophor RH 40 mixture of the current formulation, F1A. Although 
the placebo demonstrated near perfect homogeneity and clarity, there were indications of phase 
separation upon API incorporation. Each sample was diluted 100x with water followed by 
droplet size and zeta potential determination (Figure 5.12). Size histograms and zeta potential 
curves may be found in Figure D-5, Appendix D.  
  
 
Figure 5.11: Formulations comprised of Polysorbate 85 surfactant, Miglyol 812 and water. 
Drug-loaded samples are red/orange in colour versus placebo samples (clear/pale yellow). 
C40= Cremophor RH 40, P80/81= Polysorbate 80/81 






Figure 5.12: Hydrodynamic diameter and zeta potential values for microemulsion 
formulations comprised of Polysorbate 85 surfactant, Miglyol 812, water and all active 
ingredients. Results for the current formulation, F1A, are indicated by the striped bars (black= 
placebo; grey= active ingredients).	 
  
 
 Given the similarity in structure of Polysorbate 85 to both Polysorbate 80 and 
Cremophor RH 40, the large droplet sizes observed were unexpected. Both placebo and active 
ingredient samples exhibited sizes of 367 ± 13 nm,  twice that of F1A. In addition, the sample 
was quite polydisperse resulting in multiple size populations (Figure D-5, Appendix D). 
Active ingredient samples contained size populations over 1000 nm and 250 nm. These large, 
polydisperse droplets were surprising given that Polysorbate 85 possesses an HLB value of 11, 
which is remarkably similar to the HLB value of 3:1 Polysorbate 81: Cremophor RH 40 (12). 
However, the latter produced sizes in the range of 80 nm after active ingredient incorporation. 
 Despite unfavourable droplet sizes, zeta potential values were extremely favourable at 
-60 ± 0.5 mV after drug loading. Thus, droplets containing Polysorbate 85 are expected to be 
highly stable from an electrostatic standpoint. The large droplet sizes of Polysorbate 85 may 
be attributed to the lower PEO content relative to the 3:1 Polysorbate 80:Cremophor RH 40 
surfactant mixture of F1A. It is possible that this lower PEO content affords greater oil 
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replacement of a Polysorbate 80 and Cremophor RH 40 surfactant mixture with a single 
surfactant like Polysorbate 85, evidently changes the packing behaviour and film flexibility 
afforded by a surfactant-co-surfactant system. Consequently, the large droplet sizes and 
polydispersity of Tween 85-containing formulations resulted in this surfactant being 
discounted for further use. 
 
5.5.1.5. Tensiometry 
Surfactants demonstrating favourable droplet sizes were selected for critical micelle 
concentration (CMC) analysis via tensiometry in order to determine whether synergism with 
Cremophor RH 40 was a possible criterion for the formation of homogenous, emulsion systems 
capable of multi-drug delivery. The selected surfactants were Polysorbate 81, Brij 97, Brij 98 
and Polysorbate 40. The CMC of 3:1 Polysorbate 80:Cremophor RH 60 was also evaluated. 
 Tensiometry results are shown in Table 5.6. All CMC graphs and concentration tables  
are  located  in  Figures   D-6  to  D-13,  Appendix D.  Brij  97  and  98,  as  well  as  
 
Table 5.6: Critical micelle concentration (CMC) experimental and ideal results via tensiometry 
for Brij 97, Brij 98, Polysorbate 40, Polysorbate 81 and Polysorbate 80 in Cremophor RH 
40/60. Synergism occurs when experimental CMC values are below those of the ideal. All 
calculations are located in Appendix D. 
 
* standard deviations not computed due to absence of replicates 
 
Polysorbate 40, demonstrated synergism with Cremophor RH 40 as indicated by experimental 
CMC values that were below those of the calculated ideal (Appendix D). 




3:1 Brij 97:Cremophor RH 40* 0.0015 0.019 
3:1 Brij 98:Cremophor RH 40* 0.0016  0.019 
   3:1 Polysorbate 40:Cremophor RH 40* 0.0022  0.012 
3:1 Polysorbate 80:Cremophor RH 40 0.0036 ± 0.0 0.0048 
3:1 Polysorbate 80:Cremophor RH 60* 0.0047  0.0056-0.0062 
   3:1 Polysorbate 81:Cremophor RH 40 0.0059 ± 0.0 0.0057 
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 Synergism was also seen in 3:1 Polysorbate 80:Cremophor RH 40 (Chapter 2) and 3:1 
Polysorbate 80:Cremophor RH 60 samples, while in the case of 3:1 Polysorbate 81:Cremophor 
RH 40, the experimental CMC was consistent with that of the ideal. Given that thus far, the 
greatest microemulsion formation potential was seen with Polysorbate 81, it is possible that in 
terms of CMC, synergism is not an important emulsifying agent property in microemulsion, 
multi-drug delivery. Instead, it may be more important that surfactants simply not exhibit 
antagonistic behaviour, but tensiometry studies would have to be performed on the 
unsuccessful surfactants used in this Chapter in order to state this with certainty. In addition, 
tensiometry experiments would have to be repeated in order to garner sufficient statistical 
power to confirm this trend. 
 
5.5.2  Pharmaceutically Relevant Tests 
Despite the promising results observed with Brij 97, Brij 98, Polysorbate 40, Polysorbate 81 
and Cremophor RH 60, a number of considerations were necessary before subjecting these 
formulations to dissolution, disintegration and stability testing. Brij 97 exhibited very low zeta 
potentials that were significantly different from the current formulation, F1A. Thus, it was 
inferred that this surfactant would perform poorly in stability tests. Brij 98, though 
homogenous in nature, exhibited larger droplet sizes than that of the current formulation as 
well as viscous behaviour to the point of gelling, which would inhibit proper solubilization of 
active ingredients. Polysorbate 40 demonstrated favourable droplet sizes, but high 
polydispersity in the placebo sample. Finally, there appeared to be no benefit to using 
Cremophor RH 60 in place of Cremophor RH 40, as droplet sizes and zeta potentials remained 
relatively the same, except in the case of Polysorbate 81 where droplet sizes increased. The 
use of a 60:30:10 S:O:W ratio for Polysorbate 80:Cremophor RH 40 microemulsion samples, 
though exhibiting smaller sizes than that of the current formulation (S:O:W 50:40:10), was 
also not possible given the inactive ingredient (IIG) limits of Polysorbate 80 (Chapter 4). 
Based on the above observations, Polysorbate 81 was selected as the sole surfactant for future 
investigation due to its small droplet sizes, negative zeta potential value and microemulsion 
formation potential.   
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5.5.2.1. Ternary Phase Diagram (TPD) Mapping 
The ternary phase diagram for 3:1 Polysorbate 81:Cremophor RH 40 is depicted below in 
Figure 5.13. A variety of phase behaviours were obtained at room temperature and 37ºC with 
Miglyol 812 oil and water. At room temperature, the majority of monophasic, Type IV 
microemulsion behaviour was observed at high surfactant concentrations ≥ 60% w/w. Below 
60% w/w surfactant, biphasic behaviour was primarily observed. Similar to the case of 
Polysorbate 80, Type I, O/W microemulsions dominated both TPDs at and below 40% w/w 
surfactant while Type II, W/O microemulsions were observed across a wide range of surfactant 
concentrations from 10-60% w/w but particularly at low water (10-30% w/w) and high oil (70-
90% w/w) concentrations. Monophasic, opaque (coarse) emulsion regions were also observed 
largely between 20-30% w/w surfactant. As the temperature increased to 37ºC, no major phase 
changes were observed but for a slight reduction in opaque emulsion areas. Type III 
microemulsions were primarily observed at 37ºC. 
 Type I O/W regions were dominant, as expected for a non-ionic, hydrophilic surfactant. 
Though monophasic, Type IV microemulsions were present at high surfactant concentrations, 
a Type IV microemulsion was repeatedly observed at a relatively low surfactant concentration 
of 40% w/w at S:O:W 40:50:10. This phenomenon was not seen previously in the surfactant 
systems evaluated in Chapter 2. TPD results of F1A, comprised of 3:1 Polysorbate 
80:Cremophor RH 40, indicated that at least 50% w/w surfactant was required for monophasic, 
microemulsion formation. The ability of 3:1 Polysorbate 81:Cremophor RH 40 to form a Type 
IV microemulsion at this relatively low surfactant concentration of 40% w/w (S:O:W 
40:50:10) may be explained through consideration of the low EO content of Polysorbate 81 in 
comparison to that of Polysorbate 80. The low EO content of Polysorbate 81 affords higher 
lipophilicity of the surfactant mixture, possibly enhancing its amenability to Miglyol 812, 
present at a 50% w/w concentration. This is also likely responsible for the larger Type II, W/O 
microemulsion region observed here in comparison to 3:1 Polysorbate 80:Cremophor RH 40. 
Almost 50% of samples demonstrated gelling at room temperature, typically between 20-30% 
w/w surfactant. Upon heating to 37ºC, this behaviour was reduced and accounted for just under 
30% of all samples, typically at higher surfactant concentrations (40-60% w/w). The reduction 
in gelling behaviour is likely attributable to the action of heat on Cremophor RH 40 which has 






Figure 5.13: Ternary phase diagram for 3:1 Polysorbate 81:Cremophor RH 40, Miglyol 812 
and water at room temperature (left) and at 37°C (right). 
 
  
 The main difference in microemulsion phase behaviour between 3:1 Polysorbate 
81:Cremophor RH 40 and 3:1 Polysorbate 80:Cremophor RH 40 (Chapter 2) lies in the large 
Type I, O/W microemulsion region obtained in the latter.  In 3:1 Polysorbate 81:Cremophor 
RH 40, this region is much smaller and instead, coarse emulsions dominate at the S:O:W ratios 
where Type I O/W microemulsions are observed in 3:1 Polysorbate 80:Cremophor RH 40. The 
low EO content of Polysorbate 81 in comparison to that of Polysorbate 80 evidently reduces 
the propensity to form Type I, O/W microemulsions and increases the ability of the former to 
form Type II, W/O microemulsions. Other differences include a much larger bicontinuous, 
Type III microemulsion region in 3:1 Polysorbate 80:Cremophor RH 40, and lower instances 
of gelling than seen in 3:1 Polysorbate 81:Cremophor RH 40.  
 Despite the differences observed between 3:1 Polysorbate 81:Cremophor RH 40 and 
3:1 Polysorbate 80:Cremophor RH 40, TPD mapping led to the selection of two additional 
microemulsion formulations for further analysis via dissolution, disintegration and stability 
testing, both containing 3:1 Polysorbate 81:Cremophor RH 40 in S:O:W ratios: i) 40:50:10 and 





In total, three samples were subjected to dissolution testing: 
i) Formulation 1 (F1*): S:O:W= 50:40:10 
 3:1 Polysorbate 80:Cremophor RH 40, Miglyol 812, Water and all Actives  
 (*same as F1A in previous Chapters) 
ii) Formulation 2 (F2): S:O:W= 40:50:10 
 3:1 Polysorbate 81:Cremophor RH 40, Miglyol 812, Water and all Actives 
iii) Formulation 3 (F3): S:O:W= 50:40:10 
 3:1 Polysorbate 81:Cremophor RH 40, Miglyol 812, Water and all Actives   
  
Figure 5.14 depicts droplet sizes and zeta potential measurements of F1, F2 and F3 as 
determined by DLS. As discussed previously, F1 (N=14) possessed droplet size and zeta 
potential values of 164 ± 37 nm and -14 ± 2.2 mV, respectively. In contrast, F2 (N=4) and F3 
(N=6) possessed size and zeta potential measurements of 94 ± 15 nm, -16.5 ± 4 mV and 80.7 
± 2.4 nm, -23 ± 6 mV, respectively. An ordinary one-way ANOVA conducted in order to 
determine the presence of statistically significant differences in droplet size and zeta potential 
amongst all tested formulations, revealed a statistically significant difference in both size [F 
(2,6.7)=31.6, p< .001] and zeta potential [F (2,5.9)=6.10, p= .037] with surfactant type. 
Homogeneity of variance, as evaluated by Levene’s F-test, was violated in all cases. As a 
result, all p-values reported are derived from the Welch’s Equality of Means test rather than a 
standard ANOVA, with a Games-Howell post-hoc analysis. All values are fully reported in 
Table D-6, Appendix D. Rheological measurements performed on aqueous dilutions of F2 
and F3 were analogous to that of F1 (Chapter 4) and confirmed Newtonian behaviour (and 
thus, the presence of O/W droplets) at 100x aqueous dilution. (Figure D-15, Appendix D). 
 These results of this Chapter have led to the successful procurement of two 
microemulsion systems possessing smaller droplet sizes and higher electrostatic stability than 
the current formulation, due to careful, methodical surfactant selection. For dissolution testing, 




Figure 5.14: Droplet size and zeta potential values of F1, F2 and F3 depicting statistically 
significant results from Welch’s Equality of Means test and Games-Howell post-hoc analyses. 
Statistically significant differences in size were seen between F1 and F2 (p=.0002) and F1 and 
F3 (p=.000004) while significant differences in zeta potential were seen between F1 and F3 
(p=.03) Size histograms and zeta potential curves are depicted in Figure D-14, Appendix D.	
 
   
suspension reference, though not a control in the true sense of the word, represents the 
pharmaceutical standard for prenatal supplement gelatin capsules currently on the market. To 
the best of our knowledge, there is no prenatal formulation currently in existence in 
microemulsion form. Thus, this suspension reference was compared against that of F1, F2 and 
F3 in order to determine any possible advantages to utilizing prenatal formulations in 
microemulsion form. In this manner, though not an in vivo test by any means, inferences 
regarding oral absorption may be made.26 The reference used in this work is currently marketed 
as a commercial supplement and contains all the active ingredients of the current formulation, 
along with some additional active ingredients such as minerals. Details of the prenatal 
supplement reference along with its label claim may be found in Table D-7, Appendix D. 
Given that Formulations 1, 2 and 3 were unable to be filled into soft gelatin capsules, 
dissolution studies were conducted using 1 g of each formulation, along with an amount of the 
prenatal supplement reference equal to that of the label claim (1.556 g). Each formulation was 
introduced into black, PTFE caps, placed in the dissolution vessel then the apparatus set to stir. 























































Water-soluble Active Ingredients 
According to the USP25, folic acid dissolution should be performed for 60 minutes using water 
as the medium. At least 75% of folic acid should be dissolved within 60 minutes. If this fails, 
the dissolution test should be repeated in 10 mM citric acid (pH 6). Figure 5.15 displays the 
dissolution results for solely folic acid (Vitamin B9) in water while Figure 5.16 displays the 
dissolution results for both riboflavin (Vitamin B2) and folic acid (Vitamin B9) in water. 
  
Figure 5.15: Dissolution results for folic acid (Vitamin B9) in water from F1, F2, F3 and a 
suspension reference using USP Apparatus II (Paddle Method) at 100 RPM. 
 
 
 According to Figure 5.15, the percentage of folic acid dissolved in water after 60 
minutes was 67%, 62% and 68% for Formulations 1, 2 and 3, respectively. In contrast, 0% 
folic acid was dissolved in and recovered from the prenatal suspension reference. These 
observations were supplemented by the cloudy, yellow dissolution media seen after 60 minutes 
in Formulations 1, 2 and 3 and the clear dissolution medium seen after 60 minutes with the 
suspension reference. A gradual increase in dissolved folic acid with time was observed with 
Formulation 1. However, for Formulations 2 and 3, the amount of dissolved folic acid reached 
its peak at 30 minutes with 66% and 70%, respectively. After this point, a decline in dissolved 
folic acid was noted. In all instances, within 15 minutes, 65% of the folic acid was dissolved 
in the case of Formulation 1 followed by 64% in Formulation 2 and 57% in Formulation 3.  All 
results fell short of the USP required dissolution of at least 75% within one  hour.25  These  
results  were  not  unexpected  given the difficulty in dissolving folic acid  (Chapter 3), as 
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well as its low water solubility (0.0761 mg/g).33 However, more favourable dissolution results 




Figure 5.16: Dissolution results of riboflavin (Vitamin B2) and folic acid (Vitamin B9) in 
water from F1, F2, F3 and a suspension reference using USP Apparatus II (Paddle Method) 




 Despite the unfavourable dissolution results for folic acid, riboflavin (Vitamin B2) 
(Figure 5.15) exhibited highly satisfactory dissolution results in water as depicted in Figure 
5.16. Within the first 15 minutes, 89%, 89% and 109% of riboflavin was dissolved in water 
from Formulations 1, 2 and 3 respectively.  At the 60-minute mark, these values increased in 
the case of F1 to 91%, and decreased in the case of F2 and F3 to 86% and 89%, respectively. 
In the case of the suspension reference, the dissolution of riboflavin was slightly higher than 
seen in folic acid, with 2% dissolved within 60 minutes. Therefore, with the exception of the 
reference formulation, all microemulsion formulations passed USP acceptable criteria of at 
least 75% riboflavin dissolution within 60 minutes. 
 The improved dissolution of riboflavin, in comparison to folic acid, was not unexpected 
given the higher water solubility of the former, 0.657 mg/g33. In the case of both folic acid and 
riboflavin, though F1 demonstrated a steady increase in dissolution from 0 – 60 minutes, the 
dissolution of F3 was highly variable. Given that F1 and F3 differ only with respect to 
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surfactant type, this fluctuation must be attributed to Polysorbate 81, which is less hydrophilic 
than Polysorbate 80. In general, all microemulsion formulations demonstrated superior 
dissolution as compared to the suspension reference, lending credibility to claims of potentially 
improved bioavailability using microemulsion systems. 
 Given that the dissolution of folic acid was unfavourable in water, dissolution studies 
were re-performed in 10 mM citric acid buffer (pH 6), as suggested by the USP.25 Figure 5.17 
displays dissolution results for both riboflavin (Vitamin B2) and folic acid (Vitamin B9) in 10 
mM citric acid buffer (pH 6) for F1, F2, F3 and the suspension reference. The dissolution of 
folic acid was greatly improved through the use of citric acid medium. After 60 minutes, the 
percentage of dissolved folic acid in F1, F2 and F3 was 80 ± 8%, 73 ± 9% and 76 ± 14%, 
respectively. This increased to 84%, 86% and 85%, respectively after 120 minutes. No folic 
acid was dissolved in the reference formulation, even after 120 minutes. The dissolution curves 
for folic acid appeared less stable than those of riboflavin, especially in Formulations 2 and 3. 
Nevertheless, F1 and F3 passed USP criteria of at least 75% dissolution of folic acid within 60 
minutes. Formulation 2 fell just 2% short of this threshold. However, 30 minutes later at the 
90-minute mark, F1, F2 and F3 demonstrated large increases to 85%, 84% and 87% 
dissolution, respectively, which well exceeded the 75% dissolution criteria outlined by the 
USP. Overall, F1 demonstrated the highest degree of folic acid dissolution after 60 minutes at 
80 ± 8%, likely as a result of the presence of the more hydrophilic surfactant, Polysorbate 80, 
which disperses favourably in the polar medium. 
 With respect to riboflavin, higher dissolution values than those of folic acid were 
obtained. The dissolution of riboflavin in F1, F2 and F3 after 60 minutes was 107 ± 10%, 99 ± 
14 % and 107 ± 3%, respectively. In contrast, the dissolution of riboflavin in the reference 
suspension was close to 1 ± 0% dissolution after 60 minutes. The recovery of riboflavin in 
excess of 100% may be attributable to impurities. As evident in Figure 5.17, the majority of 
riboflavin was dissolved within the first 15 minutes. F1 and F3 also exhibited the smoothest 
and most stable dissolution curves for riboflavin in comparison to F2, where fluctuations were 
noted. This result is new for F3, which exhibited large fluctuations upon dissolution with water, 
suggesting that F3 with its less hydrophilic surfactant favours this slightly less polar medium. 
Overall,  F1 and F3  equally  demonstrated  the  highest  degree  of  riboflavin dissolution after 
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Figure 5.17: Dissolution results of riboflavin (Vitamin B2) and folic acid (Vitamin B9) in 10 
mM citric acid buffer (pH 6) from F1, F2, F3 and a suspension reference using USP Apparatus 
II (Paddle Method) at 100 RPM. 
 
 
 An ordinary, one-way ANOVA comparing the effect of microemulsion formulation 
type on drug dissolution percentage in 10 mM citric acid (pH 6) medium revealed statistically 
significant differences in the dissolution of riboflavin (B2) in F1, F2 and F3 samples at 15 
[F(3,1.7)= 699, p= .004], 30 [F(3,1.7)= 1180, p= .002], and 60 minutes [F(3,1.7)= 1641, p= 
.002], as compared to the reference in 10 mM citric acid with 1% sodium dodecyl sulphate 
(SDS) surfactant. With respect to folic acid (B9), a statistically significant effect of 
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microemulsion formulation type on drug dissolution percentage was also observed in F1, F2 
and F3 samples at 15 [F(3,1.7)= 84.85, p= .021], 30 [F(3,1.7)= 64.74, p= .027],  and 60 minutes 
[F(3,1.7)= 54.05, p= .031], as compared to the reference formulation in 10 mM citric acid in 
1% SDS. Homogeneity of variance, as evaluated by Levene’s F-test, was violated in all cases 
due to the near zero dissolution percentages and variance of the reference formulation. As a 
result, all p-values reported were derived from the Welch’s test rather than a standard ANOVA, 
with a Games-Howell post-hoc analysis. The results from the post-hoc analyses, including 




Figure 5.18: Combined dissolution results of riboflavin (Vitamin B2) and folic acid (Vitamin 
B9) in 10 mM citric acid buffer (pH 6) from F1, F2, F3 and a suspension reference using USP 
Apparatus II (Paddle Method) at 100 RPM. Statistical differences using the Welch’s test with 
Games-Howell post-hoc analysis are depicted here. Significance stars are representative of F1, 
F2 and F3 as a collective, in comparison to the reference formulation. Compared to the 
reference formulation, all formulations demonstrated statistically significant differences at 15 
(p=.021), 30 (p=.027) and 60 (p=.031) minutes. 
 
 
 The differences in the dissolution of folic acid as compared to riboflavin are visually 
evident in Figure 5.18. A degree of fluctuation was seen from 15 to 60 minutes in F2 and F3. 
The dissolution curve of F1 by comparison, appeared more stable. In all microemulsion 
samples, dissolution values plateaued and stabilized from the 90 to 120-minute mark. This 
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stabilization was not seen in the suspension reference, however. Rather, a small increase in 
dissolved riboflavin was seen at the 120-minute mark suggesting that this suspension 
formulation may require additional time for complete dissolution of both riboflavin and folic 
acid.  
 Although all microemulsion formulations demonstrated favourable dissolution of 
riboflavin, only F1 and F3 demonstrated USP-acceptable dissolution criteria of folic acid in 10 
mM citric acid buffer (pH 6). Thus, dissolution was also performed using phosphate buffer, as 
previously outlined in the USP.34 Figure 5.19 depicts the dissolution results of riboflavin and 
folic acid from F1, F2, F3 and the suspension reference in 50 mM phosphate buffer (pH 7.4). 
In comparison to water and citric acid, dissolution curves in phosphate buffer were remarkably 
more stable. In addition, favourable dissolution results were obtained for folic acid. Within the 
first 15 minutes, 75 ± 1%, 76 ± 8% and 82 ± 4% of folic acid was dissolved from F1, F2 and 
F3 respectively, meaning that all microemulsion formulations passed USP dissolution criteria 
within the first 15 minutes. At the 60-minute mark, 81 ± 8%, 75 ± 10% and 80 ± 8% folic acid 
was dissolved in F1, F2 and F3, respectively. Aside from F3, the dissolution curves for folic 
acid were smooth and steady. Unfortunately, the reference suspension still exhibited 0% 
dissolution of folic acid even after 120 minutes.  
 With respect to riboflavin, 93 ± 5%, 95 ± 2% and 102 ± 1% dissolution was observed 
within the first 15 minutes for F1, F2 and F3, respectively. This increased to 98 ± 5%, 92 ± 
12% and 104 ± 0% after 60 minutes. The dissolution of riboflavin was 1 ± 0% at the 15- and 
60- minute mark, but this increased to 1.5 ± 1% at the 90-minute mark and 2 ± 0% at the 120-
minute mark.  
 An ordinary, one-way ANOVA comparing the effect of microemulsion formulation 
type on drug dissolution percentage in 50 mM phosphate buffer (pH 7.4), revealed statistically 
significant differences in the dissolution of riboflavin (B2) in F1, F2 and F3 samples at 15 
[F(3,1.7)= 8341, p< .001], 30 [F(3,1.7)= 8255, p< .001], 60 [F(3,2)= 4.2*107, p< .001] and 90 
minutes [F(3,1.8)= 6968, p< .001], as compared to the reference formulation. With respect to 
folic acid (B9), a statistically significant effect of microemulsion formulation type on drug 
dissolution percentage was also observed in F1, F2 and F3 samples at 15  [F(3,1.7)= 12.81, p= 
.002], 30 [F(3,1.7)= 163.4, p= .012], 60 [F(3,1.7)= 89.88, p= .020] and 90 minutes [F(3,1.7)= 
77.4, p= .023], as compared to the reference. Homogeneity of variance was violated in all cases 
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due to the near zero variance of the reference formulation. As a result, all p-statistics reported 
are derived from the Welch’s test with Games-Howell post-hoc analysis. The results from the 
post-hoc analyses of F1, F2 and F3 versus the reference formulation are depicted in Figure 
5.19. All statistical values are fully reported in Table D-9, Appendix D. 
 
 
Figure 5.19: Dissolution results of riboflavin (Vitamin B2) and folic acid (Vitamin B9) in 50 
mM phosphate buffer (pH 7.4) from F1, F2, F3 and a suspension reference using USP 
Apparatus II (Paddle Method) at 100 RPM. Statistical significance using the Welch’s test with 
Games-Howell post-hoc analysis is depicted here. Significance stars are representative of F1, 
F2 and F3 as compared to the reference formulation. 
  
 
 Combined dissolution curves of both riboflavin and folic acid for F1, F2, F3 and the 
reference are depicted below in Figure 5.20. A reduced distance, and thus, smaller difference 
between dissolution curves of riboflavin and folic acid, in comparison to those in water and 
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citric acid media, was evident. In addition, the steadiness and smoothness of the dissolution 
curves were superior. Overall, dissolution of riboflavin was highest in F3 (102 ± 1%) while 
dissolution of folic acid was highest and similar in both F1 and F3 (81 ± 4% and 82 ± 5%, 
respectively). Considering both dissolution profiles for riboflavin and folic acid, the dissolution 
medium demonstrating the most promising dissolution results was 50 mM phosphate buffer 
(pH 7.4). The higher pH of this medium in comparison to that of water and citric acid buffer 
(pH 6), likely resulted in enhanced dissolution of these APIs, given that higher pH values were 
required for solubility. 
 
 
Figure 5.20: Conglomerated dissolution results of riboflavin (Vitamin B2) and folic acid 
(Vitamin B9) in 50 mM phosphate buffer (pH 7.4) from F1, F2, F3 and a suspension reference 
formulation using USP Apparatus II (Paddle Method) at 100 RPM. 
  
 
  Overall, Formulations 1, 2 and 3 exhibited similar drug dissolutions in citric acid and 
phosphate buffer media. One way of quantifying the similarities and differences in dissolution 
curves is through the use of the ƒ1 difference factor and ƒ2 similarity factor. Developed by 
Moore and Flanner (1996)35, ƒ1 and ƒ2 are a simple model independent approach to comparing 
two dissolution profiles at every dissolution sample time point.36 The difference factor, ƒ1, 
calculates the difference in percent between two dissolution curves at each time point:35,36 
                                            ƒ1= [nV^!U o
|`)]|
`
p) ∗ 100]                                                 (Eq. 5.1) 
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where n is the number of time points, t is time (typically, minutes), R is the percentage of drug 
dissolved in the reference formulation (%) and T is the percentage of drug dissolved in the test 
formulation (%).   
 In contrast, the similarity factor ƒ2, is a measurement of the similarity in percent 
between two dissolution curves.36 It is the logarithmic reciprocal square root transformation of 
the sum of the squared error.35,36 
 




]                                         (Eq. 5.2)                    
 
where all variables are the same as defined above.   
 In general, the mean dissolution values from both reference and test curves at each time 
interval are used; two curves are determined to be similar or equivalent when ƒ1 is less than 
15% and ƒ2 is greater than 50%.36 In addition, the FDA stipulates that only one measurement 
over 85% dissolution be considered, as this is the threshold for acceptable dissolution.36 
Therefore, in this work, values above 85% were excluded. Table 5.7 presents ƒ1 and ƒ2 values 
for all formulations tested in this work, as compared to the reference formulation and 
Formulation 1 (F1). Only folic acid curves were considered given that more than 85% 
dissolution was achieved for riboflavin. 
 In the case of citric acid medium, the dissolution curve with the largest difference when 
compared to the prenatal reference formulation was F1, followed by F3 then F2. F3 was also 
more similar to the current formulation (F1) than F2. With respect to phosphate buffer medium, 
the dissolution curve with the highest deviation from that of the prenatal reference formulation 
was F3 followed by F1 and F2. In addition, the formulation most similar to F1 was F2 followed 
by F3. In general, all microemulsion formulations (F1, F2 and F3) exhibited equivalence (ƒ1 
<15%, ƒ2 >50%). Thus, the process of surfactant selection for microemulsion, multi-drug 
delivery culminated in the manufacture of three successful formulations with similar 
dissolution profiles. ƒ1 values for the reference formulation could not be computed due to the 
fact that the dissolution of folic acid was 0% was in both media. All raw and calculated values 





Table 5.7: ƒ1 and ƒ2 factor values for all tested formulations after folic acid dissolution. The 





Oil-soluble Active Ingredients 
As stated previously in Section 5.1.2.1, with respect to multivitamin supplements there is no 
USP requirement for the dissolution of fat-soluble vitamins as it is well-known that these active 
ingredients are highly lipophilic and do not dissolve well in polar media. In addition, low 
permeation is generally not of concern with organic compounds and is not considered the rate-
limiting step of absorption.26 Nevertheless, dissolution testing was performed in an attempt to 
determine whether fat-soluble APIs could be dissolved and recovered. Given that the water-
soluble active ingredients performed well in phosphate buffer, 50 mM phosphate buffer as well 
as 100 mM tris buffer were selected as the dissolution media. Beta-carotene was selected as 
the ‘index’ vitamin given that it was the most lipophilic API used in this work, and sensitive 
to degradation via light and oxygen (Chapter 3). Non-ionic surfactants were introduced to the 
dissolution media given the high lipophilicity of beta-carotene, as suggested by de Souza 
Anselmo et al. (2016).37 Figure 5.21 depicts the percentage of dissolved beta-carotene after 60 
minutes in F1 and F2, the formulations that yielded the most and least favourable dissolution 
results thus far, respectively. 
 In general, higher recoveries of beta-carotene were seen in F1 than in F2. This was 
interesting given that F2 contains 50% w/w oil versus 40% w/w oil in F1. However, the use of 














10 mM Citric Acid  
(pH 6) 
F1 F2 0-60 6.98 61.4 
F1 F3 0-60 4.80 69.9 
Control F1 0-60 N/A 5.82 
Control F2 0-60 N/A 7.03 
Control F3 0-60 N/A 5.96 
50 mM Phosphate 
Buffer  
(pH 7.4) 
F1 F2 0-120 3.17 75.9 
F1 F3 0-90 4.68 65.5 
Control F1 0-120 N/A 4.97 
Control F2 0-120 N/A 5.56 
Control F3 0-90 N/A 1.77 
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F1, may likely have led to a lower degree of oil solubilization. Nevertheless, the lowest 
dissolution value obtained was still quite high, at 81% after 60 minutes. Given that beta-
carotene was successfully dissolved, it was inferred that other less lipophilic APIs in F1 and 
F2 could also be dissolved.  
 
 
Figure 5.21: Dissolution results of beta-carotene (Vitamin A) in 4% Triton-X-100 50 mM 
phosphate buffer (pH 6.8) and 2% Polysorbate 80 in 100 mM Tris buffer (pH 8) from F1 and 
F2 using USP Apparatus II (Paddle Method) at 100 RPM. 
 
 
 Figures 5.15 to 5.21 illustrated results from multiple dissolution trials performed on 
F1, F2 and F3. Despite variations in dissolution media, some generalizations were noted. In all 
cases, riboflavin demonstrated a much higher degree of dissolution than folic acid. This was 
not surprising given the low water solubility of folic acid in comparison to riboflavin. The 
dissolution media producing the best result was 50 mM phosphate buffer (pH 7.4). This was 
expected given the slightly alkaline favorability demonstrated by both riboflavin and folic acid, 
and the fact that this medium possessed the highest pH value of all media tested. Of all 
microemulsion formulations tested, F1 and F3 demonstrated the highest recoveries while F2 
demonstrated the lowest. The inability of the suspension reference to surpass 2% dissolution 
was unexpected. It is evident that the dissolution media and conditions utilized in this work 


































Formulation 1 & 2
4% Triton in 50 mM Phosphate buffer (pH 6.8)
2% Tween 80 in 100 mM Tris buffer (pH 8)
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formulation. However, it was interesting to note that given the presence of lecithin in the 
suspension formulation, a surface active molecule by nature, greater dissolution of either active 
ingredient was not observed. The low HLB value of lecithin may have been insufficient to 
solubilize all actives in the dissolution media. Although dissolution media are not an absolute 
reflection of physiological conditions due to variations in the GI tract such as flora, digestive 
enzymes, pH, transit time and whether in fed or fasted state26, the results from these dissolution 
studies indicate a potential benefit to the use of microemulsion systems for this type of multi-
drug delivery.   
 
5.5.2.3. Disintegration 
 Originally, microemulsion formulations were to be developed and filled into soft gelatin 
capsules for dissolution and disintegration testing. However, given the water content of this 
formulation and the possible risk of water migration into the shell of the soft gelatin capsule 
along with other factors, this process was unable to be performed. Instead, each microemulsion 
formulation was filled into 18 mm oblong, red, opaque hard-gelatin capsules before 
disintegration testing. Figure 5.22 depicts the disintegration test and apparatus in progress (in 
amber lighting) while Figure 5.23 presents the disintegration results for F1 and F2, the 
microemulsion formulations demonstrating the most and least favourable dissolution results, 
respectively.  
  Upon introduction of F1 and F2-filled capsules, a colour change was seen in the vessel 
containing hydrochloric acid. (Figure 5.22) This colour change was likely due to isomerization 
of beta-carotene in the presence of strong acid38 leading to a reduction in colour intensity.39 
From Figure 5.23, both dosage forms successfully achieved disintegration within 30 minutes, 





Figure 5.22: Disintegration test in progress for hard-shell gelatin capsules filled with F1 and 







Figure 5.23: Disintegration results of hard-shell gelatin capsules filled with F1 and F2 tested 
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 5.5.2.4. Stability 
 5.5.2.4.1. Temperature: Freeze-thaw Cycle 
 After three consecutive cycles of freezing at -25°C for 24 hours, followed by thawing to room 
temperature for 24 hours, no evidence of phase separation was seen in F1, F2 or F3. Despite 
no evidence of phase separation, F1 appeared progressively cloudy after each consecutive 
cycle, with tiny yellow/orange precipitates dispersed throughout upon close examination. No 
such changes were observed in F2 and F3. Figure 5.24 depicts changes in hydrodynamic 
diameter and zeta potential after exposure to three freeze-thaw cycles. F1 showed a droplet 
size reduction of just over 30% while zeta potential values increased by more than 3 mV and 
became less negative, indicating decreased stability. In contrast, F3 showed a droplet size 
increase of over 40% while zeta potential values remained relatively constant. F2 showed 
stable droplet size and zeta potential values before and after treatment. Size histograms and 
zeta potential curves are depicted in Figure D-17, Appendix D. 
 
Figure 5.24: Hydrodynamic diameters (left) and zeta potentials (right) of microemulsion 
formulations F1, F2 and F3 before and after three consecutive freeze-thaw cycles from -25°C 
to room temperature.  
 
 
  The rationale for the decrease in droplet size and increase in zeta potential in F1 has 
been previously explored in Chapter 4. However, the increase in droplet size experienced in 
F3 (and F2 to a low degree), is consistent with literature reports that freeze-thawing in 
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separation leads to a gradual increase in droplet size as droplets coalesce.40 Despite these 
observations, there was no visual evidence of phase separation after three freeze-thaw cycles 
in F2 and F3. The stability of the zeta potential values in F2 and F3 was also surprising despite 
the occurrence of possible phase separation. However, it could be that droplet sizes increased 
at a slow rate so as to not affect the charged APIs localized around the surfactant head groups. 
Overall stability appeared to follow the trend F2> F3> F1, with F2 exhibiting the greatest 
resistance to size and zeta potential changes.  
 
 5.5.2.4.2. Temperature: Heat Cycle 
After exposure to 48 hours of heating at 37°C, there were indications of cloudiness in all 
formulations with F1 being the most turbid. This turbidity decreased in all samples at 50°C as 
the formulations began to phase separate; an upper clear, orange phase and lower phase 
containing precipitate were observed. At this temperature, a gradual darkening of sample from 
red-brown to brown-black was also seen until 80°C. At 60°C-70°C, phase separation was 
evident and the presence of solid, yellow precipitate was observed at the bottom of the vial in 
F1. At 80°C, this lower layer of solid API appeared to disappear completely, likely due to 
degradation. In addition, lower amounts of yellow precipitate were evident in F2 and F3. 
Figure 5.25 depicts changes in hydrodynamic diameter after 48-hour consecutive heating 
cycles at 37°C, 50°C, 60°C, 70°C and 80°C. It is evident that F1 experienced a larger variation 
in size from room temperature to 80°C than F2 and F3. In F1, a size decrease of 37% was 
experienced at the first temperature point. The droplet sizes remained depressed throughout 
additional heating cycles with a final size reduction of approximately 28% (60 nm) at 80°C. 
F2 and F3 experienced less droplet size fluctuations than F1 upon consecutive heating. F2 
exhibited a 13% decrease in size after the first temperature point, culminating in a final size at 
80°C that was equivalent to room temperature. F3 exhibited virtually no change in size after 
the first temperature point and a final droplet size increase of 24% (21 nm) at 80°C. 
 Prolonged heating of all formulations resulted in colour changes and eventual phase 
separation beginning at 50°C and reaching its maximum at 70°C. Possible explanations for the 
droplet size trends and colour changes obtained have been previously explored for F1 in 
Chapter 4 and may be extended to F2 and F3 given the similarity in formulation. However, 
from room temperature to 80°C, the droplet size differences of 2 nm and 21 nm experienced 
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by F2 and F3, respectively, were considered negligible. Both formulations demonstrated 
greater heat stability than F1. 
 
 
Figure 5.25: Hydrodynamic diameters of microemulsion formulations F1, F2 and F3 before 
and after consecutive heating from 25°C - 80°C. Size histograms are depicted in Figures D-
18 – D-20, Appendix D. 
 
 
 Figure 5.26 depicts the change in zeta potential of F1, F2 and F3 upon heating. In 
general, zeta potential values increased or became less negative for F1 as described in Chapter 
4. However, F2 and F3 experienced a steady decrease in zeta potential, becoming more 
negative and eventually plateauing between 60-70oC before increasing (becoming less 
negative) at 80°C. Particularly around 60-70°C, zeta potential values for all formulations were 
observed to be at their lowest (most negative), indicating greatest stability from a colloidal 
perspective. At these temperatures, formulations demonstrated notable colour changes and 
phase separation. It is, thus, possible that thermal oxidation of some of the lipophilic APIs 
occurred resulting in the increased presence of negatively-charged fatty acid products41 as 
described in Chapter 4.  
 Overall, F1 experienced a maximum zeta potential change of 8 mV throughout all 
heating cycles while F2 and F3 experienced a maximum change of 20 mV and 15 mV, 
respectively. Thus, based on this consideration, it would appear that F1 demonstrated greater 
resistance to zeta potential changes upon heating while F2 and F3 demonstrated greater 











































































































































Figure 5.26: Zeta potential values of microemulsion formulations F1, F2 and F3 before and 
after consecutive heating from 25°C - 80°C. Zeta potential curves are depicted in Figures D-




 5.5.2.4.3. Light Exposure Test 
The beginnings of phase separation were immediately observed upon exposure to fluorescent 
light after just 24 hours, and this became more pronounced at day 5. From this point forward, 
phase separation was observed in all samples at the one-week, two-week and one-month 
marks- the latter of which demonstrated the greatest separation. A gradual darkening in colour 
was also seen beginning at the two-week mark though not to the extent of that seen during the 
heating cycle. Figure 5.27 illustrates the gradual phase separation experienced by F1, F2 and 
F3 after exposure to light over a one-month period. 
 Figure 5.28 depicts droplet sizes and zeta potentials of F1, F2 and F3 before and after 
exposure to fluorescent light for one month. Droplet sizes reduced by 37% after 24 hours for 
F1, but by only 12% for F2 and 17% for F3. In all formulations, zeta potential values were 
least negative 24 hours after exposure to fluorescent light. F1 experienced a reduction of 5 mV, 
F2 6 mV and F3 13 mV, indicating peak instability at this time point. In general, all 
formulations showed the largest fluctuations in droplet size during the first five days of 
exposure to light. After this point, droplet size values appeared to stabilize and plateau. The 
fluctuation in droplet size and zeta potential up to day 5 corresponds to the phase separation 
seen in all formulations beginning at day 5 as depicted in Figure 5.27. Zeta 























Figure 5-27: Phase separation in microemulsion formulations F1, F2 and F3 after exposure to 
light over the period of one month.  
 
 
potential values also exhibited this trend with the exception of day 14 results, which show an 
increase in negatively charged droplets. This coincides with the darkening of samples also 
observed at day 14 (Figure 5.27), which could correspond to the oxidation of fatty acids, 
yielding more negative charges in the same manner as seen during the heating cycle. In 
addition, many active ingredients in this formulation have been reported to undergo colour 
changes upon light exposure. With respect to water-soluble vitamins, Vitamin B1 has been 
reported to form thiochrome upon exposure to light and Vitamins B2 and B12 have been reported 
to undergo decolouration due to photolysis.42 With respect to fat-soluble vitamins, tocopherols 
have been reported to oxidize and darken upon exposure to air and light.43 The presence of 
multiple light-sensitive APIs in F1, F2 and F3, results in vulnerability to light exposure as 
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F1      F2        F3 F1     F2     F3 
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described in Chapter 4. However, overall, F3 exhibited the highest tolerability to light 





Figure 5.28: Hydrodynamic diameters and zeta potential values for microemulsion 
formulations F1, F2 and F3 after exposure to light over the period of one month. Size 
histograms are depicted in Figures D-21 – D-23, Appendix D. 
 
 
 5.5.2.4.4. pH Stability 
Figure 5.29 depicts pH changes in F1, F2 and F3 over the course of 1 month. According to 
Panel A, pH values were not only stable throughout this time period, but remarkably close to 
each other despite the differences in surfactant composition. A slight downward trend in pH 
was seen beginning at the 7-day mark, similar to that seen in F1 in Chapter 4. These small 




























































































































expanded. A decrease in pH of approximately 0.92 units for F1, 1.23 units for F2 and 1.12 unit 
for F3 was noted. The initial pHs for F1, F2 and F3 were 8.8, 9.0 and 9.0, respectively, while 
the pHs at the end of one month were 7.8, 7.7 and 8.0. This decrease in pH is not surprising 
given the presence of a pH-adjusted, drug-loaded water phase and the absence of buffer. 
Therefore, this decrease may be attributed to the formulation equilibrating itself. 
 
 
Figure 5.29: pH changes in F1, F2 and F3 at room temperature over the course of 4 weeks on 
a pH scale of 0-14 (Panel A). This scale was expanded (B) in order to better visualize changes. 
 
 
 F1 exhibited the smallest change in pH over the course of one month versus that of F2 
and F3. Nevertheless, all formulations displayed pH resilience and stability, despite the 
presence of differing surfactants in each formulation. These results suggested that the 
surfactant phase plays little role in the pH stability of these microemulsion formulations, and 
that the active ingredients, themselves, were likely of greater importance. 
 
 5.5.2.4.5. Conductivity Test 
Figure 5.30 depicts the change in conductivity of F1, F2 and F3 immediately after formulation 
to one week later. Conductivity of all formulations remained low, below 5 μS/cm, from the 
time of manufacture to one week later. However, despite these overall low conductivity values, 
F1 possessed a higher value than that of F2 and F3. The average conductivity of F1 was 4.07 
μS/cm with a maximum difference of 1.47 μS/cm experienced over the course of one week. In 
contrast, the average conductivities of F2 and F3 were 0.01 μS/cm and 0.00 μS/cm, 
respectively. Upon 100x aqueous dilution, however, conductivities of F1, F2 and F3 were 58 





























± 21 μS/cm, 46 ± 28 μS/cm and 35 ± 25 μS/cm, respectively. In general, conductivity values 
of F2 and F3 were consistent and did not exhibit any observable fluctuations in value.  
 Similar to results in Chapter 4, conductivity values for F1, F2 and F3 were within 
expected ranges for bicontinuous microemulsions where both oil and water serve as the 
continuous phase. However, the lower conductivity values of F2 and F3 may be attributable to 
the presence of the less hydrophilic surfactant, Polysorbate 81, in the formulation. This less 
hydrophilic surfactant possesses a lower HLB value and as such, is less likely to favour oil-in-
water systems and more likely to favour water-in-oil systems leading to lower conductivity 
values. These results were consistent with the ternary phase diagram results for 3:1 Polysorbate 
81:Cremophor RH 40 presented earlier (Figure 5.13) where the tendency to form W/O systems 
was clear. After 100x aqueous dilution, however, F2 and F3 demonstrated higher conductivity 
values indicating a possible reversion to O/W systems as seen in F1 (Chapter 4). Regardless 
of the actual values, conductivity values were consistent across the period of one week 



































 5.5.2.4.6. Centrifugation Stress Test 
Figure 5.31 depicts results for F1, F2 and F3 after centrifugation at 5000 and 10000 RPM for 
30 minutes. An equal volume of water was used as a balancer. Unlike the clear phase separation 
observed in F1 in Chapter 4, no large phase separation was evident in F1, F2 and F3 samples. 
In F1, after 5000 RPM for 30 minutes, the appearance of solid precipitate (active ingredient 
residue) was evident along the side of the centrifugation tube. This was not the case for F2, 
although F3 exhibited precipitate at the bottom of the tube. At 10000 RPM after 30 minutes, 
all formulations demonstrated a pellet of solid precipitate at the bottom of each tube.  
 As explained in the previous chapter, emulsion stability may be inferred through 
consideration of the volume of the separated phase in emulsion formulations44, using the 







Figure 5.31: Effects of centrifugation on F1, F2 and F3 after centrifugation at 5000 RPM for 
30 minutes (left) and after centrifugation at 10000 RPM for 30 minutes (right). 
 
 
Given that no clear, measureable phase separation was observed, aside from the presence of 
precipitate along the bottom and sides of each tube, it was not possible to calculate an 
estimation of emulsion stability for F1, F2 and F3. However, the presence of yellow/orange 
precipitate supports the fact that the water-soluble APIs, riboflavin and folic acid, are 
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insufficiently incorporated into the current microemulsion systems especially for Formulations 
1 and 3. Thus, despite an effort to employ pH adjustment in order to incorporate these poorly 
water-soluble active ingredients, the accelerated gravitational separation results indicated that 
these formulations fell short of being truly stable in nature. 
 
 5.5.2.4.7. Long-term Droplet Size and Zeta Potential Test 
Given the presence of multiple emulsifiers, oils and active ingredients in these formulations, 
measurements of droplet size and zeta potential were obtained over the period of one month in 
order to deduce any trends or changes that may impact stability (Figure 5.32). In general, F1 
possessed higher droplet sizes and zeta potential values than F2 and F3, which exhibited very 
similar droplet size and zeta potential results. However, no major fluctuations in size were 
seen. Average droplet sizes over the course of one month for F1, F2 and F3 were 146 ± 12 nm, 
92 ± 14 nm and 75 ± 11 nm, respectively. This amounts to total droplet size changes of 18 nm 
in F1, 22 nm in F2 and 13 nm in F3 after one month.  
 
 
Figure 5.32: Droplet size and zeta potential measurements of F1, F2 and F3 over the course 
of 1 month. 
  
 
 Zeta potential values for F1, F2 and F3 remained stable and consistent over the period 
of one month. No major fluctuations in charge were observed. Average zeta potential values 
over the course of one month were -10 ± 2 mV for F1, -21 ± 2 mV for F2 and -20 ± 1 mV for 
F3. F1 experienced a maximum difference in charge of 7 mV while the maximum charge 
differences experienced by F2 and F3 were both 4 mV. Given the droplet size and zeta potential 
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results in Figure 5.32, it appeared that Formulation 1, strictly on the basis of droplet size and 
zeta potential, was a less favourable microemulsion than Formulations 2 and 3. Formulations 
2 and 3 appeared to depict a higher degree of stability than Formulation 1. Generally, the 
greatest fluctuation in droplet size occurred within the first three to four days after which results 
appeared to stabilize. Size histograms and zeta potential curves are depicted in Figures D-24 
– D-26, Appendix D. 
 
5.6   Conclusion 
A number of surfactants with the potential to replace Polysorbate 80 in the current formulation 
(F1A) were identified in this Chapter. However, Polysorbate 81 was selected as the most 
promising surfactant based on size and zeta potential results. The ability of Polysorbate 81 (and 
Brij 97) to produce homogeneous microemulsion formulations, with favourable droplet sizes, 
was surprising given the low EO content of both surfactants when compared to that of 
Polysorbate 80. These results suggest that an optimal number of EO units exists for a given 
surfactant when formulating a microemulsion, above which these optimal effects become less 
evident. This effect was previously proposed by Myers (2006) in EO-containing ether 
surfactants.5 In this particular case, it appears that the optimal EO number for this formulation, 
barring EO contributions from Cremophor RH 40, may lie around 5 rather than 20 as in the 
case of F1A. Given that Polysorbate 80 and 81 possess the same number of carbons in the 
hydrophobic tail, this property may also be one of the most important considerations in the 
development of this type of multi-drug delivery system. Tensiometry studies indicated no 
particular importance of CMC, except for the fact that interactions between the two surfactants 
used in a microemulsion formulation should be synergistic at best and ideal at worst. 
 In microemulsions formulated with Polysorbate 80 and 81 (F1, F2 and F3), riboflavin 
was successful in meeting USP dissolution requirements of at least 75% dissolution within one 
hour in all tested media. Folic acid proved more difficult, owing to its poor water solubility, 
and only met dissolution criteria using 50 mM phosphate buffer (pH 7.4) medium. The most 
favourable results were observed in phosphate buffer where all formulations demonstrated 
almost 100% dissolution of riboflavin and approximately 80% dissolution of folic acid. The 
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successful dissolution of beta-carotene suggested that less lipophilic active ingredients would 
also be dissolved. F1 and F2 filled in hard gelatin capsules met disintegration criteria.  
 With respect to stability, the factors of greatest importance were the same as those 
observed in Chapter 4: temperature and light exposure. Reductions in size were observed at 
the first temperature point of 37°C while light exposure resulted in phase separation 
commencing at approximately day 5. These factors tended to affect Formulation 1 to a greater 
extent than Formulations 2 and 3, as greater size reductions and measurement fluctuations were 
observed. pH and conductivity of all formulations remained stable throughout the evaluation 
period of one month and one week, respectively. Accelerated gravitational separation testing 
via centrifugation was unable to yield any results with respect to emulsion stability due to 
unclear phase separation. However, the presence of precipitate at the bottom of each tube 
suggested insufficient solubilization of riboflavin and folic acid in this microemulsion 
formulation. Droplet size and zeta potential measurements over the course of one month 
indicated fluctuations in measurements in the first three to four days, but a plateau or 
stabilization after this period. Given these results, it can be concluded that all formulations are 
best maintained in cool, dark storage conditions. Similar to results in Chapter 4, the addition 
of a buffer or stabilizer to assist with the pH change of approximately 1 unit in all formulations 
could be beneficial.  
 Overall, Formulations 1 and 3 performed best during dissolution studies, but 
Formulations 2 and 3 outperformed Formulation 1 with respect to stability. All microemulsion 
formulations performed significantly better than the prenatal suspension formulation, lending 
support to the use of microemulsion systems for improved drug dissolution. In general, 
considering both dissolution and stability data, Formulation 3 appeared to be the most 
promising microemulsion candidate for this type of multi-drug delivery. The results of this 
Chapter in its entirety suggest that careful consideration of emulsifying agent properties can 
result in the development of additional microemulsion formulations superior to that of the 
original formulation. This highlights a novel process for the development of a microemulsion 
system capable of the simultaneous delivery of both hydrophilic and hydrophobic active 





Chapter 6: Conclusions & Future Directions 
  
This thesis work consisted of four main objectives: i) to design and formulate a microemulsion 
system capable of delivering multiple active ingredients of varying hydro- and lipophilicity, ii) to 
identify additional emulsifying agents suitable for this type of multi-drug delivery, iii) to determine 
emulsifying agent properties, based on results from (ii), necessary in this type of microemulsion 
formulation and iv) to use information from (i-iii) to develop microemulsion formulations capable 
of superior dissolution when compared to a prenatal, suspension reference. Objective (i) was 
accomplished through a process of careful surfactant selection, ternary phase diagram (TPD) 
mapping, optimization via the hydrophilic-lipophilic deviation (HLD) equation and active 
pharmaceutical ingredient (API) solubility enhancement using pH adjustment (Chapters 2-4). 
Objectives (ii) and (iii) were accomplished through methodical surfactant screening and variation of 
head and tail groups, specifically polyoxyethylene (PEO) content and hydrocarbon chain length, on 
the basis of size, charge, homogeneity and critical micelle concentration studies (Chapter 5) and 
finally, objective (iv) was accomplished through evaluation of dissolution, disintegration and 
stability as compared to a commercially available, prenatal suspension reference formulation 
(Chapter 5).  
 
6.1   Conclusions 
TPD mapping resulted in the identification of a 3:1 Polysorbate 80:Cremophor RH 40 surfactant mix 
to be used in conjunction with Miglyol 812 oil and water for microemulsion formation. This 
surfactant ratio was further optimized through the use of the HLD equation. Eleven (11) active 
pharmaceutical ingredients (APIs), five lipophilic and six hydrophilic, were successfully 
incorporated and further surfactant screening resulted in an additional surfactant selection of 3:1 
Polysorbate 81:Cremophor RH 40. Overall, three microemulsion formulations: F1, F2 and F3 with 
surfactant:oil:water (S:O:W) ratios of 50:40:10, 40:50:10 and 50:40:10, respectively, were used. F1 
contained 3:1 Polysorbate 80:Cremophor RH 40 surfactant while F2 and F3 contained 3:1 
Polysorbate 81:Cremophor RH 40. Sizes for F1, F2 and F3 after 100x aqueous dilution were 164 ± 
37 nm, 94 ± 15 nm and 81 ± 2.4 nm, respectively and all formulations exhibited >95% dissolution 
improvement of riboflavin compared to that of a commercial standard prenatal supplement. Stability 
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of all formulations with respect to pH, droplet size and zeta potential for a period of 1 month was 
demonstrated.  
 Based on these results, microemulsion formulations comprised of 3:1 Polysorbate 
80:Cremophor RH 40 and 3:1 Polysorbate 81:Cremophor RH 40 acted as effective solubilizers for 
lipophilic APIs loaded in Miglyol 812 with an EACN of 8. The difference in PEO content (~15 EO 
groups) yet equivalence in hydrocarbon chain length (18 carbons) of Polysorbate 80 and 81 led to 
the finding that differences in PEO content may be better tolerated than differences in hydrocarbon 
chain length for this specific multi-drug, microemulsion formulation. In other words, the optimal 
range of PEO content for this particular formulation comprised of five lipophilic and six hydrophilic 
APIs, was larger and less restrictive than that of hydrocarbon chain length. Critical micelle 
concentration was determined to be of low importance in microemulsion systems, where surfactant 
concentration is inherently high. In addition, hydrophilic lipophilic balance (HLB) appeared to be a 
poor predictor of microemulsion formation given the difference in HLB between Polysorbate 80 and 
81 (15 versus 10). The results of this thesis work support the hypothesis that the development of a 
microemulsion system with droplet sizes close to 100 nm in diameter, capable of multi-drug delivery, 
is possible through the identification of structural emulsifying agent properties, in this case 
hydrocarbon chain length and a well-defined PEO range. Overall, it is evident that careful and 
methodical surfactant screening and optimization are crucial in the development of such systems. 
  Though this work led to the development of three successful formulations capable of multi-
drug delivery, a number of limitations are evident. The identification of 3:1 Polysorbate 
80/81:Cremophor RH 40 surfactant for this type of microemulsion, multi-drug formulation is specific 
to a system comprised of an oil component of EACN 8. In addition, the characteristic curvature of 
additional promising surfactants was not experimentally evaluated, ignoring a potentially critical 
emulsifying agent property necessary in this type of drug delivery. Dissolution studies were not 
performed with filled soft gelatin capsules (the intended dosage form) or in hydrochloric acid, the 
latter of which would have shed insight into dissolution in the stomach and may have improved 
dissolution of the commercial pre-natal supplement reference. The nature of the APIs employed in 
this work also resulted in formulations with extreme sensitivity to temperature and fluorescent light 
exposure. Finally, additional replicates and controls are necessary to confirm trends noted in this 
work, particularly regarding droplet sizes as a result of surfactant screening and formulation stability. 
For the latter, chromatographic studies for the identification of possible API-API, API-surfactant and 
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API-oil interactions, degradants and related substances are likely of greater importance than the 
evaluation of droplet size changes as conducted in this work.    
 
6.2   Future Directions 
Future directions may involve two broad approaches: i) advancing our understanding of critical 
factors important in microemulsion, multi-drug delivery and ii) bridging the gap between this thesis 
work and clinical applicability. In terms of advancing our understanding of critical factors important 
in microemulsion, multi-drug delivery, a number of areas of exploration are possible. First, it is 
important to note that formulators are often limited by emulsifying agents that are commercially 
available. A truly robust approach would include synthesizing surfactants of consistent head and tail 
group variations prior to microemulsion formulation and investigation. The effect of oil type on 
microemulsion formulation would also provide insight into a much-neglected area of microemulsion 
investigation. Perhaps of greater importance is the determination of characteristic curvature values 
for the emulsifying agents employed in this work, as this is evidently an important parameter in 
microemulsion formation and optimization. The use of more appropriate physicochemical properties 
may also be explored. Particularly, in this work, log P values used to make assumptions about the 
partitioning of active ingredients into the respective microemulsion components, may be replaced by 
log D (distribution) values that take into account partitioning at a particular pH which given the pH-
adjusted nature of this formulation, would be most useful. A methodology such as that utilized by 
Lu et al. (2012) 1 may be explored using a software such as MarvinView by ChemAxon Ltd. 2 Finally, 
a high throughput methodology for the screening of factors most important in microemulsion, multi-
drug formulation is key to advancing this work. Typically, the slow utility of artificial intelligence 
(AI) systems in the pharmaceutical industry has been attributed to a combined lack of investment 
and insufficient skillset.3 However, a recent review by Damiati (2020) evaluated the use of multiple 
machine learning (ML) techniques, particularly artificial neural networks (ANN), for pharmaceutical 
pre-formulation studies.3 Damiati et al. (2017) developed a ML model using ANN for the prediction 
of solubility enhancers for indomethacin.4 Factors under consideration included log P, pKa and 
hydrotrope concentration.4 Rodriguez-Dorado et al. (2018) also utilized ANN to dictate formation of 
microemulsion-alginate core-shell systems for drug delivery.5 The authors were able to predict oil 
and surfactant concentrations, along with other properties, contributing to optimal microparticle size 
and shape.5 Employing a similar methodology to deduce the surfactant, oil and API properties most 
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critical for microemulsion, multi-drug formulation would afford rapid and efficient advancement of 
this technology. The data upon which this AI screening is based, however, must be reliable, accurate 
and reproducible3 and thus, may present a challenge when trying to obtain surfactant parameter 
values such as characteristic curvature (CC). 
  In terms of bridging the gap between this thesis work and clinical applicability, further in-
vitro and in vivo testing to ascertain an in vitro-in vivo correlation with the dissolution results 
obtained in this work, would be an excellent avenue for further investigation. Use of the Caco-2 cell 
line, widely used as a model of the intestinal epithelial barrier, may also be explored especially as it 
relates to the toxicity and safety of the surfactants employed in this work. This is particularly 
important for the most promising formulation in this work, Formulation 3 (F3) as there are no 
guidance limits for Polysorbate 81 tolerability on the US Food and Drug Administration (FDA) 
inactive ingredient (IIG) database presenting a barrier to commercialization. Another approach to 
bridging the gap between this thesis work and clinical applicability involves replacing the APIs used 
in this formulation with drugs of similar physicochemical properties used in common chronic disease 
treatment. Finally, enhancing microemulsion formulation stability through the development of a 
lyophilization process, previously proven to be effective through slow and careful reconstitution 6, 7, 
is worth investigating.  
 
6.3   Scientific Contribution 
 With respect to contribution of this work to microemulsion science, the results demand a shift 
in focus to surfactant characteristics most useful in microemulsion formulation development. This 
translates to a reduced focus on properties such as HLB and an increased focus on potentially 
important surfactant factors such as hydrocarbon chain length, surfactant mixing behaviour, PEO 
content and even characteristic curvature. In addition, a renewed interest in ternary phase mapping 
should be employed, especially as it gives the formulator a range of surfactant: oil: water ratios in 
which to operate (and avoid). Finally, a transparent body of literature including EACN results for 
multiple oil mixtures, CC results for multiple surfactants and HLD results for ensuing microemulsion 
formulations, is imperative to the advancement of this field. Efforts to develop a repository of EACN 
and CC values, such as the one undertaken by Steven Abbott 8, are imperative in affording the rapid 
development and reduced stagnation of microemulsion formulation science. Such a library may 
require increased collaboration, cooperation and time; however, the potential to alleviate the burden 
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of concurrent, chronic disease through multi-drug microemulsion development, not only in Canada 
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Figure A-1: Surface tension values versus surfactant concentration for Polysorbate 80 (CMC 
bolded) 
 
y = -14.001x + 8.5993
R² = 0.9975
































Tension (mN/m) Standard Deviation 
0 -4.30 68.61 0.25 
0.0001 -3.90 64.20 0.08 
0.0002 -3.60 58.75 0.04 
0.0005 -3.30 54.57 0.07 
0.0012 -2.91 48.86 0.09 
0.0017 -2.76 46.91 0.05 
0.0024 -2.61 45.06 0.07 
0.0036 -2.44 43.10 0.05 
0.0048 -2.32 41.61 0.03 
0.0070 -2.16 40.79 0.01 
0.0091 -2.04 40.22 0.03 
0.0111 -1.95 39.72 0.02 
0.0140 -1.85 39.50 0.01 
0.0167 -1.78 39.31 0.03 
0.0200 -1.70 39.29 0.11 
0.0259 -1.59 39.28 0.02 
0.0322 -1.49 39.29 0.03 
0.0403 -1.39 40.20 0.04 
0.0452 -1.34 40.34 0.02 
265 
 





Figure A-2: Surface tension values versus surfactant concentration for PEG-40 hydrogenated 
castor oil (Replicate 1) (CMC bolded) 
 
 
y = -11.014x + 20.059
R² = 0.9984


































0 -4.50 69.54 0.13 
0.0004 -3.45 58.03 0.10 
0.0005 -3.28 55.78 0.05 
0.0007 -3.16 54.94 0.05 
0.0010 -2.99 53.23 0.05 
0.0014 -2.87 52.08 0.06 
0.0017 -2.78 50.75 0.04 
0.0023 -2.64 49.31 0.05 
0.0029 -2.54 48.17 0.06 
0.0034 -2.46 47.24 0.05 
0.0040 -2.40 46.11 0.03 
0.0050 -2.30 45.03 0.01 
0.0064 -2.20 44.46 0.01 
0.0080 -2.10 44.31 0.01 
0.0101 -2.00 43.40 0.00 
0.0127 -1.90 44.89 0.05 
0.0158 -1.80 44.36 0.04 
0.0181 -1.74 43.76 0.03 
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Figure A-3: Surface tension values versus surfactant concentration for PEG-40 hydrogenated 
castor oil (Replicate 2) (CMC bolded) 
y = -11.197x + 18.627
R² = 0.9817

























Log Surfactant Concentration 







Tension (mN/m) Standard Deviation 
0.0000 -7.00 70.29 0.09 
0.0005 -3.34 55.15 0.03 
0.0009 -3.04 53.32 0.03 
0.0014 -2.86 51.48 0.05 
0.0018 -2.74 49.60 0.05 
0.0023 -2.64 48.16 0.04 
0.0027 -2.56 47.05 0.05 
0.0032 -2.50 46.26 0.06 
0.0036 -2.44 45.79 0.07 
0.0041 -2.39 45.39 0.06 
0.0045 -2.35 45.11 0.06 
0.0050 -2.31 44.91 0.07 
0.0054 -2.27 44.66 0.06 
0.0058 -2.23 44.49 0.06 
0.0063 -2.20 44.37 0.07 
0.0067 -2.17 44.28 0.09 
0.0071 -2.15 44.29 0.08 
0.0075 -2.12 44.14 0.08 
0.0080 -2.10 44.18 0.09 
0.0084 -2.08 44.08 0.08 
0.0088 -2.06 44.10 0.09 
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Figure A-4: Surface tension values versus surfactant concentration for PEG-40 hydrogenated 
castor oil (Replicate 3) (CMC bolded) 
y = -11.289x + 19.968
R² = 0.9761

































Tension (mN/m) Standard Deviation 
0.0000 -7.00 70.29 0.09 
0.0005 -3.34 56.61 0.02 
0.0009 -3.04 54.92 0.08 
0.0014 -2.86 53.16 0.10 
0.0018 -2.74 51.34 0.08 
0.0023 -2.64 49.83 0.08 
0.0027 -2.56 48.74 0.08 
0.0032 -2.50 47.79 0.08 
0.0036 -2.44 47.29 0.08 
0.0041 -2.39 46.73 0.09 
0.0045 -2.35 46.34 0.08 
0.0050 -2.31 46.12 0.08 
0.0054 -2.27 45.87 0.08 
0.0058 -2.23 45.66 0.09 
0.0063 -2.20 45.51 0.09 
0.0067 -2.17 45.35 0.09 
0.0071 -2.15 45.19 0.10 
0.0075 -2.12 45.04 0.09 
0.0080 -2.10 44.90 0.10 
0.0084 -2.08 44.78 0.10 
0.0088 -2.06 44.79 0.14 
0.0092 -2.03 44.71 0.10 
0.0096 -2.02 44.57 0.10 
0.0101 -2.00 44.41 0.09 
0.0105 -1.98 44.35 0.10 
0.0109 -1.96 44.31 0.10 
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PEG-40 hydrogenated castor oil 
Replicate 4 
 
Figure A-5: Surface tension values versus surfactant concentration for PEG-40 hydrogenated 
castor oil (Replicate 4) (CMC bolded) 
y = -11.084x + 19.259
R² = 0.98541

































Tension (mN/m) Standard Deviation 
0.0000 -7.00 71.04 0.01 
0.0005 -3.34 55.55 0.01 
0.0009 -3.04 53.52 0.06 
0.0014 -2.86 51.60 0.08 
0.0018 -2.74 49.87 0.08 
0.0023 -2.64 48.45 0.09 
0.0027 -2.56 47.33 0.08 
0.0032 -2.50 46.62 0.09 
0.0036 -2.44 46.08 0.09 
0.0041 -2.39 45.72 0.08 
0.0045 -2.35 45.44 0.09 
0.0050 -2.31 45.14 0.08 
0.0054 -2.27 44.95 0.09 
0.0058 -2.23 44.75 0.09 
0.0063 -2.20 44.61 0.09 
0.0067 -2.17 44.52 0.09 
0.0071 -2.15 44.44 0.09 
0.0075 -2.12 44.33 0.09 
0.0080 -2.10 44.22 0.09 
0.0084 -2.08 44.13 0.08 
0.0088 -2.06 44.04 0.09 
0.0092 -2.03 43.96 0.08 
0.0096 -2.02 43.87 0.09 
0.0101 -2.00 43.78 0.09 
0.0105 -1.98 43.74 0.09 
0.0109 -1.96 43.71 0.10 
269 
 





Figure A-6: Surface tension values versus surfactant concentration for 3:1 Polysorbate 80: 
PEG-40 hydrogenated castor oil (Replicate 1) (CMC bolded) 
y = -12.328x + 15.121
R² = 0.9898
























Surface Tension vs. Log Surfactant Concentration






Tension (mN/m) Standard Deviation 
0 -4.50 69.61 0.11 
0.0001 -4.29 68.19 0.03 
0.0001 -3.99 65.84 0.05 
0.0002 -3.81 62.91 0.07 
0.0002 -3.69 60.76 0.03 
0.0003 -3.59 58.80 0.01 
0.0004 -3.45 56.92 0.05 
0.0005 -3.34 55.52 0.04 
0.0006 -3.25 54.55 0.03 
0.0007 -3.15 53.48 0.04 
0.0009 -3.07 52.29 0.06 
0.0012 -2.91 50.88 0.04 
0.0015 -2.83 49.98 0.05 
0.0020 -2.71 48.69 0.05 
0.0024 -2.62 47.44 0.04 
0.0033 -2.48 45.88 0.04 
0.0041 -2.38 44.84 0.03 
0.0054 -2.27 43.98 0.04 
0.0068 -2.16 43.38 0.04 
0.0082 -2.09 43.01 0.02 
0.0106 -1.97 42.54 0.04 
0.0127 -1.89 42.13 0.07 
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Figure A-7: Surface tension values versus surfactant concentration for 3:1 Polysorbate 80: 
PEG-40 hydrogenated castor oil (Replicate 2) (CMC bolded) 
y = -13.296x + 11.829
R² = 0.9911
























Surface Tension vs Log Surfactant Concentraton






Tension (mN/m) Standard Deviation 
0 -4.50 68.67 0.13 
0.0001 -4.29 68.02 0.01 
0.0002 -3.69 61.60 0.06 
0.0003 -3.59 59.81 0.04 
0.0003 -3.51 58.05 0.12 
0.0004 -3.45 57.18 0.12 
0.0004 -3.39 56.69 0.02 
0.0005 -3.30 55.80 0.02 
0.0006 -3.22 54.86 0.02 
0.0007 -3.15 54.05 0.04 
0.0008 -3.09 53.00 0.02 
0.0010 -3.00 51.92 0.04 
0.0013 -2.89 49.63 0.05 
0.0016 -2.80 48.57 0.03 
0.0020 -2.71 47.65 0.03 
0.0024 -2.62 46.34 0.01 
0.0033 -2.48 45.81 0.03 
0.0046 -2.34 44.03 0.03 
0.0065 -2.19 43.34 0.02 
0.0098 -2.01 44.66 0.10 
0.0148 -1.83 42.23 0.01 
0.0184 -1.74 43.66 0.09 
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Figure A-8: Surface tension values versus surfactant concentration for 3:1 Polysorbate 80: 
PEG-40 hydrogenated castor oil (Replicate 3) (CMC bolded) 
y = -12.441x + 15.808
R² = 0.996






















Surface Tension vs. Log Surfactant Concentration






Tension (mN/m) Standard Deviation 
0 -4.50 68.75 0.17 
0.0001 -4.29 67.84 0.01 
0.0001 -3.99 66.31 0.03 
0.0002 -3.81 64.31 0.07 
0.0003 -3.51 59.58 0.14 
0.0005 -3.30 56.86 0.10 
0.0010 -3.00 53.40 0.11 
0.0015 -2.83 50.93 0.09 
0.0020 -2.71 48.94 0.04 
0.0024 -2.62 48.05 0.05 
0.0033 -2.48 46.98 0.07 
0.0041 -2.38 45.73 0.05 
0.0054 -2.27 45.10 0.05 
0.0068 -2.16 44.41 0.07 
0.0085 -2.07 44.05 0.08 
0.0112 -1.95 42.90 0.03 
0.0137 -1.86 42.13 0.02 
0.0176 -1.75 41.46 0.02 
0.0205 -1.69 42.87 0.06 





Table B-1: Health Canada recommended amounts of hydrophilic and lipophilic APIs based on 















Hydrophilic  Vitamin B1 (Thiamine 
mononitrate) 100 
1.4 1.4 
Vitamin B2 (Riboflavin) 100 1.4 1.4 
Vitamin B3 (Niacinamide) 100 18 18 
Vitamin B6 (Pyridoxine 
hydrochloride) 82.3 
2 2.43 
Vitamin B9 (Folic Acid) 94.8 0.6 0.63 
Vitamin B12 (Cyanocobalamin) 1 0.0026 0.26 
     
Lipophilic Vitamin A 30 0.55-0.77 1.84-2.57 
Vitamin D3  (Cholecalciferol) 2.5 0.015 0.6 
Vitamin E 98.8 15 15.2 
Vitamin K1 (Phytonadione) 100 0.09 0.09 

















A salinity test was performed using Sunflower Oil using the following conditions:  
HLD= 0 (at Type III microemulsion) 
S= 21 g/100 mL sodium chloride concentration 
EACN= unknown 
T= 25ºC  
















HLD= F(S) -  k. EACN -  α (T-25) + CC 
 
        0 = (0.13* 21 g/100mL)- 0.17 (EACN) –0 + 0.18 
                                            0 = 2.91 - 0.17 (EACN) 
                                         EACN = 17.12 
 
















Figure B-1: Effective Alkane Carbon Number (EACN) calculation of sunflower oil 
Salinity              20               21                22              23                33 
(g/100 mL)      
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An EACN test was performed on Polysorbate 80 using the following conditions:  
HLD= 0 (at Type III microemulsion) 
S= 30 g/100 mL sodium chloride concentration 
EACN= 2.3 (Type III microemulsion shift obtained using sodium decanoate oil, EACN 2.3) 
T= 25ºC  










HLD= F(S) -  k. EACN -  α (T-25) + CC 
 
        0 = (0.13* 30 g/100mL)- 0.17 (2.3) –0 + CC 
                                            0 = 3.9 - 0.391+ CC 
                                         CC = -3.509 
 















Figure B-2: Characteristic Curvature (CC) of Polysorbate 80 
 
Although maximum salinity of online simulator is 25 g/100 mL, (blue box) we can see the HLD 
approaching near zero close to EACN 1 (orange box). Given that 30 g/100 mL salinity was used 
in this case, it is safe to assume that a shift to a Type III microemulsion was indeed seen at 
EACN 2.3 




Surfactant Parameter Calculations/Equations  
	












where CMCMIXED is the critical micelle concentration of the mixed system 
 a is the molar fraction of surfactant 1 
 cmc1 is the critical micelle concentration of surfactant 1 
 1-a is the molar fraction of surfactant 2 
 cmc2 is the critical micelle concentration of surfactant 2 
	
	












    = 0.00475 mM 
 
where  cmc1= Polysorbate 80= 0.00473 mM (Chapter 2) 
           cmc2= Cremophor RH 40= 0.00491 mM (Chapter 2) 
 
_ _ _ _ _ _ _ 
 
• β Interaction Parameter: 
β = ln ( '('.&/
'('/.c/
)/ (1-X1)2 
where  a1= mole fraction of surfactant 1 
 cmc1= cmc of surfactant 1 
 X1= micellar composition (solved iteratively) 
 
•  X1: 
 X12 ln (cmc.a1/ cmc1.X1)                   = 1 














3:1 Polysorbate 80: PEG-40 
hydrogenated castor oil 0.75 4.77 3.59 ± 0.00 0.67 -2.2 
8:1 Polysorbate 80: PEG-40 






Calculation demonstrating F1A is above CMC at 100x aqueous dilution 
 
F1A- 3:1 Polysorbate 80:Cremophor RH 40: Experimental CMC 0.0036 mM (Chapter 2) 
MWPOLYSORBATE 80: 1309.66 g/mol 
MWCREMOPHOR RH40: 2698 g/mol 




1 mole= 6628 g 
1g       = 1/6628 mol 
In F1A, there is 5 g surfactant per 10 mL formulation 
Therefore, 5 g= 1/6628 * 5 mol 
   =  0.0008 moles of surfactant per 10 mL formulation 




At 100x aqueous dilution, 1 mL F1A in 100 mL water 
C1V1=C2V2 
0.08 M*0.001 L= C2*0.1 L 
C2= 0.00008 M/0.1 L 





Given that CMC= 3.6 x 10-6 M and C2= 8 x 10-4 M, aqueous dilution at 100X still ensures 
















Table C-1: Two sample, t-test results for size and zeta potential measurements of F1A before and 
after drug loading. 
 











F, DFn, DFd 
Size (nm) API-free 150.4 ± 18.5, 
4 
 
13.1 ± 21.3 t=0.6156 
df= 16 








API 163.5 ± 10.1, 
14 
       
























Table C-2: Two sample, t-test results for size and zeta potential measurements of F1A before and 
after exposure to three freeze-thaw cycles 
 




t, df p-value,  
p-value  
summary 




After 3X Freeze-thaw Cycles 126 ± 61, 2 
      















Table C-3: One-way ANOVA results for size and zeta potential measurements of F1A before and 
after exposure to various heating cycles. 
 
Parameter Sample Mean ± SD, N Sum of Squares F, df p-value,  
summary 




37°C 116 ± 25, 2 
50°C 142 ± 45, 2 
60°C 140 ± 49, 2 
70°C 119 ± 47, 2 
      




37°C -13.75 ± 3, 2 
50°C -13.25 ± 3, 2 
60°C -18 ± 6, 2 







Table C-4: One-way ANOVA results for size and zeta potential measurements of F1A before and 
after light exposure 
 
Parameter Sample Mean ± SD, N Sum of Squares F, df p-value,  
summary 




24 h 127 ± 8, 2 
1 week 124 ± 6, 2 
      




24 h -7.5 ± 4, 2 



























Figure C-1: Hydrodynamic diameters of F1A after various aqueous dilutions. 
 
No notable difference in size was seen in samples at 100x and 1000x aqueous dilution. Therefore, 




Size Histograms and Zeta Potential Curves (Zetasizer)  
 
Lipophilic API Incorporation (Size) 
F1A  
Figure C-2: Size histograms of F1A before and after lipophilic API incorporation at 25 and 37°C. 
F2A                        


































































Hydrophilic API Incorporation (Size) 
 
 
























Lipophilic and Hydrophilic API Incorporation (Size) 
 




Lipophilic and Hydrophilic API Incorporation (Zeta) 
 
Figure C-7: Zeta potential curves of F1A before and after multi-API incorporation 
F1A Drug-loaded  
(5 Lipophilic/4 Hydrophilic) 
F1A Placebo 
F1A Drug-loaded  
(5 Lipophilic/6 Hydrophilic) 
F1A Placebo 
F1A Placebo F1A Drug-loaded 







Figure C-8: Size histograms and zeta potential curves of F1A before (top) and after (bottom) 

































































Table D-1: Two sample, t-test results for size and zeta potential measurements of F1A before 
and after drug-loading. 





t, df p-value,  
p-value  
summary 
F-test to  
compare  
variance 
F, DFn, DFd 








Drug-loaded 268 ± 67, 10 
       
Zeta Potential 
(mV) 
Drug-free -17.5 ± 6.28,  
10 















Table D-2: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of surfactant type on droplet size for both placebo and drug-loaded samples. Only 
statistically significant results (p<.05) are presented.  
Parameter Label Sample: 
Microemulsion (S:O:W) 











A F1A- 3:1 P80:C40 (50:40:10) 182 ± 2.9, 2 91.1 C 0.037, * 
143 E 0.002, ** 
B 3:1 P80:C60 (50:40:10) 174 ± 39, 2    
C 3:1 P80:C40 (60:30:10) 90.7 ± 6.4, 2 109 G 0.033,* 
D 3:1 P80:C60 (60:30:10) 85.4 ± 14, 2    
E 3:1 P81:C40 (50:40:10) 38.5 ± 2.1, 2    
F 3:1 P81:C60 (50:40:10) 83.2 ± 10, 2 116 G 0.029,* 
G 3:1 B97:C60 (50:40:10) 199 ± 10, 2    
       
Size (nm) 
API-loaded 
A F1A- 3:1 P80:C40 (50:40:10) 182 ± 2.9, 2    
B 3:1 P80:C60 (50:40:10) 182 ± 2.9, 2 92.2 C 0.048, * 
88.2 D 0.049,* 
C 3:1 P80:C40 (60:30:10) 182 ± 2.9, 2 144.2 F 0.024, * 
118.8 G 0.049, * 
D 3:1 P80:C60 (60:30:10)     
E 3:1 P81:C40 (50:40:10)  99.9 F 0.027, * 
74.5 G 0.017, * 
F 3:1 P81:C60 (50:40:10)     
G 3:1 B97:C60 (50:40:10)     
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Table D-3: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of surfactant type on polydispersity indices for both placebo and drug-loaded samples. 
Only statistically significant results (p<.05) are presented.  
Parameter Label Sample: 
Microemulsion (S:O:W) 












A F1A- 3:1 P80:C40 (50:40:10) 0.29 ± 0.00, 2    
B 3:1 P80:C60 (50:40:10) 0.49 ± 0.05, 2    
C 3:1 P80:C40 (60:30:10) 0.57 ± 0.02, 2 109 D 0.027,* 
D 3:1 P80:C60 (60:30:10) 0.33 ± 0.02, 2    
E 3:1 P81:C40 (50:40:10) 0.17 ± 0.05, 2    
F 3:1 P81:C60 (50:40:10) 0.37 ± 0.06, 2    
G 3:1 B97:C60 (50:40:10) 0.40 ± 0.13, 2    
       
PDI 
API-loaded 
A F1A- 3:1 P80:C40 (50:40:10) 0.25 ± 0.04, 2    
B 3:1 P80:C60 (50:40:10) 0.33 ± 0.16, 2    
C 3:1 P80:C40 (60:30:10) 0.34 ± 0.01, 2    
D 3:1 P80:C60 (60:30:10) 0.34 ± 0.09, 2    
E 3:1 P81:C40 (50:40:10) 0.27 ± 0.00, 2    
F 3:1 P81:C60 (50:40:10) 0.28 ± 0.00, 2    
G 3:1 B97:C60 (50:40:10) 0.47 ± 0.01, 2 0.13 C 0.013, * 
0.19 E 0.042, * 
0.19 F 0.013, * 
 
 
Table D-4: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of surfactant type on zeta potential values for both placebo and drug-loaded samples. 
Only statistically significant results (p<.05) are presented.  
Parameter Label Sample: 
Microemulsion (S:O:W) 















A F1A- 3:1 P80:C40 (50:40:10) -10.6 ± 0.9, 2 15.7 F 0.038, * 
10.2 G 0.048, * 
B 3:1 P80:C60 (50:40:10) -13.2 ± 1.4, 2    
C 3:1 P80:C40 (60:30:10) -13.3 ± 0.5, 2 13.0 F 0.008,** 
12.7 G 0.006, ** 
D 3:1 P80:C60 (60:30:10) -11.9 ± 1.1, 2    
E 3:1 P81:C40 (50:40:10) -19.7 ± 2.0, 2    
F 3:1 P81:C60 (50:40:10) -26.3 ± 0.3, 2    
G 3:1 B97:C60 (50:40:10) -0.53 ± 0.5, 2 25.7 F 0.002, ** 





A F1A- 3:1 P80:C40 (50:40:10) -10.5 ± 0.4, 2    
B 3:1 P80:C60 (50:40:10) -11.5 ± 0.3, 2    
C 3:1 P80:C40 (60:30:10) -16.6 ± 4.8, 2    
D 3:1 P80:C60 (60:30:10) -14.2 ± 2.5, 2    
E 3:1 P81:C40 (50:40:10) -22.0 ± 3.0, 2    
F 3:1 P81:C60 (50:40:10) -22.7 ± 2.3, 2    
G 3:1 B97:C60 (50:40:10) -6.7 ± 0.5, 2    
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Table D-5: HPLC method development for quantification of water-soluble and fat-soluble 
vitamins in microemulsion solution 
Parameters Specifications 
INITIAL METHOD FINAL METHOD 
Waters Symmetry C18, 250 x 4.6 mm, 5 uM C18, 250 x 4.6 mm, 5 uM 
Column Temp. 25 ºC 35-55 ºC  
Mobile Flow Rate 0.5-1 mL/min 0.5-1 mL/min 
Wavelength 280 nm  265-270 nm 
Injection Volume 10 uL 10- 60 uL 








Time %A %B 
0 95 5 
4 95 5 
10 2 98 
30 2 98 
35 95 5 
40 95 5 
Water Solubles: 
A: 0.15% Hexansulfonate 
Sodium Monohydrate (pH 








Time %A %B 
0 60 40 
5 60 40 
35 4 96 
40 4 96 
50 4 96 
60 60 40 
 
Time %A %B 
0 99 1 
5 99 1 
20 35 65 
21 99 1 
26 99 1 










Table D-6: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of surfactant type on microemulsion droplet size and zeta potential. Only statistically 




Mean ± SD,  
N 
Homogeneity  
















 of Means: 
F(2,6.7)=31.6, 





F2 93.8 ± 15, 4 82.75   









 of Means: 
F(2,5.9)=6.10, 
 p= .037 
 
9.18 F3 .030, * 
F2 -16.5 ± 4, 4    



























Brand: Jamieson Prenatal + DHA (All-in-one) 
Package count: 60 units 
Dosage form: Soft gelatin capsules 
Dosage fill: Liquid 
 
 
Table D-7: Active ingredient list and amounts for Jamieson Pre-natal Supplement with DHA 
in softgel dosage forms. 
 
Vitamin Amount per Serving/Capsule 
Amount per 
1g F1A 
   
Active Ingredients Present in F1A   
Beta-carotene 1500 mcg  
Vitamin B1 (Thiamine Mononitrate) 1.4 mg 1.4 mg 
Vitamin B2 (Riboflavin) 1.6 mg 1.4 mg 
Vitamin B3 (Niacinamide) 18 mg 18 mg 
Vitamin B6 (Pyridoxine Hydrochloride) 5 mg 2.4 mg 
Vitamin B9 (Folic Acid) 1000 mcg 800 mcg 
Vitamin B12 (Cyanocobalamin) 2.8 mcg 2.6 mcg 
Vitamin D3 (Cholecalciferol) 15 mcg/600 IU 15 mcg 
Vitamin E (d-Alpha Tocopherol)) 19 mg AT/28 IU 15 mg 
Vitamin K1 90 mcg 90 mcg 
   
Active Ingredients NOT Present in F1A   
Vitamin A (Palmitate) 1050 mcg N/A 
Vitamin B5 (Calcium d-Pantothenate) 7 mg N/A 
Vitamin B7 (Biotin) 35 mg N/A  


















Table D-8: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of formulation type on vitamin recovery using 10 mM Citric Acid (pH 6). The medium 
for the reference formulation was 10 mM Citric Acid in 1% SDS. Only statistically significant 


























 of Means: 
F(3,1.7)=699, 
 p= .004 
100.5 Reference .040, * 
F2 105 ± 4, 2 104.0 Reference .033,* 
F3 106 ± 4, 2 104.5 Reference .028,* 
Reference 1.02 ± 0.01, 2    





 of Means: 
F(3,1.7)=1180, 
 p= .002 
116 
110 Reference .042, * 
F2 107 ± 3, 2 106 Reference .022,* 
F3 107 ± 3, 2 106 Reference .022,* 
Reference 1.01 ± 0.01, 2    





 of Means: 
F(3,1.7)=1641, 
 p= .002 
111.5 Reference .036, * 
F2 108 ± 2, 2 106.5 Reference .016,* 
F3 107 ± 3, 2 106.0 Reference .022,* 
Reference 1.02 ± 0.01, 2    
B9 15 F1 70 ± 8, 2 Welch’s Equality 
 of Means: 
F(3,1.7)=84.85, 
 p= .021 
   
F2 72 ± 7, 2    
F3 75 ± 10, 2    
Reference 0.01 ± 0.01, 2    
30 F1 77 ± 8, 2 Welch’s Equality 
 of Means: 
F(3,1.7)=64.74, 
 p= .027 
   
F2 74 ± 10, 2    
F3 77 ± 13, 2    
Reference 0.01 ± 0.01, 2    
60 F1 77 ± 8, 2  
Welch’s Equality 
 of Means: 
F(3,1.7)=54.05, 
 p= .031 
   
F2 75 ± 13, 2    
F3 76 ± 14, 2    





Table D-9: One-way Welch’s Equality of Means test with Games-Howell post-hoc for the 
effect of formulation type on vitamin recovery using 50 mM Phosphate Buffer (pH 7.4). The 
medium for the reference formulation was 10 mM Citric Acid in 1% SDS. Only statistically 
significant values (p<0.05) listed. 
 





Mean ± SD,  
N 
Homogeneity of  















 of Means: 
F(3,1.7)=8341, 
 p< .001 
91.5 Reference .044, * 
F2 95.5 ± 2, 2 94.5 Reference .018,* 
F3 102 ± 1, 2 100.5 Reference .006,** 
Reference 1.01 ± 0.01, 2    




 of Means: 
F(3,1.7)=8255, 
 p< .001 
98.0 Reference .035, * 
F2 97.5 ± 4, 2 96.5 Reference .030,* 
F3 104 ± 1, 2 102.5 Reference .006,** 
Reference 1.01 ± 0.01, 2    




 of Means: 
F(3,2)=42436150, 
 p< .001 
98.8 Reference  0.05,* 
F2 99 ± 3, 2 98 Reference .024,* 
F3 104 ± 0.01, 2 103 Reference .000,*** 
Reference 1.01 ± 0.01, 2    
90 F1 100.5 ± 5, 2 Welch’s Equality 
 of Means: 
F(3,1.8)=6968, 
 p< .001 
98.8 Reference .040, * 
F2 99 ± 3, 2 97.3 Reference .022,* 
F3 104.5 ± 1, 2 103.8 Reference .001,*** 
Reference 1.01 ± 0.5, 2    
B9 15 F1 75 ± 1, 2 Welch’s Equality 
 of Means: 
F(3,1.7)=1281, 
 p=.002 
75.0 Reference .015, * 
F2 76 ± 7, 2    
F3 81 ± 4, 2 81.5 Reference .036,* 
Reference 0.01 ± 0.01, 2    
30 F1 80.5 ± 6, 2  
Welch’s Equality 
 of Means: 
F(3,1.7)=163.4, 
 p= .012 
   
F2 77.5 ± 9, 2    
F3 82 ± 6, 2    
Reference 0.01 ± 0.01, 2    
60 F1 80 ± 10, 2 Welch’s Equality 
 of Means: 
F(3,1.7)=89.88, 
 p= .020 
 
   
F2 78.5 ± 9, 2    
F3 79.5 ± 8, 2    
Reference 0.01 ± 0.01, 2    
90 F1 81.5 ± 8, 2 Welch’s Equality 




   
F2 77.5 ± 9, 2    
F3 75 ± 14, 2    
Reference 0.01 ± 0.01, 2    
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Table D-10: Difference (ƒ1) and similarity (ƒ2) factors for F1, F2, F3 and the reference 
formulation.  
	
Media Reference vs. 
Test 
Time (mins) 









F1 vs. F2 15 70± 9.0 72± 7.0 2.00 4 
30 79± 7.0 72± 8.0 7.00 49 
60 80± 8.0 73± 9.0 7.00 49 
Sum (Σ) 229  16 102 
F1 vs. F3 15 70± 9.0 75± 10.0 5.00 25 
30 79± 7.0 77± 13.0 2.00 4 
60 80± 8.0 76± 14.0 4.00 16 
Sum (Σ) 229  11 45 
Control vs. F1 15 0± 0.0 70± 9.0 70.00 4900 
30 0± 0.0 79± 7.0 79.00 6241 
60 0± 0.0 80± 8.0 80.00 6400 
Sum (Σ) 0  229 17541 
Control vs. F2 15 0± 0.0 72± 7.0 72.00 5184 
30 0± 0.0 72± 8.0 72.00 5184 
60 0± 0.0 73± 9.0 73.00 5329 
Sum (Σ) 0  217 15697 
Control vs. F3 15 0± 0.0 75± 10.0 75.00 5625 
30 0± 0.0 77± 13.0 77.00 5929 
60 0± 0.0 76± 14.0 76.00 5776 
Sum (Σ) 0  228 17330 
       
Phosphate Buffer F1 vs. F2 15 75± 1.0 76± 8.0 1 1 
30 81± 6.0 77± 9.0 4 13 
60 80± 11.0 79± 9.0 1 1 
90 81± 8.0 77± 10.0 4 19 
120 81± 9.0 78± 10.0 3 6 
Sum (Σ) 398  13 40 
F1 vs. F3 15 75± 1.0 82± 4.0 7 50 
30 81± 6.0 82± 6.0 1 2 
60 80± 11.0 80± 8.0 0 0 
90 81± 8.0 75± 14.0 6 41 
Sum (Σ) 398  14 93 
Control vs. F1 15 0 ± 0.0 75± 1.0 75 5617 
30 0 ± 0.0 81± 6.0 81 6504 
60 0 ± 0.0 80± 11.0 80 6396 
90 0 ± 0.0 81± 8.0 81 6625 
120 0 ± 0.0 81± 9.0 81 6486 
Sum (Σ) 0  398 31628 
Control vs. F2 15 0 ± 0.0 76± 8.0 76 5776 
30 0 ± 0.0 77± 9.0 77 5929 
60 0 ± 0.0 79± 9.0 79 6241 
90 0 ± 0.0 77± 10.0 77 5929 
120 0 ± 0.0 78± 10.0 78 6084 
Sum (Σ) 0  387 29959 
Control vs. F3 15 0 ± 0.0  82 6724 
30 0 ± 0.0  82 6724 
60 0 ± 0.0  80 6400 
90 0 ± 0.0  75 5625 
Sum (Σ) 0  319 25473 
ƒ1 (difference factor): [e!|#$%|!# f) ∗ 100] 
 







Size Histograms and Zeta Potential Curves  
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Figure D-1: Size histograms and zeta potential curves of Span 80, Polysorbate 81 and 
































Brij 97  
Placebo 








Figure D-2: Size histograms and zeta potential curves of Brij 93, Brij 97 and Brij 98-containing 
















Brij 98  
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Figure D-3: Size histograms and zeta potential curves of Polysorbate 20, Polysorbate 40 and 




























































Figure D-4: Size histograms and zeta potential curves of Polysorbate 80, Polysorbate 81 and 
Brij 97 with various surfactant:oil:water (S:O:W) combinations of Cremophor RH 40 or 






















Polysorbate 85  
 
Figure D-5: Size histograms and zeta potential curves of Polysorbate 85-containing 





























Tension (mN/m) Standard Deviation 
0 -3.7 69.14 0.33 
0.0005 -3.301247089 67.82 0.02 
0.0010 -3.000434077 66.07 0.04 
0.0015 -2.824559695 64.47 0.09 
0.0020 -2.699837726 61.57 0.16 
0.0025 -2.603144373 58.61 0.12 
0.0031 -2.506505032 54.60 0.36 
0.0037 -2.427594291 51.15 0.12 
0.0050 -2.303196057 47.71 0.02 
0.0056 -2.252313535 46.09 0.04 
0.0062 -2.206825876 45.04 0.01 
0.0074 -2.128183791 44.32 0.03 
0.0099 -2.004321374 43.58 0.04 
0.0123 -1.908485019 42.60 0.02 
0.0160 -1.796147193 41.87 0.02 
0.0196 -1.707570176 41.01 0.01 
0.0244 -1.612783857 40.16 0.01 
0.0315 -1.502006699 39.61 0.03 
0.0361 -1.441956838 39.40 0.02 















Figure D-6: Surface tension versus log surfactant concentration for Polysorbate 81 was 
determined experimentally to be 0.0062 mM. CMC values are highlighted in yellow. 
 
 
y = -33.085x - 28.331
R² = 0.994






































Tension (mN/m) Standard Deviation 
0 -3.7 69.47 0.22 
0.0005 -3.303970684 68.17 0.04 
0.0015 -2.827066468 64.11 1.13 
0.0030 -2.526361827 54.36 0.41 
0.0050 -2.304946506 48.76 0.08 
0.0054 -2.26366211 44.74 0.05 
0.0059 -2.225981811 44.05 0.06 
0.0069 -2.159251465 43.05 0.03 
0.0079 -2.101475854 42.72 0.04 
0.0089 -2.05053956 42.28 0.04 
0.0099 -2.00499819 42.03 0.02 
0.0342 -1.466298502 40.59 0.01 





Figure D-7: Surface tension versus log surfactant concentration for Polysorbate 81 (replicate) 




y = -32.833x - 28.568
R² = 0.9856





































Tension (mN/m) Standard Deviation 
0 0 68.76 0.32 
0.0002 0.0002 65.47 0.08 
0.0004 0.0004 62.69 0.27 
0.0006 0.0006 59.14 0.10 
0.0011 0.0011 56.02 0.10 
0.0015 0.0015 53.30 0.10 
0.0019 0.0019 50.91 0.11 
0.0025 0.0025 48.03 0.12 
0.0034 0.0034 45.76 0.10 
0.0042 0.0042 44.01 0.05 
0.0054 0.0054 42.25 0.02 
0.0070 0.0070 41.78 0.04 
0.0090 0.0090 41.27 0.03 
0.0113 0.0113 40.79 0.04 
0.0138 0.0138 40.42 0.02 
0.0174 0.0174 40.31 0.04 
0.0224 0.0224 40.25 0.07 
0.0287 0.0287 39.69 0.06 
0.0358 0.0358 39.54 0.03 
0.0446 0.0446 39.06 0.09 













Figure D-8: Surface tension versus log surfactant concentration for 3:1 Polysorbate 
81:Cremophor RH 40. The critical micelle concentration of 3:1 Polysorbate 81:Cremophor RH 
40 was determined experimentally to be 0.0055 mM. 
y = -18.838x - 0.5343
R² = 0.9968


























Surface Tension vs. Log Surfactant Concentration
3:1 Polysorbate 81: Cremophor RH 40
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Tension (mN/m) Standard Deviation 
0 -4.6 67.76 0.02 
0.0001 -4.26757612 67.80 0.02 
0.0002 -3.791537894 67.01 0.04 
0.0006 -3.231571773 64.51 0.15 
0.0010 -2.998473904 60.53 0.45 
0.0015 -2.820100136 56.90 0.10 
0.0020 -2.696640957 54.35 0.10 
0.0025 -2.602655214 52.46 0.10 
0.0032 -2.50061385 50.32 0.19 
0.0041 -2.390826215 48.07 0.17 
0.0049 -2.306794129 46.20 0.23 
0.0058 -2.239240193 44.31 0.08 
0.0066 -2.183119259 43.61 0.08 
0.0081 -2.094046032 43.92 0.26 
0.0107 -1.970521119 43.20 0.31 

















Figure D-9: Surface tension versus log surfactant concentration for 3:1 Polysorbate 
81:Cremophor RH 40. The critical micelle concentration of 3:1 Polysorbate 81:Cremophor RH 





y = -20.329x - 0.6562
R² = 0.9977























Surface Tension vs Log Surfactant Concentration
3:1 Tween 81: Cremophor RH 40
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Tension (mN/m) Standard Deviation 
0 -4 68.71 0.28 
0.0002 -3.66362512 59.20 0.09 
0.0004 -3.363676805 52.84 0.11 
0.0006 -3.188664539 46.92 0.21 
0.0009 -3.064802121 40.98 0.09 
0.0011 -2.968965766 37.86 0.08 
0.0013 -2.890855531 36.66 0.09 
0.0015 -2.824977117 35.63 0.03 
0.0017 -2.768050923 34.80 0.06 
0.0019 -2.717961546 34.29 0.08 
0.0021 -2.673264604 33.96 0.02 
0.0023 -2.632929884 33.48 0.09 
0.0025 -2.596196717 33.09 0.02 
0.0027 -2.562487447 32.80 0.02 
0.0029 -2.531353053 32.85 0.08 
0.0031 -2.502437585 32.77 0.03 
0.0033 -2.475454095 32.72 0.09 
0.0035 -2.450167881 32.88 0.07 














Figure D-10: Surface tension versus log surfactant concentration for 3:1 Brij 97:Cremophor 
RH 40 where CMC determined experimentally to be 0.0015 mM. The CMC of Brij 97 was 
reported to be 0.940 mM (Hait 2001) such that the ideal CMC was 0.019 mM. 
 
3:1 Brij 98:Cremophor RH 40 
y = -30.27x - 50.686
R² = 0.982





















Surface Tension vs. Log Surfactant Concentration








Tension (mN/m) Standard Deviation 
0 -4.3 69.73 0.30 
0.00007 -4.13647665 67.42 0.04 
0.00015 -3.835988507 64.01 0.07 
0.00022 -3.660438424 59.82 0.07 
0.0003 -3.536040191 57.12 0.05 
0.00036 -3.43967001 54.94 0.05 
0.0004 -3.361027925 52.73 0.06 
0.0006 -3.237165508 49.80 0.05 
0.0007 -3.141329153 47.76 0.02 
0.0009 -3.063218917 46.08 0.01 
0.0010 -2.997340503 44.77 0.02 
0.0011 -2.94041431 43.90 0.04 
0.0013 -2.890324932 43.18 0.04 
0.0014 -2.845627991 42.62 0.02 
0.0017 -2.768560104 41.81 0.06 
0.0020 -2.703716439 41.14 0.02 
0.0023 -2.647817482 40.61 0.03 
0.0027 -2.576304556 40.16 0.03 
0.0030 -2.515733904 39.84 0.08 
0.0034 -2.463293055 39.69 0.08 
0.0041 -2.389191335 39.50 0.03 
0.0053 -2.274236819 39.57 0.03 
0.0065 -2.187086643 39.25 0.07 
0.0117 -1.931814138 39.38 0.03 













Figure D-11: Surface tension versus log surfactant concentration for 3:1 Brij 98:Cremophor 
RH 40 where CMC was determined experimentally to be 0.0016 mM. The CMC of Brij 98 
was reported to be 0.265 mM (Hait 2001) such that the ideal CMC was 0.019 mM. 
 
3:1 Polysorbate 40:Cremophor RH 40 
y = -21.481x - 19.045
R² = 0.9926




















Log Surfactant Concentration 
Surface Tension vs. Log Surfactant Concentration








Tension (mN/m) Standard Deviation 
0 -4.5 69.39 0.30 
0.0001 -4.14775766 67.50 0.02 
0.0001 -3.847269517 64.37 0.05 
0.0002 -3.671719435 60.99 0.07 
0.0003 -3.547321202 58.24 0.05 
0.0004 -3.372308936 56.12 0.06 
0.0006 -3.248446518 54.13 0.06 
0.0007 -3.152610163 52.54 0.03 
0.0008 -3.074499928 51.77 0.03 
0.0011 -2.95169532 50.84 0.03 
0.0014 -2.856909001 50.02 0.03 
0.0017 -2.779841114 49.24 0.03 
0.0019 -2.71499745 48.48 0.02 
0.0022 -2.659098492 47.69 0.02 
0.0025 -2.610028921 47.09 0.02 
0.0031 -2.508737676 46.06 0.03 
0.0037 -2.428410882 45.25 0.02 
0.0049 -2.305815658 44.05 0.03 
0.0067 -2.175947477 43.43 0.05 
0.0117 -1.932855905 42.61 0.06 













Figure D-12: Surface tension versus log surfactant concentration for 3:1 Polysorbate 
40:Cremophor RH 40 where CMC determined experimentally to be 0.0022 mM. The CMC of 




y = -13.24x + 11.608
R² = 0.96634























Log Surfactant Concentration 
Surface Tension vs. Log Surfactant Concentration
3:1 Polysorbate 40: Cremophor RH 40 
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Tension (mN/m) Standard Deviation 
0 -4.7 68.90 0.19 
0.0001 -4.204782704 54.75 0.09 
0.0001 -3.903806985 52.13 0.12 
0.0002 -3.602885523 51.76 0.02 
0.0004 -3.426902769 51.24 0.02 
0.0006 -3.20527095 47.28 0.08 
0.0009 -3.059359736 47.13 0.01 
0.0012 -2.904782807 46.41 0.02 
0.0019 -2.729232725 45.37 0.03 
0.0025 -2.604834491 44.40 0.02 
0.0037 -2.429822225 43.19 0.08 
0.0062 -2.210123453 41.91 0.02 
0.0110 -1.959119233 40.80 0.03 
0.0204 -1.691325568 40.13 0.01 




Figure D-13: Surface tension versus log surfactant concentration for 3:1 Polysorbate 
80:Cremophor RH 60 where CMC determined experimentally to be 0.0051 mM. The CMC of 
Polysorbate 80 was experimentally determined to be 0.0047 mM while that of Cremophor RH 
60 has been reported as 0.005-0.05 % w/v (Matsaridou, 2012) leading to an ideal CMC of 
0.0056-0.0062 mM.
y = -6.538x + 27.397
R² = 0.9652





















Surface Tension vs Log Surfactant Concentration 
3:1 Polysorbate 80:Cremophor RH 60
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Figure D-15: Rheology measurements of F2 and F3 after 100 and 1000x aqueous dilution. 
R2 values (F2: 0.999 at 100x and 0.998 at 1000x || F3: 0.997 at 100x and 0.998 at 1000x) 
Viscosity in mPa/s (F2: 1.06 ± 0.03 at 100x and 0.999 ± 0.02 at 1000x || F3: 1.06 ± 0.03 at 
100x and 0.955 ± 0.03 at 1000x) 







































P81:C40 Shear Stress (100 X)
Shear Stress (1000 X)




















P81:C40 Shear Stress (100 X)
Shear Stress (1000 X)




























































Figure D-16: HPLC Chromatogram of extracted fat soluble vitamins (top) and water-soluble vitamins 
(bottom) from microemulsion formulation 1. Both chromatograms were obtained with a C18 250 mm x 
4.6 mm, 5 uM column. Acceptability linearity of each fat-soluble vitamin using concentrations of 50, 70, 

















Figure D-17: Size and zeta potential values of F1, F2 and F3 before and after subjection to 




































































F2 After Treatment 
(70°C) 














































































































































































































































































































































Surfactant Parameter Calculations/Equations  
	












where CMCMIXED is the critical micelle concentration of the mixed system 
 a is the molar fraction of surfactant 1 
 cmc1 is the critical micelle concentration of surfactant 1 
 1-a is the molar fraction of surfactant 2 
















    = 0.019 mM 
 
 where  cmc1= Brij 97= 0.940 mM1 
















    = 0.019 mM 
 
 where cmc1= Brij 98= 0.265 mM1 



















    = 0.012 mM 
 
 where  cmc1= Polysorbate 40= 0.023 mM1 
            cmc2= Cremophor RH 40= 0.0049 mM (Chapter 2) 
 
 












    = 0.0048 mM 
 
 where  cmc1= Polysorbate 80= 0.0047 mM (Chapter 2) 
            cmc2= Cremophor RH 40= 0.0049 mM (Chapter 2) 
 
 












    = 0.0056-0.0062 mM 
 
 where  cmc1= Polysorbate 80= 0.0047 mM (Chapter 2)             
  cmc2= Cremophor RH 60= 0.005-0.05 % w/v2 
   MW: Cremophor RH 60: 3578 g/mol 
 
 












    = 0.0057 mM 
 
 where  cmc1= Polysorbate 81= 0.0061 mM (Figures D-6 and D-7, Appendix D) 
            cmc2= Cremophor RH 40= 0.0049 mM (Chapter 2) 
 
Calculation References: 
1. Hait et al. J Surf Det. 2001;4; 303-311 
2. Matsaridou et al. AAPS PharmSciTech. 2012;13:1319.  
	
